When I evaluate Microsoft Corporation today, I see an enterprise undergoing one of the most significant physical and operational transformations in corporate history. Over the past thirteen years, under the leadership of Chairman and CEO Satya Nadella, Microsoft has systematically transformed itself from an asset-light enterprise software provider into a global, capital-intensive hyperscale digital infrastructure operator. While this transition initially centered on migrating enterprise workloads to cloud infrastructure, the commercialization of foundation models and generative artificial intelligence has escalated this strategy into an intense physical infrastructure expansion.

The primary story, and the central analytical challenge, is the unprecedented surge in capital expenditures (CapEx) and the structural re-architecting of the company’s balance sheet and cash flow statement. Between fiscal years 2014 and 2026, Microsoft’s annual cash additions to property, plant, and equipment expanded from $5.49 billion, representing a modest 6.3% of revenue, to an astounding $115.90 billion, absorbing 34.9% of total consolidated sales.

This capital supercycle fundamentally alters Microsoft’s corporate finance profile and raises several critical questions for long-term equity valuation.

First, a significant structural shift has occurred in asset composition, with capital outlays pivoting away from long-lived real estate toward short-lived, high-density compute hardware such as graphics processing units (GPUs) and custom application-specific silicon.

Second, a major portion of what is currently categorized as “Growth CapEx” carries a hidden recurring maintenance burden, as fast-moving silicon wears out or becomes economically obsolete every three to four years. Consequently, growth spending today will permanently convert into a high recurring Maintenance CapEx floor in the future.

Third, management’s accounting policy choices, such as extending server useful lives from four to six years in FY2023, serve as near-term earnings-smoothing mechanisms that cushion operating margins without altering underlying cash commitments.

Ultimately, I believe this structural shift permanently resets Microsoft’s steady-state cash flow conversion profile. Over the next decade, as physical datacenter buildouts normalize, I project that CapEx as a percentage of revenue will settle into a new baseline of 20% to 25%, roughly double its historical pre-AI baseline. As a direct result, Free Cash Flow (FCF) margins will permanently adjust from historical levels of 30% to 33% down to a new equilibrium of 20% to 25%.

Equity valuation models must therefore price in a permanently higher capital reinvestment hurdle as the necessary cost of maintaining market leadership in enterprise cloud and artificial intelligence infrastructure.

Subscribe now

The author does not hold a position in Microsoft, Inc. at the time of publication. This report reflects the author’s personal views and is not investment advice. Investing carries the risk of permanent capital loss. Read full disclosure here.

1- Business Architecture, Monetization Mechanics, and Operational Scale Evolution

To understand why Microsoft is deploying hundreds of billions of dollars into physical infrastructure, we must first examine how its business model is structured, how it extracts commercial value, and how its operational footprint has evolved.

Microsoft manages its global operations across three primary reporting divisions, designed to align reporting with how enterprise solutions are deployed and managed:

1. The Productivity and Business Processes segment serves as the core of Microsoft’s commercial software suite. Its primary engine is Microsoft 365 Commercial, which integrates Office productivity applications, Microsoft Teams, Exchange, SharePoint, OneDrive, Enterprise Mobility + Security (EMS), and Windows Commercial cloud services.

   Following the reporting realignment, this division also houses developer productivity tools, including GitHub (monetized through seat-based subscriptions and GitHub Copilot), alongside per-user Power BI, Microsoft 365 Consumer subscriptions, LinkedIn (monetizing through Talent Solutions, Marketing Solutions, Premium Subscriptions, and Sales Solutions), and Dynamics business applications (comprising Dynamics 365 cloud ERP and CRM, Power Apps, and Power Automate). By consolidating all per-user SaaS software and developer productivity suites into this division, Microsoft captures steady, highly profitable recurring cash flows from corporate seat expansions.

2. The Intelligent Cloud segment operates as the enterprise public cloud, hybrid infrastructure, and technical services foundation of the company. Anchored by Azure, this segment delivers consumption-based infrastructure-as-a-service (IaaS) and platform-as-a-service (PaaS) capabilities supporting elastic compute, relational and non-relational database management, enterprise data analytics, and developer AI runtimes through Azure OpenAI Service.

   The division also encompasses hybrid on-premises server environments, including Windows Server, SQL Server, and Azure Arc, as well as Enterprise Support and Consulting services (Microsoft Customer Experience & Success). Azure serves as the physical and logical destination for enterprise workload migrations, linking Microsoft’s top-line growth directly to global digital data expansion and AI compute consumption.

3. The More Personal Computing segment connects software, content, and services directly to individual consumers and device ecosystems. This division includes Windows OEM licensing, non-cloud commercial software, Gaming hardware and content (comprising Xbox consoles, Xbox Game Pass subscriptions, Xbox Cloud Gaming, and first-party game studios following the $75.4 billion acquisition of Activision Blizzard), Search and news advertising via Bing and Microsoft Edge, and first-party Surface hardware devices.

   While More Personal Computing generates substantial cash flows, its relative share of consolidated revenue has decreased over time as enterprise cloud and software subscription divisions expand.

Microsoft extracts commercial value across four distinct operational mechanisms:

First, per-seat Software-as-a-Service (SaaS) subscriptions generate recurring revenue through multi-year enterprise agreements (E3 and E5 licensing tiers) supplemented by add-on agentic software modules such as Microsoft 365 Copilot, priced at $30 per user monthly.

Second, consumption-based hyperscale infrastructure charges enterprise clients dynamically based on compute runtime, storage volume, data egress, and API query volumes across Azure.

Third, transactional licensing and hardware sales monetize upfront software purchases for on-premises server environments, packaged consumer software, Windows OEM licenses, and physical devices.

Fourth, digital advertising and platform royalties generate revenue from Bing search queries, LinkedIn sponsored feeds, and third-party game sales on the Xbox platform.

This commercial architecture is supported by a physical and operational footprint. Microsoft operates over 400 physical datacenters located across more than 70 Azure availability regions globally, connected by millions of miles of terrestrial and subsea dark fiber. This physical network underpins a contracted Commercial Remaining Performance Obligation (RPO) of $678 billion, representing committed multi-year enterprise cloud and software spending.

The company’s digital distribution channels reach deep into global corporate workflows, supported by more than 400 million commercial Microsoft 365 seats, 30 million paid Copilot seats, 89 million consumer M365 subscribers, 1.2 billion registered LinkedIn members, and a cybersecurity telemetry footprint protecting over 1.5 million institutional customers worldwide.

2- Structural Moats and Competitive Advantages

The fundamental reason Microsoft can commit over $100 billion annually to physical capital expenditures is the durability of its underlying economic moats. In my analysis, Microsoft’s competitive advantages stem from four reinforcing structural drivers that protect its return on invested capital and generate high customer retention across economic cycles.

The Four Pillars of Microsoft’s Economic Moat:

High Switching Costs and Identity Layer Integration

Enterprise operations are embedded into Microsoft’s identity management and authentication architecture. Microsoft Entra ID (formerly Azure Active Directory) serves as the primary authentication, single sign-on, and security clearance layer for global corporate IT environments. Replacing Entra ID, Microsoft Exchange Server, SharePoint file structures, and mission-critical Excel spreadsheet models introduces severe operational risk, massive regulatory compliance overhead, and multi-year implementation timelines. Furthermore, as enterprise data estates built on legacy SQL Server instances are migrated into Azure Synapse or Microsoft Fabric, they create structural data gravity. Cloud data egress costs and complex database interdependencies make switching to competing hyperscalers architecturally difficult and cost-prohibitive.

Proprietary Data Gravity and the Microsoft Graph

Generative AI models and enterprise software agents depend heavily on internal business context to deliver actionable output. Microsoft possesses an irreplaceable structural asset in the Microsoft Graph, a repository of enterprise operational telemetry spanning corporate emails, calendar schedules, Teams collaboration logs, file repositories, and organizational hierarchies. This repository provides the grounding context required for generative AI tools like Microsoft 365 Copilot and autonomous software agents built via Copilot Studio. Standalone model providers and competing software vendors lacking access to this proprietary business context cannot replicate the contextual accuracy of Microsoft’s AI tools, creating a data-gravity advantage that strengthens as enterprise interaction frequency increases.

Supply-Side Hyperscale Economies of Scale

Operating hyperscale cloud networks and deploying high-density AI clusters requires vast capital resources. Microsoft amortizes its $115.90 billion annual cash CapEx budget across more than 400 million commercial seats, millions of enterprise virtual machines, and broad consumer surfaces including Bing, Xbox, and LinkedIn. This massive distribution base provides distinct unit-cost advantages in server procurement, power purchase agreements (PPAs), custom silicon development (such as Maia AI accelerators and Cobalt CPUs), and automated datacenter cooling infrastructure that mid-tier cloud providers and pure-play software vendors cannot match.

Enterprise Packaging and TCO Bundling Dynamics

Microsoft leverages its global enterprise sales force and distribution channels by packaging adjacent software tools into unified commercial licensing tiers, such as Microsoft 365 E5. By bundling advanced cybersecurity (Microsoft Defender, Sentinel, Purview), corporate communications (Teams Phone), and business analytics (Power BI) into existing commercial contracts, Microsoft delivers total-cost-of-ownership (TCO) savings of 40% to 60% compared to purchasing standalone point solutions from independent vendors. This packaging capability allows Microsoft to capture market share across new enterprise software categories with minimal incremental customer acquisition costs.

3- Competitive Landscape and Market Share Dynamics

Microsoft operates across several core technology sectors against well-capitalized hyperscale peers, enterprise software providers, pure-play cybersecurity vendors, and digital entertainment networks.

In the worldwide cloud infrastructure sector, Microsoft Azure maintains the second-largest market share globally at approximately 21%, trailing Amazon Web Services (28% to 30% share) and leading Google Cloud Platform (14% share). Azure’s strategic advantage remains its hybrid cloud bridge, Azure Arc, which enables enterprise clients to manage multi-cloud and on-premises server environments seamlessly.

Azure’s annual revenue surpassed $100 billion in FY2026, driven by hybrid enterprise workload migrations and expanding demand for AI model training and real-time inference runtimes.

In enterprise productivity and SaaS, Microsoft 365 maintains a dominant position, commanding over 50% market share in enterprise office suites. While Google Workspace competes effectively in the small-to-medium business and education sectors, Microsoft retains a strong hold among Fortune 500 companies and regulated institutional clients due to its enterprise compliance controls, identity integration, and legacy desktop software dependencies. In enterprise application software, Dynamics 365 competes against Salesforce, ServiceNow, and SAP, maintaining double-digit revenue growth by offering native integrations with Microsoft Teams and Power Platform automation workflows.

In cybersecurity, Microsoft has expanded into a major industry vendor, generating over $20 billion in annualized security revenue across Microsoft Defender, Sentinel, Entra, Purview, and Intune. Microsoft competes directly against pure-play security vendors such as Palo Alto Networks, CrowdStrike, Fortinet, and Zscaler. Microsoft’s market position is supported by its integration at the operating system and identity layers, allowing it to aggregate threat telemetry across 1.5 million enterprise clients and package security solutions directly into the Microsoft 365 E5 licensing suite.

In enterprise generative AI, Microsoft established an early leadership position through its partnership with OpenAI, which granted exclusive cloud infrastructure hosting rights for OpenAI model training and inference alongside commercial distribution rights through Azure OpenAI Service. It competes primarily against Alphabet (Google Gemini and Vertex AI) and Amazon (AWS Bedrock and its partnership with Anthropic). Microsoft’s AI-related revenue run rate reached $37 billion in early FY2026, driven by Azure AI compute consumption and Copilot seat expansion.

4- Macro Financial Performance & Detailed Statement Breakdown

Looking at Microsoft’s financial trends over the past six fiscal years (FY2021–FY2026), we see top-line revenue compounding, significant operating margin expansion, and a major decoupling between accounting earnings and free cash flow generation.

When I examine Microsoft’s revenue trajectory over the past decade, I see a clear transition from transactional software licensing to recurring cloud annuities. Consolidated revenue expanded from $168.09 billion in FY2021 to $331.80 billion in FY2026, representing a compound annual growth rate of 14.6%. Following a brief enterprise IT spending slowdown in FY2023 (+6.9% growth), top-line growth re-accelerated to 17.8% in FY2026.

This growth has been propelled by three main structural forces:

Azure Hyperscale Expansion: Azure revenue crossed $100 billion in FY2026, driven by core enterprise migration of mission-critical databases and an acceleration in AI compute demand via Azure OpenAI Service.

Commercial SaaS Seat & ARPU Upselling: Microsoft 365 Commercial revenue expanded consistently as enterprise agreements were upgraded from standard E3 tiers to premium E5 suites, boosted by initial seat additions for Microsoft 365 Copilot.

Cross-Platform Gaming & Dynamic Application Growth: The consolidation of Activision Blizzard expanded cross-platform gaming subscriptions (Xbox Game Pass), while Dynamics 365 maintained double-digit growth by integrating AI workflow automation.

Operating Margin Expansion & Segment Contribution Analysis

Consolidated operating margin expanded from 41.59% in FY2021 to an extraordinary 46.78% in FY2026. To understand how Microsoft achieved this 519-basis-point margin expansion during a period of massive physical buildouts, we must analyze segment operating profitability:

Productivity and Business Processes (PBP): PBP is the crown jewel of Microsoft’s operational profitability, expanding segment operating margins from 55.9% to 59.9%. Because per-seat SaaS applications and developer suites (Office 365, GitHub Enterprise/Copilot, LinkedIn, Dynamics 365) incur very low incremental marginal costs once the core software is built, seat expansions and E5 suite upgrades flow directly into operating profit. PBP has been the single largest contributor to consolidated margin expansion, providing a highly profitable recurring software cushion.

Intelligent Cloud (IC): Intelligent Cloud operates at high absolute profit levels ($140.5 billion revenue in FY2026), with operating margins contracting from 43.2% to 41.3%. While scale efficiencies in server procurement and automated datacenter management supported margin expansion through FY2024, rising server depreciation charges flowing into Cost of Goods Sold have begun to temper margin upside.

More Personal Computing (MPC): MPC operates at lower and more volatile operating margins (25% to 35%), as hardware sales (Surface, Xbox consoles) carry lower gross profitability and search advertising involves traffic acquisition costs. The relative mix shift of Microsoft’s business away from MPC and toward PBP and Intelligent Cloud has naturally pulled consolidated operating margins higher over time.

Net income expanded alongside operating income, reaching $133.75 billion GAAP in FY2026. Excluded from core operational performance is a ~$5.0 billion non-cash net investment gain from the OpenAI restructuring, yielding an Adjusted Net Income of $128.75 billion (representing a 52.07% FCF conversion rate). If the $3.2 billion Anthropic valuation gain is also excluded, combined adjustments total $8.2 billion, resulting in a further-adjusted net income of $125.55 billion and a FCF conversion rate of 53.40%.

Earnings Per Share (EPS) vs. Free Cash Flow Per Share Divergence

One of the most critical trends in this financial analysis is the sharp decoupling between Diluted EPS growth and Free Cash Flow (FCF) per share growth.

Between FY2021 and FY2026, GAAP Diluted EPS grew by 123.0% (rising from $8.05 to $17.95). Over that exact same period, Free Cash Flow per share grew by just 22.1% (rising from $7.38 in FY2021 to $9.92 in FY2024, before falling back to $8.99 in FY2026).

Why did this divergence occur? It is the direct mathematical consequence of CapEx intensity. Under GAAP accounting rules, cash spent on capital expenditures is capitalized to the balance sheet and recognized on the income statement gradually over 3 to 15+ years through depreciation expense. Consequently, Net Income and EPS benefit from delayed cost recognition.

Free Cash Flow, however, subtracts cash CapEx immediately ($115.90 billion in FY2026) from Operating Cash Flow ($182.935 billion). As CapEx expanded from 12.27% of revenue in FY2021 to 34.93% in FY2026, cash outlays drained Free Cash Flow generation while accounting EPS continued to print new highs. FCF conversion relative to Net Income compressed from 91.59% down to 50.12% (52.07% on an adjusted basis).

Capacity Buildout Lag Led to Declining Return Metrics

Return on Capital peaked at 30.30% in FY2021 before entering a steady multi-year decline to 20.7% in FY2026.

This decline in return metrics is not caused by operational decay or failing pricing power. Rather, it is driven by a classic capacity buildout lag.

When Microsoft spends $115.90 billion in cash CapEx in a single year, Property, Plant, and Equipment (Gross PP&E) and total invested capital expand on the balance sheet immediately. However, mega-scale datacenter campuses, high-voltage power substations, and supercomputing clusters take 12 to 36 months to construct, power up, and populate with paying enterprise software workloads.

Because the invested capital denominator expands instantly while the operational profit numerator arrives with a multi-year delay, Return on Capital temporarily compresses. Return metrics will only stabilize once these massive fixed assets become fully operational and productive.

Balance Sheet Strength and Debt Structure

Despite elevated capital spending, Microsoft retains an extraordinarily strong balance sheet. The Debt-to-Equity ratio improved from 0.48x in FY2021 to 0.11x in FY2026, as total stockholders’ equity expanded to $442.4 billion. Cash, cash equivalents, and short-term investments totaled $76.7 billion against $47.6 billion in total debt, leaving Microsoft in a solid net cash position of nearly $29.1 billion, backed by AAA credit ratings.

Furthermore, Microsoft finances its physical buildouts entirely through internal operating cash flow ($182.935 billion in FY2026), eliminating any need for debt financing and preserving complete financial flexibility.

Subscribe now

5- Granular CapEx Breakdown, Accounting Mechanics, and The Maintenance Treadmill

Connecting the macro financial performance to the physical asset base, we now examine the structural composition of Microsoft’s capital expenditures, its accounting policy adjustments, and the downstream maintenance treadmill.

Analytical Note: Microsoft does not break out an explicit line-item dollar split between hardware and real estate in Form 10-K filings. The estimates below reflect executive disclosures from CFO Amy Hood indicating that capital allocation shifted as high-density AI clusters accelerated, moving from an even split early in the cloud era to approximately two-thirds allocated to short-lived compute assets (GPUs, CPUs, and network gear) and one-third to long-lived datacenter facilities and physical infrastructure during the peak FY2025–FY2026 buildouts.

Hardware vs. Real Estate Breakdown (Analytical Modeled Estimate, CFO Guided Mix)

In the early cloud scaling phase (FY2014–FY2021), capital spending maintained a balanced profile, averaging an estimated 50% for servers/hardware and 50% for real estate/physical structures. Long-lived outlays were necessary to construct physical shells, acquire land, and build electrical substations.

During the AI infrastructure surge (FY2023–FY2026), outlays tilted heavily toward short-lived compute assets (~66.7%), leaving long-lived real estate at roughly one-third (~33.3%). High-density AI compute clusters command significantly higher hardware costs per square foot than traditional cloud servers, directing outlays into technology hardware subject to shorter depreciation cycles. In FY2026 alone, $77.27 billion out of the $115.90 billion cash CapEx budget went toward fast-moving silicon and server hardware.

Growth CapEx & Quantifying the “Maintenance Treadmill”

Analytical Note: Microsoft does not publish a GAAP split between Growth and Maintenance CapEx. The figures below reflect financial modeling estimates based on server fleet replacement lifecycles.

During FY2023–FY2026, Growth CapEx expanded to represent an estimated 82% to 85% of total outlays ($98.52 billion in FY2026) as Microsoft raced to expand AI compute capacity. A critical structural insight of this analysis is that a significant portion of today’s “Growth CapEx” is a recurring maintenance obligation in disguise.

When Microsoft spends $10 billion on real estate, that asset lasts 15+ years with minimal upkeep. But when it spends $77.27 billion in a single year on GPUs, custom accelerators, and networking gear, those assets experience physical wear and technological obsolescence every 3 to 4 years. To quantify this conversion:

In FY2026, Microsoft deployed an estimated $65.70 billion in Growth CapEx specifically for short-lived server/GPU hardware ($98.52B Growth CapEx × 66.7% hardware mix). Because this hardware must be turned over every 3 to 4 years, approximately $50 billion to $60 billion of this annual Growth spend will permanently convert into recurring Maintenance CapEx by FY2028–FY2030.

Combined with facility upkeep ($15B–$20B), this establishes a permanent annual Maintenance CapEx floor of $75 billion to $85+ billion. Microsoft is establishing a permanently higher capital floor. What is characterized as growth investment today will become the baseline cost of staying operational tomorrow.

Evaluation of Accounting Treatment Policy Shifts

As disclosed in the 10-K filings, Microsoft’s official property and equipment accounting schedule is as follows: “software developed or acquired for internal use, three years; servers and network equipment, two to six years; buildings and improvements, five to 15 years; leasehold improvements, three to 15 years; and furniture and equipment, one to 10 years. Land is not depreciated.”

Analyzing these policy choices reveals critical insights:

FY2023 Server Useful Life Extension (Quantified Fact): In FY2023, Microsoft extended the estimated useful life of server and network equipment from 4 to 6 years, which reduced FY2023 depreciation expense by $3.7 billion across the full fiscal year (with approximately $1.1 billion recognized in the first quarter of FY2023), directly boosting pre-tax operating income during an enterprise cloud growth deceleration.

Buildings & Improvements Schedule (10-K Anchored): As explicitly stated in Note 1 of the Form 10-K, physical buildings and site improvements are depreciated over 5 to 15 years. In discussing the extension of datacenter building depreciable lives into FY2027, CFO Amy Hood explicitly characterized the accounting adjustment as having a “minimal benefit to FY27 operating income,” reflecting that rapid hardware depreciation continues to dominate the cost profile.

My View on Accounting Alignment is that while depreciating physical buildings over 15 years matches standard commercial real estate schedules, amortizing fast-moving AI silicon over up to 6 years outpaces technological reality. High-density AI accelerators running under continuous 100% utilization face thermal degradation and performance-per-watt obsolescence every 3 to 4 years. Depreciating AI hardware over 6 years creates an ongoing disconnect where accounting earnings benefit from delayed depreciation while the balance sheet retains assets whose true economic value is decaying faster than reported.

6- Growth Levers, Addressable Target Markets (TAM), and Catalysts

To justify this massive infrastructure spending, Microsoft must expand its top-line revenue across large growth vectors. The potential runway for enterprise software and cloud monetization remains substantial, provided execution stays on track.

The monetization of artificial intelligence represents Microsoft’s most direct organic growth lever. With over 400 million commercial Microsoft 365 seats globally and paid Copilot seats standing at 30 million, current penetration remains under 10%.

The primary growth catalyst is not merely acquiring new users, but driving average revenue per user (ARPU) expansion. Standard commercial Microsoft 365 seats generate between $15 and $38 per user monthly. Adding Microsoft 365 Copilot at $30 per user monthly increases subscription ARPU by 80% to 150% per converted seat.

Furthermore, as enterprise workflows evolve from simple copilot assistance toward autonomous AI agents built via Copilot Studio, monetization expands into multi-agent orchestration billing. This transition enables Microsoft to capture value from workflow automation rather than basic software licensing.

The global cloud infrastructure market (IaaS and PaaS) continues to expand as enterprises migrate core workloads out of corporate datacenters. Azure’s primary catalyst is enterprise data estate modernization. Foundation AI models cannot generate useful enterprise output without access to clean, structured, and secure internal business data.

Microsoft Fabric addresses this requirement by unifying data engineering, data warehousing, real-time analytics, and governance into a single cloud environment. As corporate clients deploy Fabric to organize their operational data estates, Fabric adoption drives downstream consumption into Azure SQL databases, Azure Cosmos DB, and Azure AI runtimes, creating a compounding revenue feedback loop inside Intelligent Cloud.

The enterprise cybersecurity market represents an expanding target addressable market, accelerated by rising cyber threat frequency and strict regulatory compliance requirements. Chief Information Officers (CIOs) are actively seeking to reduce operational complexity by consolidating fragmented point-security tools into unified platforms.

Microsoft is uniquely positioned to capture this consolidation trend. By packaging advanced security, including Microsoft Defender endpoint protection, Sentinel SIEM analytics, Entra ID identity governance, and Purview data compliance, directly into the Microsoft 365 E5 licensing suite, Microsoft offers total-cost-of-ownership savings of 40% to 60% compared to purchasing standalone security solutions from Palo Alto Networks, CrowdStrike, or Zscaler. Upselling commercial clients from E3 to E5 licensing tiers expands enterprise SaaS ARPU while expanding high-margin security revenues.

While top-line growth vectors expand revenue, internal custom silicon development serves as a major margin catalyst. Relying exclusively on merchant third-party GPUs creates a margin bottleneck due to high chipmaker procurement premiums.

Microsoft’s ongoing deployment of first-party custom silicon, specifically its Maia AI accelerators for model training/inference and Cobalt ARM-based CPUs for general cloud workloads, improves unit compute economics. Custom silicon delivers an estimated 30%+ improvement in performance-per-dollar, allowing Azure to process AI API queries at lower operational costs and protecting long-term cloud margins as AI consumption scales.

7- Valuation

Growth Engines

The future return on Microsoft stock is a function of two engines: the future growth in free cash flow per share, and any valuation re-rating. Both are explained below.

Engine 1: Fundamentals

The first engine is the business itself. FCF per share grows over time through revenue expansion, operating leverage, and share count reduction from buybacks. That growth, compounded annually, is what the fundamental engine delivers regardless of any valuation re-rating.

For Microsoft, I assume FCF per share growth averaging between 12% and 15% over the first decade of the projection period. The primary driver is the Productivity and Business Processes segment continuing to expand margin, from 55.9% toward 59.9% and beyond, compounding on top of Azure and Intelligent Cloud, which kept growing revenue well above 30% even as the segment absorbs the cost of the current infrastructure buildout.

Buybacks add a further per-share amplification effect, diluted share count has already fallen from 7.61 billion to 7.45 billion over the past five years, even through a period where capital was heavily redirected toward the current capex program.

Unlike a business whose elevated capital spending is a maturing, finite buildout set to normalize, I don’t expect Microsoft’s free cash flow conversion to recover toward its historical levels as this cycle plays out. The maintenance treadmill argument covered earlier in this report, that a large share of today’s growth capex converts into permanent recurring replacement spending as short-lived AI hardware turns over every three to four years, means this fundamental engine has to deliver its growth without the tailwind of capital intensity falling back toward its historical baseline.

Engine 2: Valuation Re-Rating

At today’s price of approximately $500, the investor is paying for everything this business will earn over roughly the next 21 years, in today’s money. Everything it earns beyond that point comes to the investor at no additional cost. The fewer the embedded years, the more of the future the investor receives without paying for it.

At 21 embedded years, the price sits in the Neutral zone on my own valuation scale. This is a price shaped by the open questions I addressed in the Financial Performance and Risks sections, specifically whether the maintenance treadmill argument proves accurate and whether the OpenAI relationship continues sending the concentration of compute demand through Azure that today’s backlog assumes.

At 21 embedded years, I expect future returns to come primarily from Engine 1, the underlying growth in free cash flow per share, with only a slight additional boost from Engine 2, since the valuation itself has relatively limited room to re-rate meaningfully from here.

Hold, Add, and Exit Logic

This framework isn’t a mechanical buy-and-sell signal, it’s a way of thinking about price relative to value. In the Deep Value and Attractive zones, the price is working in the investor’s favor, more future cash flow is embedded per dollar paid than the market typically offers for a business of this quality. In the Neutral zone, future returns are expected to come primarily from Engine 1 with only a slight boost from Engine 2, whereas the Stretched and Exorbitant zones embed high optimism with little to no margin for error.

8- Major Strategic Risks and Threats

Analyzing Microsoft’s multi-year outlook, I highlight four primary enterprise risks that could impact corporate valuation and operational execution:

The CapEx Intensity Treadmill & Operating Leverage Reversal

The primary financial risk facing Microsoft is the potential mismatch between capital expenditure pacing and enterprise revenue realization. With cash CapEx reaching 34.9% of revenue ($115.90 billion in FY2026), Microsoft has established a high fixed physical cost structure.

If enterprise adoption of Copilot seats or generative AI agents develops more slowly than anticipated, or if algorithmic efficiency gains reduce the compute power required for inference, Microsoft could face excess compute capacity. Because short-lived silicon and high-density servers carry rapid 3-to-4-year physical replacement lifecycles, an expanded capital asset base will generate elevated ongoing depreciation drag, compressing operating margins if top-line revenue growth decelerates.

Strategic Interdependence & OpenAI Concentration Risk

Out of Microsoft’s $678 billion commercial Remaining Performance Obligation (RPO), it is estimated that approximately 32% (nearly one-third) is tied to OpenAI infrastructure commitments.

This creates a circular operational dependency as Microsoft deploys cash CapEx to construct specialized supercomputing clusters, which host OpenAI model workloads that form a large portion of Microsoft’s commercial backlog. If OpenAI experiences corporate governance friction, intellectual property challenges, or chooses to diversify its compute hosting across competing cloud providers (such as Oracle or AWS), Microsoft could face unutilized compute capacity carrying fixed depreciation and facility power commitments.

Enterprise Customer ROI Friction & Model Commoditization

While early enterprise adoption of Microsoft 365 Copilot has been strong, corporate IT buyers are increasingly scrutinizing the clear return on investment (ROI) of paying $30 per user monthly. If enterprise clients determine that generative AI tools deliver incremental productivity gains rather than transformational cost savings, renewal rates could slow.

Furthermore, rapid advances in open-source foundation models (such as Meta’s Llama series and Mistral) could commoditize general reasoning models. If open-source models achieve performance parity with proprietary frontier models at zero software licensing cost, pricing power across Azure AI model APIs and Copilot seat add-ons could face competitive pressure.

Hyperscaler Custom Silicon Competition & Datacenter Power Constraints

Alphabet (Google TPUs) and Amazon (AWS Trainium/Inferentia) have invested in proprietary custom silicon architectures for over a decade. If competitors achieve superior cost-per-token efficiency using custom hardware compared to Azure’s merchant GPU and custom silicon mix, Azure could face cloud compute pricing pressure.

Simultaneously, real-world physical infrastructure bottlenecks pose operational challenges. AI datacenters require 3x to 5x more electrical power density than traditional cloud facilities. Securing multi-gigawatt utility power interconnects, nuclear power purchase agreements, and liquid-cooling hardware involves real-world construction delays. Power availability bottlenecks could prevent completed datacenter shells from being brought online, delaying revenue generation from capitalized assets.

The Verdict

When I synthesize this entire deep-dive analysis, the fundamental takeaway is that Microsoft’s core enterprise franchise remains one of the most powerful, highly defensible cash-generating engines in modern corporate history. Generating $182.935 billion in annual operating cash flow, building a contracted commercial Remaining Performance Obligation of $678 billion, scaling Azure past $100 billion in annual revenue, and expanding Microsoft 365 Copilot past 30 million paid seats all confirm that the company’s software monetization engine is operating at peak capacity. The enterprise identity layer anchored by Microsoft Entra ID, combined with deep software switching costs, total-cost-of-ownership suite packaging, and the proprietary grounding context of the Microsoft Graph, creates an expansive economic moat that protects organic profitability and generates immense customer retention across economic cycles.

At the same time, my analysis demonstrates that Microsoft’s underlying business model has undergone a permanent, structural shift. The enterprise is no longer an asset-light software pure-play capable of converting 90% of its net income directly into free cash flow; it has evolved into a hyperscale digital infrastructure utility. Deploying $115.90 billion in annual cash capital expenditures, absorbing 34.9% of consolidated revenues, alongside carrying $329.1 billion in off-balance-sheet uncommenced lease commitments, establishes a heavy physical cost base that fundamentally alters the company’s corporate finance profile. Because approximately two-thirds of this annual capital spending is concentrated in high-density GPUs, custom silicon, and server hardware that face physical degradation and technological obsolescence every three to four years, a major portion of today’s growth capital will permanently convert into a $75 billion to $85+ billion annual maintenance CapEx floor by the end of the decade.

Crucially, Microsoft possesses the balance sheet strength and cash-generating power to absorb this capital supercycle without compromising its financial integrity. Operating cash flow of $182.935 billion fully self-funds this $115.90 billion cash CapEx program with zero reliance on debt issuance, leaving $67.035 billion in residual free cash flow to support dividend growth and share buybacks. Supported by $442.4 billion in stockholders’ equity, $76.7 billion in liquid cash reserves against $47.6 billion in total debt, a 0.11x Debt-to-Equity ratio, and an impeccable AAA credit rating, Microsoft’s financial fortress is unmatched.

While equity investors must accept lower free cash flow conversion efficiency as the structural cost of artificial intelligence market leadership, Microsoft’s ability to monetize enterprise workflows while self-funding hyperscale infrastructure makes its long-term compounding thesis rock-solid. Taking all strategic, operational, and financial dimensions into account, the investment case and strategic buildout for Microsoft Corporation are fully APPROVED.

The author does not hold a position in Microsoft, Inc. at the time of publication. This report reflects the author’s personal views and is not investment advice. Investing carries the risk of permanent capital loss. Read full disclosure here.

Before getting into any numbers, it’s worth being upfront about what this is and isn’t.

Copart is a name Bearhold covers, and it’s currently a position in both the Bearhold model portfolio and my own personal portfolio

This report is an attempt to understand what autonomous vehicles (AVs) mean for Copart’s business, and to do that honestly, we have to work through the problem in two stages. First, we need a grounded view of where AV technology and adoption are actually headed, not the hype-cycle version, but a reasonable read on the pace of change.

Only once we have that can we ask the second question, how does that AV trajectory ripple through the auto insurance industry, and from there, into Copart’s salvage and auction business, over time.

No one has a crystal ball when modeling a multi-decade technological transition. The assumptions used throughout this report; adoption curves, cost declines, total loss rates, fleet turnover; are built on the best available data, but they remain projections with error bars that widen the further out we look.

The goal is to figure out, as objectively as possible, whether AVs represent an existential threat to Copart, a drag, a catalyst, or something that shifts character entirely depending on which decade you’re looking at. The honest answer, as you’ll see, is “it depends on the time horizon”. And I’ve tried to lay out the reasoning, so you can judge the assumptions for yourself.

One more note before diving in; this is an analytical exercise, not investment advice. Copart is a publicly traded company (NASDAQ: CPRT), and nothing here should be read as a recommendation to buy, hold, or sell its stock. It’s a framework for thinking about a structural risk, built on projections that are inherently uncertain.

Executive summary

For over a century, auto insurance and salvage were built around human driver error. As control shifts to software, sensors, and commercial AV fleets, two forces move in opposite directions at once as explained below:

Fewer crashes reduce the raw pool of vehicles entering the claims pipeline, that’s the drag. But the vehicles that do crash are increasingly loaded with expensive perimeter sensors, LiDAR, and high-voltage battery packs, which pushes a rising share of them past the total-loss threshold, that’s the catalyst.

For Copart, whose engine is essentially volume times price on total-loss units, the verdict this report lands on is a two-part one. Over the next decade, the data points to a positive impact, rising total-loss frequency and improving vehicle quality look set to outweigh the gradual decline in raw accidents. In the long term, the data points to accident volumes diminishing sharply enough that the current accident-salvage model can’t carry the business on its own, Copart will need to actively become something more than a salvage auctioneer to stay viable, and even then, the size, growth rate, and margin profile of that future business aren’t yet knowable. The full case for both halves is below.

Part 1: Where autonomous vehicles are actually headed

Let me first start with the obvious, there’s a big difference between driver-assistance features that are already common (adaptive cruise control, lane-keeping, automatic emergency braking, what’s usually called Level 2 or “L2+”) and genuine autonomy, where the car is making driving decisions without a human ready to take over (Level 3 and above).

L2+ features are already mainstream. A meaningful share of new vehicles sold today come with some version of this technology standard, and that share is climbing quickly. True high-autonomy vehicles, L3 “eyes off” systems and L4 robotaxi-style fleets, are much earlier in their curve. They exist today in limited, geofenced deployments (think Waymo in a handful of cities), but broad consumer availability is still a matter of years, not months.

The working assumption in this report is that L2+ penetration in new vehicle sales climbs from roughly a fifth of the market today toward near-universal by the mid-2030s, while true L3/L4 penetration follows a slower curve, starting in the low single digits today, crossing into double digits around 2030, and reaching majority status only by the late 2030s to early 2040s in leading markets.

Because the global vehicle fleet turns over slowly (the average car stays on the road for over a decade, longer in developing economies), the share of the operating fleet that’s actually autonomous lags new-sales penetration by many years. Even if every new car sold in 2035 were highly autonomous, most cars on the road that year would still be older, human-driven vehicles bought years earlier.

This lag matters enormously, because it means the transition isn’t a light switch. It’s a slow-moving wave where, for a long stretch of time, arguably the entire next decade, the roads are a mixed environment. Autonomous and semi-autonomous vehicles sharing space with a large, aging population of ordinary human-driven cars. That mixed environment turns out to be the most financially interesting period for the businesses sitting downstream of collisions, which is where Copart comes in.

It’s also worth flagging that the AV timelines have a long history of being overly optimistic. Robotaxi services and “full self-driving” have been promised as imminent for the better part of a decade, and regulatory approval, public trust, insurance frameworks, and edge-case software reliability have all taken longer than boosters expected. Any timeline in this report should be read as a central estimate surrounded by a wide range, skewed toward “later than projected” based on the industry’s track record.

The adoption curve, laid out

New-vehicle sales always lead, the in-use fleet catches up slowly behind them, which is the mechanical reason the “mixed roads” period lasts so long.

The table below is the full modeled timeline showing new-vehicle sales penetration for both L2+ and true L3/L4 autonomy, the resulting share of the in-use fleet that’s actually autonomous, and where that leaves absolute global collision volume and total loss frequency.

First, it is important to note that the in-use fleet column (”Active AV fleet share”) consistently lags the new-sales columns by years, that’s the slow-turnover effect discussed above, and it’s why the mixed-fleet period stretches out for so long.

Second, collision volume and total loss frequency move in opposite directions for the entire modeled horizon, they never really “resolve” into one trend; they’re a permanent tension that just shifts weight over time.

Part 2: Why AVs rewire car insurance from the ground up

For essentially the entire history of the automobile, insurance has been built around one core fact that humans make mistakes, and those mistakes are what insurers are pricing. Underwriting looks at the driver’s age, record, location, even credit score, because the driver is the primary source of risk. Claims get resolved by figuring out who was at fault, usually through police reports and eyewitness accounts.

Autonomous driving breaks that model at the root, because it removes the thing the whole system was built to price, which is human judgment behind the wheel. When software is making the driving decisions, responsibility for a crash starts shifting away from the person in the seat and toward whoever built the system, the automaker, the software developer, the sensor supplier, whoever wrote the code that made the call.

That’s a shift from personal tort law toward product liability, and it changes who buys insurance, what kind of insurance they buy, and how claims get investigated in the first place. A dispute over an AV collision increasingly turns into a forensic exercise, pulling sensor logs, camera footage, and software decision trails to figure out whether a piece of hardware failed, the software misjudged a scenario, or something else entirely happened. That’s a fundamentally different (and more expensive) process than reading a police report.

As this plays out, industry projections suggest the personal auto insurance market, historically the dominant chunk of the P&C insurance pie, could shrink substantially over a multi-decade horizon, with those premium dollars migrating toward commercial fleet policies, product liability coverage for automakers and software companies, and new categories like cyber-risk coverage for connected vehicle fleets. That’s a real structural drag for traditional personal-lines insurers. It is not, on its own, a drag for Copart, but it sets up the more interesting dynamic underneath it.

Frequency goes down, severity goes up, but they don’t cancel out.

Here’s the part that’s genuinely counterintuitive, safety technology is very good at preventing crashes, but it doesn’t make the crashes that still happen any cheaper, in fact, it usually makes them more expensive.

Features like automatic emergency braking and lane-keeping assistance are estimated to cut crash frequency meaningfully, on the order of high single digits to mid-teens percentage reductions for the specific coverages they affect, and full autonomous fleets should reduce it further still by removing distraction, fatigue, and impairment from the equation entirely. That’s real and it’s good news for road safety.

But think about where the sensors that make this possible actually live on the car, bumpers, side mirrors, windshields, grilles, exactly the parts of the vehicle most likely to get clipped in a minor fender-bender or parking mishap. Twenty years ago, that kind of minor damage meant popping off a plastic bumper cover and bolting on a new one. Today, it often means replacing a radar unit or camera module and then running a specialized recalibration procedure that requires certified technicians, proprietary software, and equipment most independent body shops don’t have. A relatively trivial bump can now trigger a repair bill that would have been unthinkable for equivalent damage a decade ago.

So you end up with two forces moving in opposite directions, fewer accidents, but each one that does happen costs more to fix. And critically, they don’t cancel out cleanly, because the cost side is compounding faster than the frequency side is shrinking, at least so far.

Laid out side by side, the divergence looks like this:

Part 3: The total loss math, and why it keeps climbing

Insurers don’t decide to total a car out of sentiment, it’s a straightforward economic threshold. If the estimated cost to repair a vehicle (plus related costs like a rental car during the repair) exceeds what the vehicle was worth before the crash, minus whatever the insurer can recover by selling the wreck for salvage, the math says total it out, not fix it.

That threshold has been moving steadily in one direction for decades, and the reason is that cars have gotten dramatically more complex. A vehicle from 1980 had essentially no onboard computing. A modern vehicle can carry well over a thousand microprocessors. Every one of those systems adds cost when it’s damaged and needs replacing or recalibrating. The result shows up directly in the data, total loss frequency, the share of insurance claims that end in a total loss not a repair, has climbed steadily for four decades, with sensor calibration now showing up in over a quarter of all collision repair estimates.

That’s not a projection, 1980 through today is observed history, which is part of why the near-term thesis in this report rests on a firm ground.

There’s also a friction point worth calling out, many automakers restrict independent repair shops from accessing the diagnostic tools and calibration software needed to fix modern sensor suites, funneling that work toward authorized dealer networks. Less competition on the repair side tends to mean higher repair estimates, which pushes more borderline cases over the total-loss threshold. This is a real dynamic today and, depending on how right-to-repair regulation evolves, could either intensify or ease over the coming years.

Put simply, the more sophisticated the sensor and compute hardware on a vehicle, the more likely a modest collision is to total it out. As AV-capable hardware becomes standard equipment, this dynamic should intensify, with total loss frequency across the industry plausibly climbing from today’s ~23% toward the low-to-mid 30s by the mid-2030s under the assumptions used here, and higher still, perhaps 40-50%, specifically for the subset of crashes involving AV-equipped vehicles, given how much more hardware they’re carrying.

Part 4: What this actually means for Copart

Copart processes something on the order of 40% of North American salvage vehicle auction volume, and its financial engine is really just two numbers multiplied together, how many total-loss vehicles flow into its lots, and what they sell for once they get there, and AVs affect both.

First, the drag that’s easy to see coming. As AVs and driver-assist systems reduce the number of crashes on the road, the raw pool of candidate vehicles entering the insurance claims pipeline shrinks. Fewer accidents, all else equal, means fewer cars for Copart to eventually process.

Second, the catalyst that offsets it, at least for a long while. As covered above, the vehicles that do crash are increasingly likely to be declared total losses rather than repaired, because of how expensive their sensor and compute hardware is to fix. So even as the number of accidents falls, a rising share of those accidents feed the salvage pipeline not the repair pipeline. For a meaningful stretch of time, plausibly the next five to ten years, while the roads are still dominated by a mix of older human-driven cars and increasingly tech-laden newer ones, this rising total-loss rate can offset, or even more than offset, the decline in raw crash counts. That’s a genuinely counterintuitive but reasonably well-supported near-term conclusion, crash frequency and Copart’s volume don’t have to move in the same direction.

Third, a quality and pricing effect that’s easy to overlook. Because higher repair costs push vehicles into salvage earlier in their lives, a two-year-old car with a damaged sensor suite may get totaled where a two-year-old car with a dented bumper wouldn’t have been, the vehicles landing at Copart’s auctions skew newer and more mechanically intact than the salvage inventory of twenty years ago. Better vehicles draw more competitive bidding, particularly from international buyers who operate in markets with lower labor costs and looser regulatory restrictions on rebuilding damaged cars. Higher average selling prices translate directly into higher fee revenue per vehicle for Copart, since its business model is largely built around auction and processing fees tied to sale value.

This international buyer demand is a real and currently active part of Copart’s model, it’s also a dependency worth flagging, it relies on continued cross-border demand and trade conditions that could shift with tariffs, regulation, or currency dynamics in ways this report doesn’t attempt to forecast.

Collision volume and total loss frequency cross paths somewhere in the 2030s under these assumptions, fewer crashes, but a bigger share of them worth more to Copart when they happen.

There’s a longer-horizon structural point too. As autonomous fleets scale, robotaxi networks, autonomous freight, vehicle ownership consolidates away from millions of individual retail owners toward large enterprise fleet operators. Those operators need serious physical infrastructure to store, stage, and process vehicles that are retired, damaged, or being decommissioned at the end of a duty cycle.

Copart owns north of 21,000 acres of real estate, much of it in locations near major metro areas that would be very difficult for a new entrant to replicate given zoning and permitting realities. That land footprint, combined with a strong balance sheet, positions Copart as a plausible long-term infrastructure partner for fleet operators managing large numbers of vehicles at scale, though it’s worth noting this is a strategic opportunity Copart would need to actively capture through contracts and relationships, not something that accrues automatically.

Part 5: A decade, roughly sketched out

Trying to pin exact numbers to exact years is a mug’s game this far out, but it’s useful to sketch the shape of the transition year by year to see where the crossover points plausibly sit. Please treat everything below as illustrative of a trend not an accurate forecast to bank on.

• 2026 - the record baseline. Fleet mix roughly 95% legacy, ~5% active AV/L2+. TLF sits at 23.1%, an industry record, with sensor calibration required on over 28% of estimates. Copart’s yards run near-maximum utilization on the back of high collision counts from legacy drivers hitting newer, sensor-heavy cars.

• 2027 - mass-market L2+ expansion. Fleet mix ~89–91% legacy. Hands-free features go standard on mid-tier consumer cars; perimeter damage on those cars becomes cost-prohibitive to repair, accelerating inflow of lightly damaged, 2-to-4-year-old vehicles and pushing ASPs higher.

• 2028 - the volume “sweet spot.” Fleet mix ~84–86% legacy. Absolute crash volume falls only modestly (roughly -2% to -4%) since legacy cars still dominate miles driven, while TLF climbs over 200 basis points versus 2025 — high volume multiplied by a meaningfully higher total-loss rate.

• 2029 - OEM diagnostic lockouts accelerate salvage. Fleet mix ~80–82% legacy. Automakers increasingly restrict independent shops from calibration software; repair estimates surge, pushing more borderline claims into salvage, with international buyers bidding aggressively for the resulting inventory.

• 2030 - the robotaxi and enterprise-fleet onset. Fleet mix ~76–81% legacy (new-sales penetration reaches ~50%). Commercial robotaxi networks expand across dozens of metro centers; Copart’s real estate footprint starts converting into direct enterprise staging and salvage contracts.

• 2031 - ASP expansion offsets the first real crash-volume dip. Fleet mix ~71–76% legacy. Global collisions decline a more noticeable 12–15% below the 2025 baseline, but revenue per vehicle rises as auction inventory skews newer and richer in salvageable hardware.

• 2032 - Level 3 “eyes-off” total losses spike. Fleet mix ~66–71% legacy. L3 conditional sedans reach the secondary market in real numbers; replacing dual-redundant steering, braking compute, and central processors after a highway collision pushes total-loss rates for crash-involved L3 vehicles above 30%.

• 2033 - peak international salvage arbitrage. Fleet mix ~61–66% legacy. Developing-market demand for lightly damaged, tech-rich 2026–2030 model-year vehicles is at its strongest, reinforcing high recovery values and the economic logic of totaling rather than repairing.

• 2034 - transition toward enterprise asset management. Fleet mix ~56–61% legacy. Absolute crash frequency is down roughly 25% from 2025, but Copart’s per-unit margins rise through EV battery handling, AV component harvesting, and fleet decommissioning services.

• 2035 - high-margin infrastructure hub. Fleet mix ~52–58% legacy (new-sales penetration near 94%). Over one in three claims now ends in a total loss. Copart’s role shifts from pure salvage auctioneer toward a broader staging, storage, and recycling infrastructure hub for the commercial AV fleet economy.

The broad pattern, the next five to eight years look like a genuinely favorable environment for Copart’s volume and pricing simultaneously. Past that point, the balance gradually shifts from “more volume” to “better economics on less volume” which is a very different growth story.

Part 6: The pivot after 2035, from growth engine to infrastructure utility

If the 2026–2035 stretch is characterized by strong, arguably double-digit-capable earnings growth driven by rising total loss rates and improving vehicle quality, the period beyond that looks structurally different.

By the 2040s and beyond, under these assumptions, connected-vehicle networks and mature autonomous fleets could reduce total crash counts by half or more relative to today’s baseline. Even with total loss frequency staying elevated on a per-crash basis, the absolute number of vehicles flowing into the salvage system would eventually plateau or decline, simply because there are fewer crashes overall to draw from.

The offsetting factor in this later period is about fleet lifecycle management, commercial robotaxi and freight fleets run high-mileage duty cycles and get retired or decommissioned on a schedule, independent of whether they ever crash. That creates a different, steadier revenue stream tied to enterprise fleet turnover, battery recycling, and component harvesting. It’s a lower-growth, higher-margin, more utility-like business model, plausible, but it also depends on Copart successfully building out those enterprise relationships and specialized capabilities (high-voltage EV handling, fleet contracts) well ahead of when it needs them, which is an execution risk.

Part 7: The assumptions this whole analysis rests on

Since the conclusions here are only as good as the inputs, it’s worth listing the core assumptions plainly:

1. Fleet turnover and scrappage. Light vehicles last roughly 12–15 years in high-income markets, 18–22+ years in developing ones. New “legacy” (non-automated) vehicle production is assumed to fall from roughly 70 million units a year today to under 15 million by 2035 and under 1 million by 2050, while global scrappage and total-loss retirement removes 80–90 million vehicles a year, so the legacy fleet contracts steadily (from ~1.44 billion vehicles in 2025 toward under 50 million by 2060) even though it stays large for a surprisingly long time.

2. Total-loss threshold economics vs. repair labor. Repair cost for damaged AV/ADAS hardware is assumed to keep growing faster than a vehicle’s pre-accident value, consistent with the trajectory already observed from 4% (1980) to 23.1% (today). That pushes crash-involved AV total-loss rates toward the 40–50% range over time, even as absolute crash counts fall.

3. Secondary export-market arbitrage. Developed-market insurers are assumed to keep totaling lightly damaged, technology-dense vehicles because domestic repair labor is expensive; developing-market buyers are assumed to keep importing and rebuilding them at lower cost, which is what keeps Copart’s global auction prices supported.

4. Sensor cost deflation vs. hardware parity. LiDAR and sensor-suite costs are assumed to keep falling sharply (down roughly 65% between 2020 and 2025 already), reaching rough parity with traditional powertrain budgets around 2030–2032, the assumption that unlocks mass-market AV deployment.

5. Bifurcated regulatory and infrastructure speed. Frontrunner markets (US, China, Germany, UAE) are assumed to reach high L3/L4 new-sales penetration by 2038–2042; many developing markets are assumed to lag until 2048–2055 on infrastructure and regulatory grounds.

6. Global production bounds. Global light-vehicle manufacturing is assumed to hold in the 85–100 million unit per year range, with no assumed permanent bottleneck in semiconductor or sensor supply chains.

Part 8: Where this thesis could break, the case for skepticism

AV timelines could slip further than assumed. The industry’s track record on self-driving timelines has consistently run behind schedule. If L3/L4 adoption lags the curve used here by five or ten years, the near-term “total loss catalyst” story still probably holds (it depends more on L2+ sensor proliferation), but the later-decade transition to a fleet-management business model would also push out correspondingly, which isn’t necessarily bad for Copart but does compress the confidence of any specific-year projection.

Frequency reduction could outpace severity increases sooner than modeled. This report assumes total loss frequency gains continue offsetting crash frequency declines through the early 2030s. If safety technology matures faster than repair-cost inflation, or if repair costs come down (say, if right-to-repair regulation forces OEMs to open up calibration access, or if standardized sensor modules become cheaper and easier to replace), that crossover could arrive earlier, putting real pressure on Copart’s volumes sooner than this timeline suggests.

Insurance industry consolidation and self-insurance among fleet operators is a genuine wildcard. If large AV fleet operators (automakers, tech companies, ride-hail platforms) increasingly self-insure or vertically integrate their own salvage and remarketing operations rather than routing through independent auction platforms like Copart, that would undercut the “essential infrastructure partner” thesis regardless of how total loss rates trend.

International arbitrage demand isn’t guaranteed to persist. Copart’s pricing power depends significantly on strong overseas buyer demand for damaged vehicles. Trade policy shifts, tariffs, currency swings, or the same technology trends eventually reaching developing markets (making complex AV hardware harder to profitably rebuild anywhere) could all soften this dynamic.

Competitive dynamics matter. This report focuses on Copart in isolation, but its main competitor (IAA/RBA, now under Ritchie Bros.) faces the same industry catalysts and drags. Market share shifts between the major salvage platforms aren’t addressed here and could matter as much to Copart specifically as the industry-wide trends.

These are model outputs, not observed facts. Every percentage in the timeline tables is a projection built on the assumptions in Part 7, not a measured outcome. Treat the specific numbers as directional signals about the shape of the transition.

None of this reverses the core logic, the mechanical relationship between rising vehicle complexity and rising total loss frequency is well-supported by data already observed through 2025–2026, not just projected. But the further out the timeline goes, the more these uncertainties compound, and the 2040s-and-beyond picture should be held much more loosely than the 2026–2030 picture.

So, existential threat, or not?

Over the next decade, the data points to a positive impact on Copart. Rising total loss frequency (climbing from today’s record 23.1% toward the high-20s/low-30s by 2035) and improving vehicle quality at auction are on track to outweigh the gradual decline in raw accident counts. That’s a fairly well-supported near-term read, resting on a trend that’s already observed rather than purely projected.

In the long term, the data points to accident volumes diminishing sharply, potentially by half or more from today’s baseline by the 2040s and beyond, as connected-vehicle networks and mature autonomous fleets take hold. At that scale of decline, even a much higher total-loss rate per crash isn’t enough to sustain Copart’s current accident-salvage model on its own.

That means the long-term conclusion isn’t “Copart is fine”. It’s that Copart has to actively change what kind of business it is to stay viable. Leaning into enterprise fleet decommissioning, battery and component recycling, and infrastructure/logistics services built on its land and balance sheet, instead of continuing to ride pure accident-salvage volume. And even then, the fundamentals of that model will be uncertain, there’s no clear line of sight yet on how big that business ends up being, what growth rate it can sustain, or what margin profile it carries.

Executive Summary

Alphabet is still widely understood as a search advertising company. For most of the last decade, that was a fair description, but it’s no longer true.

Over the last five years, the company built a second real profit engine in Google Cloud, which moved from a $3.1 billion annual operating loss in 2021 to a $13.9 billion profit in 2025.

Crucially, the core business isn’t slowing down to make room for this growth, nor is AI killing it off. Search revenue grew 13.2% in 2025. Even better, paid clicks went up 6% while cost-per-click rose 7%. When both metrics move up together, it proves AI Overviews are creating more monetizable searches and are not killing off traditional clicks.

Three core drivers explain this transition:

Distribution: Google still owns the gateways to the internet. It holds over 85% of global search market share, sits on more than 3 billion active Android devices, and controls over 65% of browser usage via Chrome. That reach becomes even more powerful as user behavior moves from simple search boxes to AI assistants.

In-house silicon: By designing its own TPUs instead of relying solely on expensive, off-the-shelf GPUs, Google drives down its internal compute costs faster than competitors relying on market rates. That structural cost advantage compounds as inference costs fall across the industry.

Cloud margin expansion: Google Cloud’s operating margin swung from -16.1% in 2021 to 23.7% in 2025. On top of that, its contracted backlog has more than doubled since late 2025. That shows enterprise clients are actually spending real money on these AI tools.

Still, there are two real risks here, whether AI search tools eventually steal actual market share from Google, and whether the massive AI capex, on track for $175 to $185 billion in 2026, will actually yield an acceptable return on capital anytime soon. Both will be covered in detail in the report. But weighed against what the business has actually delivered over the last five years, I’d call it Approved; a two-decade-old moat that’s come out more profitable, from every platform shift thrown at it, now running a second engine underneath it that didn’t exist five years ago.

The author does not hold a position in Alphabet, Inc. at the time of publication. This report reflects the author’s personal views and is not investment advice. Investing carries the risk of permanent capital loss. Read full disclosure here.

1. The Business

What it Does

Whether you search for something online, open YouTube, or pull up directions on your phone, Alphabet is almost always somewhere in that loop, and getting paid for it. At its core, the company is an ad machine sitting on top of daily utility products like Search, YouTube, Maps, Gmail, Chrome, and Play. Advertisers pay to show up where attention already goes, and Alphabet takes a cut off the top.

Beyond advertising, Google Cloud rents out compute, storage, and AI capacity to companies that don’t want to build their own data centers. Then there’s Other Bets, a collection of moonshots funded by the core business’s cash flow. Waymo is the biggest and most visible, but the bucket also holds Verily (life sciences), Calico (longevity research), Wing (drone delivery), and venture arms like GV and CapitalG.

Underneath almost all of this sits Gemini, Alphabet’s AI model family, powered by their custom chips. Gemini flows through their consumer lineup, including AI Overviews in Search, the standalone app, and features across Docs and Gmail. It is also what Google Cloud sells to business clients.

Running this at global scale only works because Alphabet uses its own silicon. Their Tensor Processing Units run AI workloads far cheaper than the standard Nvidia GPUs most competitors buy or rent.

How the Company Makes Money

The ad business runs on an auction system. Advertisers bid for placements across Search, YouTube, and millions of third-party sites in the Google Network. Alphabet gets paid when someone clicks a performance ad or views a brand ad. From that revenue, it pays distribution partners and site publishers a fee called traffic acquisition costs. Whatever stays in the account after those payouts is Alphabet’s net take.

Outside of advertising, Google Services brings in recurring subscription revenue through YouTube Premium, YouTube Music, YouTube TV, and Google One. It also takes a cut of app sales and in-app transactions on Google Play, alongside direct hardware sales from Pixel devices.

Google Cloud operates under a different financial model entirely: clients pay consumption-based usage fees for infrastructure and AI services, monthly subscriptions for Google Workspace, and direct purchase fees for TPU hardware systems sold to companies that prefer owning their infrastructure outright.

Scale and Footprint

Alphabet generated $402.8 billion in revenue in fiscal 2025. The US accounts for roughly half of total sales, followed by EMEA at 28–30%, APAC at 16–17%, and the remainder across non-US Americas. Headcount stood at roughly 191,000 employees at year-end 2025.

Powering this operation is a vast physical backbone. Technical infrastructure and data centers totaled $246.6 billion on the balance sheet at the end of 2025, built out to handle Search, YouTube, and AI model training at global scale. Alphabet has now deployed seven generations of custom TPU chips across this network, keeping its compute stack tailored specifically for AI workloads.

Governance also matters for long-term holders. Alphabet uses a dual-class voting structure established at its 2004 IPO: Class A shares carry one vote per share, Class C shares carry no votes, and Class B shares carry ten votes per share. Because Larry Page and Sergey Brin hold almost all the Class B shares, they retain majority voting control over the company regardless of their actual economic stake.

2. The Moat

Alphabet’s position rests on four interconnected advantages; default distribution, a massive data feedback loop, custom chip economics, and enterprise cloud stickiness.

1. Default Distribution

Google owns the main entry points to the web. Between revenue-sharing deals, 3+ billion active Android devices, and Chrome holding over 65% browser market share, Alphabet controls default search placement on most devices. As search shifts toward conversational AI, controlling the underlying OS and default browser gives Alphabet the strongest defensive position in the market.

2. The Data Feedback Loop

That distribution fuels a massive data loop. Google processes trillions of searches a year with over 85% market share. Each query provides commercial intent signals that refine ad pricing and search relevance. That scale flows straight into their AI models: the Gemini 3 family handles over 22 billion tokens per minute across developer APIs, while the standalone Gemini app has passed 750 million monthly active users. Newer AI labs cannot match that volume of real human interaction data through synthetic data or research alone.

3. Custom Compute Economics

Controlling the full stack lowers Alphabet’s AI costs. Running workloads on custom TPUs rather than relying strictly on Nvidia GPUs keeps their cost per unit of compute below market rates. Selling these TPU systems directly to enterprise clients shows that their proprietary hardware competes head-to-head with standard market chips.

4. Enterprise Cloud Stickiness

Google Cloud combines standard enterprise switching cost, like data migration and workflow setup, with AI ecosystem lock-in. Once a company builds applications on specific models and hardware architectures, changing providers becomes expensive and messy. Google Cloud remains smaller than AWS and Azure, but it continues to grow faster than both.

Evidence of the Moat

The financial numbers back this up. Google Services expanded its operating margin from 38.7% to 40.4% between 2021 and 2025, even as the segment matured and Alphabet invested heavily in AI development.

Google Cloud offers an even clearer proof point, showing a moat being built in real time. The segment swung from a $3.1 billion operating loss in 2021 to a $13.9 billion profit in 2025, marking a $17 billion turnaround in four years.

Competitive Landscape

Alphabet operates across four primary competitive arenas, each defined by distinct market dynamics. In digital advertising, the company faces strong competition from Meta, Amazon, retail media networks, and connected TV platforms; however, none match Google’s combination of commercial intent data and native platform distribution. In cloud computing, Google Cloud functions within a three-horse market alongside Amazon Web Services and Microsoft Azure where, despite remaining the smallest of the three in absolute dollar terms, it continues to capture market share by outgrowing the broader industry. Within frontier AI models, Google DeepMind navigates a rapidly shifting landscape alongside OpenAI, Anthropic, and Meta, standing out by pairing its model research directly with proprietary hardware infrastructure and immediate global distribution. Finally, in autonomous mobility, Waymo competes against Tesla, Zoox, and Cruise, maintaining a clear lead in actual driverless commercial miles while testing its sensor-heavy hardware architecture against Tesla’s vision-only approach.

The key takeaway is structural. Very few companies own proprietary distribution, custom compute silicon, and a top-tier AI lab simultaneously. Replicating that full-stack position requires decades of capital and scale.

The Inference Cost Curve, and Why It Favors Alphabet

An underappreciated structural trend working in Alphabet’s AI strategy is the dramatic drop in model execution costs. Inference prices, defined as the compute cost required to generate a response, have collapsed faster than historical chip cost curves.

In 2021 and 2022, output matching GPT 3 performance cost roughly $20 per million tokens. By late 2024, an equivalent small model cost as little as $0.07 per million tokens, representing a 280x reduction in under two years. Frontier models followed the same path. GPT 4 class output launched at $30 to $60 per million tokens in early 2023. By 2025 and 2026, models at or above that capability level priced between $0.50 and $5.00 per million tokens.

Falling model costs impact Alphabet in several concrete ways.

First, it eliminates what was Search’s biggest threat two years ago; the compute expense of AI answers. Generative responses cost far more than traditional indexed queries. Had inference costs not collapsed, rolling out AI Overviews across trillions of searches annually would have squeezed Search margins.

Second, cheaper inference expands the Cloud market instead of shrinking it. As compute gets cheaper, enterprises run significantly more of it, the classic rebound effect known as Jevons paradox. This dynamic explains why Google Cloud’s API volume and contracted backlog continue to accelerate.

Third, In-house TPUs bypass third-party chip markups, letting Alphabet’s internal cost per token fall faster than market rates. That gives them room to price Cloud aggressively while maintaining margins that GPU-dependent competitors can’t match.

Finally, lower unit costs allow Alphabet to bundle Gemini features into existing Workspace subscriptions at negligible incremental cost, while offloading routine processing directly to Pixel phones via Gemini Nano to cut cloud compute expenses entirely. Falling AI costs hurt companies that merely resell third-party compute, but they reinforce companies that own the entire stack.

3. Financial Performance

Revenue Growth

Alphabet expanded revenue from $257.6 billion in 2021 to $402.8 billion in 2025, compounding at roughly 12% annually. That trajectory included a noticeable dip and recovery. Growth slowed to 9.8% in 2022 and 8.7% in 2023 during an ad market slowdown, before picking back up to 13.9% in 2024 and 15.1% in 2025 as Google Cloud and AI features gained momentum.

After crossing $400 billion for the full year in 2025, top-line growth accelerated further in Q2 2026, reaching $119.8 billion (up 24.2% year over year). That marked Alphabet’s twelfth straight quarter of double-digit revenue growth.

The segment breakdown highlights where that top-line expansion originated. Google Cloud compounded at roughly 32% annually from 2021 through 2025. Google Subscriptions, platforms, and devices grew at nearly 15% annually over the same stretch, while Google Search remained the largest revenue driver, compounding at roughly 11%.

Google Network, covering third-party site and app advertising, was the sole line item to shrink in absolute terms. After peaking in 2022, Network revenue dropped each subsequent year as ad spend shifted toward Alphabet’s owned-and-operated properties.

Sub-Segment Detail: Google Services

Google Search remains the anchor of the overall business, generating $224.5 billion in FY2025, or 55.7% of consolidated revenue, up from $149.0 billion (57.8%) in FY2021. Growth slowed to 9.1% in 2022 during an advertiser pull-back against tough pandemic comparisons, before accelerating to 13.2% in both 2024 and 2025 as commercial queries rebounded and monetization of AI Overviews and Circle to Search kicked in. Search revenue reached $63.3 billion in Q2 2026, up 16.8% year over year, offering clear evidence that generative search features expand total search activity without cannibalizing ad inventory.

YouTube advertising grew from $28.8 billion in 2021 to $40.4 billion in 2025. Growth flattened to 1.4% in 2022 amid competition from TikTok and broader market weakness, before rebounding as Shorts monetization scaled and direct-response formats matured. YouTube ad revenue grew 11.7% in 2025 and hit $11.1 billion in Q2 2026 (up 12.9% year over year), supported by connected-TV viewing and live sports. Including subscription revenue across Premium, Music, and TV, the broader YouTube property reached an annualized run rate above $60 billion by late 2025.

Google Network, covering ads placed on third-party sites via AdSense and Ad Manager, is the one segment experiencing a steady decline. Revenue dropped from a peak of $32.8 billion in 2022 to $29.8 billion in 2025, reaching $7.3 billion in Q2 2026, where growth was essentially flat year over year. Its share of total revenue fell from 12.3% in 2021 to 7.4% in 2025. This reflects industry-wide shifts like third-party cookie deprecation and ad dollars moving to retail media and owned platforms.

Subscriptions, platforms, and devices, including YouTube paid tiers, Google One, Play Store fees, and Pixel hardware, remains the fastest-growing line inside Google Services. Revenue grew from $28.0 billion in 2021 to $48.0 billion in 2025 (up 19.1% in 2025 alone) and hit $12.9 billion in Q2 2026. Paid subscriptions across YouTube and Google One passed 325 million at year-end 2025 and reached roughly 350 million in Q1 2026. This recurring revenue stream addresses long-standing concerns around total reliance on advertising cycles.

Sub-Segment Detail: Google Cloud

Google Cloud grew from $19.2 billion in 2021 to $58.7 billion in 2025, lifting its share of total revenue from 7.5% to 14.6%. Top-line growth in Cloud continues to gain momentum. Revenue accelerated to $24.8 billion in Q2 2026, up 81.8% year over year, pushing the segment to 20.7% of Alphabet’s quarterly revenue.

Growth was driven across custom TPU v6 (Trillium) clusters, Nvidia GPU capacity, Gemini Enterprise API adoption, and Workspace AI add-ons. Contracted backlog, representing unearned revenue under contract, nearly doubled from roughly $242.8 billion at the end of 2025 to over $460 billion in early 2026, reaching $514 billion by the end of Q2. That expansion shows long-term enterprise commitments actively converting into recognized revenue.

Sub-Segment Detail: Other Bets

Other Bets, which includes Waymo, Verily, Calico, Wing, and Alphabet’s venture arms, grew from $753 million in 2021 to a peak of $1.65 billion in 2024, before edging down to $1.54 billion in 2025. The segment generated $382 million in Q2 2026. Revenue comes primarily from Waymo ride-hailing fares and Verily health research deals. This section currently acts as a drag on overall cash flow. While these ventures could become meaningful income sources in the future, significant contribution remains unlikely in the near term.

Profitability

Consolidated operating margin rose from 30.5% in 2021 to 32.0% in 2025. Margins bottomed at 26.5% in 2022 during the broader tech slowdown before rebounding as Alphabet slowed hiring, cut costs, and gained operating leverage in its growth segments, reaching 34.0% in Q2 2026.

That overall number masks much stronger profitability at the segment level. Google Services expanded its operating margin from 38.7% to 40.4% over the period. The primary driver of consolidated margin expansion was Google Cloud, which swung from an operating loss of $3.1 billion (-16.1% margin) in 2021 to an operating profit of $13.9 billion (23.7% margin) in 2025, expanding further to 35.6% in Q2 2026.

Consolidated margins grew slower than both individual segments due to unallocated corporate expenses. Unallocated costs, driven primarily by central AI research for Gemini along with legal fines and corporate overhead, increased from $4.8 billion in 2021 to $15.8 billion in 2025, reaching $5.8 billion in Q2 2026 alone.

Google Cloud went from a $3.1 billion operating loss in 2021 to $8.8 billion in operating profit in Q2 2026 alone, with margins reaching 35.6%. That shift reflects how quickly earnings compound once cloud infrastructure utilization passes its fixed-cost base. Other Bets presents the opposite dynamic, posting cumulative operating losses of roughly $27.4 billion from FY2021 through FY2025. This includes a $7.5 billion loss in 2025, which contained a $2.1 billion stock-based compensation charge related to Waymo equity units.

Net income increased from $76.0 billion in 2021 to $132.2 billion in 2025, with diluted EPS rising from $5.61 to $10.81 (an ~18% CAGR), supported by share repurchases that reduced diluted share count from 13.55 billion to 12.23 billion. However, FY2025 net income includes approximately $24 billion in unrealized gains on equity investments, primarily Alphabet’s stake in SpaceX. Excluding these non-recurring gains provides a clearer baseline, with adjusted EPS growing from $4.87 to $9.16 over the period, representing a ~17% compound annual rate.

Free Cash Flow

Free cash flow grew from $67.0 billion in 2021 to $73.3 billion in 2025, compounding at roughly 2% annually. This lags behind operating income (13% CAGR) and diluted EPS (18% CAGR) over the same timeframe.

This divergence stems from reinvestment instead of weakening cash generation. Operating cash flow grew from $91.7 billion to $164.7 billion over those four years, outpacing revenue growth. The gap reflects increased capital expenditure, which expanded from $24.6 billion in 2021 to $91.4 billion in 2025 to build data centers and TPU infrastructure ahead of expanding Cloud backlog demand. Consequently, capex absorbed 56% of operating cash flow in 2025, up from 27% in 2021, marking an intensive capital cycle.

Return on Invested Capital

ROIC declined from 35.5% in 2021 to 29.8% in 2025. That drop reflects a capital base expanding ahead of near-term operating income, as massive AI infrastructure investments hit the balance sheet prior to full monetization.

Despite compressed returns, profitability remains exceptionally strong. Even with the compressed return profile, Alphabet’s ROIC sits comfortably above its cost of capital.

Balance Sheet

Alphabet’s balance sheet has expanded, but leverage remains conservative. Total debt and lease obligations rose from $26.2 billion in 2021 to $59.3 billion in 2025, bringing debt-to-equity from 0.11 to 0.14. Cash, cash equivalents, and marketable securities fell slightly from $139.6 billion to $126.8 billion over the same period. Rather than accumulating idle cash, management directed capital back into data center investments, share repurchases, and dividends.

Debt issuance and asset expansion continued into 2026. Long-term debt reached roughly $77.5 billion by the end of Q2 2026, up from $46.5 billion at year-end 2025. Over the same stretch, net property and equipment grew from $246.6 billion to $281.0 billion, capturing the ongoing infrastructure buildout in real time.

Capital Expenditure

Capital expenditure is the primary variable underpinning free cash flow trends, ROIC, and overall risk profile. Viewing capex relative to revenue, provides a clearer picture of whether infrastructure investments are growing in line with top-line expansion or outpacing it.

Between 2021 and 2023, capex stayed within a narrow range of 9.6% to 11.1% of revenue. It broke out of that range in 2024 and 2025. Based on management’s 2026 guidance, capital intensity could approach the high 30s as a percentage of revenue, an unprecedented level for Alphabet. This reflects a structural increase in capital intensity: Alphabet is committing a significantly higher share of every incremental revenue dollar to infrastructure than it did historically.

The bulk of this outlay represents growth capital, land acquisition, data center construction, and custom TPU manufacturing capacity, backed by expanding Cloud backlog demand. Section 7 covers key metrics to monitor for signs of overbuild and evaluates potential outcomes if capital outlay stays ahead of revenue realization longer than anticipated.

4. Growth Levers & Addressable Market

A) Google Cloud and the Enterprise AI Buildout

Google Cloud’s transition from a distant third player to a peer alongside AWS and Azure represents its largest growth lever. With over 90% of Fortune 100 companies using Alphabet’s enterprise AI tools, near-term expansion relies primarily on increasing spend within existing accounts instead of acquiring new logos from scratch.

Monetization spans three product layers, each carrying a distinct margin profile:

Infrastructure Layer: Raw TPU and GPU compute consumption for training and running proprietary models.

Platform Layer (Vertex AI): Token- or query-based pricing for model fine-tuning, RAG pipelines, and agent workflows.

Application Layer (Workspace): Per-user monthly subscriptions for AI add-ons integrated into Docs, Sheets, Gmail, and Meet.

Offering all three tiers allows Alphabet to capture value across different enterprise consumption models without relying on a single pricing structure.

B) TPU Systems as a Standalone Product Line

Alphabet began selling TPU hardware systems directly to external enterprise customers in 2026, introducing a new revenue stream to its financial statements. This direct hardware sales model adds incremental revenue on top of the existing cloud-hosted rental offering. More importantly, selling systems externally validates that Alphabet’s custom silicon competes directly with merchant GPUs on price and performance, instead of serving solely as an internal cost-saving measure. If direct hardware sales scale at a pace similar to the TPU rental business, it becomes a meaningful, high-margin complement to Alphabet’s core Cloud business

C) Subscriptions, Platforms, and Devices

The non-advertising bundle represents the fastest-growing component inside Google Services. This includes YouTube paid tiers, Google One (which bundles access to Gemini models), Google Play, and Pixel hardware. The segment grew 71% between 2021 and 2025, expanding from $28.0 billion to $48.0 billion, more than doubling the growth rate of advertising over the same stretch. Its share of Google Services revenue rose from 11.8% to 14.0%, providing a sticky, recurring revenue stream that compounds faster than core ad inventory.

Growth across these product lines relies on leveraging existing distribution instead of building channels from scratch. For instance, Google One evolved from basic cloud storage into the main consumer gateway for premium Gemini access, while YouTube Premium and YouTube TV use live sports rights like NFL Sunday Ticket to drive initial subscriber acquisition across the broader ecosystem.

D) Search Query Expansion Through Generative Formats

A primary concern regarding AI Overviews and AI Mode was that synthesized answers would eliminate organic clicks and ad monetization. In practice, generative formats encourage longer, multi-step queries—such as planning complex travel itineraries or evaluating financing options—that traditional keyword search was not built to support. These longer prompts introduce new commercial touchpoints, embedding product comparisons, booking links, and sponsored recommendations directly within the generated response. This expansion in query complexity underpins Search’s 16.8% revenue growth in Q2 2026; user queries are becoming commercially richer.

E) Other Bets and the Waymo Option

Other Bets remains small in total top-line terms, generating $1.5 billion in 2025 revenue against $402.8 billion consolidated, and represents an ongoing cash draw, with operating losses widening from $4.1 billion to $7.5 billion over four years. Revenue roughly doubled over the same timeframe, driven primarily by Waymo’s expansion of commercial robotaxi operations across markets like Phoenix, San Francisco, Los Angeles, and Austin.

Waymo completes hundreds of thousands of paid weekly trips and leverages a partnership with Uber to access established dispatch demand without replicating ride-hailing distribution infrastructure. Private funding rounds value Waymo in the tens of billions of dollars, positioning Other Bets as a funded long-term option on autonomous mobility despite near-term operating drag and an unannounced path to profitability.

What the TAM Picture Tells Us

Alphabet’s core markets, digital advertising and public cloud infrastructure, remain massive and continue to grow at double-digit rates. Global digital ad spending grew from $375 to $400 billion in 2020 to an estimated $570 to $650 billion in 2025, with industry projections pointing to $1.2 to $1.5 trillion by 2031. Public cloud expanded even faster, rising from $310 to $350 billion in 2020 to roughly $1.29 trillion today, with forecasts reaching $2.28 trillion by 2030 or 2031. Adding consumer subscriptions and streaming (~$150 billion today expanding toward $350 billion) alongside autonomous mobility (~$15 billion today compounding above 30% annually toward $120+ billion), Alphabet’s combined addressable market exceeds $2 trillion today and could reach roughly double that over the next decade. While third-party market-size estimates carry inherent variance, even conservative figures indicate that a company generating $402.8 billion in revenue maintains substantial market runway.

5. Management

Leadership and Tenure

Sundar Pichai has led Google since 2015 and Alphabet since 2019, having joined the company in 2004 and advanced through leadership roles in Chrome and Android. His tenure spans three major technological transitions, mobile, cloud, and artificial intelligence, each of which expanded Alphabet’s addressable opportunities. Executive leadership transitioned in 2024 when long-time CFO Ruth Porat shifted to President and Chief Investment Officer, with Anat Ashkenazi stepping in as CFO to manage the current capital allocation and financing programs.

Skin in the Game

Co-founders Larry Page and Sergey Brin retain majority voting control through supervoting Class B shares while holding a smaller percentage of total equity. Established at the 2004 IPO, this dual-class ownership structure insulates executive management from short-term market fluctuations and activist pressure. While this voting power supports long-term infrastructure planning, it limits minority shareholder influence over major strategic initiatives, including capital expenditure targets.

Capital Allocation Track Record

Alphabet’s capital allocation strategy shifted meaningfully between 2024 and 2026. Share repurchases peaked at $62.2 billion in 2024 before scaling back to $45.7 billion in 2025, with no buybacks executed during the first half of 2026 as operating cash was reprioritized toward infrastructure development. Alongside share repurchases, Alphabet introduced a quarterly dividend in 2024 and increased it twice, bringing the payout to $0.22 per share quarterly.

To fund its expanded capital plan, Alphabet raised approximately $49.6 billion in external capital during Q2 2026 across debt, equity, preferred stock, and private placements. This active external financing marks a departure from a long-standing reliance on internal cash generation to fund growth, reflecting the massive capital requirements of the current AI infrastructure investment cycle.

6. Valuation

Growth Engines

The future return on Alphabet stock is a function of two engines; the future growth in free cash flow per share and any valuation re-rating. Both are explained below:

Engine 1: Fundamentals

The first engine is the business itself. FCF per share grows over time through revenue expansion, operating leverage, and share count reduction from buybacks. That growth, compounded annually, is what the fundamental engine delivers regardless of any valuation re-rating.

For Alphabet, I assume a FCF per share growth over the projection period, from the roughly 5% pace of the last four years toward something closer to the high teens, in line with normalized earnings growth. The primary driver is Google Cloud’s continued march toward Amazon Web Services and Microsoft Azure-level margins which are currently above 30%, still expanding from 23.7% today, compounding on top of the Search business that keeps growing revenue faster than click volume as monetization per click improves.

Margin recovery at the consolidated level is the second component of this growth rate; as the current AI infrastructure buildout matures and depreciation growth normalizes relative to revenue, operating leverage should reassert itself the way it already has inside Google Services and Cloud individually. Buybacks add a further per-share amplification effect once they resume at scale, diluted share count has already fallen from 13.55 billion to 12.23 billion over the past four years, even through a period where repurchases were curtailed to help fund the current capex program.

I also expect free cash flow conversion to improve as the current elevated capital expenditure cycle cools. The data center and TPU manufacturing buildout behind the 2025 and 2026 capex figures is a maturing, finite investment program built to capture a specific, already-contracted Cloud backlog, not a permanent step-up in the business’s capital intensity. As that backlog gets built out and capacity catches up with the demand behind it, capex should normalize back toward a lower share of revenue, and a larger share of operating cash flow should convert directly to free cash flow without a corresponding reinvestment offset, a tailwind to the fundamental engine on top of the growth rate assumption itself.

Engine 2: Valuation Re-Rating

At today’s price of approximately $355, the investor is paying for everything this business will earn over roughly the next 18 years, in today’s money. Everything it earns beyond that point comes to the investor at no additional cost. The fewer the embedded years, the more of the future the investor receives without paying for it.

At 18 embedded years, the price sits in the Attractive zone on my own valuation scale. This is a price still shaped by lingering doubts about whether generative AI erodes Search’s economics and how the current capital spending cycle plays out, both of which I addressed in the Financial Performance and Risks sections.

At 18 embedded years, I believe both engines are working in the investor’s favor here; a genuinely growing free cash flow base compounding through Cloud’s margin inflection and Search’s continued monetization gains, and a valuation that still has room to re-rate.

Hold, Add, and Exit Logic

This framework isn’t a mechanical buy-and-sell signal, it’s a way of thinking about price relative to value. In the Deep Value and Attractive zones, the price is working in the investor’s favor, more future cash flow is embedded per dollar paid than the market typically offers for a business of this quality. The Neutral zone reflects fair valuation, whereas the Stretched and Exorbitant zones embed high optimism with little to no margin for error. My own approach is to sell when a position moves into Stretched or exorbitant territory and reallocate to names sitting in the Deep Value or Attractive zones elsewhere in the portfolio; holding an expensive position when an attractive alternative exists is an opportunity cost that compounds against you.

7. Risks

AI-Native Search Disruption

This represents the primary risk facing Alphabet and receives the greatest market attention. If conversational AI interfaces replace traditional search faster than Alphabet’s own AI offerings capture the transition, both query volume and unit query value across its largest, highest-margin segment risk erosion. Beyond demand, a fundamental cost dynamic exists: traditional keyword queries rely on indexed database lookups—low-cost and fast—whereas generative answers require real-time neural network inference across large language models, carrying higher compute and electricity costs per query. If AI-format ad monetization fails to keep pace with the higher compute expense required to serve these queries, Search margins face structural compression even if overall query volume remains stable.

There are two potential trajectories for Search monetization from here. In the primary scenario, AI Overviews and conversational formats serve as a richer front end to the auction-based ad model, where complex queries unlock additional commercial touchpoints and Search continues compounding in line with recent trends. In the alternative scenario, users transition to standalone AI assistants outside Google’s ecosystem, compressing both query volume and per-query monetization.

Historical disclosures support the first outcome. While paid click growth decelerated from a post-pandemic peak of 23% in 2021 to single digits annually, Search revenue continued to compound at 10% to 15% per year over the same period. This disconnect demonstrates that revenue growth has decoupled from raw click volume, driven instead by rising cost-per-click and improved monetization efficiency through ad tech enhancements like Performance Max. This shift reflects an expansion in query quality and value capture rather than a maturing market.

Antitrust and Regulatory Overhang

Alphabet faces substantial ongoing regulatory pressure across multiple jurisdictions. In Europe, the company has paid or accrued billions of dollars in fines covering Android, AdSense for Search, and AdTech self-preferencing. In the US, Alphabet remains subject to Search antitrust remedies currently under appeal, alongside a pending Department of Justice AdTech lawsuit where proposed remedies include the divestiture of publisher ad-server and supply-side exchange assets (Google Ad Manager and AdX). Company disclosures indicate a forced divestiture could materially impact Google Network, a third-party advertising segment that is already contracting organically. Additionally, the EU’s Digital Markets Act and Digital Services Act enforce operational constraints, including user data combination restrictions and self-preferencing bans in search results, that increase compliance overhead and limit product integration flexibility.

None of the regulatory matters resolved to date have altered Alphabet’s underlying competitive moats. Historical settlements and rulings have resulted in financial penalties, mandated data-sharing provisions, and adjustments to distribution agreements, shifting from exclusive default placements toward user-choice frameworks, without impairing the core ability to monetize distribution networks, infrastructure, or platform ecosystem stickiness.

However, the multi-year sequence of adverse or partially adverse regulatory outcomes across global jurisdictions warrants monitoring. The pending decision regarding US AdTech remedies is particularly material, as a potential structural divestiture could impact Google Network’s economic model in a manner distinct from previously settled cases.

Whether the AI Capital Expenditure Pays Off

This risk links all core investment variables together, functioning primarily as a question of capital timing; whether $175 billion to $185 billion in projected 2026 capex, partially funded via external capital, can generate returns before depreciation schedules and financing expenses accumulate.

This capital deployment trajectory breaks down into three potential scenarios:

Extended Return Compression (Primary Scenario): Data centers and compute hardware depreciate over short timeframes, whereas enterprise software monetization typically requires five to seven years to reach scale. If physical infrastructure expansion outpaces revenue conversion, consolidated margins experience temporary pressure while core profitability remains intact.

Standard Timeline Alignment: Cloud contracted backlogs convert into recurring revenue at current paces, declining inference costs drive API adoption, and infrastructure generates returns above cost of capital without extended margin drag.

Overcapacity Misallocation (Low-Probability Scenario): Infrastructure is deployed significantly ahead of end-market demand. Unlike speculative past infrastructure cycles, current capex is backed by existing revenue expansion, including 82% Cloud revenue growth, expanded subscription tiers, and continued Search compounding.

What tips the outcome one way or the other comes down to three variables:

• Monetization lag: the industry-wide gap between how fast hyperscalers are building infrastructure and how fast enterprises are actually paying for AI software seats.

• Hardware depreciation pace: AI accelerator chips turn over roughly every 12 to 18 months, which could force faster write-downs on what’s being built today.

• Power and grid constraints: rising electricity costs and grid bottlenecks raise the ongoing cost of running these clusters, on top of the upfront capital.

Alphabet retains specific structural mitigations against these pressures. Unutilized compute capacity can be redirected internally toward Search ranking, YouTube recommendations, Waymo driving models, and DeepMind research. In addition, proprietary custom silicon (Trillium TPUs) maintains lower compute costs per unit compared to purchasing merchant GPUs at supplier markups.

To manage physical power constraints, Alphabet has secured over 240 clean energy contracts representing nearly 35 gigawatts globally, signed long-term power agreements covering nuclear (Kairos Power) and geothermal energy (Fervo Energy), acquired Intersect Power for $4.75 billion to co-locate power generation directly with data centers, and maintained dual-sourcing across custom TPUs and Nvidia GPUs. Consequently, temporary margin compression from overinvestment represents a manageable cost, whereas underinvesting risks ceding market position in Cloud and AI-native Search to better-capitalized competitors.

8. Thesis Breakers

Primary operational and structural metrics indicating potential thesis invalidation break down across four core categories:

Search and Advertising Key risks include traffic acquisition costs growing meaningfully faster than Google Advertising revenue, a signal that Alphabet is overpaying to preserve default distribution as organic user preference weakens. Additionally, cost-per-click or click-through rates on AI Overviews falling noticeably below traditional search formats would indicate that synthesized answers fulfill user intent without driving monetizable ad interactions. Finally, Search revenue decelerating into low single digits alongside continued market share gains by alternative search tools like ChatGPT Search or Perplexity would point to structural user migration rather than initial experimentation.

Cloud and AI Infrastructure For the Cloud segment, a thesis breaker includes a sequential contraction in contracted backlog, reversing the steady expansion trajectory built through 2025 and 2026. Furthermore, Google Cloud’s operating margin retreating back toward single digits or low teens after reaching the mid-30s would signal a competitive price war eroding segment profitability. Lastly, a decline in developer API usage from current baselines would indicate enterprise workloads actively migrating to alternative foundation model platforms.

Capital Efficiency Capital efficiency metrics to watch center on free cash flow turning negative, or capital expenditures consistently consuming more than 70% to 80% of operating cash flow for consecutive quarters. A scenario where depreciation and amortization grow faster than total revenue over an extended period would indicate that underlying physical infrastructure is aging or becoming obsolete faster than software-layer monetization can offset it. Finally, a sustained, multi-quarter decline in consolidated ROIC beyond expected near-term compression would signal inefficient capital deployment.

Distribution and Regulation On the distribution and regulatory front, a key trigger would be a material loss in Chrome or Android market share to competing web browsers, operating systems, or emerging AI-native hardware form factors. Structurally, a final judicial ruling mandating a breakup of Google’s adtech ecosystem, or prohibiting core distribution agreements that secure Google as the default search provider without an effective operational alternative, would directly impair monetization reach.

The author does not hold a position in Alphabet, Inc. at the time of publication. This report reflects the author’s personal views and is not investment advice. Investing carries the risk of permanent capital loss. Read full disclosure here.

Adobe is, on almost every conventional measure, one of the better businesses in software. It carries gross margins near 90 percent, converts more than 40 cents of every revenue dollar into free cash flow, has grown revenue every year for well over a decade, and sits on top of a Creative Cloud franchise that remains the default toolset for professional creative work worldwide.

The stock has also pulled back meaningfully over the past several years, and on a simple extrapolation of its own five-year free cash flow growth rate, Adobe screens as genuinely cheap today relative to almost anything comparable in software. Judged purely on the business Adobe has been for the last decade, and the price it trades at today, this looks like an easy buy.

The stock has been beaten down, and the headlines since have mostly been arguments about what that beating down means. One camp reads it as noise; the moat described later in this report, the workflow lock in, the indemnification, the installed base, is strong enough to absorb whatever generative AI throws at Adobe, seat contraction included, and the business that comes out the other side looks close enough to the business that went in. The other camp reads it as signal; that generative AI does something structurally different to Adobe than any prior disruption, that the story effectively ends here, and that the Adobe of the next five years does not resemble the Adobe of the last five no matter how strong today’s moat looks on paper. I am not writing this from inside either camp. I am examining both claims against the actual disclosure available and trying to arrive at a rational conclusion; whether this is a clear buy, a clear pass, or something genuinely too uncertain to call.

The author does not hold a position in Adobe, Inc. at the time of publication. This report reflects the author’s personal views and is not investment advice. Investing carries the risk of permanent capital loss. Read full disclosure here.

1. The Business

What it Does

Adobe builds the software stack that creative, marketing and document heavy work runs on: Creative Cloud Pro (Photoshop, Illustrator, Premiere Pro, After Effects, Lightroom, Substance 3D), Acrobat and Acrobat Studio for document productivity, Adobe Express for quick turn content, and Adobe Experience Platform and GenStudio for enterprise marketing execution.

Generative AI is delivered primarily through Adobe’s own Firefly family of models, but Firefly is not the only option inside Adobe’s apps. Within Photoshop, the Firefly app and a growing number of other surfaces, customers can also choose from an expanding roster of third party partner models built by other AI labs, generating and editing content without ever leaving Adobe’s interface.

Firefly itself is sold both embedded inside subscriptions and standalone through the Firefly app, Firefly Services and Firefly Foundry. In November 2025 the company agreed to acquire Semrush, a brand visibility and SEO platform, for approximately $1.9 billion in cash. The deal closed in the first half of fiscal 2026 and was already contributing roughly $480 million of ARR by the second quarter.

How the Company Makes Money

Revenue is overwhelmingly subscription based, 96 percent of fiscal 2025 revenue, recognized ratably over contract terms that typically run one to thirty six months. Historically this has meant per seat licensing. An individual, a team, an enterprise buys access for a named user, and that is the whole model.

Creative Cloud and Firefly plans now bundle a fixed monthly allotment of generative credits on top of that. Those credits get consumed whether the customer generates output with Firefly or with one of the partner models available inside the same application. Adobe collects a toll either way. I think that is an important nuance, and I come back to it in the Moat section, because it means Adobe monetizes usage of its competitors’ models as well as its own, distinct from Firefly Services, the separate enterprise API business it sells directly for automated content generation at scale.

Management has begun disclosing an AI first ARR line separately from the legacy subscription base. The company says it tripled year over year to exceed $500 million as of the second quarter of fiscal 2026. That is real growth. It is also worth sizing against a roughly $27 billion total ARR base. Still a small fraction of the whole. Not yet a second engine.

Segments and Reporting

Fiscal 2025 was reported across three segments. Digital Media did $17.65 billion in revenue, up 11 percent. Digital Experience did $5.86 billion, up 9 percent. The legacy Publishing and Advertising business did $256 million, down 7 percent, and took a $70 million non cash goodwill impairment in the second quarter of fiscal 2026.

In the first and second quarters of fiscal 2026 Adobe introduced a new categorization, Business Professionals and Consumers, or BPC, to group knowledge-worker-facing tools like Acrobat AI Assistant and Adobe Express together for internal tracking and go to market purposes. I think that reclustering is worth watching in its own right, since it looks like the lens management is using to think about the casual, lower switching cost side of its customer base discussed in the Moat section.

Scale and Footprint

Adobe employed 31,360 people at the end of fiscal 2025, roughly split evenly between the United States and international locations, with large development centers in Bangalore and Noida, India. The company operates a hybrid work model and reported 9.9 percent total attrition for the year. Corporate headquarters remain in San Jose, California.

2. The Moat

I see Adobe’s moat resting on three pillars discussed as follows:

1. The Interface and Workflow Moat

Commercial creative production runs on local canvas control, layer based non destructive editing, timeline orchestration and plugin ecosystems that a single prompt to image or prompt to video model does not replicate on its own. An agency producing a client deliverable needs to take a rough concept through revisions, client feedback, color correction and final packaging as a layered, editable file that another editor can pick up months later, not a flattened image generated in one shot.

Photoshop’s layer stack, Premiere Pro’s timeline and multi camera workflow, and Illustrator’s vector editing model are specific, learned skill sets that an entire generation of working designers, video editors and illustrators trained on, and that agencies and in house creative teams have built their production pipelines, file formats and quality control processes around. Ripping out that stack in favor of a cheaper or even a better performing standalone generative model means retraining staff, rebuilding pipelines and renegotiating client delivery formats, a cost that sits on top of and separate from whatever the new tool itself costs.

This is also where Adobe’s decision to plug competing AI models directly into its own interface matters more than it might first appear. Adobe does not force customers to choose only Firefly. Within several of its applications, customers can select from Adobe’s own Firefly models alongside an expanding roster of third party partner models, generating and editing inside the same Photoshop, Premiere or Firefly app canvas regardless of which underlying model actually produced the output.

That is a genuinely different competitive posture than most software incumbents facing a foundation model threat have taken. Rather than treating outside models purely as competition to be out built, Adobe is positioning its own interface as the neutral surface where any model’s output gets refined, layered and delivered into a finished, brand safe asset.

If a customer’s favorite generative model changes next year, or a new lab releases something better, Adobe’s bet is that the customer stays inside Adobe’s canvas and simply points it at a different model, rather than leaving Adobe altogether. I think this meaningfully lowers the risk that a single superior foundation model from OpenAI, Google or another lab pulls creative professionals away from Adobe wholesale, though it does mean Adobe is also giving up some of the pricing power it might otherwise have captured if Firefly were the only option inside its own apps.

There is a second, more literal kind of lock in sitting underneath the interface argument, the file format itself. A .psd file with fifty layers, built up over years of campaign work. A .ai vector file with a full history of edits. A .prproj timeline with linked media, color grades and multi camera sync.

These are not portable formats. An agency that needs to revise a client’s three year old campaign asset cannot open that history in a text to image prompt tool. It has to open it in Photoshop, or Illustrator, or Premiere, because that is the only software that reads the file the way it was built. Ripping Adobe out means either abandoning that historical asset library or paying to convert terabytes of legacy project files into something a different tool can read, and I think that cost is separate from, and in some ways harder to shake than, the muscle memory argument above.

2. Commercially Safe Data and IP Indemnification

Firefly is trained on Adobe Stock’s licensed library and public domain content, which allows Adobe to offer enterprise customers intellectual property indemnification on Firefly generated output through certain enterprise and teams plans. For a Fortune 500 marketing or legal department, that indemnification is frequently the deciding factor in whether generative AI can be used in a public facing campaign at all. A chief marketing officer who greenlights the use of an ungoverned or scraped data model in an ad campaign is personally exposed if that campaign later becomes the subject of a copyright claim, and general counsel at large enterprises have become considerably more conservative about this exposure as litigation against several open source and general purpose foundation model providers continues to work through the courts. Adobe’s indemnification effectively transfers that legal risk away from the customer’s own legal department.

3. Ecosystem and Enterprise Lock In

Creative Cloud bundling, GenStudio’s bridge between creative production and marketing execution, Adobe Stock’s asset library, and now Semrush’s SEO and content visibility layer alongside the newly launched Adobe LLM Optimizer, aimed at brand visibility inside AI powered search, all extend the surface area a customer has to walk away from simultaneously in order to leave.

A large installed base of professionals trained specifically on Adobe’s tools, a certification and training ecosystem built around those tools, and a network of systems integrators and agencies whose own businesses are built around implementing Adobe products, all reinforce the switching cost independent of any single product’s own merits. This is the pillar I think is most exposed to erosion at the margin, and I want to spend a moment on where that erosion is actually most likely to show up.

There is also a layer of lock in that has nothing to do with what individual designers prefer, it cuts against the seat contraction argument in a way worth weighing. Large enterprises do not buy Adobe seat by seat. They buy through Enterprise Term License Agreements, administered centrally through the Adobe Admin Console, with unified billing and security compliance built around SAML and single sign on. An individual designer who would rather use a lightweight, standalone AI tool for a specific task still has to get that tool past the same IT department that negotiated the Adobe ETLA and does not want to manage security review, billing and access control for a dozen fragmented, unvetted AI startups on top of it.

I think this means Adobe’s enterprise revenue base is protected by procurement and IT inertia for longer than a pure count of how many designers still prefer Adobe’s tools would suggest, and it is worth weighing against the seat contraction risk in the Outlook section. It does not eliminate that risk. A large enough shift in how much output a given number of seats can produce still shows up eventually, admin console or not. But it probably slows how fast it shows up, and slower is a meaningfully different risk than fast.

Where the Moat Is Weakest: Casual Users Versus Professional and Institutional Clients

Not every Adobe customer faces the same switching cost, and I think it matters to separate the two customer groups Adobe itself now reports around. Business Professionals and Consumers, the audience for Acrobat and Adobe Express, are disproportionately casual users; A small business owner creating social graphics. A student annotating a PDF. An individual using Acrobat Sign to sign a document occasionally. These users have comparatively little invested in any particular tool’s specific workflow, often started on a free or low cost tier in the first place, and face a wide field of genuinely adequate free or near free alternatives, Canva chief among them, alongside a growing set of AI native tools that can produce a passable social graphic or summarize a document without touching an Adobe product at all.

I think this segment is the one most exposed to outright substitution the moment a free or materially cheaper alternative reaches good enough quality, because the switching cost for a casual user is close to zero. There is no institutional workflow to rebuild, no client delivery format to renegotiate, no certification to retrain.

Creative and Marketing Professionals, the audience for Creative Cloud’s flagship apps and for GenStudio, sit at the opposite end of that spectrum. These are institutional customers with production pipelines built around specific file formats, brand governance requirements, indemnification needs and, often, multi year enterprise agreements.

A professional colorist, video editor or brand design team is not making a casual, one off purchase decision the way a consumer choosing between a free app and a five dollar app is. I think this is precisely why Adobe’s enterprise and professional revenue has proven far stickier than a simple read of consumer software competition would suggest.

Competitive Landscape

Adobe’s competitive set spans several distinct fronts, and I think it matters to sort them the same way I sorted Adobe’s own customer base above, because the threat each poses is different depending on which side of that line it sits on.

On the casual and prosumer side, Canva remains the clearest threat; a free or low cost, browser based tool that has never required any of the workflow investment Creative Cloud demands, and one that is increasingly credible even for small business and social content use cases that used to default to Photoshop or Express.

Canva’s ownership of Affinity extends that reach to one time purchase, no subscription creative tools aimed at freelancers and hobbyists who specifically want to avoid a recurring fee, a positioning that speaks directly to the price sensitive, low switching cost segment I flagged in the Moat section.

A number of the foundation model native tools, particularly consumer facing image generators like Midjourney and the free or low cost tiers of OpenAI’s and Google’s own generative products, compete on this same casual end today; a hobbyist or social media manager generating a one off image has essentially no reason to open Photoshop first.

On the professional and institutional side, the picture looks different. Figma is the clearest example; despite sitting in the same broad design category as Illustrator, Figma competes almost entirely for institutional product design and UI/UX teams inside enterprises, not casual users, and it remains independent after the terminated 2023 merger agreement, for which Adobe paid a $1 billion termination fee in fiscal 2024.

HubSpot, Ahrefs and other marketing and SEO point solutions competing with the newly acquired Semrush are similarly business tools sold into marketing departments. And the same foundation model labs competing casually through consumer apps, OpenAI and Google chief among them, are simultaneously building enterprise API and licensing businesses aimed at the exact large, brand governed customers Adobe’s indemnification pitch is built to hold onto, meaning they are pushing upmarket on the professional front at the same time they compete downmarket on the casual one.

No single competitor matches Adobe’s combination of workflow depth, enterprise indemnification and installed base on the professional and institutional side, which is where I think Adobe’s moat is genuinely strongest. But the casual side is where the credible fronts have multiplied fastest, and the number of fronts Adobe has to defend simultaneously across both ends of that spectrum has grown over the past years.

3. Financial Performance

There is not much to relitigate about the historical numbers, and I do not want to spend this report doing so. The five year record is, on its face, impressive; revenue compounded from $12.87 billion in fiscal 2020 to $23.77 billion in fiscal 2025, gross margin held near 90% throughout, net income grew to $7.13 billion in fiscal 2025, up 28% Y-O-Y, and free cash flow reached $9.85 billion, a margin above 40%. Diluted EPS grew from $10.83 to $16.70 over the same window, helped by a buyback program that cut the diluted share count from 485 million to roughly 402 million. ROIC improved from about 20% to nearly 25% across the period. None of this is in dispute, and none of it is really what this report is about.

The point of this report is not to re confirm a clean historical trend. It is to stress test whether the next several years look anything like the last five, and I do not think they do. Generative AI changes the relationship between headcount, seats and output in a way that has no precedent in Adobe’s own history, which means extrapolating the trailing growth rate forward is exactly the wrong instinct here. The rest of this report, particularly the Outlook section, is my attempt to explain why.

4. Management

A Leadership Transition That Lands at the Wrong Moment

Shantanu Narayen announced on March 12, 2026 that he intends to step down as CEO once a successor is named, after eighteen years in the role, and will remain as Chair of the Board once that transition completes. As of this writing, no successor has been named. A special committee led by Frank Calderoni, Adobe’s Lead Independent Director, is running the search across both internal candidates, David Wadhwani, President of the Creativity and Productivity Business, is widely described as the likely internal front runner, with Anil Chakravarthy, President of the Customer Experience Orchestration Business, also mentioned, and external candidates, reportedly including AI first leaders from outside the company. Narayen remains CEO today, meaning Adobe is running an open ended succession process in parallel with everything else in this report.

Layered on top of that, CFO Dan Durn departed abruptly on June 15, 2026 for Marvell Technology, where he had already served as a board member prior to his departure. Steve Day, a twenty year Adobe finance veteran and SVP of Corporate Finance, was installed as interim CFO effective the same day and reports directly to the CEO. As of this writing Day remains interim, with no permanent CFO named.

Capital Allocation

The Board’s $25 billion repurchase authorization runs through March 2028, and Adobe spent $11.28 billion of it in fiscal 2025 alone, a pace that would exhaust the remaining authority well before the deadline if sustained. Stock based compensation was $1.94 billion in fiscal 2025 with $3.24 billion unrecognized over a 2.19 year weighted average period, meaning a real share of the buyback program is offsetting dilution from the compensation program.

Outstanding senior notes rose from $5.65 billion to $6.15 billion at par during fiscal 2025, and Adobe entered interest rate swaps converting a portion of that fixed rate debt to floating. Buybacks at this pace are increasingly assisted by debt issuance and are not funded purely out of free cash flow. None of this is alarming on its own for a company generating the free cash flow Adobe generates, but it does mean the EPS growth discussed in the Financial Performance section is not purely an organic story.

5. Outlook

This is the section I would ask a reader to actually sit with, because the standard way to model a name like this, grow revenue at a steady mid to high single digit rate, hold margins roughly flat, assumes a stability in Adobe’s unit of monetization that I do not think currently exists.

I want to walk through the scenario tree as I actually see it, with the pros, cons and genuine uncertainty left in.

Start with what I would call the seat problem. Generative tools compress the historical link between headcount and creative output. An agency or in house marketing team using Firefly, partner models, GenStudio and Acrobat AI Assistant can plausibly produce the same volume of images, video and documents with fewer entry level designers and production staff than it needed two or three years ago.

If that holds at scale across Adobe’s own customer base, the number of paid seats a given enterprise needs could shrink over time, and Adobe’s own AI is one of the tools accelerating that shrinkage inside its own installed base, which is the uncomfortable part.

Management’s stated answer is Generative Credits; monetize the same customer on compute consumed rather than headcount employed. In principle this could work. If seat count contracts while credit consumption expands to fill the gap, Adobe could hold or even grow revenue per customer even as the seat count itself falls. This is what the AI first ARR line is meant to capture, and it has tripled year over year to exceed $500 million as of the second quarter of fiscal 2026. That is genuine growth. It is also still roughly 2 percent of total ARR, nowhere near the scale that would need to be reached to offset outright legacy seat attrition if that attrition turns out to be significant.

Then there is what I would call the Value Deflation problem. The cost of AI inference, the compute behind every generated image, video or document, keeps falling as models get more efficient and the underlying hardware gets cheaper. In isolation, that is good for Adobe’s margin on the credits it sells. But Adobe does not set AI pricing in a vacuum. It competes for the same wallet against Canva, Affinity and a wide field of open source and API native tools facing the identical falling cost curve, most of which have far less legacy subscription revenue to protect and are correspondingly more willing to pass the savings straight through as lower prices.

If Adobe holds its credit pricing while competitors cut theirs, it risks losing the consumption dollars elsewhere. If Adobe cuts its own pricing to stay competitive, the consumption revenue that was supposed to backfill the lost seat revenue shrinks in dollar terms even as usage volume climbs. Either path could land Adobe back close to where the seat problem started; a shrinking seat base sitting on top of a consumption layer that is not growing in dollars fast enough to cover the gap. I want to be clear this is one plausible path among several, not a certainty, but it is exactly the kind of two sided cost dynamic that makes me unwilling to model consumption revenue with real confidence in either direction.

There is a cleaner sounding fix that gets raised in the market; price on the outcome the software helps produce, campaign performance or engagement or conversion, not on seats or raw compute. I do not think this actually resolves the problem. Isolating how much of a marketing outcome came from Adobe’s tools versus the client’s own creative strategy, media spend and brand equity is not something either side can cleanly measure, and a pricing model built on a number neither party can verify tends not to survive real contract negotiation.

Even setting that aside, outcome based revenue would track the marketing success of Adobe’s customers not Adobe’s own execution, meaning Adobe’s reported revenue would start moving with the ad campaigns, budgets and business cycles of thousands of unrelated companies rather than anything Adobe directly controls. That is a source of revenue volatility I do not think the market currently prices into a stock that has traded for years on smooth, highly predictable subscription revenue, and I would expect Wall Street to penalize the loss of that predictability.

My own guess, and I want to flag it as exactly that, a guess, is that if Adobe moves in this direction at all, it lands on some hybrid of a smaller fixed subscription floor plus a variable consumption or outcome layer on top, not a full jump to either pure metering or pure outcome based pricing. But I do not know, and I do not think Adobe’s own management knows yet either, what that split would look like; whether the variable piece ends up larger or smaller than today’s subscription base, how procurement departments used to fixed software budgets react to a variable line item, or what the resulting mix does to the ARR growth rate the market has spent years underwriting.

It could turn out that the consumption and outcome layers together add up to more revenue per customer than the seats they replace, in which case this entire risk resolves favorably and this report will have been too cautious. It could just as easily turn out smaller. I do not think this is resolvable from outside the company with the disclosure currently available, and I would treat anyone who claims to know with confidence which way it breaks as guessing dressed up as analysis.

There is also a regulatory constraint sitting on top of all of this that I think is easy to overlook. The Department of Justice filed a civil complaint against Adobe in June 2024 alleging violations of the Restore Online Shoppers’ Confidence Act, tied specifically to how Adobe discloses subscription terms and how easy or difficult it makes cancellation. Adobe’s motion to dismiss was denied in May 2025, and the case remains in discovery.

I raise it here because it lands directly on top of the pricing question this section is about. Whatever hybrid of fixed subscription and variable consumption or outcome based pricing Adobe eventually settles on will itself have to be disclosed and unwound in a way that satisfies the same regulatory standard currently being litigated, and a company under active scrutiny for how clearly it presents subscription terms and cancellation mechanics has less room to experiment with a more complex, harder to explain pricing structure than one operating without that overhang.

6. Valuation

Running the standard two engine framework, fundamental free cash flow per share compounding plus any change in the valuation the market assigns, on Adobe’s own trailing record, the stock screens as undervalued today. Free cash flow per share grew from roughly $10.94 in fiscal 2020 to $23.07 in fiscal 2025, a compound rate in the mid teens, funded partly by real cash flow growth and partly by the buyback program that cut the diluted share count from 485 million to about 402 million over the same period. At a price near $225, against that trailing growth rate and a business still generating a free cash flow margin above 40 percent, a straightforward extrapolation of the last five years forward would put Adobe in objectively cheap territory relative to its own history and against most software peers on a growth adjusted basis.

I do not think that extrapolation is the one to trust, and that is the entire reason I am not willing to call this attractive. The free cash flow growth rate I would need to extrapolate assumes the monetization model of the last five years, a largely fixed, predictable per seat subscription engine, carries forward roughly intact. Everything in the Outlook section above is about why I do not think that assumption is safe to make right now. If the seat base holds up and Generative Credits genuinely add revenue on top rather than merely replacing what seats used to generate, Adobe at today’s price is probably attractive, and by a meaningful margin.

If seat contraction runs ahead of credit monetization, or credit pricing gets competed down before it scales, the growth rate that makes today’s price look cheap simply does not materialize, and the market’s current valuation could turn out entirely appropriate, or the market could still be too generous even now.

7. The Verdict

This is not a business I think is broken today. Revenue, ARR, margins and free cash flow all look like a company executing well against the model it has run for years, and the moat around its existing seat base, workflow depth and IP indemnification remains genuinely strong.

My verdict is Pass, because too much of the next five years rests on questions this report cannot answer with the disclosure currently available; whether generative AI nets out to a shrinking or expanding revenue base per customer, whether whatever pricing model emerges from that shift is one the market will reward with anything close to today’s valuation, and who will actually be running the company and its finance organization by the time those decisions get made. I would rather pass on a name I cannot underwrite with real confidence than force a valuation call on top of the unknowns I have just spent this report laying out.

I do not think this resolves quickly. A pricing model transition of this scale, layered on top of an open ended leadership search, is the kind of thing that plays out over years. Consequently, I choose to remain on the sidelines until the company delivers consistent positive net seat expansion alongside a stabilized, predictable pricing framework under stable leadership.

The author does not hold a position in Adobe, Inc. at the time of publication. This report reflects the author’s personal views and is not investment advice. Investing carries the risk of permanent capital loss. Read full disclosure here.

Tractor Supply is the largest rural lifestyle retailer in the United States, built on a needs based model that has produced 30+ consecutive years of revenue growth. The business is not glamorous. It sells livestock feed, fencing, work boots, and pet food to recreational farmers, ranchers, and rural homeowners, and it has done this with a discipline that has compounded steadily for three decades.

The stock has fallen by roughly half from its 2025 peak, while the business grew its revenue base explosively during the pandemic, held onto nearly all of that gain once demand normalized, and is now absorbing the cost of continued store growth against a slower, more ordinary sales backdrop. I believe the market is currently pricing this normalization as if it were deterioration.

At a Glance

Company: Tractor Supply Company

Ticker: $TSCO, NASDAQ

Sector: Consumer Discretionary

Industry: Rural Lifestyle & Specialty Retail

Status: Approved

Valuation Zone: Attractive (17 embedded years, at approximately $29.4)

The author does not hold a position in Tractor Supply Company at the time of publication. This report reflects the author’s personal views and is not investment advice. Investing carries the risk of permanent capital loss. Read full disclosure here.

1. The Business

What it Does

Tractor Supply sells the products that support what the company calls the “Out Here” lifestyle: livestock and equine feed, fencing, seasonal and recreational goods, truck and tool hardware, work clothing, and companion animal products.

It operates under two banners, Tractor Supply Company and Petsense by Tractor Supply, and it owns an online pet pharmacy, Allivet, acquired in December 2024, and a veterinary services business, VIP Petcare, acquired in May 2026.

At the end of fiscal 2025, the Company operated 2,602 retail stores in 49 states, 2,395 under the Tractor Supply banner and 207 Petsense locations, supported by 10 distribution centers with a combined 7.8 million square feet of capacity.

How the Company Makes Money

Tractor Supply is a straightforward merchandise retailer. Revenue comes from in store and online sales across five major product categories. In fiscal 2025, Livestock, Equine & Agriculture represented 27% of net sales, Companion Animal 24%, Seasonal & Recreation 24%, Truck, Tool & Hardware 15%, and Clothing, Gift & Décor 10%. No single product accounted for more than 10% of sales in fiscal 2025, and the Company sources from over 1,100 vendors, with no single vendor representing more than 10% of purchases. Owned brands and exclusive product categories made up approximately 30% of total sales in fiscal 2025, a mix I believe supports margin meaningfully relative to a pure national brand assortment.

History and Origin

Founded in 1938, Tractor Supply has operated for more than 85 years. The Company has grown from 2,105 stores at the end of fiscal 2020 to 2,602 stores at the end of fiscal 2025, a five year net addition of nearly 500 locations, while sustaining a five year net sales compound annual growth rate of approximately 7.9%.

Scale and Footprint

Tractor Supply stores typically range from 15,000 to 20,000 square feet of inside selling space, supplemented by outdoor “Side Lot” or Garden Center space. The Company leases approximately 97% of its stores, with roughly 61% in freestanding buildings and 39% in shopping centers. Approximately 81% of Tractor Supply store merchandise flows through the Company’s own distribution network, which I view as central to in stock consistency and freight efficiency. A new distribution center in Nampa, Idaho, the Company’s 11th, is under construction and expected to begin operations in the fourth quarter of 2026, adding approximately 865,000 square feet of capacity to serve the Pacific Northwest.

2. The Moat

I believe Tractor Supply’s moat rests on three pillars:

1. Geographic Isolation, or Efficient Scale

Tractor Supply deliberately avoids dense metropolitan areas. It builds stores in small towns and rural communities, markets that are often underserved by large national retailers and cannot support a full size Home Depot, Lowe’s, or Walmart. A market too small to justify a big box competitor’s investment is a market Tractor Supply can occupy and effectively monopolize at a much smaller store footprint and a much lower capital cost. Once a Tractor Supply store is established as the dependable supplier in one of these towns, it becomes the default destination for that entire trade area, and a national retailer has little economic incentive to build a second, larger store to contest a position that strong.

This geographic position creates a genuine convenience moat on top of the economic one. For a hobby farmer living 40 miles outside a major city, a 10 minute drive to the local Tractor Supply for a replacement tractor belt is far more practical than an hour’s drive to a metropolitan home center.

2. From “Bring Your Own Truck” to a Controlled Delivery Network

Historically, Tractor Supply’s delivery model placed the burden on the customer. Its distribution network was built to move inventory from centralized distribution centers onto store shelves, not into a customer’s driveway, and a hobby farmer needing fencing, a trailer, or several hundred pounds of feed was expected to load it into their own vehicle. Where e-commerce did exist, the Company relied on traditional parcel carriers whose networks are optimized for small, light packages, an economically poor fit for heavy, bulky agricultural goods, especially down low-density rural roads. This was a real vulnerability, the exact seam a well capitalized e-commerce competitor could have exploited.

The Company has spent the past two years closing that seam, and I believe what it has built is now a genuine structural barrier. The Final Mile initiative is built around Tractor Supply’s own local hub network, drivers and inventory from different facilities brought together at dedicated hub locations for last-mile delivery to nearby customers. That network has scaled to approximately 375 hubs, giving the Company last-mile delivery capability across more than 1,200 stores and reaching over 15 million customers, alongside continued use of gig delivery partners like UPS’s Roadie to further lower cost per delivery. The economics are already proving out, with roughly $10 million a year in freight-related savings identified so far, a program that is close to funding its own continued expansion.

This matters because it directly defends the same vulnerability this moat pillar is built around. A pure e-commerce competitor shipping heavy, bulky goods through standard parcel networks faces a structurally worse cost position than a company delivering the same items from a store already sitting a few miles from the customer, using its own fleet and hub infrastructure rather than renting space on a network built for small packages. The gap between those two cost structures does not close as a competitor scales, it is a function of physical weight and distance. Tractor Supply is deliberately widening that gap further, with a stated ambition to handle up to 95% of large-item deliveries entirely in-house by the end of the decade.

The July 2026 Instacart partnership handles the other half of the problem, fast delivery for light, everyday items that do suit a standard parcel network, without diverting capital from the harder, more defensible problem. Together, this is a business that has identified its single greatest e-commerce vulnerability and is systematically converting it into an advantage instead, which I consider one of the more underappreciated developments in the Company’s recent strategy.

3. Deep Customer Intangibles and a Proprietary Ecosystem

Tractor Supply serves recreational farmers and rural landowners, and it has built real, hard to replicate intangibles around that specific customer. The Neighbor’s Club loyalty program captures more than 80% of total Company sales, giving management a data asset most retailers of this size do not have; a granular, store level view of what a specific rural household actually buys and when. Exclusive, in house private label brands make up roughly 30% of total revenue. A customer who has built a habit around 4health pet food or Producer’s Pride livestock feed cannot simply walk into a Rural King or a Walmart and buy the identical product; they have to change brands, not just change stores.

I believe this is a genuine proprietary ecosystem. Layered on top of this is a growing services ecosystem; VIP Petcare’s in store veterinary clinics, now brought fully in house, alongside Allivet’s pharmacy and expanding Garden Center formats. Each of these deepens the reason a customer drives to a physical Tractor Supply store rather than defaulting to whatever is cheapest or fastest online.

The Company deepens this ecosystem further by hiring locally, drawing its store teams from the same rural and exurban communities it serves, and this local hiring practice reinforces the moat in three distinct ways.

The first is genuine local knowledge; employees drawn from the surrounding area often share the exact hobbies and occupations as the customers walking through the door, and a team member who owns horses or maintains a hobby farm can give authentic, practical advice on specific livestock feed formulas, fencing types, or small tractor parts, an authoritative sales environment I do not believe a generic retail giant can easily replicate.

The second is community-led trust; in a small town market, shopping at a store staffed by recognizable neighbors, relatives, or a local high school sports coach creates a kind of brand equity that elevates Tractor Supply from a transactional storefront to a reliable community anchor, reinforcing the “dependable supplier” positioning this entire section describes.

The third is operational; employees who live within the town they work in generally have shorter commutes and report higher job satisfaction than long distance commuters, and hiring people already familiar with agricultural or rural living meaningfully lowers the time and cost required to train staff on complex, technical product categories. I view this local hiring model as a genuine extension of the trust this ecosystem depends on.

While standard big-box retailers often face significant customer churn, Tractor Supply’s Neighbor’s Club loyalty program shows some of the stronger retention figures the Company has disclosed. Approximately 75% of members remain active in the program year over year, and retention rises to over 90% among the Company’s highest-spending tier, the core hobby farmers and livestock owners purchasing premium feed and heavy equipment on a recurring basis. I believe this reflects the same needs-based purchasing pattern discussed elsewhere in this report; livestock feeding schedules and property maintenance needs recur on a fixed cycle regardless of season or sentiment, giving Tractor Supply’s most valuable customers a structural reason to keep returning that a discretionary or fashion-driven retailer does not have. This retention data is, in my view, the clearest proof that the ecosystem described above, loyalty, private label, services, and local hiring together, is functioning as intended.

Evidence of the Moat

The clearest evidence, in my view, is longevity and consistency; 30+ consecutive years of revenue growth, a five year net sales CAGR of approximately 7.9%, and a gross margin that has held in a narrow, gradually improving band, 35.4% to 36.4%, across a period that included a pandemic demand shock, a sharp normalization, tariff pressure, and an aggressive store expansion program. I do not believe a business without real pricing power and genuine customer stickiness holds gross margin steady through that sequence of shocks.

Moat Trajectory

I read the moat as being extended. The VIP Petcare acquisition brought an existing in store veterinary clinic network, already operating in 1,700 Tractor Supply locations as a retail partnership, in house alongside Allivet’s pharmacy and the Neighbor’s Club program. Management has described the combination as an end to end pet care offering spanning veterinary services and pharmacy, built in what the Company itself calls a capital efficient, asset light manner. I believe this is exactly the kind of adjacency expansion that deepens a needs based moat rather than diluting it, provided integration is executed well, a qualification I return to in the Risks section given how recent the acquisition is.

The Final Mile delivery buildout described in the second moat pillar is doing the same kind of work, extending the moat rather than merely defending it. As that network scales toward its stated goal of handling up to 95% of large-item deliveries in-house, I expect it to make the overall model stickier in two distinct ways.

First, a customer who receives a heavy, awkward item like fencing or a riding mower delivered directly, rather than having to haul it themselves, has a materially better experience than the “bring your own truck” model this Company operated under for decades, and I believe that improved satisfaction compounds into exactly the kind of retention already visible in the Neighbor’s Club data discussed above.

Second, and just as important, it raises the bar for anyone trying to compete with Tractor Supply on its own turf. A regional competitor without a comparable hub network cannot match this delivery experience without absorbing years of infrastructure investment first, and a national e-commerce competitor still faces the same structurally unfavorable shipping economics for heavy goods that this moat pillar describes, only now facing a Tractor Supply that has closed its own weakest point rather than left it exposed. I view this as the moat’s most active front of expansion, converting what was until recently a genuine vulnerability into a further reason for competitors to stay out.

Competitive Landscape

Tractor Supply’s competitive set spans several distinct categories rather than a single direct rival: regional farm and ranch chains (Rural King, Fleet Farm, Blain’s Farm & Fleet, Bomgaars, Atwoods), none of which are publicly traded or operate at comparable national scale; home improvement giants (Home Depot, Lowe’s, Menards) that overlap on tools, fencing, and lawn care but do not share Tractor Supply’s rural lifestyle focus or store format; pet specialty retailers and e-commerce (Chewy, PetSmart, Petco) that compete for companion animal spend; and mass merchants and Amazon competing on price and convenience for commodity items. I do not see a single competitor that matches Tractor Supply’s specific combination of rural geographic density, needs based product mix, and now in house veterinary services. The absence of a single dominant challenger across four decades is itself evidence, in my opinion, that this specific niche is harder to contest than it looks from the outside.

3. Financial Performance

The Revenue Story: Why the Base Year Matters

I want to lead with revenue, because I believe every other line in the income statement, all the way down to net margin and ROIC, only makes sense once the revenue story is understood correctly.

Comparable store sales exploded in 2020 and 2021. In 2020, comps grew 23.1%. In 2021, they grew another 16.9% on top of that. This was not ordinary retail execution. It was driven by urban to rural migration, a surge in pet adoption, and a wave of new hobby farming during a period when Americans were spending far more time and money at home. This two year stretch permanently raised Tractor Supply’s revenue base to a structurally higher level than it had ever operated at before.

Here is the table that tells the story:

Look at what happens after 2021. Every year from 2022 onward is being measured against a base that is already roughly 40% higher than it was in 2019, because that is the combined effect of the 2020 and 2021 spikes compounding on top of each other. When a retailer grows 23% and then 17% in consecutive years, the following years cannot simply repeat that pace. There is no natural mechanism for a rural farm and ranch retailer to grow another 20% on top of an already 40% higher base.

What I believe actually happened is this; Tractor Supply successfully defended the new, much larger revenue baseline it had won during the pandemic, rather than losing that baseline once the impulsive, one time demand for new chicken coops, new fencing, and new pets receded.

A flat or barely positive comp print in 2023 and 2024, against that elevated base, is a business holding onto nearly all of an extraordinary, one time gain in its customer base, and then adding a modest amount of further growth on top of an already much larger number. I consider this a genuine achievement, not a warning sign, even though at first glance a 0.0% comp print looks like stagnation.

How the Revenue Story Flows Through the Income Statement

Once the revenue base is understood this way, the rest of the story follows logically, line by line.

Gross margin has actually improved, from 35.42% in fiscal 2020 to 36.42% in fiscal 2025, a genuine gain of 100 basis points. It reflects two direct initiatives I believe deserve credit; the expansion of exclusive, higher margin private label brands, which bypass third party markups and now represent roughly 30% of total sales, and supply chain efficiencies from the Company’s growing distribution network, including lower ocean freight costs compared to pandemic era peaks. Cost of goods sold as a percentage of sales has fallen steadily across the last decade, from roughly 65.6% in 2015 to 63.6% in 2025. This is the part of the business that management directly controls, and it has executed well.

SG&A as a percentage of sales, however, has risen even faster, from approximately 22.0% in 2015 to 23.8% in 2025. This is where the revenue story becomes the cost story. A retail store carries largely fixed costs, rent, base staffing, utilities, management salaries, regardless of whether comparable sales grow 20% or 0% in a given year. During 2020 and 2021, the explosive comp growth diluted those fixed costs across a rapidly growing sales base, and it also helped fund the continued opening of new stores and the remodeling of existing ones through Project Fusion.

Once comps normalized to flat or barely positive from 2022 onward, that dilution effect disappeared, while the Company continued opening new stores and continued remodeling existing ones at a similar pace. New, unmatured stores carry higher SG&A as a percentage of their own sales until they reach the productivity of the mature chain average, and that drag has been compounding across roughly 490 net new stores over the past five years and 99 new stores in fiscal 2025 alone. Layered on top of that is straightforward wage inflation across the retail sector, which the Company has had to absorb to remain competitive for labor in rural markets.

Operating margin is where these two forces net out, and I want to state plainly what the data shows: gross margin expansion of roughly 100 basis points over five years has been more than offset by SG&A deleverage, and operating margin has compressed from a peak of 10.26% in fiscal 2021 to 9.45% in fiscal 2025. The gross margin wins were real. They were simply not large enough to absorb the fixed cost burden of continued store growth against a comp sales backdrop that, for entirely explainable reasons rooted in the 2020 and 2021 spike, is not growing fast enough yet to fully dilute that overhead.

Net income and ROIC are the final destination of this same story. Net income was effectively flat in fiscal 2025 at $1.096 billion versus $1.101 billion in fiscal 2024, with diluted EPS up modestly to $2.06 from $2.04, aided by share buybacks. ROIC, by my own methodology, net operating profit after tax divided by total assets less goodwill, accrued liabilities, and cash, has declined in each of the past four years: 19.5% in 2021, 18.1% in 2022, 16.7% in 2023, 15.3% in 2024, and 13.8% in 2025. Even after this compression from its pandemic era peak, ROIC remains well above the Company’s cost of capital, meaning every dollar of the elevated capital program discussed below is still being invested at a real, positive spread over what it costs the Company to raise that capital.

I believe this decline is the compounded effect of the exact same dynamic described above, continued capital deployed into new stores, remodels, and now distribution capacity and bolt on acquisitions, at a pace that has outrun the rate at which post pandemic comparable sales growth is expanding the earnings base.

My conclusion is that once comparable sales growth returns closer to the low single digit range, the same fixed cost base that is currently a drag becomes a source of leverage again, and I expect margins and ROIC to move back toward their historical range. This recovery is likely to be delayed, however, given the heavy capital expenditure and remodeling costs still working through the system, discussed in detail below.

Why Capital Expenditure Rose After 2020, and How That Flows Into ROIC

Capital expenditure as a percentage of revenue stepped up meaningfully starting in 2021, from roughly 3% of revenue in 2020 to a sustained 5% to 6% from 2021 through 2025. I believe four distinct initiatives explain this, and I want to walk through each one rather than treat elevated capex as an unexplained drag.

The first is Project Fusion, a multi year program to completely overhaul the interior layout of existing stores, reconfiguring floor plans, improving lighting, and optimizing space for higher margin goods. This is a real, ongoing capital commitment across a store base of more than 2,600 locations, not a one time expense.

The second is the Side Lot Garden Center expansion. Tractor Supply capitalized directly on the wave of Americans moving to rural areas during the pandemic by converting the exterior space of its stores into secure, climate sheltered outdoor structures for live plants, lawn goods, and garden equipment, now numbering approximately 700 locations. Building physical, localized infrastructure store by store is inherently capital intensive.

The third is supply chain infrastructure. The explosive sales volume growth of 2020 and 2021 exposed real bottlenecks in the Company’s fulfillment network, and Tractor Supply responded by building next generation, automated regional distribution centers, including facilities in Ohio and Arkansas among its ten current distribution centers, to sustain high in stock rates for heavy, consumable goods like livestock feed. The Nampa, Idaho facility now under construction is a continuation of this same investment cycle.

The fourth is omnichannel and digital investment. The rapid scaling of e-commerce demand during this period forced genuine capital investment into digital architecture, including the Company’s mobile app, buy online pickup in store infrastructure, and inventory tracking technology.

I believe the mechanism connecting this capital program to the ROIC decline operates through three channels.

First, capital expenditure flows directly onto the balance sheet and expands the invested capital base immediately, while major projects like automated distribution centers and full store remodels take real time to ramp up to their intended productivity, a straightforward timing lag between cash outlay and earnings contribution.

Second, launching initiatives at this scale creates upfront operational drag, store downtime, staff retraining, project management, and pre-opening logistics, that hits the income statement immediately and compresses operating margin before the investment reaches its full efficiency, which lowers the earnings numerator in the ROIC calculation in the near term.

Third, Tractor Supply’s capital profile before 2021 was comparatively asset light, resting on an older, largely depreciated store base. Anchoring meaningfully more capital into physical real estate, distribution mega hubs and permanent garden center structures, has lowered the Company’s overall asset turnover, and generating less revenue per dollar of fixed physical plant naturally pressures ROIC downward even when the underlying investments are sound.

Free Cash Flow

Free cash flow per share requires the same careful read of the base period as revenue does. Fiscal 2020’s figure of $1.87 per share was distorted by COVID era dynamics, compressed capital spending and unusual working capital swings, and is not a representative starting point. Measured from fiscal 2021, a cleaner base year, free cash flow per share grew from $0.88 to $1.39 in fiscal 2025, a compound annual growth rate of approximately 12%. I consider this real, meaningful growth, achieved despite an elevated capital expenditure program funding new stores, remodels, and distribution capacity, and it is the figure I anchor to, not the distorted 2020 to 2025 comparison.

Capital expenditure rose from $784 million in fiscal 2024 to $895 million in fiscal 2025, consistent with the accelerated store opening pace and the Nampa distribution center build described above.

Balance Sheet

Total funded debt stood at $1.765 billion at the end of fiscal 2025: $750 million in 5.25% Senior Notes due 2033, $650 million in 1.75% Senior Notes due 2030, $150 million in 3.70% Senior Notes due 2029, and $230 million drawn on the revolving credit facility. The Company carries an investment grade credit rating, Baa1 from Moody’s and BBB from Standard & Poor’s, both stable outlook, and was in compliance with all debt covenants as of fiscal year end. Separately, the balance sheet carries approximately $4.14 billion in operating lease liabilities. This figure reflects standard retail lease accounting for the Company’s store footprint, not funded borrowing, and I do not conflate it with financial debt when assessing leverage. Cash and equivalents were $194.1 million at fiscal 2025 year end.

Working Capital

Inventory days tell a reversion story, not a deterioration story, once the pre-pandemic period is included. From 2015 through 2019, inventory days ran between 106.3 and 108.7, a stable band comfortably above 100 days. In 2020 and 2021, inventory days fell sharply to 90.1 and 87.9, as the explosive demand spike discussed above pulled inventory off the shelves faster than it could be replenished. From 2022 onward, inventory days climbed back toward their historical norm: 96.9 in 2022, 104.8 in 2023, 105.5 in 2024, and 109.6 in 2025, a level essentially identical to where the Company sat every year from 2015 through 2019. I do not read this as a new or abnormal buildup. I read it as the inventory position normalizing back to where it always sat before the pandemic temporarily depleted it. The cash conversion cycle shows the same pattern, and I see nothing in this data that concerns me on its own.

4. Growth Levers & Addressable Market

A) Continued Store Growth

The Company opened 99 new Tractor Supply stores in fiscal 2025 and plans approximately 100 more in fiscal 2026, continuing a steady expansion pace that has run since 2019: 80 new stores in 2019, 80 in 2020, 80 in 2021, 63 in 2022 alongside the acquisition of 81 Orscheln Farm & Home locations that same year, 70 in 2023, 80 in 2024, and 99 in 2025. As part of its Life Out Here 2030 strategy, management had set a long term domestic store count target of 3,200 Tractor Supply locations, raised from a prior target of 3,000. Against 2,395 stores at the end of fiscal 2025, that target implied roughly 800 additional stores of disclosed, management endorsed runway ahead of the Company at its current pace of expansion. Following its second quarter fiscal 2026 results, management withdrew this long-term financial framework and indicated an updated framework will be provided alongside fourth quarter fiscal 2026 results, so this figure should be treated as a prior target pending replacement.

B) Existing Store Sales Growth

Comparable store sales, the growth in existing, already mature stores, is its own distinct lever, and I believe it is the one most directly tied to the operating leverage discussion in the Financial Performance section above. The Company’s original fiscal 2026 guidance called for comparable store sales growth of 1% to 3%, since revised downward following second quarter results to a range of flat to 1%. I continue to expect that once comparable sales normalize, a 1% to 3% growth range is achievable on a sustained basis, and I view this as a genuine re-acceleration lever in its own right, separate from and additive to new store openings. Once the Company returns to that range, I expect it to translate directly into the kind of fixed cost dilution that would meaningfully help operating margin and ROIC recover, given everything discussed above about how SG&A deleverage has been driven by a normalizing comp base.

C) Pet Care Vertical Integration

The combination of Allivet, acquired December 2024, and VIP Petcare, acquired May 2026, gives Tractor Supply a genuinely differentiated, end to end pet care, offering pharmacy and veterinary services under one roof, anchored by the Neighbor’s Club loyalty program. Companion Animal already represents 24% of net sales. I believe that if integration is executed well, this vertical has real room to grow both same store spend per pet owning customer and overall customer stickiness, since a customer using in store veterinary care has a meaningfully higher switching cost than one simply buying commodity pet food.

D) Digital Convenience Without Abandoning the Core Model

The Company’s approach to digital and delivery, renting fast, light-parcel convenience through partners like Instacart while building and controlling the harder, heavy-freight problem in-house through Final Mile, is discussed in full in the Moat section above. Direct Sales, launched in fiscal 2025 and targeting larger and more complex B2B style purchases, is a related, still early stage initiative, and the Company has not yet disclosed specific revenue contribution from it.

E) Loyalty Data

Neighbor’s Club, at more than 80% of sales, is both a moat pillar and a growth lever. It gives management a live view into customer purchasing patterns that can inform localized assortment, targeted promotion, and personalized digital engagement, without requiring incremental store level capital.

What I Conclude

Store growth is a continuation of an established, repeatable process. Pet care integration is a real, if recent, strategic bet with a plausible payoff in customer stickiness. Instacart, Direct Sales, Final Mile, and loyalty data are lower capital, still developing levers that management has flagged but not yet proven at scale. I read this as a business with several credible, non speculative paths to continued growth, rather than one dependent on any single initiative succeeding.

5. Management

Leadership and Tenure

Harry A. Lawton III has served as President and CEO since January 2020, with prior senior leadership roles at Macy’s, eBay, and Home Depot. In November 2025, the independent members of the Board approved a retention equity award to Lawton with a target grant value of $20 million, 60% performance share units tied to five year relative total shareholder return, 40% time based restricted stock units vesting on a back loaded schedule through 2030. The award was explicitly designed for retention through the Company’s Life Out Here 2030 strategic horizon, in a market the Compensation Committee described as competitive for proven retail chief executives. I read an award of this size, granted outside the Company’s normal annual compensation cycle, as a genuine signal of Board confidence in current leadership continuing to execute the strategy discussed throughout this report, not a routine event.

Under Lawton’s leadership the Company has made two notable bolt on acquisitions in successive years, Allivet in December 2024 and VIP Petcare in May 2026, both deepening the same pet care vertical rather than diversifying into unrelated categories. I consider that a coherent, additive pattern of capital deployment, not scattered dealmaking.

Capital Allocation Track Record

The Company returned approximately $848.5 million to shareholders in fiscal 2025 through buybacks and dividends. In February 2026, the Board raised the quarterly dividend to $0.24 per share, an annualized $0.96, marking the 17th consecutive year of dividend increases. $1.13 billion remains authorized under the Company’s $7.5 billion share repurchase program. Set against this, capital expenditure has risen materially, from $784 million to $895 million year over year, reflecting a deliberate tilt toward reinvestment, new stores and distribution capacity, over incremental buybacks in the current period. I consider this the correct capital allocation choice given the returns the store growth program has historically generated, and I would want to see it reflected in a stabilizing ROIC over the next one to two years.

6. Valuation

The future return on Tractor Supply stock is a function of two engines: the future growth in free cash flow per share and any valuation re-rating. Both are explained below:

Engine 1: Fundamentals

The first engine is the business itself. FCF per share grows over time through revenue expansion, operating leverage, and share count reduction from buybacks. That growth, compounded annually, is what the fundamental engine delivers regardless of any valuation re-rating.

For Tractor Supply, I assume a gradual acceleration in FCF per share growth over the projection period until it reaches 8% to 9% annually, rather than applying that rate uniformly from the start. The primary driver is continued store growth, roughly 100 new stores a year against a previously disclosed long-term target of 3,200 locations, now under review following the Company’s withdrawal of its long-term framework, compounding on top of a comparable store sales base that I expect to gradually re-accelerate toward the low single digits. Margin recovery is the second component of this growth rate, as the gross margin gains from private label expansion and supply chain efficiency, already real and demonstrated over the past five years, begin to flow through to operating margin once comparable sales growth dilutes the Company’s fixed cost base again. Buybacks add a further per-share amplification effect as the diluted share count declines.

I also expect free cash flow conversion to improve further as the current elevated capital expenditure cycle cools. Project Fusion remodels, the Side Lot Garden Center rollout, and the current distribution center build-out, including Nampa, are each maturing, finite programs rather than permanent step-ups in the Company’s capital intensity. As they complete and capital expenditure normalizes back toward its historical share of revenue, a larger share of operating cash flow should convert directly to free cash flow without a corresponding reinvestment offset, a tailwind to the fundamental engine on top of the growth rate assumption itself.

Engine 2: Valuation Re-Rating

At today’s price of approximately $29.4, the investor is paying for everything this business will earn over roughly the next 17 years, in today’s money. Everything it earns beyond that point comes to the investor at no additional cost. The fewer the embedded years, the more of the future the investor receives without paying for it.

At 17 embedded years, the price sits in the Attractive zone on my own valuation scale, a level Tractor Supply has rarely occupied across its history as a public company. This is a price shaped substantially by a genuine, if overstated, market reaction to decelerating comparable sales and compressing margins, both of which I addressed directly and at length in the Financial Performance and Risks sections above.

Tractor Supply’s own stock traded at more than three decades of embedded years at its 2025 peak of $63. Getting back even partway toward a more ordinary premium, well short of that peak, would represent a meaningful valuation tailwind on top of the fundamental engine described above.

At 17 embedded years, I believe both engines are working in the investor’s favor here, a genuinely growing free cash flow base compounding through continued store growth and margin recovery, and a valuation that has moved from one extreme to the other in the span of a single year without the underlying business changing nearly as much as the price did.

7. Risks

1. Companion Animal Softness and Pet Care Integration Risk

Management explicitly flagged companion animal as underperforming the Company average in the first quarter of fiscal 2026, citing softer demand trends, category shifts, and an unfavorable product mix, and stated it is “taking decisive actions to improve its performance” without detailing what those actions are. In the second quarter, the Company followed through with a concrete action, restructuring its Petsense banner and closing approximately 75 of its 209 stores, recording a $65.8 million impairment and restructuring charge in the process. I take this risk seriously because Companion Animal is 24% of net sales, the second largest category, and because the Company has now made two consecutive acquisitions, Allivet and VIP Petcare, specifically to strengthen this vertical.

My own read of the Petsense closures, is that this represents a deliberate pivot away from low-margin, low-differentiation standalone pet retail, generic pet food and supplies that Chewy, PetSmart, and Petco can match or undercut on price, and toward the higher-margin veterinary services now offered through VIP Petcare, integrated directly into the Company’s higher-traffic core Tractor Supply stores. If that reading holds, this is Tractor Supply choosing to concentrate its pet care capital into the part of the category genuinely resistant to e-commerce competition. I want to see this confirmed by management commentary before treating it as established strategy, but I view it as the more likely explanation given the timing alongside VIP Petcare’s integration.

The recency of the VIP Petcare acquisition means there is no operating track record yet on integration execution, and an acquisition described as “capital efficient” and “asset light” still carries real execution risk in bringing an outside veterinary services workforce and clinic operation in house, now compounded by a simultaneous restructuring of an adjacent banner. The mitigation, in my view, is that the Company is not simply talking about this weakness, it has made three direct actions in relatively quick succession, the Allivet acquisition, the VIP Petcare acquisition, and the Petsense restructuring, all pointing in the same strategic direction. That consistency gives management real tools to address the softness rather than relying on hope alone, though it also means more moving pieces to integrate successfully at once.

2- Weather and Seasonality Risk

A large share of Tractor Supply’s inventory is seasonal, and the Company’s own filings state that sales and profits are historically highest in the second and fourth fiscal quarters. A late, cold, or unusually wet spring damages sales of live poultry, lawn and garden equipment, fencing, and fertilizer. A mild winter eliminates urgent demand for wood pellets, heating stoves, snow removal gear, and heavy winter workwear. The mitigation here is the Company’s needs based product floor, feed, pet food, basic maintenance supplies, which I believe provides a genuine partial offset, since that demand is recurring rather than seasonal, even though it does not fully insulate results from a genuinely unusual season.

3- Commodity and Supply Chain Cost Exposure

Tractor Supply’s business model relies on bulky, heavy items, animal feed, horse bedding, fencing, that carry high distribution and transportation overhead. Severe fluctuations in corn, soy, and grain pricing directly affect the manufacturing cost of livestock feed, and I believe this squeezes margin whenever those costs cannot be passed through to a cash strapped rural customer. Because of the heavy physical footprint of what the Company ships, sudden spikes in diesel fuel and domestic shipping rates rapidly drive up baseline cost of goods sold. The mitigation is twofold: the expansion of exclusive private label brands, already a meaningful driver of the gross margin improvement discussed above, reduces dependence on third party brand markups and gives the Company more direct control over sourcing, and the Company’s continued localization of regional distribution centers, including the new Nampa, Idaho facility, shortens the distance between distribution nodes and storefronts, which I believe partially insulates it against future freight volatility, though I have not seen this quantified by management.

4- Rural Consumer and Demographic Concentration Risk

Tractor Supply’s core customer base is intensely concentrated in rural communities, which makes the business dependent on the localized economic health of American agriculture. When net farm income declines, whether from falling federal agricultural subsidies or cratering crop prices globally, I believe rural discretionary spending on non essential tools, trailers, and apparel freezes quickly, well before spending on the needs based C.U.E. floor is affected. Separately, some portion of Tractor Supply’s pandemic era growth was plausibly tied to the migration of urban workers into rural areas and a resulting wave of hobby farming.

If hybrid workers who moved during the pandemic return to major metropolitan areas at scale, I believe the hobby farming customer pipeline that has partly fueled the Company’s elevated post pandemic baseline could contract, though I have no way to quantify this risk precisely with current disclosure. The mitigation is the Company’s Neighbor’s Club data, which gives management real time visibility into shifting customer spending priorities and the ability to respond with targeted promotion faster than a retailer without a comparable loyalty program.

8. The Verdict

Tractor Supply is the largest player in a niche it has spent 85 years building and largely owns; rural lifestyle retail, in towns and markets too small for a Home Depot, Lowe’s, or Walmart to profitably enter. That leadership position has not weakened. What has happened is a normalization after an extraordinary, unrepeatable two year surge in demand during the pandemic, layered on top of a period of unusually high capital expenditure funding store remodels, garden center expansion, distribution infrastructure, and technology investment.

The stock has been beaten down as if this combination represented deterioration. I believe the market has read it backwards. A flat or barely positive comparable sales print in the years following a 23% and then 16.9% spike is a business that successfully defended an extraordinary, one time gain in its revenue base rather than giving it back, which I consider a genuine strength once the base year is properly understood, not the warning sign a surface level read of recent comp prints suggests. The elevated capital spending sitting alongside that normalization is the ordinary cost of a decades long, still-running growth playbook, remodeling stores, building distribution capacity, and investing in the digital and pet care capabilities that extend the moat, continuing at a scale that a slower post pandemic sales backdrop has made more visible and, for now, more expensive to carry.

None of this changes what Tractor Supply fundamentally is; the largest, most entrenched rural lifestyle retailer in the country, with a needs based product core, a real and growing loyalty and pet care ecosystem, and a store growth runway still years from exhausted. I believe the fundamentals here are intact, and that the price today reflects a market mistaking a normalization story for a structural one.

The author does not hold a position in Tractor Supply, Inc. at the time of publication. This report reflects the author’s personal views and is not investment advice. Investing carries the risk of permanent capital loss. Read full disclosure here.

Quarterly Update Log

This section is updated with each subsequent quarterly result and is kept separate from the annual analysis above, which reflects the fiscal 2025 full year record.

Q2 Fiscal 2026 (reported July 23, 2026)

Net sales increased 2.3% to $4.54 billion. Comparable store sales decreased 1.5%, with positive results in April and June offset by a weaker May. Adjusted diluted EPS was $0.81, flat compared to $0.81 in the second quarter of 2025, with reported diluted EPS of $0.69 reflecting a $65.8 million impairment and restructuring charge tied to the planned closure of approximately 75 Petsense stores, alongside VIP Petcare acquisition costs. The Company updated its full year guidance downward and withdrew the long-term financial framework introduced at its December 2024 Investor Day, indicating an updated framework will accompany fourth quarter results.

This quarter includes real one-time items, the Petsense restructuring and acquisition costs, that make the headline numbers noisier than usual, and I’ll let the picture clarify over the next few quarters before drawing any conclusions from it.

My initial concern with Sprouts was straightforward, Walmart, Kroger, and Costco had all moved into organic, and a small-box specialty grocer built around produce would eventually get squeezed. That concern was reasonable, but it was missing something.

Sprouts is not a produce stand with a grocery section attached. It is a full grocery store built around a different philosophy, same categories as any conventional supermarket, but the sequencing, the curation, and the supply chain behind it are fundamentally different. Adding an organic aisle to a supercenter is not the same as rebuilding an entire store around fresh food. Those are two different operations, and conflating them was the flaw in my original thinking.

By the time Walmart and Kroger meaningfully expanded their organic offerings, Sprouts already had decades of site selection data, supplier relationships, and a customer base with established shopping habits. That accumulation is not something a competitor can shortcut, and the competitive pressure I was worried about had been building for most of Sprouts’ history, not arriving for the first time now.

What shifted my view was several data points together, a grocery format that is hard to replicate piecemeal, two decades of accumulated operational knowledge, margins and returns on capital that held through inflation and a store closure cycle, and a supply chain built specifically to support a freshness claim.

The author does not hold a position in Sprouts Farmers Market, Inc. at the time of publication. This report reflects the author’s personal views and is not investment advice. Investing carries the risk of permanent capital loss. Read full disclosure here.

1- The Business

Sprouts Farmers Market is a specialty grocery retailer built around fresh, natural, and organic products, operating 483 stores across 25 states as of the most recent quarter. The standard store format runs between 21,000 and 25,000 square feet, trimmed down from an older prototype of roughly 28,000 square feet.

Produce occupies the center of every store, about 20% of selling space, and anchors the shopping experience from the moment you walk in. Revenue in fiscal 2025 split 57% perishables and 43% non-perishables, a breakdown close enough to a conventional grocery basket that Sprouts carries the category breadth for a full weekly shop.

The freshness claim is backed by real infrastructure. Sprouts self-distributes nearly all of its produce through six company-operated distribution centers in Arizona, Texas, two sites in California, Colorado, and Florida, with a third-party partner covering the Mid-Atlantic. 80% of stores sit within 250 miles of one. In 2025, Sprouts extended self-distribution to meat and seafood, a transition that caused disclosed availability challenges during the changeover. By fiscal year end, four of the six distribution centers had converted, covering approximately 70% of stores, with the remainder targeted for 2026 and a projected end state of 95% coverage. For categories not self-distributed, primarily dry grocery and frozen, Sprouts relies on two external suppliers, KeHE at approximately 52% of total purchases and United Natural Foods at approximately 12%, with the remainder sourced directly from local growers.

Sprouts Brand, the company’s private label line, made up just over a quarter of revenue in fiscal 2025 following a full assortment redesign completed that year. Within the standardized store layout, a portion of the assortment rotates, vendor products and limited availability items cycling through specific shelf space, creating a discovery dynamic that keeps part of the product mix feeling different visit to visit. The store layout itself doesn’t change, only this slice of the assortment does.

The target customer is the health enthusiast and the selective shopper, someone already seeking fresh, natural, and organic products who is willing to pay for a curated experience. The first Sprouts store opened in Chandler, Arizona in July 2002. The twenty-four years since have gone toward building the things that matter, site selection knowledge across 25 states, supplier relationships negotiated and renewed many times over, and a customer base that formed its shopping habits around this format before conventional and mass-market grocers gave it serious competitive attention.

2- The Moat

This is where the analysis gets honest, and where I spent the most time.

My first instinct was that Sprouts has no real moat. There are no switching costs, a grocery shopper can walk into Whole Foods or Trader Joe’s tomorrow with zero friction. There are no network effects. The store format, while differentiated, is not patented. A well-capitalized competitor could technically lease a 23,000 square foot space, place produce bins in the center, and call it a specialty grocer. The product is available elsewhere. The customer is not locked in.

That instinct is partially right. Sprouts does not have a structural moat in the classic sense, no membership fee forcing customers through the door the way Costco does, no proprietary technology creating dependency, no regulatory barrier protecting the category. If management stops executing well, the structure alone will not save the business. I believe that is true and worth saying clearly.

But fifteen years of intensifying competition from Walmart, Kroger, Amazon-backed Whole Foods, and Trader Joe’s, and Sprouts has expanded margins, grown returns on capital, and accelerated revenue. A business with no competitive protection at all does not produce that record. Something is working, even if it doesn’t fit neatly into a textbook moat category.

What I believe is actually protecting Sprouts is four things working together, none of which constitutes a moat individually, but which collectively create a competitive position that is genuinely difficult to replicate piecemeal.

The first is the small format real estate advantage. A 23,000 square foot store fits into dense, high-traffic neighborhoods that a conventional 50,000 to 60,000 square foot supermarket physically cannot enter. That is a structural cost and location advantage, lower construction costs, cheaper lease terms, faster path to store-level profitability, and access to real estate a Kroger or Walmart simply cannot use. No backroom storage means inventory goes directly from delivery trucks to the floor, eliminating a cost layer that conventional grocers carry.

The second is private label density. Just over 25% of revenue comes from Sprouts Brand products, items customers cannot find anywhere else. That is the closest thing to a switching cost that grocery retail can produce. It is not a lock-in, but it is friction, and friction compounds over time. A customer who builds a weekly shop around several Sprouts Brand products has a reason to return that has nothing to do with produce freshness or store atmosphere.

The third is the distribution infrastructure. Six self-operated distribution centers, positioned so 80% of stores sit within 250 miles of one, took years and significant capital to build. The 2025 disruption from converting meat and seafood to self-distribution is itself evidence of how difficult that transition is, even for the incumbent that designed it. A new entrant cannot buy that footprint quickly. An existing large-format competitor already has its own distribution network optimized for a different format and would need to rebuild, not adapt.

The fourth is deliberate customer targeting. Sprouts actively cycles products out of its assortment once they become mainstream items at conventional grocers, preserving the specialty status of what remains on the shelf. That curation discipline, foraging for niche, attribute-driven products and retiring them when they go mass-market, keeps the format feeling differentiated to a customer who specifically does not want to shop where everyone else shops. Maintaining that discipline requires ongoing execution, which is precisely the vulnerability, but the discipline itself is a real competitive characteristic.

Together, these four components have produced gross margins of 38-39% in a category where conventional grocers operate at 20-25%. That is not a coincidence. It is also not permanent, it requires all four components to keep working simultaneously, which brings me to the risk I cannot dismiss.

The historical record contains one clean test of what happens when execution falters. Before 2019, under different leadership, Sprouts competed on aggressive produce promotions and loss-leader discounts, built stores averaging 30,000 square feet, and chased the price-sensitive shopper it was never going to win against Kroger or Walmart. Gross margins were stuck between 29% and 33%. The stock went nowhere for years. The structure did not save the business from a strategy that was fighting the wrong battle on the wrong terms. That period is the clearest evidence that the competitive position described above is real but not self-sustaining, it requires the right strategy to activate it.

The honest conclusion is that Sprouts has a narrow but real competitive position, not a wide structural moat. The four components working together create something durable enough to have survived fifteen years of serious competitive pressure. Whether they survive the next fifteen depends on execution remaining disciplined, which is a different and harder underwriting bet than structural protection provides.

3- Financial Performance

Revenue grew from $6.1 billion in 2021 to $8.8 billion in 2025, a compound annual growth rate of approximately 9.6%, accelerating to 14% in 2025 on new store contribution and a 7.3% increase in comparable store sales.

Reading that comp sales trend correctly requires understanding something specific about perishables. Produce makes up the majority of the 57% perishables revenue, so reported comparable store sales are sensitive to the price of underlying crops, not just transaction count. When produce prices spike, comps for that period can look stronger than underlying volume justifies, and the following period is then measured against an inflated base. That is precisely what the most recent data shows. Comparable store sales ran at 3.4%, 7.6%, and 7.3% for 2023 through 2025 before turning negative 1.7% in the thirteen weeks ended March 29, 2026, against an unusually strong 11.7% comparison quarter a year earlier. Stacked across both periods, two-year growth is still approximately 9.8%, consistent with the underlying trend.

The base-effect reading is not speculative. California, where Sprouts sources 40% to 70% of its produce depending on the season, experienced severe drought conditions through 2024 and into 2025 per USDA data. Elevated produce costs during that window plausibly inflated the Q1 2025 comparison base. The Q1 2026 decline is a base effect compounded by a documented weather event. This pattern has happened before, comparable store sales turned negative in 2021 as the business lapped the extraordinary grocery stockpiling of 2020, recovered cleanly, and the underlying business was unchanged. I see the current period as the same mechanism, not a different one.

Operating margin expanded from 5.6% in 2021 to 7.9% in 2025, dipping to 5.7% in 2023 when the company closed eleven underperforming stores in a single month, stores its own disclosure described as approximately 30% larger than the current prototype and financially underperforming. The recovery from that trough to 7.9% came through two mechanisms: fixed cost leverage as the newer, smaller stores ramped up, and meaningfully better inventory shrink management in 2025, which management specifically cited as a driver of gross margin expansion in that year’s earnings release. Average square footage per store declined from 27,820 in 2023 to 27,552 in 2024 to 27,237 in 2025 as the smaller prototype entered the fleet at scale.

Over the same period, sales per square foot rose from approximately $604 in 2023 to $637 in 2024 to $678 in 2025. A shrinking average footprint and rising sales per square foot in the same period is not purely an artifact of comparable store sales growth, though it is worth noting that elevated produce prices during California’s documented drought period likely inflated the revenue numerator in 2024 and 2025. The underlying productivity trend is real, but the magnitude of the per-square-foot improvement should be read with that pricing tailwind in mind.

ROIC held in a range of 11.8% to 13.6% from 2021 through 2024 before climbing to 17.6% in 2025 alongside the margin recovery. The capital-light model contributes: Sprouts leases nearly all stores and distribution centers, keeping capital expenditure low relative to revenue and funding new store growth largely from free cash flow.

Diluted EPS grew from $2.10 in 2021 to $5.31 in 2025, faster than revenue. Part of that is operating leverage and margin expansion. Part is buybacks: diluted share count fell from 116.1 million to 98.7 million over the period, a 15% reduction, funded from free cash flow rather than debt.

Sprouts carries no outstanding funded debt as of fiscal year end 2025. The credit facility exists, a $600 million revolving line maturing in 2030, but nothing is drawn against it. The largest liability on the balance sheet is lease obligations, $1.86 billion in operating leases tied to 477 store and distribution center locations with terms extending through 2048. That is not leverage in the conventional sense. It is the contractual footprint of a business that leases rather than owns its real estate, and every new store opening adds to it. The liability grows because the business is expanding, not because it is borrowing to survive.

One of the cleaner financial decisions under the current leadership was eliminating the funded debt entirely, $125 million repaid in each of 2023 and 2024, while simultaneously running a buyback program funded from the $716 million in operating cash flow the business generated in 2025 alone. The balance sheet today reflects a business that finances its growth from operations, not from the credit markets.

Sprouts has not paid a dividend since its 2013 IPO and does not plan to. The entire return to shareholders runs through buybacks, $203 million in 2023, $228 million in 2024, and $472 million in 2025, all from free cash flow. Diluted shares fell from 116.1 million in 2021 to 98.7 million in 2025. Each remaining share carries a growing claim on a growing pool of earnings. There is no dividend check, the return runs through a shrinking denominator against a growing numerator.

4- Management

Jack Sinclair has served as Chief Executive Officer since June 2019. Before joining Sprouts, he spent more than three decades in grocery retail, fourteen years at Safeway in the United Kingdom, followed by eight years as Executive Vice President of Walmart’s entire U.S. grocery division, responsible for operations across more than 4,000 stores. He served briefly as CEO of 99 Cents Only Stores before joining Sprouts.

What Sinclair actually changed at Sprouts is worth being precise about, because the temptation is to attribute everything that improved after 2019 to his arrival. Revenue growth was already happening before he arrived, the format and the category tailwind were working regardless of who was running the company. What Sinclair specifically changed was the margin structure. He stopped the aggressive loss-leader promotions. He engineered the smaller store prototype. He pushed private label penetration from a modest base to over 25% of revenue. He initiated the self-distribution buildout for meat and seafood. Gross margin went from 33-34% under prior leadership to 38.8% by 2025. That is his contribution, not the top line, the bottom line.

The succession question matters here because Sinclair is 64, and the margin structure he built is the primary thing an investor in this business is underwriting. I thought carefully about whether the performance of the last six years is person-dependent in a way that creates a real holding risk.

My conclusion is that it is less person-dependent than it initially appears, for a specific reason. Sprouts has had multiple CEO transitions since 2002 and revenue growth continued through all of them, including through the leadership vacuum between Amin Maredia’s departure in December 2018 and Sinclair’s appointment in June 2019. That is a pattern of a format with enough operational momentum to carry through leadership gaps. What changes with leadership is the strategic direction, and the risk is not a leadership transition per se but a strategy drift that takes the business back toward competing on price against Walmart and Kroger.

The bench Sinclair has assembled is the specific reason I think that risk is manageable. Nick Konat, President and Chief Operating Officer, joined in March 2022 from Petco where he was Chief Merchandising Officer, and before that spent nearly a decade at Target running food operations and private label development. He is the person actually running day-to-day store operations, supply chain, and product innovation, the current strategy is his execution as much as Sinclair’s design. Don Clark, appointed Chief Merchandising Officer in February 2026, brings deep specialty retail sourcing experience. Amanda Rassi, appointed Chief Customer Officer at the same time, oversees the loyalty program and digital data strategy. Curtis Valentine as CFO is the capital allocation gatekeeper who has been the architect of the buyback program and the self-distribution investment decision.

The risk of strategy drift after a CEO transition is real. But a board that replaced Sinclair with someone who decided to abandon small-format stores, drop private label, and compete on bulk produce discounts would be dismantling the margin structure it spent six years building.

Insider ownership is small, all directors and executive officers as a group held approximately 1.3% of shares outstanding as of March 2026, with Sinclair individually below 1%. The largest shareholders are institutional, Vanguard at 11.3%, Fidelity at 10.5%, and BlackRock at 9.9%. This is not a founder-controlled company, which is a real governance consideration for an execution-dependent business.

5- Competition

Sprouts operates in a large, fragmented, and highly competitive industry with few barriers to entry, per its own filings. The directly comparable specialty formats are Whole Foods Market, Trader Joe’s, and Natural Grocers by Vitamin Cottage.

Whole Foods has operated as an Amazon subsidiary since 2017 and reports no separate financials. It competes on broader assortment and national brand equity built over three decades, with Amazon’s logistics network and Prime membership integration behind it. Its stores run larger than the Sprouts prototype, which cuts the other way on cost structure and shopping trip efficiency.

Trader Joe’s is privately held and discloses nothing. Its format is closest to Sprouts in physical footprint, small box, curated, largely private label, but the value proposition differs. Trader Joe’s competes primarily on price with higher private label penetration than Sprouts’ disclosed 25%, and a cultural brand identity that creates loyalty beyond what a rewards program delivers.

Natural Grocers is the only publicly traded name in this set. It generated $1.33 billion in net sales for the fiscal year ended September 30, 2025, roughly one sixth of Sprouts’ scale, with an operating margin of approximately 4.7% against Sprouts’ 7.9%. It is a controlled family business with a store count of 169, growing at a pace Sprouts exceeded years ago.

The mass market question, Walmart, Kroger, Costco, deserves direct treatment because it was the starting point of my concern. These retailers collectively hold the majority of U.S. organic dollar sales, and that share has grown from 46% in 2005 to 56% in 2020. That is a real fact about the category. It is not the same as being a relevant competitor for Sprouts’ specific customer.

The majority-share figure blends every organic purchase made in the country, including the price-sensitive shopper who picks up organic milk alongside laundry detergent and was never going to make a dedicated specialty grocery trip. None of these retailers has built a format around the produce-centered, curated, discovery-oriented experience Sprouts sells. Kroger folds organic into existing mainstream aisles through its Simple Truth private label. Costco competes on bulk volume and membership economics. Walmart carries organic as one line among tens of thousands of SKUs rather than as the organizing principle of the store. Their scale is a real fact about the category. It is not evidence that they are competing for the same trip.

6- Growth

Sprouts’ growth rests on two mechanisms: more stores in places it barely operates today, and more productivity from stores it already has.

The unit growth runway is real and geographically specific. California alone accounts for 156 of 477 stores, roughly a third of the entire fleet. Fourteen of the twenty-four states Sprouts operates in have single-digit store counts. Roughly half the country has no Sprouts at all. Management has stated a long-term ambition of reaching 1,400 stores nationwide. The constraint is not demand, it is distribution center density. A produce-centered format cannot operate profitably without a hub close enough to maintain freshness, which is why the self-distribution buildout is a growth enabler, not just an efficiency measure. Each new distribution center unlocks a new radius of viable store locations. Sprouts entered New York for the first time in early 2026 and has named Chicago, Boston, and the broader Midwest and Northeast as the next expansion targets once distribution capacity supports them. The near-term pipeline is more concrete than the long-term ambition: over 140 approved locations as of early 2026, against the 40-plus openings guided for 2026, a pace of approximately 10% annual unit growth.

On the existing-store side, Sprouts Rewards, launched nationally in 2025, is the data and personalization lever management is counting on to increase visit frequency and basket size through targeted offers rather than blanket discounting. E-commerce grew 10% year over year in Q1 2026 and now represents approximately 16% of quarterly sales, delivered through Instacart, DoorDash, and Uber Eats across every market Sprouts operates.

7- Valuation

At today’s price, an investor is paying for everything this business will earn over roughly the next 15 years, in today’s money. Everything beyond that comes for free.

To put that number in context, Costco and Walmart, two of the most competitively protected businesses in retail, are currently priced at above 40 embedded years. The market is paying for more than four decades of future cash flows, in today’s money, for businesses whose structural moats justify a high degree of confidence in that long-term earnings stream. That premium is earned. Both businesses have structural lock-in mechanisms, Costco’s membership model, Walmart’s unmatched cost scale, that give an investor legitimate confidence holding through decades of uncertainty.

Sprouts at 15 embedded years is priced at less than half that level. The gap reflects two things: a smaller business with a narrower competitive position that the market is not yet willing to pay a structural premium for. Both of those are fair assessments.

What the gap also reflects is that the market has already shown what it is willing to pay for Sprouts when sentiment is favorable. When the stock peaked at approximately $180 in 2025, the implied embedded years reached 35, approaching the premium territory reserved for structurally protected businesses. That valuation was not sustainable at Sprouts’ current stage of development, and the subsequent decline to today’s price reflects both the comp sales normalization and a rational repricing of execution-dependent growth. But it is a meaningful data point. It tells us the market is capable of pricing this business at near-structural-premium levels when the financial momentum is visible, and that an investor entering at 15 embedded years today is buying at less than half of what that same market was willing to pay less than a year ago.

The return from this entry point comes from two engines. The first is the business itself, free cash flow per share growing through revenue expansion, operating leverage, and share count reduction from buybacks. The second is valuation re-rating as the market moves the price back toward a fair recognition of the business’s durability. At 15 embedded years, there is room for both engines to contribute.

Sell discipline triggers when the embedded years reach a level inconsistent with the quality and structural characteristics of the business.

8- Risks

Weather and Crop Cost Volatility

Sprouts sources 40% to 70% of its produce from California depending on the season, and produce alone accounts for approximately 20% of selling space and sits at the center of the format’s entire value proposition. That concentration is not incidental, California’s climate is uniquely suited for the variety and volume of specialty crops Sprouts’ assortment requires, and no comparable domestic alternative exists at the same scale. It is also a structural exposure that cannot be diversified away without fundamentally changing what the business is.

California experienced severe drought conditions from 2020 through 2022, with 2020 to 2022 representing the driest three-year period on record according to USDA data, followed by continued drought stress through 2024 and into 2025. The financial record through that period shows gross margin holding, Sprouts passed elevated produce costs through to customers and margins expanded rather than contracted. That is the best available evidence of pricing resilience under cost pressure, and it is a genuinely reassuring data point.

But it needs to be read carefully. The ability to pass costs through depends on competitive market conditions at the time, not on a structural pricing advantage Sprouts holds regardless of circumstances. During the recent drought period, elevated costs were an industry-wide phenomenon affecting conventional grocers and specialty retailers alike, a competitor could not undercut Sprouts on produce without absorbing the same cost pressure. That is a different situation from a Sprouts-specific cost shock in a period when competitors face no equivalent pressure, which is the scenario the record has not yet tested.

A more severe or prolonged supply disruption, a multi-year drought deeper than what California experienced from 2020 to 2022, a disease event affecting specialty crop yields, or a logistics disruption concentrated in the California growing regions, would pressure gross margin in a way the current track record does not fully address. Sprouts’ format depends on fresh produce being available, abundant, and reasonably priced relative to what the health enthusiast customer is willing to pay. If any of those three conditions breaks down for an extended period, the format’s central value proposition is impaired in a way that operational discipline alone cannot fix.

The self-distribution buildout partially mitigates this by improving freshness and reducing spoilage in transit, which protects margin from the shrink side rather than the cost side. But it does not change the sourcing geography or the fundamental California dependency. This is a risk that warrants monitoring at every earnings cycle.

Execution Dependency

This is the risk I think about most with Sprouts, and the one that most distinguishes it from the other names in the Bearhold universe.

The competitive position described in the moat section requires four components working simultaneously, small format real estate, private label density, tight distribution infrastructure, and deliberate customer targeting through continuous product curation. None of those four protects the business on its own. But the mechanism that connects them is strategy, not structure. If the strategy changes, the margins change. There is no membership fee forcing customers through the door, no network effect deepening with scale, no switching cost keeping the health enthusiast from walking into Whole Foods or Trader Joe’s tomorrow. The business earns its competitive position every day through execution, and it has to keep earning it.

The pre-2019 period is the clearest empirical evidence of what happens when execution is average. Under prior leadership, Sprouts competed on aggressive loss-leader produce promotions and discount couponing, built stores averaging 30,000 square feet, and chased the price-sensitive shopper it was never going to win against Kroger or Walmart on their own terms. The result was gross margins stuck between 29% and 33%, a stock that went nowhere for years, and a business that looked structurally similar to what Sprouts is today, same format, same category, same distribution infrastructure, but produced a fundamentally different financial outcome because the strategy was wrong. The structure did not save it. The right strategy, executed consistently, is what produced the improvement. That is the lesson and the risk at the same time.

The specific form execution dependency takes at Sprouts is strategy drift, the risk that a future leadership change, a board that loses patience during a period of weak comps, or an activist pushing for mass-market expansion causes the business to abandon what works in pursuit of a broader customer that will never be loyal to a specialty format on price terms. That scenario does not require management to be incompetent. It requires one strategic decision to go the wrong way, and the financial consequence would be visible in margins within few quarters. The bench Sinclair has assembled, Konat, Clark, Rassi, Valentine, are the people who built and optimized the current playbook, which mitigates but does not eliminate this risk. A board can always make a different decision, and at 1.3% insider ownership there is no controlling shareholder to prevent it.

Mass Market Channel Share

Conventional supermarkets, club stores, and supercenters have held the majority of U.S. organic dollar sales since the mid-2000s, and that share has grown, from 46% in 2005 to 56% in 2020 according to USDA data citing the Organic Trade Association. That trajectory did not slow Sprouts’ margin expansion or revenue growth over the same period, which is the most important context for reading this risk correctly. The mass market gaining share of organic spending and Sprouts expanding margins simultaneously are not contradictory, they reflect two different customers making two different decisions.

The mass market organic buyer is the price-sensitive, opportunistic shopper who picks up organic milk or bananas as one line inside a much larger conventional basket. That customer was never Sprouts’ customer, and Kroger gaining more of their spending does not reduce Sprouts’ addressable market in any direct sense. The health enthusiast who makes a dedicated trip to a specialty grocer for curated, attribute-driven products is a different person making a different decision, and the organic category’s overall growth means more of both types of buyers exist over time, not fewer.

The risk this creates for Sprouts is more subtle than the headline share number suggests. It is not that Walmart is taking Sprouts’ existing customers, the evidence does not support that. It is that as organic becomes more mainstream and more available everywhere, the category loses some of the scarcity and discovery value that makes a dedicated specialty trip feel worth making. A health enthusiast who can find a reasonable selection of organic produce, keto snacks, and gluten-free packaged goods at their regular Kroger may make fewer dedicated Sprouts trips over time, because the incremental value of the specialty trip declines as the gap in availability narrows. That is a slow-moving structural pressure rather than a acute competitive threat, and it is the version of the mass market risk worth watching. Sprouts’ response, cycling out products once they go mainstream, continuously foraging for new niche items, deepening private label penetration, is the correct strategic answer to exactly this pressure.

The Verdict

I am approving Sprouts Farmers Market.

I did not arrive at this easily. I came in worried about mass market competition and left still believing the moat is narrow. I spent time genuinely uncertain about whether the post-2019 improvement was person-dependent in a way that created a holding risk I couldn’t accept. I considered whether the negative comp sales in Q1 2026 was the first visible crack in a thesis that looked better on paper than in reality.

None of those concerns resolved cleanly. What changed my mind was the weight of evidence across the whole picture.

Fifteen years of intensifying organic competition from better-resourced competitors has not compressed Sprouts’ margins, it has watched them expand. Multiple CEO transitions have not broken revenue momentum, the format carried through all of them. The comp sales decline has a credible, historically precedented explanation tied to a documented weather event inflating the prior year base, not to a collapse in demand or traffic.

What I believe is protecting this business is not one thing but four things working together, small format real estate, private label density, tight distribution infrastructure, and deliberate customer targeting, none of which individually constitutes a classic moat, but which collectively have produced gross margins of 38-39% in a category where conventional grocers operate at 20-25%. That is the fact I keep coming back to. Margins at that level, sustained through an inflationary period and a leadership transition, do not happen in a business with no competitive protection.

The execution dependency is real and I am not dismissing it. This is not a Costco or a Walmart businesses where the structural protection is clear enough that I can hold through almost anything. With Sprouts, I am underwriting a team and a strategy in addition to a business, and that requires active monitoring. I am comfortable with that, because the team Sinclair assembled, Konat, Clark, Rassi, Valentine, are the people who built and optimized the current playbook. A succession from Sinclair to Konat would represent continuity.

Q2 2026 Update

Q2 2026 came in at the better end of what management guided. Comparable store sales of negative 1.0% against guidance of negative 2% to flat, a sequential improvement from the negative 1.7% posted in Q1.

Net sales grew 5% to $2.33 billion, driven by new store contribution. Diluted EPS of $1.37, slightly above the $1.35 posted in the same period last year despite the negative comp environment. The business opened 7 new stores, bringing the total to 490 across 25 states.

Full year 2026 guidance on a 52-week basis calls for net sales growth of 5.5% to 6.5%, and diluted EPS of $5.32 to $5.40, essentially flat to modestly above fiscal 2025’s $5.31, reflecting the comp challenges absorbed in the first half. The balance sheet remains clean with zero revolving debt, $224 million in cash, and $369 million in operating cash flow generated year to date.

Nothing in this quarter changes the thesis. The comp recovery is tracking as expected, new store economics remain strong, and the business continues to generate cash at a level that funds both expansion and buybacks without touching the credit facility.

The author does not hold a position in Sprouts Farmers Market, Inc. at the time of publication. This report reflects the author’s personal views and is not investment advice. Investing carries the risk of permanent capital loss. Read full disclosure here.

Disclosure:

The author does not hold a position in Wingstop, Inc. at the time of publication. This report reflects the author’s personal views and is not investment advice. Investing carries the risk of permanent capital loss. Read full disclosure here.

1. The Business

Wingstop began franchising in 1997 and listed on NASDAQ in June 2015. As of the first quarter of 2026, the system operated 3,153 restaurants worldwide, of which 57 were company-owned. Approximately 98% of the system is owned and operated by independent franchisees who fund their own construction and equipment, typically an investment of approximately $580,000 per restaurant, and who bear the operating risk day to day.

Each restaurant occupies approximately 1,700 square feet of retail space, with no dining room and no drive-through. The format is designed entirely for order pickup and digital delivery. This small footprint keeps build-out costs predictable and accessible for franchisees, and enables the location density that the delivery model requires. When the majority of orders are placed through a digital platform for delivery, the restaurant closest to the customer captures the order. A 1,700 square foot location two miles away serves that customer more reliably than a larger format eight miles away.

Consolidated revenue of approximately $697 million in 2025 comes from three lines:

1. Royalty revenue, franchise fees, and other income totaled approximately $322 million, calculated as a percentage of franchisee sales with essentially no incremental cost to Wingstop. This is the highest-quality revenue line: it scales with the system rather than with anything Wingstop itself must build or staff.

2. Advertising fees totaled approximately $248 million, collected from franchisees and spent entirely on national marketing. This line passes through the income statement as both revenue and expense with no net contribution to operating income.

3. Company-owned restaurant sales totaled approximately $128 million, generated by the 57 locations Wingstop operates directly as testing grounds for new products, technology, and operational practices.

The technology infrastructure underpinning the system includes the proprietary ordering platform and mobile application, the Wingstop Smart Kitchen operating platform completed across all domestic restaurants in 2025, and the point-of-sale and restaurant management systems that franchisees are required to use. These are not the franchisee’s restaurant-level equipment. They are the shared digital backbone that makes the franchise operate as a single brand. The ordering data they generate feeds Club Wingstop, the national loyalty program launched in June 2026 following a pilot phase across 2025 and early 2026.

The domestic pipeline is entirely franchisee-driven. Every domestic development commitment as of December 2025 came from existing franchisees. These are operators who already run Wingstop restaurants, see their own cost structures, and continue to commit capital to additional locations. The strategy covers both existing markets, where density deepens brand presence and delivery coverage, and emerging markets where the brand is new. The long-term goal is to double the current domestic restaurant count, which implies expansion well beyond the markets where Wingstop currently operates. The pipeline committed to reach that target represents capital from franchisees who have seen enough in their existing stores to bet more.

Internationally, the system operated approximately 500 restaurants across 18 countries and U.S. territories as of early 2026, all franchised through master franchisee arrangements. The United Kingdom, under the ownership of Sixth Street Partners following the 2025 sale of Lemon Pepper Holdings, added more than 20 locations in 2025 and is the largest international market by restaurant count. India is planned for entry in 2026. Wingstop holds an 18.75% non-controlling equity stake in the UK entity following the sale of its larger prior position. International results are not broken out separately.

2. The Moat

Wingstop’s competitive advantage rests on a flavor-led brand with genuine cultural identity in the chicken wing category, and on the capital-light franchise structure that brand has enabled. These two things together, a brand that commands consistent consumer demand and a model that captures royalties from that demand without owning the infrastructure delivering it, are what makes Wingstop a structurally superior investment relative to a business that must own, staff, and maintain the restaurants it operates.

The Brand

Wingstop has spent thirty years building recognition in one specific product category. Twelve core flavors built around a flavor variety that no QSR format has replicated at the same depth. The brand competes on a specific eating experience. Cultural partnerships with musicians and athletes, and the 2024 designation as the official chicken partner of the NBA, have embedded the brand into sports and entertainment occasions in ways that persist through advertising cycles. A new entrant cannot acquire that positioning quickly.

The financial evidence for brand durability is in the pipeline. Existing franchisees, who see the full cost and revenue data for their own restaurants, are continuing to commit capital to new locations. In 2025, 100% of domestic development commitments came from existing operators. They are expanding into markets they already know with a product they have already proven. That behavior reflects genuine conviction in the brand’s ability to sustain demand, not compliance with a franchisor requirement.

The Capital-Light Model

The franchise structure is the source of Wingstop’s investment superiority. A company that collects royalties on approximately $5.3 billion in annual retail sales while deploying a corporate capital base of approximately $693 million in total assets is generating returns on capital that a restaurant operator bearing its own build-out costs and operating leverage could not approach.

ROIC averaged in the mid to high thirties for nine consecutive years against a WACC of approximately 11%. That 20-plus percentage point spread sustained across a decade is the direct financial expression of what it means to own the brand and the royalty right rather than the physical restaurants.

Each new restaurant a franchisee opens adds to the royalty income base at no capital cost to Wingstop. When same-store sales grow, royalty income grows proportionally on the existing base.

Saturating Markets as a Competitive Defense

The infill strategy that is currently compressing same-store sales at existing restaurants also builds a competitive barrier. When Wingstop reaches high density in a major market, it becomes significantly harder for a new chicken competitor to find viable real estate, build brand awareness from zero, and compete effectively against a system with multiple established locations, an active loyalty base, and a dominant delivery presence in the area. Wingstop’s management frames this explicitly as maximizing brand market share and visibility in key priority markets before extending into emerging ones. The short-term consequence is same-store sales redistribution. The long-term consequence is a market where a competitor would need to outspend and outoperate an already-entrenched network to gain a foothold.

Moat Assessment

The moat is strong. A competitor with sufficient capital and time could build a brand in the chicken wing category, but thirty years of single-category focus, genuine cultural recognition, and a franchise network of this scale create a lead that is meaningful and costly to close. ROIC at 32% in 2025 remains well above the cost of capital, the development pipeline is active, and no competitor has displaced the brand in its category. The same-store sales decline does not reflect a weakening of the competitive position. It reflects a deliberate expansion strategy adding delivery coverage in markets with proven demand, combined with temporary weather effects in Q1 2026.

3. Financial Performance

Total revenue grew from $248.8 million in fiscal 2020 to $696.9 million in fiscal 2025, a compound annual growth rate of approximately 23%. Royalty revenue, franchise fees, and other income grew from $108.9 million to $321.8 million, consistently representing between 43% and 46% of total revenue in every year. This is the only line that flows to Wingstop at essentially no incremental cost: it scales directly with system-wide sales and carries no operational overhead beyond the brand and technology infrastructure already in place. Advertising fees grew from $74.9 million to $247.6 million but pass through as both revenue and expense with no net contribution to operating income. Company-owned restaurant sales grew from $65.0 million to $127.5 million, representing approximately 20% of total revenue over the past five years. The count of company-owned restaurants grew from 32 at the end of fiscal 2020 to 57 at the end of fiscal 2025, representing approximately 2.4% of system-wide sales.

The 2025 net income figure of $174.3 million includes an $87.2 million gain on the sale of Wingstop’s UK equity stake, which inflated diluted EPS from a range of $0.78 to $3.70 between 2020 and 2024 to $6.21 in 2025. Adjusted EPS of $4.08, which excludes that gain alongside other non-recurring items, is the more accurate measure of what the underlying business produced. Adjusted EPS grew from $1.09 in 2020 to $4.08 in 2025, a compound annual growth rate of approximately 30%, running ahead of the 23% revenue CAGR over the same period. This outperformance reflects the starting point: net profit margin stood at 9.4% in 2020, a low base relative to the 13.7% average recorded in the five years prior and the 15.6% average in the four years that followed. The depressed starting amplified the adjusted EPS CAGR of approximately 30%.

Wingstop issues debt every other year through the securitized financing structure and distributes the proceeds to shareholders through dividends or share repurchases. In 2020, a $496 million issuance netted $162 million after repaying the prior tranche and was returned almost entirely as a special dividend of $163.8 million. In 2022, a $250 million issuance netted $247 million, of which $141.3 million was distributed as a special dividend. In 2024, a $500 million issuance netted $471 million, funding $314.7 million in share repurchases that year and leaving a cash balance that funded a further $221.9 million in repurchases in 2025. The buybacks reduced the diluted share count from approximately 29.8 million in 2020 to approximately 28.1 million in 2025, a reduction of 5.8%. Total debt to OCF ranged from 6.0 times at its tightest in 2023 to 9.7 times at its widest in 2021, and stood at approximately 8.3 times in 2025 following the $500 million 2024-1 issuance, which suggests it shall take Wingstop around 8.3 years to pay off its debt using its cash generated from its operations alone.

The interest burden is a direct consequence of the securitized debt structure, the proceeds of which are distributed to shareholders rather than retained in the business. Interest expense ranged from $14.9 million to $35.8 million, growing in line with each debt issuance. As a percentage of OCF, which ranged between $65.5 million and $157.6 million over the five-year period, interest consumed between 13.5% and 30.7%, moving with both the timing of each issuance and the level of OCF in any given year. In every year across the period, operating cash flow was sufficient to cover interest expense comfortably.

Capital expenditure was $6.1 million in 2020 and grew to a range of $24 to $52 million annually from 2021 onward, representing 7 to 10% of revenue. This capex does not build restaurants. Franchisees fund their own construction. Wingstop’s capex funds the shared digital infrastructure the entire franchise system runs on: the ordering platform, the Smart Kitchen operating system, the enterprise resource planning system, and the point-of-sale infrastructure across all domestic restaurants. This is largely growth capex rather than maintenance; however, as the major build phase completes and ongoing maintenance costs migrate from capital expenditure to operating expenses, the capex percentage should gradually moderate from current levels. The FCF margin moved from approximately 20.5% in 2020 to approximately 11.6% in 2025, compressing materially despite operating margin expansion, because elevated capex and growing SBC consume an increasing share of operating cash flow.

Q1 2026 Update

Domestic same-store sales fell 8.7% in the first quarter of 2026 against a decline of 0.5% in the same period a year earlier. On the Q1 2026 earnings call, CEO Michael Skipworth stated that atypical winter weather resulted in temporary closures across over 700 domestic restaurants during the quarter, concentrated in the Midwest and Northeast where the franchise network is densely penetrated. Management attributed approximately 4 percentage points of the decline to those disruptions. The 8.7% figure covers the entire domestic system. Company-owned restaurants within that system declined only 2.2%, reflecting their concentration in Texas markets that largely avoided the most severe weather. The gap illustrates how heavily the impact was concentrated in the franchised network’s Midwest and Northeast footprint.

Adjusting for weather, the underlying same-store sales trend is negative by roughly 4 to 5 percentage points. A portion of that residual reflects the hard comparison against 19.9% growth in fiscal 2024. The remainder reflects the infill strategy: new restaurants opening in the same markets as existing ones, capturing delivery occasions from nearby locations and reducing those locations’ same-store sales in the process. The existing restaurant loses some transactions to the new one next door, but the franchisee who owns both sees their total portfolio revenue grow. System-wide sales, which count every restaurant, grew 5.9% to approximately $1.4 billion in the quarter, confirming that total demand through the system continued expanding even as the per-store metric contracted. Zero permanent domestic restaurant closures were recorded. Ninety-seven net new restaurants opened.

4. Capital Allocation

Wingstop is a capital-light business by design. Franchisees fund the construction and operation of every restaurant. The company itself deploys capital through three channels: dividends, technology infrastructure investment, and share repurchases.

The dividend has grown annually since its introduction in 2017, reaching $1.14 per share in 2025. At the current price this yields approximately 0.8%, with a payout ratio of approximately 28% of adjusted net income, adjusted for the UK equity stake gain and other non-recurring items. Dividends are paid out of the recurring royalty cash flows the business generates, with special dividends distributed amidst the debt issuance.

The buyback program is funded not from organic free cash flow but from the proceeds of debt issuances. Wingstop borrows against its royalty cash flows through the securitized financing structure and uses the proceeds to retire shares. Three authorizations have run since August 2023: an original $250 million program, an additional $500 million in December 2024, and a further $300 million in March 2026. Across all repurchases through Q1 2026, the company retired approximately 2.96 million shares at a blended average price of approximately $252.

Capital expenditure, has run between 6.7% and 11.3% of revenue in every year since 2019. It covers the shared digital infrastructure described in the Financial Performance section and does not fund restaurant construction, which is the franchisee’s cost.

5. Competition

Wingstop is the largest chicken wing-focused restaurant chain in the world by location count. The wing category has several direct competitors, all of which compete primarily on occasion rather than on the same digitally-native, delivery-first, small-footprint franchise model Wingstop operates.

Buffalo Wild Wings

Buffalo Wild Wings operates approximately 1,600 locations in the United States and is the most visible brand associated with the chicken wing occasion. The format is fundamentally different: larger footprint, full-service bar, dine-in oriented, and heavily tied to the sports bar occasion. Buffalo Wild Wings has been owned by Inspire Brands since 2018 and does not report separately. The dining format means it competes for the same wing consumer on a different occasion type, the planned in-venue sports viewing experience rather than the everyday delivery order. Wingstop’s digital-first delivery model largely avoids that direct occasion comparison.

Chicken Category Competitors

KFC operates more than 25,000 locations globally across dine-in and drive-thru formats, owned by Yum Brands. It competes on a full chicken menu at a broad price range and targets a different consumer occasion entirely: a planned, family-style meal rather than a digital delivery wing order. The scale comparison is instructive for understanding Wingstop’s long-term runway, but the format, occasion, and ownership model share little with Wingstop’s delivery-first franchise structure.

Popeyes is the most operationally comparable publicly observable franchise by product category: chicken-focused, predominantly franchised, and reporting same-store sales through Restaurant Brands International. Popeyes comparable sales declined 6.5% in Q1 2026, against a decline of 4.0% in Q1 2025, a result its management described as among the weakest in roughly 20 years. The surface parallel with Wingstop’s 8.7% decline does not hold under examination. Popeyes grew its restaurant count at only 1.2% net in Q1 2026, with system-wide sales declining 3.9% as a result. Wingstop, by contrast, opened 97 net new restaurants in the same quarter with system-wide sales growing 5.9%. Wingstop’s SSS decline at existing locations reflects demand being redistributed to nearby delivery hubs that the same franchisee owns, a deliberate and self-funded consequence of the infill strategy. Popeyes does not operate the same delivery-first, small-footprint densification model. Its SSS decline reflects competitive pressure on a relatively static store base. The two numbers look similar. The business logic behind them is different.

Third-Party Delivery Platforms

Approximately 73% of Wingstop’s system-wide sales flow through digital channels, with a meaningful portion through third-party delivery platforms at commission rates typically in the 15 to 30% range. Wingstop earns its royalty on gross sales regardless of channel. The commission cost sits entirely with the franchisee. A restaurant generating significant volume through aggregators at a 25% average commission rate is absorbing a material cost that reduces the net economics of each order but does not appear in Wingstop’s own income statement. This is a structural cost at the franchisee level that must be held in mind when reading system-wide sales growth as a measure of franchisee profitability.

6. Management

Michael J. Skipworth, President and Chief Executive Officer

Michael Skipworth joined Wingstop in December 2014 and progressed through finance and operations roles, including CFO and Chief Operating Officer, before being appointed President and CEO in March 2022. He has been present for the digital platform build-out, the international expansion, and the current same-store sales cycle.

His standard annual compensation comprises a base salary of $1,000,000 and a performance-based cash incentive with a target of $1,200,000 weighted 80% to adjusted EBITDA growth and 20% to net new unit openings. In 2025, the company opened 493 net new units against a maximum bonus threshold of 360, exceeding the ceiling by 37%. The annual cash incentive paid at 142% of target. The unit opening metric creates a direct link between management’s annual compensation and the infill strategy that simultaneously drives same-store sales lower at existing locations. The independent check on whether the strategy is commercially justified, rather than compensation-driven, is franchisee behavior: existing operators committing voluntary capital to new locations in the same markets at double-digit annual rates.

Total 2025 compensation was approximately $35.3 million, elevated by a retention award of approximately $25 million approved in September 2025. The award comprises $12.5 million in service-based RSUs with a five-year cliff and no performance condition, and $12.5 million in performance-based units measured against system-wide sales targets from Q3 2029 through Q2 2030. Half the award is guaranteed by continued employment alone. The deliberation ran from April through September 2025, a period during which the same-store sales deterioration was already visible.

Skipworth’s personal beneficial ownership stands at approximately 44,100 shares, worth approximately $6.3 million at current prices. The four largest institutional holders are BlackRock at approximately 9.96%, T. Rowe Price at approximately 7.83%, Lone Pine Capital at approximately 5.43%, and Massachusetts Financial Services at approximately 5.12%. There is no founder stake and no controlling shareholder.

7. Growth Levers & Addressable Market

The Infill Strategy: Why Franchisees Are Expanding in Existing Markets

The domestic expansion strategy concentrates new openings in markets the system already serves before extending into new geographies. This is not an accident of franchisee preference. It is a deliberate commercial rationale built into the economics of the model.

When a new Wingstop opens in a city where the brand already operates and advertises, the advertising fund is already covering that market. The new restaurant pays into the fund and immediately benefits from existing brand awareness at no incremental marketing investment from Wingstop or the opening franchisee beyond what the fund already commits. In a new geography, building brand recognition requires months of local marketing investment before the first regular customer develops a habit. The financial model for an infill restaurant is therefore more predictable and less capital-intensive in marketing terms than a greenfield entry.

Supply chain efficiency reinforces this. All food and packaging for domestic restaurants flows through a single national distributor with 23 geographically diverse distribution centers. Clustering restaurants in existing markets reduces last-mile delivery costs, improves freshness, and simplifies logistics.

The delivery format makes density a functional requirement. Wingstop’s 1,700 square foot restaurant serves a realistic delivery radius of roughly three to five miles at acceptable delivery times. A major metropolitan area requires multiple locations to achieve the coverage needed to serve every delivery zone within a reasonable window.

Existing franchisees are the ones driving this expansion because they see it working in their own portfolio. An operator who owns one restaurant and opens a second two miles away may see the original store’s same-store sales decline by 5 to 8%, but their total portfolio revenue grows substantially if the new restaurant reaches even 70 to 80% of the original’s AUV. The combined economics of the expanded portfolio are what franchisees are optimizing, not the per-store metric. Their continued commitment to opening at double-digit rates, in markets they already know and where they are already invested, is the clearest available signal that the combined portfolio economics justify the expansion.

The Path to 10,000 Restaurants

The domestic pipeline is pointed at a long-term goal that requires substantial geographic expansion beyond current markets. The company has stated it can double the domestic restaurant count from approximately 2,650 to over 5,000 through both existing and emerging markets. At an annual unit growth rate of 15 to 16%, the domestic system would reach approximately 5,000 restaurants within roughly seven years. Reaching the company’s broader stated ambition of more than 10,000 total restaurants worldwide requires both the full domestic buildout and continued international expansion across markets where Wingstop is still early.

The committed domestic pipeline already represents the foundational layer of this growth. Development agreements signed by existing franchisees commit them to specific opening schedules across specific markets. When 100% of those commitments come from existing operators, it reflects franchisees who have already operated in the system, verified the unit economics in practice, and made a forward commitment to expand further. This is not speculative demand from untested franchisees. It is contracted growth from proven operators.

International Runway

The system operated approximately 500 international restaurants across 18 countries and U.S. territories as of early 2026. The United Kingdom added more than 20 locations in 2025. India is planned for entry in 2026. The 1,700 square foot format, requiring no dining room, minimal staffing relative to a full-service restaurant, and compatible with any cuisine culture that accepts chicken as a protein, travels well across international markets. The master franchisee structure concentrates local market knowledge in a partner who assumes the development risk, limiting Wingstop’s direct capital exposure to international growth. International results are not separately disclosed.

8. Valuation

The future return on Wingstop stock is a function of two engines: the future growth in free cash flow per share and any valuation re-rating. Both are explained below.

Free cash flow throughout this report is operating cash flow less capital expenditure less stock-based compensation.

Engine 1: Fundamentals

The first engine is the business itself. FCF per share grows over time through revenue expansion, operating leverage, and share count reduction from buybacks. That growth, compounded annually, is what the fundamental engine delivers regardless of any valuation re-rating.

For Wingstop, the primary driver is unit growth compounding royalty income on a growing system-wide sales base. At 15 to 16% annual net new restaurant openings, system-wide sales grow even when same-store sales are flat or modestly negative. Each new restaurant adds to the royalty income base at no capital cost to Wingstop. Buybacks add per-share amplification effect as the diluted share count declines.

Engine 2: Valuation Re-Rating

At today’s price of approximately $166, the investor is paying for everything this business will earn over roughly the next 23 years, in today’s money. Everything it earns beyond that point comes to the investor at no additional cost. The fewer the embedded years, the more of the future the investor receives without paying for it.

At 23 embedded years, the price is not offering an investor a meaningful valuation tailwind. The fundamental engine is doing the work here: unit growth compounding royalty income on a growing system-wide sales base, with same-store sales expected to normalize as the hard prior year comparison fades, weather effects clear, and new restaurants mature into the same-store calculation. That engine is sufficient on its own to generate a reasonable return from this price.

However, it is worth mentioning that Capital-light franchise businesses with this degree of cash flow predictability have historically traded at a persistent premium to the broader market, which suggests the valuation here carries less downside risk than the embedded years figure alone would imply for a typical business.

For a detailed explanation of how this valuation framework works, please read A Comprehensive Guide to Business Valuation.

9. Risks

Same-Store Sales Normalization Timeline

The 8.7% domestic same-store sales decline in Q1 2026 reflects several identifiable components. Management attributed approximately 4 percentage points to weather-related temporary closures in Midwest and Northeast markets. A meaningful portion reflects the hard comparison against 19.9% growth in fiscal 2024, which fades progressively over the next four quarters. And a portion reflects the natural redistribution of demand within markets where the infill strategy has added new locations near existing ones.

The first two effects ease or resolve without any change in business strategy. The fourth resolves as new restaurants mature past their first year and enter the same-store calculation as contributors, and as the infill strategy progressively pivots toward new geographic markets where the redistribution dynamic does not apply. The risk is the timeline: if the normalization takes longer than expected, or if the hard comparison is followed by category-level demand softness, same-store sales could remain negative beyond the period explained by known transient factors.

Product Economics and Value Competition

Bone-in chicken wings cannot be restructured to hit a sub-$10 price point without reducing wing count below the threshold that makes the order satisfying. The average Wingstop ticket runs above $20. At that price, a consumer recalculating food spend compares Wingstop against cheaper alternatives: a burger, a pizza, or a home-cooked meal. Wingstop cannot build a value floor the way a burger operator can engineer a $5 meal around inexpensive protein. When consumer budgets tighten, ordering frequency at premium-ticket formats falls first. This is a structural feature of the product category that has always existed and will persist regardless of what management does.

Bone-in wings also carry no meaningful commodity hedge. There are no established fixed-price markets for fresh bone-in chicken, which accounted for approximately 20.5% of company-owned restaurant cost of sales in 2025. The 2019 episode, when COGS grew 53.8% against 30.4% revenue growth as wing prices spiked, established the precedent for how quickly input cost pressure translates into restaurant-level margin compression. If chicken wing costs rise during a period of same-store sales pressure, franchisee margins compress from both revenue and cost simultaneously.

10. Original Verdict

The business has demonstrated through a decade of operation that its franchise model generates exceptional returns on a minimal corporate capital base. ROIC averaging in the mid to high thirties against a WACC of approximately 11%, sustained across a full decade that included a pandemic, a commodity cost event, and the same-store sales decline now dominating the stock’s narrative. A brand with thirty years of category identity in chicken wings that no competitor has displaced. A system that grew from approximately $2.7 billion to approximately $5.3 billion in system-wide sales in four years on capital deployed overwhelmingly by franchisees rather than by the company. These are the financial expressions of a model that earns the Approved designation.

Domestic same-store sales have been negative for five consecutive quarters. System-wide sales have grown in every one of those quarters. The two facts coexist because same-store sales measures only mature, existing restaurants, while system-wide sales counts everything. When a new restaurant opens near an existing one and serves customers who were previously too far for a reasonable delivery, the existing restaurant’s same-store metric declines and the system’s total sales grow. That is not brand deterioration. That is the delivery-focused franchise model expanding its physical coverage in markets where the brand has already demonstrated demand.

The franchisees make this case more compelling than any financial metric. Every domestic development commitment in 2025 came from existing operators who see the full cost and revenue data for their own restaurants. They are expanding into adjacent delivery zones in markets they already serve, committing their own capital at double-digit annual rates, because the combined economics of their growing portfolio justify the investment. Franchisees who believed the economics were broken would not be doing this. They are.

The risks are real and stated plainly. The product economics of bone-in wings do not allow Wingstop to match the value floor available to burger or pizza operators, which creates exposure to consumer spending pressure that is structural, not cyclical. The compensation structure links management’s cash incentive to unit openings in a way that warrants monitoring. None of these individually or collectively changes the Approved designation. They are costs to the return on a business whose model continues to compound.

Disclosure: The author does not hold a position in Wingstop, Inc. at the time of publication. This report reflects the author’s personal views and is not investment advice. Investing carries the risk of permanent capital loss. Read full disclosure here.

The Outlook

Termites cost American homeowners more than $5 billion in structural damage each year, and homeowner insurance covers almost none of it. That single fact explains more about Rollins’s business model than any earnings release.

When the damage is invisible until it is severe, when the insurance exclusion is permanent, and when the repair bill arrives without warning, the rational response is prevention. And when prevention requires a licensed technician applying regulated chemicals on a scheduled basis, the rational response is a contract. Rollins has been collecting on that contract for more than sixty years. Today it serves more than two million residential and commercial customers across approximately 70 countries.

Rollins is not a pest control company in the sense that most investors understand a service business. It is a route-based recurring revenue platform whose economic model rewards local density, operational discipline, and patient acquisition of family-owned businesses at rational prices.

The company O. Wayne Rollins built after acquiring Orkin Exterminating in 1964 has produced 24 consecutive years of revenue growth, including through the 2008 financial crisis, the pandemic year of 2020, and the labor inflation cycle of 2021 to 2023. The record reflects a business structure in which three quarters of revenue renews automatically on a fixed schedule, the service is non-discretionary for the commercial segment and financially irrational to cancel for the residential one, and the competitive dynamics of route density mean that the market leader in any local geography earns structurally higher margins than anyone chasing it.

The governance picture is in transition. Gary W. Rollins stepped back from the Board at the April 2026 Annual Meeting after 45 years of active involvement, with Jerry Gahlhoff serving as President and CEO since January 2023. The Rollins family retains approximately 37.86% of shares outstanding, controlled jointly through two voting trusts requiring consensus between Gary’s branch of the family and the descendants of his late brother R. Randall Rollins.

Disclosure update: The author now holds a position in Rollins. The position was initiated after the original publication date of this report. All analysis and conclusions remain unchanged. This report reflects the author’s personal views and is not investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

At a Glance

Company: Rollins, Inc.

Ticker: $ROL · NYSE

Sector: Industrials

Industry: Pest and Termite Control Services

Market Capitalization: ~$22.7 billion (at $47)

First Coverage: June 2026

FY2025 Revenue: $3.76 billion

1. The Business

O. Wayne Rollins and his brother John Rollins built their early business through broadcasting and advertising in the 1950s. The defining transaction came in 1964 when O. Wayne acquired Orkin Exterminating Company, founded in 1901 by Otto Orkin and already the largest pest control operator in the United States at the time of purchase. In 1965 the parent company changed its name from Rollins Broadcasting to Rollins Inc., and in 1968 it began trading on the New York Stock Exchange under the symbol ROL.

What O. Wayne recognised in Orkin was an economics model that rewarded concentration, created recurring customer relationships, required almost no capital to grow, and served a demand that existed in every geography regardless of the economic cycle. He spent the following three decades building on that insight. His sons Gary and Randall carried it forward. Gary served as CEO from 2001 to 2022. The company that Jerry Gahlhoff now leads is the compound output of sixty years of disciplined execution on the original insight.

What Rollins Does

Rollins provides pest and termite control services to residential and commercial customers through a portfolio of brands that includes Orkin, Clark Pest Control, HomeTeam Pest Defense, Fox Pest Control, Saela Pest Control, Western Pest Services, Northwest Exterminating, Critter Control, Trutech, Waltham Services, and approximately a dozen others. The company operates through more than 850 branch locations in the United States and internationally across approximately 70 countries, employing 21,946 people as of December 31, 2025. Each technician assesses conditions at customer properties, applies appropriate treatments, inspects for signs of infestation, and moves to the next stop.

The same technician returns on the same schedule, month after month or quarter after quarter. Each additional customer added to an existing route increases revenue at a marginal cost that is lower than the average cost because the fixed infrastructure of vehicle, route management, branch overhead, and technician time is already in place.

Revenue Structure

Rollins generates revenue across three service lines:

Residential pest control contributed approximately 45% of 2025 revenue, serving homeowners under recurring contracts. Commercial pest control contributed approximately 33%, serving food service, healthcare, logistics, and other regulated industries where pest-free environments are a regulatory and reputational requirement rather than a preference. Termite and ancillary services contributed approximately 21%, encompassing termite protection programs with warranty structures alongside crawlspace encapsulation, wildlife exclusion, mosquito control, and insulation services. Franchise and other revenue contributed approximately 1%, consisting of royalties from 131 domestic and 66 international franchise agreements.

Approximately 75% of the business is recurring, renewing automatically under service agreements. Approximately 10% is ancillary, representing deeper service relationships with existing customers. Approximately 15% is one-time, consisting of individual treatments for specific infestations or initial termite installations. The one-time layer generates above-average margins but is the component most sensitive to weather conditions, which affect pest activity levels and the urgency of unscheduled service demand.

The Branch as Atomic Unit

Each branch is a local operating hub serving a defined geographic territory, housing technicians, vehicles, chemical inventory, scheduling infrastructure, and customer service functions.

The branch manager is accountable for revenue growth, technician retention, customer retention, route efficiency, and local regulatory compliance. Corporate provides technology, supply chain leverage, training infrastructure, and financial discipline. The operational execution is local.

The Branch Operating Support System, which Rollins calls BOSS, is the proprietary technology platform running routing, scheduling, service tracking, and payment processing across the network. Most of the business runs on it. InSite, a separate proprietary web reporting capability available exclusively to commercial customers, provides real-time service data and pest activity tracking that management describes as a competitive advantage in winning and retaining commercial accounts. Rollins has been named among Training magazine’s Top 125 US Training Companies 17 times in the past 23 years, a credential that reflects the combination of technology investment and people investment that defines the service delivery model.

The Acquisition Strategy

Over the last three years Rollins completed 94 acquisitions, including 26 in 2025, deploying $309.5 million in acquisition capital in the most recent year. The typical target is a privately owned regional or local operator: a family business founded one or two generations ago with loyal customers, established route density, and local brand recognition. The company sits at the top of the credible-buyer list in every market it operates, and the pipeline of aging founder-owned businesses is structural and long-duration.

When Rollins acquires a local operator serving 2,000 customers in a geography where Rollins already runs routes, the acquired customers can often be absorbed into existing routes with minimal incremental fixed cost. The technician who previously served 20 stops per day now serves 24. The vehicle, the management overhead, and the branch infrastructure are already in place. The acquired revenue flows through at margins that typically exceed the company average because the fixed cost base does not grow proportionally.

Larger acquisitions serve a different strategic purpose: Fox Pest Control in April 2023 for $339.5 million and Saela Pest Control in April 2025 for $207.2 million brought digitally-native customer acquisition models, modern sales infrastructure, and brand platforms that Rollins studies and deploys across the broader network.

2. The Moat

Rollins’s competitive position rests on four reinforcing pillars:

Route Density Economics

In a route-based service business, the fixed costs of field operations are spread across the customer base. The operator with the highest customer concentration per square mile serves more stops per technician per day, generating more revenue from the same cost base. It compounds with every acquisition that adds customers to an existing route.

Rollins expanded operating margin from 16.2% in 2015 to 19.3% in 2025 through a period that included aggressive acquisition-driven growth, a global pandemic, and labor cost inflation running at levels not seen in decades. That expansion happened while Rollins was simultaneously absorbing 94 acquisitions over three years and growing headcount from 11,268 employees in 2015 to 21,946 in 2025.

Termite Warranty Stickiness

The termite business is the most structurally embedded revenue Rollins owns. When a customer purchases an initial termite treatment and enters a protection agreement, they receive a warranty: if termites return and cause damage while the contract is active, Rollins covers the cost of treatment and repair.

Most homeowner insurance policies exclude termite damage entirely, so the warranty is the customer’s only protection against a repair bill that typically runs into thousands or tens of thousands of dollars. Cancelling the contract means losing the warranty. For a homeowner in a termite-endemic region, primarily the Southern and Southeastern United States, that cancellation is financially irrational. The rational decision is to keep paying.

Rollins carried $233 million in unearned revenue on December 31, 2025, the majority representing prepaid pest and termite service contracts. Customers paying in advance for services not yet rendered is the most direct measure of the stickiness of the relationship.

Proprietary Technology

BOSS, the Branch Operating Support System, calculates the most efficient sequence of stops for each technician on each day, minimising drive time and maximising customer visits per hour. Rollins has invested in evolving and modernising BOSS over multiple years.

An independent operator with 50 technicians has no economic basis for a proprietary routing optimisation platform. It uses generic software or manual scheduling. The efficiency gap between Rollins’s optimised routing and a competitor’s manual scheduling translates directly into stops per day and therefore revenue per technician. That gap widens with scale and cannot be closed by a competitor whose scale does not justify the investment.

Brand Recognition

Orkin was founded in 1901, predating Rollins’s ownership by over six decades. It is a household name across the United States with brand awareness that no regional competitor can replicate without a generation of sustained investment. Brand strength reduces customer acquisition cost by generating inbound demand, reduces price sensitivity because customers associate the name with reliability, and creates a trust advantage when a technician arrives at a property for the first time.

None of these effects appears directly in the income statement, but all of them lower the cost of growing revenue. The multi-brand portfolio, which now includes Clark, HomeTeam, Fox, Saela, Western, Northwest, and approximately a dozen others operating in specific geographies and customer segments, extends this brand moat into markets and demographics where Orkin alone would not be the customer’s first instinct.

3. Financial Performance

Total revenue grew 11% year over year in 2025, from $3.4 billion to $3.8 billion. Organic growth contributed 6.9 percentage points and acquisitions contributed the remaining 4.1 percentage points. Within that organic number, termite and ancillary grew 9.9%, the fastest of the three segments, and the one where pricing discipline is structurally highest: a customer facing a termite price increase must weigh it against losing the warranty entirely. Management guided for 7% to 8% organic growth in 2026. The ten-year compound annual growth rate from 2015 to 2025 was approximately 9.7%.

Gross margin has been remarkably stable across the decade, ranging between 50.5% and 52.8%, a signal that pricing discipline has consistently offset input cost inflation across every cycle the business has faced.

The 2019 operating margin compression from 17.0% in 2018 to 15.8% tells an important story. SG&A expanded aggressively as Rollins accelerated headcount, sales infrastructure, and acquisition activity, a deliberate decision to spend ahead of revenue. The compression was temporary, fully absorbed by 2021. By 2023 operating margins had reached 19.2%, exceeding any prior year in the decade, and by 2025 they stood at 19.3%.

Diluted EPS grew from $0.31 in 2015 to $1.09 in 2025, a compound annual rate of approximately 13%. The share count declined modestly from approximately 492 million to approximately 484 million over the decade, confirming that buybacks contributed almost nothing to the per-share growth. Operating margin expanded from 16.2% to 19.3% over the same period, and that expansion, compounding on a revenue base growing at nearly 10% annually, is what drove earnings per share higher.

4. Capital Allocation

Rollins generated $678 million in operating cash flow in 2025. That cash funded the acquisition program of $309.5 million and the full dividend payment of $327.9 million, with a modest surplus. The $200 million block share repurchase from the founding family and the broader acquisition activity across the year were funded in part by the $500 million in senior notes issued in February 2025, which replaced the revolving credit facility as the primary long-term debt instrument.

The acquisition program deployed $309.5 million in 2025, completing 22 acquisitions and 4 franchise buybacks. The largest was Saela Pest Control, acquired in April 2025 for $207.2 million, with management describing post-acquisition performance as exceeding expectations.

The Romex acquisition closed April 1, 2026 for $90 million plus $10 million of contingent consideration. Goodwill has grown from $250 million in 2015 to $1.37 billion at year-end 2025. That growth has not compressed ROIC. The returns on the operating assets of acquired businesses have held above the cost of capital across the decade.

Rollins paid $0.6775 per share in dividends during 2025, a total of $327.9 million. The dividend has been raised in every year of the past decade, growing from $0.14 per share in 2015 to $0.6775 in 2025, an increase of approximately 384% over ten years. The 2025 payout ratio against net income was approximately 62% and against FCF was approximately 54%.

Rollins does not run a consistent open-market repurchase program. It executed two block repurchases directly from the founding family through secondary offerings: 8.7 million shares for $300 million at $34.39 in September 2023, and 3.5 million shares for $200 million at $56.93 in November 2025. In the November 2025 transaction, LOR Inc. and Rollins Holding Company sold approximately 20 million shares at $57.50 in the public offering; Rollins repurchased 3.5 million of those shares at the underwriter price. The company received no proceeds from either offering. The diluted share count declined from approximately 492 million in 2015 to approximately 484 million in 2025, a reduction of less than 2% over a decade.

Capital expenditure was $28.1 million in 2025, or 0.7% of revenue. In February 2025 Rollins issued $500 million in ten-year senior notes at 5.25%, due February 2035, and in March 2025 established a $1 billion commercial paper program, of which $114.4 million was outstanding at year-end. The revolving credit facility of $1 billion was undrawn. Total financial debt at December 31, 2025 was approximately $624 million against operating cash flow of $678 million. At less than one time operating cash flow, the balance sheet carries no meaningful constraint on the acquisition program that drives most of the revenue growth.

5. Competition

Rollins operates in a fragmented market with low barriers to entry at the local level. Any licensed technician with a vehicle and a supply of chemicals can start a pest control business. The barriers to operating at scale are substantial: route density economics, brand recognition, proprietary technology, and the financial discipline to execute acquisitions at rational prices over decades are not characteristics that entry-level operators possess. The competitive landscape has three distinct layers.

Rentokil Initial

Rentokil is the only direct public peer comparable in business model and geographic reach. Before the Terminix acquisition, Rentokil’s ROIC was rising consistently, from 14.1% in 2015 to 28.6% in 2020 and 30.0% in 2021, as it executed a systematic European consolidation strategy that generated genuine returns. The $6.7 billion Terminix acquisition, which closed in 2022, reversed that trajectory abruptly. The acquired invested capital base expanded dramatically while integration complexity suppressed operating income, collapsing ROIC to 6.5% in 2022. By 2025 it stood at 10.1%, still less than a third of Rollins’s 34.6%.

The goodwill comparison tells the same story in a different register. Rentokil carries approximately $6.6 billion of goodwill against a market capitalisation of approximately $14.9 billion. Nearly half its market value is acquisition premium sitting on the balance sheet generating no cash. Rollins carries $1.4 billion of goodwill against a market capitalisation of approximately $22.7 billion at current prices, less than 7%. The difference is not simply that Rentokil made a large acquisition. It is that the premium paid has not yet been justified by the returns generated on the acquired assets. Rollins has spent two decades demonstrating that its acquisition premiums earn their cost. Rentokil is still working to demonstrate the same.

The operating margin comparison reinforces the picture. Rollins runs at 19.3%. Rentokil ran at 9.5% in 2025. That nearly 10 percentage point gap reflects route density economics, technician productivity, pricing discipline, and brand strength that Rentokil has not achieved at the same level. Three years after closing the Terminix transaction, Rentokil continues to manage integration complexity, customer attrition, and margin pressure in a business whose domestic economics have historically been weaker than Rollins’s. The Terminix acquisition was intended to create the world’s largest pest control operator by revenue. It achieved that goal. It has not, to date, translated into the operational economics that Rollins has demonstrated over decades.

Ecolab

Ecolab is a $16.1 billion diversified chemicals and services company whose businesses span institutional cleaning, water treatment, food safety, healthcare hygiene, and pest elimination. The pest division competes with Rollins primarily in large commercial and institutional accounts where pest service is bundled into a broader Ecolab relationship. Ecolab’s ROIC was 19.5% in 2025, meaningfully below Rollins’s 34.6% but a strong absolute result that reflects genuine competitive advantages across its core chemicals and services businesses. Ecolab is a formidable operator in the specific commercial and institutional segment where it concentrates, but its pest business is one division among many and it does not compete meaningfully with Rollins in residential, termite, or small commercial work.

Anticimex

Anticimex is a private Swedish operator owned by EQT Partners and the dominant pest control platform in Europe, with growing North American ambitions. No audited financial data is publicly available. Its strategic relevance is twofold: it represents direct competition in the international markets where Rollins is building, and it is the most logical future competitor for the North American acquisition targets that Rollins currently pursues with limited competition. The absence of public financials prevents any direct comparison, but Anticimex’s trajectory warrants monitoring.

Massey Services

Massey Services is a privately held, family-owned operator founded by Harvey L. Massey in 1985 and headquartered in Orlando, Florida, with estimated annual revenues of approximately $500 to $600 million. It is the most formidable regional independent in the Southeast, competing directly with Rollins’s Orkin and other brands in Florida and Georgia, which are among Rollins’s densest domestic markets. Massey competes for the same customers and technicians in its home markets and has built genuine brand recognition over four decades of operation. It also represents the archetypal succession opportunity: a well-run family business that will eventually face a transition decision, and for which Rollins would be among the most credible and operationally sensitive buyers.

The Fragmented Long Tail

The United States pest control market contains thousands of independent operators, most generating under $5 million in annual revenue. These businesses are not competitive threats to Rollins at the scale level. They are the raw material of the acquisition strategy. An independent operator competing against Rollins in any local market faces two structural disadvantages simultaneously: lower route density means higher cost per customer served, and lower purchasing volume means higher cost per chemical unit applied. Neither gap closes without the scale that only years of consolidation can produce. An estimated 75% to 80% of the domestic market remains outside the hands of the top national and regional operators, representing decades of acquisition runway for a disciplined consolidator.

6. Management

Jerry E. Gahlhoff Jr. — President and Chief Executive Officer

Jerry Gahlhoff has served as President and CEO since January 1, 2023. He joined Rollins in 2008 through the HomeTeam Pest Defense acquisition, not through the Orkin legacy or the founding family, and spent 24 years inside the organisation before assuming the top role. He holds a Master of Science in Entomology from the University of Florida.

Pest control is a technical business. The economics that make it attractive, recurring contracts, route density, termite warranties, rest on a service that must be delivered correctly by licensed technicians applying the right treatment to the right infestation. A CEO who understands the product at the entomological level understands why the route matters, why the technician retention rate matters, and why the warranty claim rate matters, in a way that a generalist manager does not.

Gahlhoff’s 2025 total compensation was $8.97 million. Base salary of $1.1 million represented approximately 12% of the total. The annual cash incentive of $1.68 million paid at 100% of target on the EBITDA element and 105% of target on the revenue element, reflecting 100.1% and 101.6% plan achievement respectively. Stock awards comprised $4.40 million in restricted stock and $1.73 million in performance share units tied to three-year revenue CAGR, adjusted EBITDA margin, and relative TSR against the S&P 500. The 2023 PSU cycle concluded at year-end 2025 with 11.7% three-year revenue CAGR and 22.6% average adjusted EBITDA margin, earning maximum payouts on both operating components.

Ownership and Governance

The Rollins family controls approximately 37.86% of shares outstanding through the Significant Shareholder Group, consisting of Gary W. Rollins, his niece Amy R. Kreisler, and the children of the late R. Randall Rollins: Pamela R. Rollins and Timothy C. Rollins. The primary holding vehicle is LOR Inc., which controls 152.2 million shares, or 31.58% of shares outstanding, through two voting trusts that each hold a 50% interest. Neither trust can direct LOR’s votes without the agreement of the other. The Vanguard Group holds 7.94% and BlackRock holds 5.92%.

Gary W. Rollins stepped back from his formal Board seat at the April 2026 Annual Meeting after 45 years of active involvement, remaining as a non-voting honorary Chairman Emeritus. Timothy C. Rollins, Gary’s nephew and Randall’s son, was elected to the Board at the same meeting. With Pamela R. Rollins already a Board member since 2015, the third generation now occupies two board seats.

The six-decade record is the most direct evidence of how family control has been exercised. Revenue has compounded from a single acquired business to $3.8 billion. ROIC has averaged above 30% for five consecutive years. The acquisition discipline that built the goodwill on the balance sheet has not compressed the returns on the operating assets beneath it. The concentrated control has served long-term shareholders well across this history.

The governance risk is not that the structure fails mechanically. The 50/50 voting trust split means no single family member or branch can act unilaterally, and the structure has held without visible disruption for over three decades. The risk is that the informal consensus-building that made it work under the founding generation becomes more difficult as the number of family members with independent interests grows across the third generation. Gary’s personal authority as the patriarch was a form of governance that voting trust documents alone cannot replicate.

7. Growth Levers & Addressable Market

The United States pest control market generates approximately $20 billion in annual revenue and remains deeply fragmented, with the top operators collectively controlling an estimated 20% to 25% of the total. Rollins generated $3.8 billion of that revenue in 2025. The remaining 75% to 80% is served by thousands of independent operators, most of whom lack the scale, the technology, and the succession plan to compete with a disciplined consolidator over a decade. The growth runway follows directly from that fragmentation.

Organic Price Increases

Rollins has demonstrated consistent ability to raise prices across its customer base. Organic revenue growth of 6.9% in 2025 and 6.6% in Q1 2026 reflects the combination of new customer additions and price increases on the existing base. In the termite segment, where the warranty creates a financial disincentive to cancel, price sensitivity is structurally lower than in discretionary service categories. Management has guided for 7% to 8% organic growth in 2026.

The key constraint on price increase capacity is technician quality and customer retention: customers absorb price increases when the service relationship is strong and do not when it is not. The people investment and the pricing power are not independent variables.

Cross-Selling to the Existing Customer Base

With average services per customer below 2.0 across a base of more than two million customers, the cross-selling opportunity does not require acquiring new territories or building new routes.

It requires a trained conversation on an existing visit. Moving from approximately 1.8 to 2.2 services per customer over five years would add approximately 22% to the revenue contribution from the existing base at near-zero incremental customer acquisition cost. Rollins added 14 dedicated commercial branches and 3 dedicated commercial regions in 2025 specifically to deepen the commercial services-per-customer ratio, and the commercial segment’s 7.6% organic growth is the early evidence of that investment producing results.

Acquisition of Independent Operators

The top operators collectively control an estimated 20% to 25% of a market generating approximately $20 billion in annual revenue domestically. The remaining 75% to 80% is served by thousands of independent family businesses facing a generational succession problem.

Management guided for 2% to 3% inorganic revenue contribution in 2026, consistent with a pace of acquisition activity that has been sustained for years. The pipeline of willing sellers is structural and long-duration.

Geographic and International Expansion

International operations contributed $269.7 million, approximately 7% of 2025 revenue, primarily from company-owned operations in Canada, Australia, the United Kingdom, and Singapore. The global pest control market is estimated at over $20 billion annually and is more fragmented internationally than domestically. Rollins’s acquisition playbook has been tested almost exclusively in North America.

The international opportunity is real but carries execution risk that domestic bolt-on acquisitions do not: different regulatory environments, different pest species requiring different treatment protocols, and different competitive landscapes all increase complexity. Management has been deliberately measured in international expansion, consistent with the operational discipline that characterises the domestic business.

Adjacent Services and the Ancillary Layer

The 10% of revenue currently classified as ancillary services is the highest-growth and highest-margin component of the mix. As crawlspace encapsulation, insulation, wildlife exclusion, and mosquito control grow as a share of the revenue mix, the overall margin profile improves structurally.

Fox and Saela were acquired in part because of their success in selling adjacent services to residential customers alongside core pest control. The cross-brand deployment of those capabilities across the Orkin network is a multi-year initiative still in early stages.

8. Valuation

Every price paid for a business contains an implicit question: how many years of future cash flows are already baked into what you are paying today? The Bearhold framework constructs a year-by-year series of discounted free cash flows and asks: at today’s stock price, how many years of future earnings are embedded? Everything the business earns beyond that point comes to you for free. The fewer the embedded years, the more of the future you receive without paying for it.

At approximately $47 per share, my model puts Rollins at approximately 28 years of embedded discounted cash flows. The zone is Stretched.

Businesses with Rollins’s profile, three quarters of revenue recurring, non-discretionary demand across the customer base, and ROIC consistently above 30%, have historically commanded premium valuations. Over the past decade Rollins has traded a far more stretched valuation than the 28 years recorded at the time of this report. At $47 the implied number of embedded years of cashflow is the lowest it has been in ten years. The Stretched designation reflects where the embedded years framework places the current price. The historical context is that this business has rarely been available at this valuation.

For a detailed explanation of how this valuation framework works and the thinking behind it, please check A Comprehensive Guide to Business Valuation

9. Risks

Labor Cost and Technician Retention

Employee expenses at cost of services represented 31% of revenue in 2025, the single largest cost line in the business. Rollins is a people business. Every customer interaction is delivered by a licensed technician who cannot be automated away.

When labor markets tighten, wage inflation runs through the cost structure immediately.

Management acknowledged in 2025 that retention of newer team members, particularly those in their first six months, remains an area requiring improvement. A technician who leaves carries route knowledge and customer relationships that take time and cost to replace.

Acquisition Execution Risk

Each of the 94 acquisitions completed over three years requires customer integration, technician onboarding, technology migration, and retention management through the transition. If integration quality deteriorates as acquisition velocity increases, acquired customer attrition rises and the return on deployed acquisition capital falls.

The FTC inquiry into Rollins’s post-employment non-compete practices adds a secondary dimension: if the FTC compels a significant narrowing of these restrictive covenant agreements, the cost of retaining trained technicians and protecting the customer relationships acquired at premium prices may increase.

Separately, Rollins faces ongoing litigation under California’s Private Attorneys General Act related to employment practices at its California operations, which contributed approximately 11% of 2025 revenues. Management does not expect either matter to be material, but both carry uncertainty that warrants monitoring.

Governance Transition

The transition from Gary W. Rollins’s active leadership to the third generation of family stewardship is the governance risk I carry explicitly rather than minimise. Gary spent over 45 years building and running this business. The discipline, the acquisition culture, the people philosophy, and the capital allocation framework that produced the decade-long financial record belong to his generation of leadership.

The voting trust structure requires consensus between Gary’s branch and Randall’s three children. What made that consensus durable under the second generation was a combination of shared personal history, Gary’s demonstrated results, and the informal authority of a patriarch still actively present in the business. That combination is now changing. The structure holds. The question is whether the culture it encased holds equally well.

Insurance and Claims Costs

Rollins retains a substantial layer of general liability, workers’ compensation, and auto liability risk through a high-deductible insurance program. At December 31, 2025, total accrued insurance liabilities were $123 million, and the company maintained $82.4 million in letters of credit as security for these obligations under its insurance carrier agreements. Insurance and claims costs at cost of services ran at 1.8% of revenue in 2025, down 20 basis points from 2024, but this line is volatile. Q1 2026 saw higher insurance and claims costs as a specific driver of operating margin compression.

10. The Verdict

Rollins is Approved on the strength of a route-based recurring service platform that has demonstrated genuine structural durability across a full economic cycle and through conditions that would have exposed a weaker franchise.

The case rests on three things. The economics of the underlying model. The financial record that validates those economics across a full cycle. And the structural durability of the competitive position under conditions that compressed the margins of every comparable service business.

The economics are genuine. A route-based recurring service business whose primary demand driver is the financial irrationality of cancellation, whose capital expenditure runs at 0.7% of revenue, whose gross margin has held between 50% and 53% for a decade without interruption, and whose operating assets generate returns above 34% is not a business whose qualities are explained by management skill alone. The model is structurally sound at its foundation. O. Wayne Rollins recognised it in 1964. The sixty years of compounding since then are the output of a correct original insight applied with consistent discipline by three generations of stewardship.

The financial record is the empirical case. ROIC compressed from 36.4% in 2015 to 24.4% in 2019 when acquisition spending accelerated faster than operating profit, yet remained more than 19 percentage points above the cost of capital even at that trough. By 2025 ROIC stood at 34.6% against a WACC of 8.5%, a spread of 26 percentage points.

Operating margins expanded from 16.2% to 19.3% over the decade, with the adjusted margin reaching 20% once acquisition-related amortisation is stripped out. FCF per share grew at approximately 16% compounded over ten years, almost entirely fundamental.

The risks are real and have been stated plainly. Labor cost and insurance claims volatility are the most immediate operational watch items, both evidenced clearly in the Q1 2026 results. The governance transition from Gary W. Rollins to the third generation introduces uncertainty that voting trust documents alone cannot resolve. None of these risks, assessed honestly against what has been built over sixty years, changes the Approved designation.

Q1 2026 Update

Total revenue of $906.4 million grew 10.2%, with organic growth of 6.6%. Residential organic growth was 4.2%, commercial 7.7%, and termite and ancillary 9.8%, all consistent with the full-year 2025 trajectory. Operating margin fell 120 basis points year-over-year to 16.1%, driven by weather-suppressed one-time service volumes in January and February alongside higher fleet, insurance, and selling costs. Management noted that March recovered strongly, with approximately 12% total revenue growth and over 8% organic growth as conditions normalised. The quarterly results introduce no new concerns about the underlying thesis.

Disclosure update: The author now holds a position in Rollins. The position was initiated after the original publication date of this report. All analysis and conclusions remain unchanged. This report reflects the author’s personal views and is not investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

The Outlook

More than 1 in 4 American adults lives with a mental illness or substance use disorder, according to the Substance Abuse and Mental Health Services Administration. The infrastructure available to treat them has never kept pace with that need; behavioral health has historically attracted less capital, lower reimbursement, and less institutional attention than any other major category of inpatient care. Universal Health Services has been building inside that gap since 1979, when Alan B. Miller founded the company in a single acute care hospital in King of Prussia, Pennsylvania. Today it operates one of the largest behavioral health networks in the world; 346 inpatient facilities across the United States, the United Kingdom, and Puerto Rico, alongside 29 acute care hospitals and 35 freestanding emergency departments.

The regulatory environment introduces real pressure. The One Big Beautiful Bill Act, enacted July 4, 2025, is expected to reduce UHS’s aggregate annual net benefit from Medicaid supplemental payment programs by $432 million to $480 million by 2032, phasing in gradually from 2028 on a pro rata basis. Those programs generated $1.339 billion in net benefit in 2025 alone, representing approximately 67% of consolidated operating income that year. The pressure extends beyond the supplemental reduction: Medicaid work requirements and the expiration of ACA premium tax credits are simultaneously shifting patients from insured to uninsured status. Management has runway to offset the headwind through volume growth, pricing discipline, and operational improvement, but the trajectory warrants close attention. What partially offsets this picture is the balance sheet; total debt of $5.2 billion against operating cash flow of $1.864 billion puts the leverage ratio at approximately 2.8 times, structurally cleaner than most for-profit hospital peers. The founder’s family retains majority voting control through a dual class share structure, a concentration of decision-making authority that has historically favored consistent capital allocation over short-term market appeasement.

Key Terms

Acute Care Hospital

A facility providing short-term medical treatment for severe injuries, illnesses, and surgical procedures requiring continuous clinical oversight. UHS operates 29 inpatient acute care hospitals, supplemented by 35 freestanding emergency departments and 13 outpatient centers. The acute care segment generated approximately 57% of UHS’s consolidated revenues in fiscal year 2025.

Behavioral Health

Inpatient and outpatient services treating psychiatric conditions, substance use disorders, and related conditions. UHS’s behavioral health segment encompasses 346 inpatient facilities across the United States, United Kingdom, and Puerto Rico, together with 119 outpatient locations. Revenue from behavioral health represented 43% of consolidated revenues in fiscal year 2025.

Same-Facility Metrics

Financial and operational results calculated only for facilities that operated in both the current and prior year period, eliminating distortions caused by new openings, acquisitions, or closures. UHS discloses same-facility revenue growth, admissions, and revenue per admission separately or each segment. Same-facility data is the most analytically useful measure of organic operating performance.

Revenue Per Adjusted Admission

A measure of revenue generated per patient visit, adjusted to incorporate outpatient volume on a standardized basis. When revenue per admission rises without a corresponding increase in admissions, it reflects pricing power, payer mix improvement, or acuity shift rather than volume. In the first quarter of 2026, UHS reported revenue per admission growth of 6.3% in acute care and 6.2% in behavioral health on a same-facility basis.

One Big Beautiful Bill Act (OBBBA)

Federal legislation enacted July 4, 2025, that restructures several healthcare financing mechanisms with direct implications for hospital operators. The Act imposes a gradual reduction in the provider tax rates that states may use to fund Medicaid supplemental payment programs, capping the mechanism that has historically allowed states to generate federal matching funds above standard Medicaid base rates. It also introduces work and community service requirements for certain Medicaid beneficiaries and eliminates the enhanced premium tax credits that subsidised ACA exchange-based insurance for lower income Americans. The combined effect of these three provisions is a reduction in both the supplemental payment net benefit hospitals receive and the size of the insured patient population. The Act phases in its most significant provisions beginning with the 2028 state fiscal years.

ACA Exchange

A government-run online marketplace where individuals purchase private health insurance plans from competing insurers. Exchange-based insurance is distinct from employer-sponsored coverage, Medicaid, and Medicare. Lower income individuals who purchased exchange plans were eligible for federal premium tax credits that subsidised their monthly premiums. The expiration of enhanced premium tax credits at year-end 2025 made exchange plans unaffordable for many enrollees, converting previously insured patients to uninsured status. Exchange admissions at UHS declined approximately 15% in the first quarter of 2026 while uninsured admissions increased approximately 16%.

Medicaid Supplemental Payment Programs (SDPs)

State-directed Medicaid arrangements that compensate hospitals at rates above standard fee-for-service, funded jointly by states and the federal government. These programs, which vary by structure and state, contributed $1.339 billion in aggregate net benefit to UHS in fiscal year 2025. The One Big Beautiful Bill Act restricts the future structure of these programs, capping payments at Medicare rates for newly established programs and imposing reductions on grandfathered programs beginning in 2028.

Medicaid Managed Care

A system in which states contract with private health plans to administer Medicaid benefits on their behalf. Managed Medicaid plans pay rates negotiated with providers, which may differ materially from standard Medicaid fee-for-service rates. Approximately 42% of UHS’s behavioral health revenues come from Medicaid and managed Medicaid combined; the acute care segment’s comparable exposure is approximately 20%.

Certificate of Need (CON)

A regulatory requirement in many states compelling healthcare providers to obtain state approval before constructing new facilities, adding licensed beds, or expanding services. CON laws create a structural barrier to competitive entry in regulated markets, protecting the revenue base of established providers like UHS.

Return on Invested Capital (ROIC)

A measure of how efficiently a business generates operating profit from its deployed capital base. We here compute ROIC as NOPAT, net operating profit after tax, divided by invested capital, defined as total assets less goodwill, accrued liabilities, and cash. This methodology isolates operational efficiency by removing acquisition premiums, supplier financing, and non-operational assets from the capital base, measuring the return generated by the operating assets of the business rather than the accounting residual after financing decisions. ROIC figures will therefore differ from those published by standard financial data providers.

At a Glance

Company: Universal Health Services, Inc.

Ticker: $UHS · NYSE

Sector: Healthcare

Industry: Hospital Operations & Health Services

Market Capitalization: ~$8.8 billion (at $146)

First Coverage: June 2026

FY2025 Revenue: $17.365 billion

Disclosure: The author holds a position in Universal Health Services, Inc. This report reflects the author’s personal views and is not investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here.

1. The Business

Alan B. Miller founded Universal Health Services in 1979, the day after his previous company was acquired in a hostile takeover. He had built American Medicorp into the second largest hospital management firm in the United States before losing it, and he structured UHS from the outset so that it could never happen again; the publicly traded share class was designed to carry the majority of economic equity but minimal voting power, concentrating control permanently in management’s hands. That structure remains intact today, with Alan B. Miller serving as Executive Chairman and his son Marc D. Miller serving as Chief Executive Officer since January 2021. What began with six employees and zero revenue is today a Fortune 500 company generating $17.365 billion in annual revenues and employing approximately 101,500 people across 40 states, the United Kingdom, and Puerto Rico.

What the Company Does

UHS owns and operates acute care hospitals and behavioral health facilities through its subsidiaries. Acute care hospitals treat patients with immediate or urgent medical needs; emergency presentations, surgical procedures, cardiac events, and obstetrics. The patient receives treatment over an average inpatient stay of approximately 4.8 days, and is discharged.

Behavioral health facilities treat patients with psychiatric conditions, substance use disorders, and related diagnoses. Average length of stay at UHS behavioral health facilities was 13.7 days in 2025, nearly three times the acute care average. The cost structure is predominantly labor rather than equipment and supplies, and revenue is driven by daily census rather than procedure volume.

Geographic Concentration

UHS organizes its acute care operations primarily across Sun Belt states with above-average population growth. Texas and Nevada together contributed approximately 33% of consolidated revenues in 2025, with California contributing a further 11%. Texas and Nevada are also the two states where UHS generates its largest Medicaid supplemental payment program benefits, making the geographic concentration analytically significant for both the revenue growth story and the regulatory risk discussion. The behavioral health division operates across a substantially broader geography, with 182 US inpatient facilities spanning 40 states and the District of Columbia. The United Kingdom operations, comprising 161 inpatient behavioral health facilities, generated approximately $1.001 billion in revenues in 2025 under contracts with the National Health Service and other local government bodies.

Revenue Mix

UHS derives its revenues from four primary payer categories. Managed care and private insurers account for approximately 28% of consolidated revenues. Medicare accounts for approximately 11%, with managed Medicare adding a further 12%. Medicaid accounts for approximately 15%, with managed Medicaid adding 14%. Together, government programs account for approximately 52% of consolidated revenues. The payer mix diverges materially between segments. Managed care accounts for approximately 33% of acute care revenues, giving that segment meaningful commercial pricing leverage. In behavioral health, Medicaid and managed Medicaid together account for approximately 42% of segment revenues, reflecting the patient population this segment serves. Serious mental illness and substance use disorders disproportionately affect lower-income populations covered by Medicaid, making the behavioral health segment structurally more dependent on government reimbursement than acute care.

Medicaid Supplemental Payment Programs

Embedded within the Medicaid revenue line an analytically important revenue layer: state-directed supplemental payment programs that compensate UHS above standard Medicaid base rates. These programs, which vary by state and require periodic reapproval, generated $1.339 billion in aggregate net benefit to UHS in 2025. Federal legislation enacted on July 4, 2025, restricts the future structure of these programs, with management estimating that the aggregate annual net benefit will be reduced by $432 million to $480 million by 2032. The supplemental payment layer is an essential component of the current business model, not a peripheral benefit. It is legislatively contingent and now in mandated decline. At current levels it is the primary driver of reported consolidated profitability, and its gradual reduction is what the trajectory of this business must be measured against.

2. The Moat

UHS’s competitive advantage is the structural economics of its behavioral health platform: a category with low capital intensity, recurring length-of-stay revenue, and a referral network built over 47 years.

Structural Economics of Behavioral Health

Behavioral health inpatient facilities do not require the physical infrastructure that defines acute care hospitals. There are no surgical theaters, no imaging suites, no intensive care units demanding continuous capital replacement. The dominant cost is labor. Revenue is generated by daily census across an average length of stay of 13.7 days rather than by episodic high-cost procedures. That combination produces a cost structure that is predictable in its composition and generates margins that acute care cannot match.

The financial proof is in the consistency. Same-facility behavioral health operating margins were 20.5% in 2025 and 20.3% in 2024, held across a period of labor inflation, reimbursement uncertainty, and an active federal legislative headwind. Acute care margins over the same period were 12.1% and 10.0% respectively. The 850-basis point differential between the two segments is a structural feature of the behavioral health business model that has persisted across multiple reimbursement cycles. A business whose margins hold in a narrow band through those conditions while simultaneously growing same-facility revenues at 7.7% is demonstrating structural pricing power.

Referral Network Density

Psychiatric patients do not self-refer. They arrive through primary care physicians, emergency rooms, schools, court systems, and other hospitals. A referral source needs to know a qualified bed is available and that the facility has the clinical capability to treat the patient’s specific condition. UHS’s national footprint of 182 US inpatient facilities across 40 states, with approximately 24,200 available behavioral health beds, means that referral sources across a wide geography can direct patients to a UHS facility with a level of reliability that a regional operator cannot match.

The shortage of inpatient behavioral health beds in the United States is structural and chronic. Patients requiring the highest-acuity placements, those who are hardest to place and who generate the highest revenue per day, flow toward networks with proven capacity and clinical breadth. UHS’s four-decade presence across 40 states positions it to capture that flow in a way that a newer or more geographically concentrated operator cannot replicate without years of facility construction and relationship building. Certificate of Need (CON) laws in most states UHS operates in add a further structural dimension: a new competitor cannot simply build a facility in a market where UHS holds existing CON approvals. The barriers to replicating the referral network are both relational and regulatory.

The financial expression of this pillar is in the volume consistency. Same-facility behavioral health admissions have grown in each of the past two years despite reimbursement uncertainty, and the first quarter of 2026 confirmed the trajectory with adjusted admissions up 1.2% and revenue per adjusted admission up 6.2%.

Financial Evidence

The moat is genuine on both dimensions. The structural economics of behavioral health are defensible competitive characteristics that do not depend on legislative outcomes. The referral network density, built over 47 years and expressed in consistent volume and pricing growth, compounds with time and becomes more defensible as the facility count grows. What introduces conditionality is the role of Medicaid supplemental payments in the current margin structure. The 20.5% behavioral health operating margin reflects not only competitive position but also $1.339 billion in supplemental payment net benefits that are now being reduced under federal legislation. The structural advantages are intact. The margin level may compress as the supplemental phase-down takes effect. The spread between what UHS earns and what it costs to operate may narrow. But at 15.8% ROIC in 2025, against a decade average of approximately 13.7%, there is considerably more cushion than the reported operating margin alone suggests. The structural advantages are real and should outlast the supplemental phase-down.

3. Financial Performance

Revenue grew from $9 billion in 2015 to $17.4 billion in 2025, a compound annual growth rate of 6.7%. Acute care contributed approximately 57% of 2025 revenues at a same-facility operating margin of 12.1%. Behavioral health contributed approximately 43% at a same-facility operating margin of 20.5%. Both margins are same-facility figures reflecting the established facility base only and exclude new facilities still in their ramp-up phase, corporate overhead, and provider tax assessments. The segment generating the smaller share of revenues generates the higher quality economics. The consolidated margin of 11.5% is a blended figure that simultaneously understates the behavioral health business and overstates the acute care one. The gap between the blended same-facility segment margin of approximately 15% and the consolidated margin of 11.5% is explained primarily by approximately $515 million in corporate-level operating costs not allocated to either segment, together with startup losses at recently opened facilities, most notably the $49 million pre-tax loss at Cedar Hill Regional Medical Center in its first year of operation.

The revenue trend also needs a specific adjustment. The $1.339 billion in Medicaid supplemental payment net benefits recorded in 2025 is embedded within reported revenues and operating income. That figure was approximately $1.016 billion in 2024 and around $629 million in 2023. A portion of the margin expansion over the past two years reflects the scaling of supplemental programs, not organic competitive improvement. Those programs are now in legislatively mandated decline.

Operating margins tell the decade’s story most directly. The margin was 13.75% in 2015. It compressed steadily through the late 2010s as physician costs and labor expenses rose, then collapsed to 7.49% in 2022. Three forces hit simultaneously: the nursing shortage forced reliance on expensive temporary agency staff, physician expenses in emergency medicine and anesthesiology rose sharply, and Medicaid supplemental payment timing created a revenue recognition gap. The result was the lowest operating margin in the decade-long record, 6.26 percentage points below the 2015 level.

The segment data reveals how the two-segment structure functions under pressure. Acute care same-facility operating margin collapsed from 10.6% in 2021 to 7.4% in 2022, a 320 basis point decline driven almost entirely by the labor crisis. Behavioral health same-facility operating margin declined from 19.4% to 18.1%, a 130 basis point decline over the same period. The differential between the two segments widened to 1,070 basis points at the trough. Behavioral health held at 18.1% in both 2022 and 2023 while acute care absorbed the full force of the nursing shortage and physician cost inflation. Behavioral health was the stable anchor. Acute care was the volatile component. Acute care generates 57% of revenues and receives most of the analytical attention. The segment data shows that behavioral health was the more stable business through the cycle.

Operating margins recovered to 8.23% in 2023, 10.63% in 2024, and 11.48% in 2025. The 2022 compression was driven by identifiable external forces. When those forces resolved, the margins followed.

Diluted EPS grew from $6.76 in 2015 to $23.1 in 2025, a compound annual growth rate of 13%, against revenue growth of 6.7%. Operating income grew from $1.244 billion to $1.994 billion over the same period, a CAGR of approximately 4.8%. The difference between 4.8% operating income growth and 13% EPS growth comes almost entirely from the share count. Diluted shares fell from approximately 100.7 million in 2015 to 64.5 million in 2025, a 36% reduction over the decade. That reduction was funded predominantly through operating cash flow rather than debt issuance. The share count reduction explains most of the gap. The underlying business grew earnings at roughly half the per-share rate.

Revenue per adjusted admission grew 5.4% on a same-facility basis in acute care in 2025 and 7.5% in behavioral health. In the first quarter of 2026, the figures were 6.3% and 6.2% respectively. Both segments are growing revenue per admission faster than admission volumes, confirming that pricing rather than volume is the primary revenue driver across the business.

The OBBBA reduction phases in from 2028 on a pro rata basis, reaching approximately $432 million to $480 million annually by 2032. Using the midpoint of approximately $456 million and applying the 2025 effective tax rate of 23.4%, the after-tax earnings impact is approximately $70 million per year of additional drag once the phase-down is fully active. On the current diluted share count of 64,462 thousand, that translates to approximately $1.08 per share per year, cumulating to approximately $5.41 per share by 2032. The historical operating income CAGR of 4.8% over the past decade has added more than $1.08 per share of annual earnings power, and the buyback program has consistently amplified that per-share growth by reducing the denominator. The headwind is real, quantified, and phased over seven years. It does not reverse the compounding capacity of the business. It reduces its pace during the active phase-down window.

Capital expenditure has ranged between $609 million and $1.155 billion over the decade, averaging approximately 7% of revenues. The 2025 figure of $1.015 billion is elevated relative to the mid-decade average and reflects two specific projects: the Alan B. Miller Medical Center in Palm Beach Gardens, which opened in the second quarter of 2026 with 156 beds, and the Henderson Hospital expansion in Nevada. Management guided 2026 capex of $950 million to $1.1 billion, consistent with the current investment cycle. Once these projects complete, capex should normalize toward its historical average, releasing cash for buybacks and debt service.

ROIC started at 15.8% in 2015, held in a narrow band between 13.7% and 14.8% through 2021, then collapsed to 9.3% in 2022. The collapse had two components. Operating income fell sharply as the labor crisis and physician cost inflation compressed margins, reducing the numerator. Capital expenditure continued through the downturn, growing the invested capital base and compressing the denominator simultaneously. ROIC recovered to 10.4% in 2023, 14.6% in 2024, and 15.8% in 2025, fully returning to its 2015 level. That complete cycle recovery is the most direct financial confirmation that the underlying economics survived the 2022 trough intact. UHS generates substantial economic value above its cost of capital today. That spread faces pressure as the supplemental programs phase down. The 2022 recovery demonstrated that the underlying economics hold when external pressure resolves.

Subscribe now

4. Capital Allocation

Over the past decade, UHS deployed capital across three primary uses: capital expenditure totaling approximately $9.2 billion, share repurchases totaling approximately $6.5 billion, and dividends totaling approximately $510 million. Capex was the dominant use of cash. The buyback program was the dominant capital return mechanism. Dividends were consistent but minimal relative to cash generation.

The buyback program is the most consequential capital allocation decision UHS has made over the past decade. The diluted share count fell from approximately 100.7 million in 2015 to 64.5 million at year-end 2025, a 36% reduction over 10 years. In 2025 alone, UHS repurchased 4.65 million shares at an aggregate cost of $899.3 million, an average price of $193.38 per share. In October 2025, the board authorized a further $1.5 billion increase to the repurchase program. As of March 31, 2026, approximately $1.298 billions of authorization remained outstanding. In the first quarter of 2026, UHS repurchased 675,000 shares at approximately $189 per share for $127.3 million, continuing the program at a consistent pace even as the share price declined from its 2025 levels.

The share count reduction at UHS was funded predominantly through operating cash flow rather than debt issuance. Total debt on December 31, 2025, including senior notes, term loan, revolving credit, and capital lease obligations, was approximately $5.2 billion. The debt to OCF ratio at year-end 2025 was approximately 2.8 times, and the interest to OCF ratio was 8.4%, both reflecting a balance sheet that carries leverage but services it comfortably at current cash generation levels.

UHS has paid a dividend in every year of the past decade. The per share amount was $0.40 through the late 2010s, fell to $0.20 in 2020, and has held at $0.80 since 2021. At $51.3 million in 2025 against OCF of $1.864 billion, the dividend consumes less than 3% of operating cash flow. UHS is not a dividend growth story. The capital return vehicle of choice is the buyback program, and the flat dividend reflects that priority.

The debt structure warrants specific attention at two points. Current maturities of long-term debt on December 31, 2025, totaled $748 million, of which $700 million represents the senior notes carrying a 1.65% coupon that mature on September 1, 2026. Those notes were issued in August 2021 when market interest rates were at historic lows. UHS expects to refinance these notes at significantly higher interest rates than the original 1.65% coupon. The September 2024 debt issuance, in which UHS placed $500 million at 4.625% and $500 million at 5.050%, is the most current reference point for UHS’s borrowing cost. Refinancing $700 million at rates in that range versus the existing 1.65% coupon would add approximately $21 million to $24 million in annual interest expense. That is manageable at current OCF levels but will partially reverse the interest expense improvement achieved in 2025, when interest expense fell from $186 million to $156 million following the September 2024 debt restructuring.

The second capital structure event is the April 2026 credit agreement amendment, which added $900 million in borrowing capacity including a $400 million delayed draw term loan designated for the pending acquisition of Talkspace, Inc. The revolving credit facility was simultaneously increased by $200 million to $1.5 billion, and the tranche A term loan was increased by $300 million to $1.455 billion. The maturity date of September 26, 2029, was unchanged. If the Talkspace acquisition closes and the $400 million delayed draw term loan is drawn, total debt will increase to approximately $5.6 billion, pushing the debt to OCF ratio toward approximately 3 times at current cash generation levels. That remains within a range UHS can service comfortably, but it reduces the financial flexibility available to absorb the OBBBA revenue headwind if it materializes more severely than management currently projects.

Stock-based compensation of $95.7 million in 2025, $99.3 million in 2024, and $87.7 million in 2023 represents a real economic cost to shareholders that does not appear as a cash outflow in the operating results. At approximately 5% of operating income in 2025, SBC is not a dominant factor in the capital allocation picture but is material enough to warrant inclusion in any honest assessment of cash generation.

The consistency of the buyback program through the 2022 trough, when OCF compressed to approximately $1 billion and UHS still repurchased shares, is the clearest expression of management’s capital allocation priorities over time.

5. Competition

UHS operates in two distinct competitive environments simultaneously. In acute care it competes against the largest for-profit hospital platforms in the United States. In behavioral health it competes against a fragmented landscape of regional operators, small single-facility providers, and not-for-profit systems, with only one publicly traded pure-play peer of meaningful scale.

HCA Healthcare

HCA is the most instructive benchmark for evaluating UHS’s acute care competitive position and the clearest illustration of why scale alone does not determine investment quality Its ROIC has averaged 16.3% over the past decade, approximately 2.6 percentage points above UHS’s decade average of 13.7%, reflecting the structural advantages of market density, purchasing scale, and clinical data infrastructure that UHS’s acute care network cannot match. The business remains operationally superior, though the margin of that advantage is narrower than it appears at first glance.

The basis for different treatment rests on two factors that interact with each other in a specific way. Approximately 45% of HCA’s revenues flow from government programs whose reimbursement rates are determined by legislative and regulatory decisions rather than market negotiation. Total debt including lease obligations of approximately $48.7 billion means that any sustained reduction in government reimbursement flows directly into a highly leveraged capital structure with relatively limited capacity to absorb it. UHS carries $5.2 billion in total debt against $1.864 billion in OCF, a ratio of approximately 2.8 times. HCA carries $48.7 billion against approximately $12.6 billion in OCF, a ratio of approximately 3.85 times.

Tenet Healthcare

Tenet generates $21.3 billion in revenues across approximately 60 hospitals and a large ambulatory surgery center network. Its operating margin of 16.1% in 2025 is the highest among the three publicly traded for-profit hospital operators, reflecting a multi-year portfolio restructuring that divested underperforming hospital assets and concentrated capital in higher-margin ambulatory care. The margin improvement is real. What requires scrutiny is the 2024 net income figure of $3.2 billion, which was inflated by approximately $3.2 billion in facility sale gains recorded in the other income line. That figure is not recurring and should not anchor any assessment of normalized earnings power.

ROIC of 11.65% in 2025 is the highest in Tenet’s available record and represents genuine improvement from a decade average of approximately 7.4%, excluding a 2017 outlier driven by a specific transaction rather than operational performance. Total debt of $13.2 billion against OCF of $3.54 billion produces a debt to OCF ratio of approximately 3.7 times, materially higher than UHS’s 2.8 times. Tenet operates no behavioral health segment and competes with UHS only in acute care, where Sun Belt geographic overlap creates some direct market competition primarily around commercial payer contract negotiations rather than patient volume.

Acadia Healthcare

Both companies operate inpatient behavioral health facilities under the same payer frameworks in largely overlapping markets. The financial divergence between them is therefore a direct expression of operational quality rather than structural differences in the competitive environment.

UHS behavioral health same-facility revenues grew 7.7% in 2025 with revenue per adjusted admission up 7.5% and an operating margin of 20.5%. Acadia same-facility revenues grew 4.9% with revenue per patient day up 2.8% and an adjusted operating margin of approximately 11.9%. UHS is growing faster, pricing better, and generating 860 basis points more margin per dollar of revenue in the same market. That divergence has persisted across multiple reporting periods and is not explained by Acadia’s current legal and regulatory difficulties alone. It reflects a structural quality difference in operational execution. The ROIC divergence makes the same point in a different register. UHS generated 15.8% ROIC in 2025 against Acadia’s 10.96%. Nearly 500 basis points of return on capital separated the two businesses operating under identical payer frameworks.

Acadia’s reported results require decomposition before any financial comparison is meaningful. The company reported a pre-tax loss of $1.066 billion in 2025, which includes a $996.2 million goodwill impairment, $151 million in legal settlement costs, and $163.6 million in transaction and investigation expenses. Stripping those items, adjusted operating income was approximately $395.5 million on revenues of $3.3 billion, producing the 11.9% adjusted margin referenced above. The debt to OCF ratio of 20 times in the competition table reflects reported OCF of $131.9 million compressed by a $147.5 million Securities Litigation settlement payment. Normalized OCF excluding that payment would be approximately $279.4 million, producing a normalized ratio of approximately 9.5 times against total debt of $2.644 billion.

The operational context compounds the financial picture. The DOJ Criminal Division issued a grand jury subpoena in September 2024 investigating admissions, length of stay, and billing practices. The SEC issued a parallel subpoena covering the same subject matter. The CEO departed in January 2026, the CFO resigned in August 2025, and the COO resigned in November 2025. The professional and general liability reserve more than doubled from $87.5 million on December 31, 2024, to $181.8 million on December 31, 2025. New commercial insurance effective September 2025 excludes sexual molestation and abuse coverage. The combination of active criminal and regulatory investigations, leadership instability makes it impossible to assess the future earnings power of the business with any confidence.

Not-for-Profit Systems

The most substantive competitive pressure UHS faces in behavioral health does not come from its publicly traded peers. Not-for-profit behavioral health systems and state-operated psychiatric facilities operate in many of the same markets under materially different financial conditions. They do not pay federal or state income taxes, can issue tax-exempt bonds at lower borrowing costs, and receive government grants and philanthropic funding that UHS cannot access. These advantages matter most in psychiatrist and behavioral health clinician recruitment, where not-for-profit systems can offer mission-driven compensation structures that attract clinical talent, and in underserved markets where the economics do not justify for-profit investment but where not-for-profit operators can absorb losses through grant funding.

The competitive pressure from not-for-profit operators is real but structurally limited. They cannot match UHS’s capital deployment capacity, national geographic reach, or management infrastructure. The behavioral health market remains highly fragmented with the majority of beds operated by small regional operators, both for-profit and not-for-profit. UHS’s scale advantage over this fragmented landscape is more competitively significant than its position relative to any single not-for-profit system. The structural shortage of inpatient behavioral health beds in the United States means demand consistently exceeds available supply across most markets, reducing the intensity of direct competition for patients relative to what would exist in a balanced market.

6. Management

Marc D. Miller — Chief Executive Officer

Marc D. Miller has served as Chief Executive Officer and President since January 1, 2021. He joined UHS in 1995 and spent 26 years inside the organization before taking the top role, progressing from operational roles at individual hospitals through Vice President in 2005, Senior Vice President and co-head of the Acute Care Division in 2007, and President since May 2009. He was elected to the board in 2006. His father founded UHS and held the CEO role from inception until the day Marc Miller assumed it. UHS has never appointed an external CEO. Managing 375 inpatient facilities across 40 states, two distinct clinical businesses operating under separate reimbursement frameworks, and reimbursement relationships spanning every major government program and commercial insurer in the United States requires institutional knowledge that takes decades to build. Marc Miller spent 26 years building it. He is 55 years old and his employment agreement runs through January 1, 2029.

That background is directly relevant to the two most consequential external challenges his tenure has covered so far. The 2022 labor crisis drove premium nursing pay to $170 million in a single quarter and collapsed operating margins to 7.49%, the lowest in the decade-long record. On the Q3 2022 earnings call Miller was direct about what had happened and specific about where the pressure was already easing, with premium pay already falling from $170 million in Q2 to $81 million in Q3. On the One Big Beautiful Bill Act, Miller described the then-published impact estimates as a worst-case scenario on the Q2 2025 earnings call, pointed to active state and federal discussions around modification, and said the legislation simply cannot be left as is. The speed and completeness of the margin and ROIC recovery from the 2022 trough reflects a management team that understood the operational levers of both segments deeply enough to pull them correctly while the crisis was still unfolding.

Marc Miller’s 2025 total compensation was $16.1 million. Base salary of $1,430,769 was approximately 9% of the total. His annual cash incentive paid at $4,292,307, the maximum permitted, after adjusted net income per diluted share reached $21.74 against a maximum threshold of $21.12 and return on capital reached 12.1%, also at the ceiling. Stock awards of $9,999,904 at grant date fair value were split equally between time-based RSUs vesting over four years and performance-based RSUs tied to three-year adjusted EBITDA net of noncontrolling interests growth. The 2023 performance-based RSUs vested at 150% of target, the maximum, after the business delivered 147% of the three-year EBITDA target. Approximately 91% of his target total compensation is variable. A CEO whose pay is predominantly performance-linked across both annual and multi-year metrics has incentives pointing in the right direction.

Alan B. Miller — Executive Chairman and Founder

Alan B. Miller is 88 years old and has served as Executive Chairman since January 1, 2021, having held the Chairman and CEO role from the company’s founding in 1979. He founded UHS the day after American Medicorp, the second largest hospital management company in the United States which he had built from nothing, was taken from him in a hostile takeover. He incorporated UHS the following day and designed the share structure so it could never happen again. He served as Chairman and CEO for 42 years before passing the role to his son. His employment agreement runs through January 1, 2027.

The 346-facility behavioral health network was constructed facility by facility over four decades under a founder who recognized the structural economics of behavioral health early and built toward them consistently. The capital allocation discipline that has reduced the share count by 36% over the past decade, funded through operating cash flow rather than debt, originates with the person who built the business. It has transferred to the person now running it.

His 2025 total compensation was $8.1 million. The largest components were stock awards of $5,062,102 at grant date fair value, a base salary of $1,073,077, and a discretionary cash bonus of $1,073,077.

Ownership and Alignment

As of March 23, 2026, Alan B. Miller held 88.9% of the company’s general voting power through his combined holdings of Class A, Class B, and Class C Common Stock. The Class B shares that most investors hold represent 88.1% of the outstanding share count and 8.7% of the voting power. BlackRock holds 7.7% of Class B. First Eagle holds 8.6%. Together they own approximately 16% of the economic float and cannot influence the outcome of any shareholder vote that Alan Miller opposes.

The 47-year record is the most direct evidence of how that authority has been used. Revenues have compounded from zero to $17.4 billion. The share count has fallen 36% over the past decade funded through operating cash flow. ROIC reached 15.8% in 2025 against a decade average of approximately 13.7%. No value-destructive acquisition of scale has been made. The concentrated control has served long-term shareholders well across this history.

7. Growth Levers & Addressable Market

Organic Behavioral Health Bed Utilization

The most capital-efficient growth lever available to UHS does not require building a single new facility. Same-facility behavioral health adjusted admissions grew 1.2% in the first quarter of 2026 against revenue per adjusted admission growth of 6.2%, confirming that pricing rather than volume remains the primary revenue driver and that the admissions gap relative to underlying demand has not yet fully closed. More than 1 in 4 American adults lives with a mental illness or substance use disorder. The infrastructure available to treat them has never kept pace with that need. UHS operates approximately 24,200 available behavioral health beds across 182 US inpatient facilities. The bottleneck is clinical labor, not demand. Every additional patient day at a facility that is already built and staffed at the margin falls almost entirely to operating income. Closing the admissions gap through recruitment and retention improvement is the highest-return use of operational energy available to this business.

Behavioral Health Capacity Expansion

UHS is simultaneously expanding the physical bed base in targeted markets. The Alan B. Miller Medical Center in Palm Beach Gardens, Florida opened in the second quarter of 2026 with 156 beds. The Henderson Hospital expansion in Nevada added capacity in one of UHS’s most commercially concentrated markets. Both projects are embedded in the 2026 capital expenditure guidance of approximately $950 million to $1.1 billion. Once these projects are complete, capex should normalize toward the historical average of approximately 7% of revenues, releasing cash for buybacks and debt service.

Thousand Branches Wellness and the Outpatient Continuum

UHS operated 119 outpatient behavioral health locations as of year-end 2025, including 16 confirmed Thousand Branches Wellness sites. The Thousand Branches concept targets patients who require step-down care after inpatient discharge or ongoing outpatient treatment without requiring hospitalization. These facilities carry no licensed beds, lower facility overhead, and a payer mix weighted toward commercial rather than Medicaid. A patient discharged from a UHS inpatient facility who continues treatment at a UHS outpatient location stays within the same network. That continuity has clinical and commercial value simultaneously. The direction is right and the unit economics of outpatient behavioral care are structurally superior to inpatient on a capital intensity basis.

Acute Care Commercial Pricing

UHS’s acute care network holds meaningful pricing leverage in its core markets. In Texas and Nevada, which together contributed approximately 33% of consolidated revenues in 2025, the concentration of UHS facilities gives commercial insurers limited ability to construct a competitive health plan without including UHS hospitals. That network density translates into structural pricing power at managed care contract renewal. Same-facility acute care revenue per adjusted admission grew 4.1% in 2025 and 6.3% in the first quarter of 2026, consistently outpacing same-facility admissions volume growth of 2.4% in 2025 and 0.9% in the first quarter of 2026. The pattern is unambiguous. Price is doing more work than volume and has been for several years. Managed care and private insurers account for approximately 33% of acute care revenues, the commercially negotiated category that drives the majority of acute care profitability. Each contract renewal cycle in markets where UHS holds density is an opportunity to compound that advantage further.

Talkspace and the Virtual Behavioral Health Platform

UHS has entered into a definitive agreement to acquire Talkspace, Inc., a virtual behavioral healthcare company, with the transaction pending at the time of this report. The April 2026 credit agreement amendment designated a $400 million delayed draw term loan specifically for the Talkspace acquisition, confirming the capital commitment.

The strategic logic is clear from UHS’s existing operational picture. The inpatient behavioral health network has been capacity-constrained by clinical staffing shortages. A virtual platform that connects patients with licensed professionals without requiring physical facility infrastructure addresses that bottleneck from a different direction. Patients who cannot access a UHS inpatient bed can receive virtual care while awaiting placement or as an alternative to inpatient admission entirely. The combined platform creates a behavioral health continuum that the inpatient network alone cannot offer.

Technology and Clinical Infrastructure

UHS is deploying a new enterprise-wide electronic health record platform across its hospital network and implementing an AI-assisted nursing platform across its facilities. Both programs are multi-year investments whose financial returns will not be fully visible in the near-term reported numbers. The competitive significance is in what they build over time. A unified clinical data infrastructure across 375 inpatient facilities generates the kind of system-wide performance benchmarking and best-practice standardization that no regional competitor operating across a smaller footprint can replicate at equivalent scale. The AI-assisted nursing platform directly addresses the labor constraint that has bottlenecked behavioral health admissions growth. If it reduces the dependency on premium agency staff and improves retention among permanent clinical employees, the margin benefit compounds across the entire behavioral health segment simultaneously. These are not near-term catalysts. They are investments in the operational foundation that the next decade of growth sits on.

8. Valuation

The future return on UHS stock is a function of two engines: the future growth in free cash flow per share and any valuation re-rating. Both are explained below.

Free cash flow throughout this report is defined as operating cash flow less capital expenditure less stock-based compensation. SBC is deducted as a real economic cost to shareholders that does not appear as a cash outflow in the operating results.

Engine 1: Fundamentals

The first engine is the business itself. FCF per share grows over time through revenue expansion, operating leverage, and share count reduction from buybacks.

The operational component is driven by same-facility revenue growth across both segments, behavioral health at 7.7% in 2025 and acute care at 8.5%, and the improvement in FCF conversion as the current elevated capital expenditure cycle completes and capex returns toward its historical average of approximately 7% of revenues. The structural behavioral health economics, 20.5% same-facility operating margins held across a period of labor inflation and legislative headwind, continue compounding. The OBBBA phases in gradually over seven years and management has runway to offset it through volume growth and pricing discipline.

The capital return component compounds the operational growth at the per share level. UHS retired 4.65 million shares in 2025 from a diluted count of approximately 67.9 million at the start of the year. The board authorized a further $1.5 billion in repurchase capacity in October 2025 with approximately $1.298 billion remaining as of March 31, 2026. The program has run without interruption for a decade. The cash generation to sustain it is not in question at current operating levels.

Engine 2: Valuation Re-Rating

At the price of $146, the investor is paying for everything this business will earn over roughly the next 8 years, in today’s money. Everything it earns beyond that point comes to you for free. The fewer the embedded years, the more of the future the investor receives without paying for it.

UHS sits in the Deep Value zone. The expected return is the fundamental FCF per share growth rate plus a meaningful upward revaluation as the market prices in a longer earnings horizon over time. At 8 embedded years the margin of safety is substantial. The investor does not need a heroic growth assumption or a perfect regulatory outcome to generate an exceptional return. The fundamental engine delivers a strong return on its own. The re-rating is additional.

For a detailed explanation of how this valuation framework works and the thinking behind it, please check A Comprehensive Guide to Business Valuation

9. Risks

OBBBA Medicaid Supplemental Payment Reduction

The most quantified financial risk in this analysis is already legislated. The One Big Beautiful Bill Act, enacted July 4, 2025, is expected to reduce UHS’s aggregate annual Medicaid supplemental payment net benefit by approximately $432 million to $480 million by 2032, against a 2025 net benefit of $1.339 billion, representing approximately 67% of consolidated operating income that year. The reduction phases in gradually from 2028 on a pro rata basis, which gives management runway to offset through volume growth, pricing discipline, and operational improvement. The headwind operates through three simultaneous channels. The first is the direct supplemental payment reduction as the federal government caps the provider tax mechanism that funds these programs. The second is Medicaid work requirements, which may convert some Medicaid-covered patients to uninsured status, replacing government-reimbursed admissions with patients who generate little or no revenue. The third is the expiration of enhanced ACA premium tax credits at year-end 2025, which has already begun shifting exchange-insured patients to uninsured status, with exchange admissions down approximately 15% and uninsured admissions up approximately 16% in the first quarter of 2026.

The per share earnings impact of the supplemental reduction is quantified in the Financial Performance section above. Management’s possible responses shall combine political lobbying to soften the final implementation rules, admissions recovery through clinical staffing improvement, commercial pricing leverage at contract renewal, and capex normalization once the current investment cycle completes. UHS cannot meaningfully reduce its Medicaid patient volumes in response; EMTALA requires emergency treatment regardless of payer status, and behavioral health patients are structurally Medicaid-dependent in a way that makes withdrawal from the program operationally and commercially unviable. The metrics I watch most closely are same-facility behavioral health adjusted admissions growth, and revenue per adjusted admission in both segments.

Government Reimbursement Dependency

Government programs account for approximately 52% of UHS’s consolidated revenues. In behavioral health, Medicaid and managed Medicaid alone account for approximately 42% of segment revenues. The OBBBA is one manifestation of a dependency that runs deeper than any single piece of legislation. The history of Medicare and Medicaid reimbursement is a series of periodic legislative adjustments that have recurred across administrations of both parties for four decades. The scenario I monitor most closely is a slow, multi-year base rate compression where reimbursement rates are held flat or increased below the rate of cost inflation. That version of the risk affects every government payer admission simultaneously and has no discrete offset available to management.

Legal Exposure

Cumberland Hospital for Children and Adolescents is a defendant in multi-plaintiff litigation in Virginia relating to allegations of inappropriate sexual contact by a former independent contractor medical director. A September 2024 jury verdict awarded three initial plaintiffs $60 million in compensatory damages and $180 million in trebled damages under the Virginia Consumer Protection Act, with punitive damages subsequently reduced to a combined maximum of $1.05 million. UHS Inc. and UHS Delaware were dismissed as defendants during the September 2024 trial for the initial three plaintiffs, leaving Cumberland itself as the defendant. However, UHS Inc. and UHS Delaware remain named defendants for the approximately 40 additional plaintiffs still pending, with the next trial tentatively scheduled for August 2026. Aggregate insurance coverage of approximately $143 million remains under commercial policies applicable to the 2020 policy year. Commercial insurance commencing March 2025 excludes coverage for sexual molestation or abuse. Any future claims of this nature fall directly to the balance sheet with no insurance offset.

UHS Delaware is separately a primary named defendant in Washoe County, Nevada, where a September 2025 jury verdict awarded approximately $4.7 million in compensatory damages and $500 million in punitive damages. UHS Delaware intends to challenge the verdict in post-judgment proceedings and on appeal. The Cumberland insurance exclusion is the element I watch most closely. It creates an open-ended balance sheet exposure for the category of claim that has already produced the largest verdict in the company’s recent litigation history.

Dual-Class Governance

Alan B. Miller holds 88.9% of the company’s general voting power. No external shareholder action can change strategic direction, management succession, or capital allocation priorities without his agreement. Alan Miller is 88 years old. The transition of that concentrated voting authority has no publicly disclosed roadmap and no structural mechanism that gives Class B shareholders any role in shaping its outcome. The 47-year record argues in favor of the structure. What it cannot provide is a corrective mechanism if that record were ever to change. That asymmetry is permanent.

California Staffing Regulations

New acute psychiatric hospital staffing regulations in California became effective June 1, 2026, following a postponement that allowed the California Department of Public Health to assess public comments. The regulations require staffing standards specific to acute psychiatric hospitals and determination of appropriate licensed staffing based on patient acuity and care needs. California contributed approximately 11% of consolidated revenues and 13% of income from operations in 2025. The specific financial impact will depend on UHS’s ability to recruit and retain the required clinical staff at its California facilities. The scenario I monitor is whether additional states where UHS operates adopt mandatory staffing ratios at comparable levels, which would compound the aggregate annual cost impact beyond what California alone implies.

10. The Verdict

Universal Health Services is Approved in the Bearhold Universe on the strength of a behavioral health platform that has demonstrated genuine structural durability across a full decade and through a period of serious adversity.

The case rests on three things. The behavioral health structural economics. The 2022 recovery. And the balance sheet that makes it possible to hold through a period of regulatory pressure that has caused comparable operators to be treated differently.

The behavioral health platform is the foundation. The 346-facility inpatient network generates 20.5% same-facility operating margins, held across a period of labor inflation, reimbursement uncertainty, and an active federal legislative headwind. The 850-basis point differential between behavioral health and acute care margins is a structural feature of a business model built over four decades by a founder who recognized the economics of behavioral health early and built toward them consistently. The cost structure that produces those margins, labor-dominant with no surgical theaters or imaging suites, generates revenue by daily census across an average length of stay of 13.7 days. That cost structure produces margins that acute care cannot match and has done so across multiple reimbursement cycles.

The 2022 recovery is the most analytically important single data point. Premium nursing pay reached $170 million in a single quarter. Operating margins collapsed to 7.49%, the lowest in the decade-long record. Three external forces hit simultaneously. A franchise with structurally weakening competitive advantages does not recover from that combination in a single year. UHS recovered in a single year. By 2023 operating margins had already returned to 8.23%. By 2025 they had reached 11.48%. ROIC recovered from 9.3% in 2022 to 15.8% in 2025, fully returning to its 2015 level.

The risks are real and have been stated plainly. The One Big Beautiful Bill Act will reduce the aggregate annual Medicaid supplemental payment net benefit by around $432 million to $480 million by 2032. Government programs account for approximately 52% of consolidated revenues and that dependency is a permanent feature of the business model. The Cumberland litigation carries an open-ended balance sheet exposure following the commercial insurance exclusion for sexual molestation and abuse. The dual-class governance structure concentrates 88.9% of voting power in a single person with no publicly disclosed succession roadmap. None of these risks changes the Approved designation.

What distinguishes UHS from comparable hospital operators facing the same regulatory environment is the balance sheet. UHS carries total debt of approximately $5.2 billion against operating cash flow of $1.864 billion, a ratio of approximately 2.8 times. HCA Healthcare, the most operationally superior for-profit hospital platform in the United States, carries approximately $48.7 billion in total debt against approximately $12.6 billion in OCF, a ratio of approximately 3.85 times. Both businesses face structural government reimbursement dependency. The primary distinction between the two businesses is not competitive quality. It is balance sheet resilience under regulatory pressure. UHS can absorb a sustained regulatory headwind without its financial flexibility narrowing to a point that forces operational compromise. That is why one earns Approved and the other does not.

The behavioral health structural economics are genuine and durable. They hold independent of the legislative environment that determines what the government pays. The referral network density, built over 47 years, compounds with time. The balance sheet provides the durability to hold through regulatory pressure. What I watch from here is the pace of behavioral health admissions recovery and the trajectory of the supplemental payment phase-down. If the admissions gap closes as the staffing environment continues to normalize and the OBBBA impact tracks management’s base case rather than the worst case, the investment case strengthens from an already compelling starting point.

Disclosure: The author holds a position in Universal Health Services, Inc. This report reflects the author’s personal views and is not investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

Quarterly Update Log

This section is updated with each subsequent quarterly result and is kept separate from the annual analysis above, which reflects the fiscal 2025 full year record.

Q2 2026 Update

Same facility acute care revenues grew 8.2% with adjusted admissions up 2.9% and revenue per adjusted admission up 3.0%, consistent with the volume and pricing pattern established across 2025 and Q1 2026. Same facility behavioral health revenues grew 7.4% with adjusted admissions up 0.5% and revenue per adjusted patient day up 6.1%. Both segments continue to grow on both volume and price simultaneously.

Diluted EPS of $5.98 compares to $5.43 in Q2 2025. Q2 included a favorable $100 million pre-tax catch-up from the Florida Medicaid managed care directed payment programme covering October 2024 through September 2025, recognised following CMS approval in April 2026. This item is non-recurring and is not reflected in revised forward guidance. Absent this item, the underlying operational performance was solid.

Full year 2026 guidance was revised modestly. Net revenues of $18.501 to $18.762 billion are essentially unchanged. Adjusted EPS was trimmed to $22.28 to $23.65, a midpoint reduction of approximately 2.6% versus the original forecast, reflecting the non-recurring Florida Medicaid item not repeating and a $28 million liability reserve increase. Neither item reflects a change in the underlying operational trajectory.

The quarterly results are consistent with the annual thesis and introduce no new concerns about the underlying operational performance.

Q1 2026 Update

UHS reported first quarter 2026 results on April 28, 2026. The annual analysis above is built on full year figures. Quarterly data is included here only to test whether the 2025 thesis holds at the edges.

Same-facility acute care revenues grew 8.2% with revenue per adjusted admission up 6.3%, consistent with the price-driven growth pattern established in 2025. Same-facility behavioral health revenues grew 7.3% with adjusted admissions up 1.2% and revenue per adjusted admission up 6.2%. Both volume and pricing remain positive simultaneously. Operating cash flow of $402 million compared to $360 million in Q1 2025. The quarterly results are consistent with the annual thesis and introduce no new concerns about the underlying operational performance.

The Outlook

In 1960, twenty-two-year-old Tom Monaghan and his brother James borrowed $900 to buy a small pizza shop called DomiNick’s in Ypsilanti, Michigan, with Tom intending to use the income to fund his architecture studies. He never went back to architecture. He bought out his brother’s share, trading him a Volkswagen Beetle for his half of the business, dropped sandwiches from the menu, focused entirely on delivery to college campuses, and invented an insulated pizza box that could be stacked without crushing the pizzas inside. The model he built, make the same product consistently, deliver it fast, price it within reach of anyone, turned out to be not just a business but a replicable system. By the mid-1980s, nearly three new Domino’s franchises were opening every day. Sixty-five years later, that system operates in over 90 countries across 22,142 locations, and Domino’s has delivered 32 consecutive years of global retail sales growth in constant currency.

The business Domino’s operates today is almost entirely a franchise. Approximately 99% of stores are owned by independent franchisees who pay a royalty on every dollar of sales, contribute to a national advertising fund, and purchase their food ingredients through Domino’s own supply chain infrastructure. The company itself owns 262 stores in the United States. While the overall count has remained broadly stable over the decade, the strategic direction is toward franchise, the refranchising of the Maryland market in May 2025 being the most recent example, with company-owned stores serving primarily as operational laboratories and training grounds rather than profit centres. What Domino’s keeps is the brand, the system, and the royalty stream. What franchisees keep is the operating risk.

That structure creates an economic engine of unusual quality. Royalties arrive as a percentage of system-wide retail sales regardless of whether individual stores are profitable. When a new store opens anywhere in the world, the royalty income base expands at no incremental capital cost to the company. When same-store sales grow, royalty income grows proportionally.

The tension in the Domino’s story today is not about the franchise or the brand. It is about what the right price is to own them, and whether the growth levers available over the next decade can sustain the rate of per-share cash flow compounding that the last decade delivered. The United States is a mature market. International expansion continues but the low-hanging fruit of early market entry is largely harvested. The capital structure, approximately $4.8 billion in total debt against negative book equity, requires management and periodic refinancing. These are not disqualifying concerns. They are the context within which the investment case must be made honestly.

Key Terms

System-Wide Sales / Global Retail Sales

Global retail sales refers to total worldwide retail sales at all Domino’s stores, both company-owned and franchised. This is not revenue to Domino’s, it is the retail volume flowing through the entire system. Franchise royalties are calculated as a percentage of this figure. In 2025, global retail sales reached approximately $20.1 billion against consolidated company revenues of approximately $4.9 billion.

Same-Store Sales

Same-store sales growth measures the change in sales for stores open in both the current and prior comparable period. It is the clearest indicator of whether the brand is gaining or losing traction at the store level, independent of new unit openings. International figures are reported on a constant currency basis.

Asset-Backed Securitisation (ABS)

Domino’s finances its debt through an ABS structure in which subsidiaries securitise the royalty and supply chain cash flows and issue fixed-rate notes against those cash flows. The structure provides borrowing costs lower than conventional corporate debt but introduces covenants tied to cash flow coverage ratios and creates scheduled refinancing events at each note maturity.

At a Glance

Company: Domino's Pizza, Inc.

Ticker: $DPZ · NASDAQ

Sector: Consumer Discretionary

Industry: Restaurants / QSR

Market Cap: $11 billion (at $330)

First Coverage: May 2026

FY2025 Revenue: $4.94 billion

This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. The author does not hold a position in DPZ. Read the full disclaimer here

1. The Business

Domino’s Pizza was founded in 1960 in Ypsilanti, Michigan and has grown into the largest pizza company in the world by store count and global retail sales. The company went public in 2004 and has operated as a publicly traded entity since. As of December 28, 2025, the system operated 22,142 stores across more than 90 countries, of which approximately 99% are franchised.

Consolidated revenue of approximately $4.94 billion in 2025 is divided across five reporting lines within three operating segments. Understanding the composition matters more than the total, because the economic quality of each stream is fundamentally different.

The supply chain segment is the largest at approximately 60.5% of consolidated revenue, generating about $2.99 billion in 2025 through the manufacture and distribution of dough and food ingredients to franchisees in the United States and Canada. This segment exists to support the franchise network, not to generate standalone returns, its margin reflects a distribution business, not a franchise business.

The U.S. stores segment contributed approximately $1.61 billion, comprising royalties and fees from franchisees, advertising contributions, and revenue from the 262 company-owned stores. Within this segment, U.S. franchise royalties and fees of $677.1 million in 2025 are the highest-quality revenue the company generates, collected as a percentage of franchisee sales with essentially no direct cost. The advertising contribution of $559.5 million is collected from franchisees and spent entirely on brand promotion with no margin contribution. It passes through the income statement as both revenue and expense, inflating the top line without adding any economic value to the company. The international franchise segment contributed $338.7 million in royalties from master franchisees outside the United States.

A U.S. franchisee pays Domino’s a royalty of approximately 5.5% of store retail sales, plus contributions to the national advertising fund. The company bears no capital responsibility for franchised stores. Franchisees finance their own build-outs and carry their own operating risk.

When same-store sales rise, royalty income rises proportionally. When a new store opens, royalty income increases with no additional capital outlay by the company. Global retail sales grew from approximately $9.9 billion in 2015 to approximately $20.1 billion in 2025, slightly more than doubling the royalty income base over the decade with no proportional increase in capital deployed by the company

Internationally, master franchisees pay Domino’s a royalty and take on responsibility for developing the brand within a defined geography. The largest, Domino’s Pizza Enterprises (DMP: ASX), operates across 12 markets including Australia, New Zealand, Japan, France, Germany, and several other European and Asian markets. As of year-end 2025, DMP operated approximately 3,524 stores, representing about 16% of the global Domino’s store count.

2. The Moat

Domino’s competitive advantage is built on three reinforcing pillars: a value equation that consumers trust and return to, a network density that makes the system structurally faster than competitors, and franchisee economics that sustain the investment required to keep both of those pillars intact. Each pillar can be tested against the financial record, a moat that cannot be demonstrated in the numbers is not a moat.

The Value Equation

Nobody orders Domino’s because they believe it is the finest pizza available. They order it because it delivers on every dimension simultaneously, reliably good, consistently fast, predictably priced, and available almost anywhere. That combination at scale is what creates the habit. A local pizzeria might produce a superior product. It cannot match the reliability of delivery time across thousands of locations, the pricing consistency, or the brand familiarity that decades of investment have built.

The financial evidence for this pillar is in the same-store sales record. Domino’s has grown U.S. same-store sales in the substantial majority of years over the past decade, including through the pandemic, through inflationary pressure, and through the rise of third-party delivery platforms that expose the brand to direct price comparison. The one meaningful period of same-store sales decline, 2022 through early 2023, was driven by identifiable external pressures: commodity driven menu price increases that disproportionately affected lower-income consumers, and a delivery driver shortage that degraded service times below the standard the brand is built on. When those pressures resolved, same-store sales returned immediately to positive territory, 3.0% in 2025. A brand with a structurally weakened value proposition does not recover that cleanly. The speed of the recovery is the evidence.

The brand itself reinforces the value equation. Recall was built over decades of advertising investment funded through franchise contributions of approximately 6% of sales, a pooled fund that no individual competitor can match in scale or consistency. That recall was tested severely in the late 2000s when the product was widely criticised. The company’s response in 2010, a public admission that the product was inadequate, followed by a documented recipe overhaul, produced one of the more notable brand recoveries in QSR (Quick Service Restaurant) history and demonstrated that the consumer relationship is based on trust that can be repaired when it is damaged honestly. That institutional willingness to confront reality rather than manage perceptions is a cultural characteristic that has defined how the company has operated since, and it is part of why the brand has held its position through multiple competitive cycles.

Network Density

Delivery speed is a function of store density. A market with high Domino’s store concentration serves customers faster than any competitor with fewer, more dispersed locations. This creates a self-reinforcing dynamic: denser networks produce better delivery times, better delivery times attract more orders, more orders justify more stores, more stores increase density further. In mature markets such as the United States, the density Domino’s has built is not replicable from scratch without a decade of sustained capital investment and operational losses during the build-out period.

The financial expression of this pillar is in the royalty yield on global retail sales. Domino’s extracts royalty income on approximately $20.1 billion of system-wide retail sales through 22,142 stores. A new entrant seeking to challenge this position would need to build a comparable store network to generate comparable delivery density, at franchisee investment levels of roughly $150,000 to $400,000 per store, the capital requirement for a 10,000-store network alone exceeds $1.5 billion at the low end, before accounting for the years of brand-building required to reach Domino’s order frequency. Network density is a moat that compounds with time and becomes more defensible precisely because it is expensive and slow to replicate.

Franchisee Economics

A franchise system is only as strong as the economics it delivers to its operators. If franchisees are not profitable, they stop investing, stop opening new stores, and eventually stop maintaining existing ones. The quality of the Domino’s franchise proposition is best evidenced by two facts: net store growth has been consistently positive for over two decades, and nearly all U.S. franchisees developed from within the system, beginning as delivery drivers or in-store operators before earning store ownership through the Franchise Management School programme.

That internal development pipeline is analytically significant. Franchisees who understand the Domino’s system from the inside are more likely to operate it correctly, maintain quality standards, and continue investing in their locations. It is also a natural selection mechanism; operators who struggle at the store level do not make it to ownership. The result is a franchisee base with above-average operational competence and genuine institutional alignment with the brand, because their entire career trajectory runs through it.

The supply chain infrastructure strengthens franchisee unit economics in a way that is often underappreciated. Domino’s manufactures and distributes the dough and key ingredients at scale, providing franchisees with food at prices that individual operators could not access independently. This built-in cost advantage makes the Domino’s franchise more economically attractive than alternatives where the franchisee bears full procurement risk, which in turn supports the continuous new unit openings that expand the royalty base.

Moat Assessment

The moat is stable. All three pillars are mutually reinforcing and have been tested by a difficult external environment. The competitive landscape has genuinely changed, third-party aggregators have made delivery available from any restaurant, which reduces the structural advantage of delivery availability itself and exposes the value equation to direct comparison. But the evidence from the financial record is that the value equation has held up in that environment. The 2025 same-store sales recovery, the decade-high operating margin, and the record FCF per share all point to a franchise that is generating stronger cash returns now than at any point in its history, despite operating in a more competitive delivery environment than existed a decade ago. That combination, more competition, better financial results, is the strongest possible evidence of a structural moat rather than a circumstantial one.

3. Financial Performance

Revenue grew from $2.2 billion in 2015 to $4.9 billion in 2025, a 10-year CAGR of 8.3%. That headline number requires immediate disaggregation because the revenue mix is not uniform and the economic quality of each stream is fundamentally different. Supply chain accounts for approximately 60% of consolidated revenue but operates at an 11.5% gross margin. Franchise royalties, the economically important stream, account for approximately 20% of revenue excluding the advertising pass-through, but generate the vast majority of operating profit. Company-owned stores account for the remainder, broadly flat over the decade.

The contrast between the two non-supply-chain streams tells the story of the decade precisely. Company-owned store revenue was $397 million in 2015 and $375 million in 2025, essentially flat. Combined franchise royalties, U.S. and international, grew from $436.4 million in 2015 to $1,015.8 million in 2025, a 10-year CAGR of 8.8%, marginally above the blended revenue CAGR of 8.3%. Every dollar of meaningful revenue growth in the business over the decade came from the franchise model.

The 1.3% revenue decline in 2023 requires precise treatment. Supply chain revenue fell as commodity prices normalised from their 2022 peaks, the food basket price Domino’s charged franchisees declined proportionally, mechanically reducing the top line. But the underlying franchise business strengthened that year: operating margins expanded from 16.5% to 18.3%, net income grew from $452 million to $519 million, and operating cash flow recovered from $475 million to $591 million. Revenue fell while profitability improved sharply across every metric that matters. That divergence is the clearest possible signal that the consolidated revenue line was distorting the picture, 2023 was a better year for the business than 2022 by every measure of economic quality.

Operating margins have been stable in the 17–19% range for most of the decade, which is analytically significant in itself. A business that sustains margins in a narrow band across a decade that included a global pandemic, a commodity shock, a historic labour dislocation, and aggressive competitive entry from aggregator platforms is demonstrating genuine pricing power and cost discipline. The stability is the signal, not just the level.

The 2022 compression to 16.5% is the decade’s outlier. Three forces converged simultaneously. The food basket cost rose 13–15% driven by the Russia-Ukraine war, wheat, dairy, and fuel all spiked together. A post-pandemic labour dislocation created a driver shortage severe enough to produce an 11.7% decline in delivery sales at its worst point, eliminating a high-margin revenue stream precisely when costs were rising. And the company’s defensive response, aggressive promotional discounting through Boost Week and inflation relief deals, protected transaction volumes but compressed unit margins further. The confirmation that 2022 was exogenous rather than structural comes from the recovery: operating margins reached 18.3% in 2023, 18.7% in 2024, and 19.3% in 2025. If the compression had reflected a structural deterioration in competitive position or unit economics, the recovery would not have been this clean or this fast.

Diluted EPS grew from $3.47 in 2015 to $17.57 in 2025, a 10-year CAGR of 17.6%. That rate is 9.3 percentage points above the revenue CAGR of 8.3% and requires decomposition. Operating income grew from $405 million to $950 million, a CAGR of approximately 8.9%, consistent with the revenue growth rate and modest operating leverage. The gap between 8.9% operating income growth and 17.6% EPS growth is explained by the sustained reduction in diluted share count from 55.5 million to 34.2 million, a 38% decline, alongside tax rate changes over the period. The share count reduction is the dominant driver of the per-share amplification.

SBC-adjusted FCF per share grew from $3.80 in 2015 to $18.31 in 2025, a 10-year CAGR of 17.0%, nearly identical to the EPS CAGR of 17.6%. The alignment between EPS and FCF per share growth over a full decade is an important quality signal. It means earnings are not being manufactured through accounting choices that diverge from cash reality. The business earns what it reports.

The 2022 drop in FCF per share to $9.96, a 29% decline from the $14.10 peak in 2021, was more severe than the EPS decline of 7.5% in the same year. The divergence is explained by the capex cycle: capital expenditure rose from $87 million in 2022 to $105 million in 2023 as the company invested in supply chain and technology infrastructure during a period of operational stress. Higher capex compressed FCF independently of the earnings compression. The recovery in FCF per share was correspondingly faster once both earnings normalised and capex returned to its longer-run trend, FCF per share reached $13.40 in 2024 and $18.31 in 2025.

The 2025 OCF reading of $792 million, a 27% year-on-year increase, produced the highest FCF per share of the decade. That jump deserves scrutiny. A single-year OCF increase of this magnitude in a business growing revenue at 5% is unusual and typically reflects favourable working capital timing rather than a step-change in underlying cash generation. The accounts payable and accrued liabilities movements in 2025 were a meaningful contributor. I treat the 2025 OCF as directionally correct but modestly overstating the sustainable run-rate; normalised FCF per share is probably closer to $17 on a through-cycle basis.

Total debt has ranged from $2.2 billion to $4.8 billion across the decade, and the absolute level is less informative than the trend in debt relative to cash generation. The debt / OCF ratio started at 7.7x in 2015, peaked at 10.5x in 2022, and declined to 6x in 2025. Both historical peaks require context. The 2022 spike to 10.5x was driven by OCF compression during the margin crisis, the same event that drove EPS and FCF lower, not by new debt issuance. Both were recoverable and both recovered, confirming that the leverage metrics are a mirror of operating performance rather than an independent variable.

The interest / OCF ratio tells a cleaner story across the decade: from 34% in 2015 to 24.7% in 2025, an improvement driven entirely by OCF growth since interest expense has been remarkably stable in the $190 million range annually since 2021. That stability reflects the fixed-rate ABS structure, existing notes do not reprice as market rates move. The risk is forward-looking: the 2017 Ten-Year Notes ($940 million) and 2018 9.25-Year Notes ($379 million) carry anticipated repayment dates in July 2027, and refinancing at current rates will increase the annual interest expense. The September 2025 refinancing, $1 billion in notes at 4.93% and 5.22%, is the most recent reference point for what the 2027 event will likely cost. A $30–50 million annual increase in interest expense is probable, which will compress the interest / OCF improvement trend modestly but is not expected to reverse it given the current OCF trajectory.

4. Capital Allocation

Domino’s carries negative total stockholders’ equity of approximately negative $3.9 billion, the direct result of a series of leveraged recapitalisations in which the company borrowed against its securitised royalty cash flows and returned the proceeds to shareholders through special dividends and buybacks. The consequence is that book-based return metrics produce meaningless results for this business.

Since 2015, Domino’s has retired approximately 21.3 million shares, a 38% reduction in the diluted count, from 55.5 million to 34.2 million. The company repurchased approximately 785,000 shares in 2025 for approximately $358 million. In April 2026, the Board authorised an additional $1 billion repurchase programme, bringing total outstanding authorisation to approximately $1.29 billion.

The buyback programme is the single largest contributor to the gap between 8.3% revenue growth and 17.6% EPS growth over the decade. Operating income grew from $405 million to $950 million, a CAGR of approximately 8.9%. The gap between that and the per-share earnings growth rate is almost entirely explained by the share count reduction, a 38% decline from 55.5 million to 34.2 million shares, funded through a combination of operating cash flow and leveraged recapitalisations.

The forward contribution of the buyback programme is discussed in the Valuation section. What the historical decomposition establishes here is the distinction between the two sources of per-share growth: the operational engine, which grew at approximately 8.9% annually, and the capital return engine, which amplified that into 17.6% EPS growth per share. Both engines have been running for twenty years. Understanding which contributed what is essential to forming a credible view of what the next decade delivers, and why the forward estimate differs from the historical CAGR.

Dividends of $6.96 per share in 2025 represent approximately 38% of SBC-adjusted FCF, a conservative payout ratio relative to cash generation. Dividends have grown every year of the decade, from $1.24 per share in 2015, a CAGR of approximately 18.9% over the period. Interest expense has been stable at approximately $190-196 million annually since 2021, reflecting the fixed-rate ABS structure. The 2025 refinancing added approximately $1 billion in new notes at 4.93% and 5.22%, extending maturities while adding modest incremental interest cost. The 2017 Ten-Year Notes ($940 million) and 2018 9.25-Year Notes ($379 million) carry anticipated repayment dates in July 2027, the next scheduled capital structure event of consequence.

Capital expenditure has run between $59 million and $121 million annually over the decade, averaging approximately 2.5% of revenue. The franchise architecture keeps this number structurally low; the physical infrastructure of the system is built and maintained by franchisees, not by the company. Domino’s own capex is concentrated in supply chain facilities, and technology investment.

5. Competition

Pizza Hut

Pizza Hut, owned by Yum! Brands, is Domino’s closest global competitor by store count at approximately 19,900 locations. The brand has historically been stronger in dine-in and carryout than delivery, and its delivery infrastructure has lagged in most markets. The financial evidence for Domino’s competitive superiority is in the same-store sales comparison: Domino’s has consistently outperformed Pizza Hut on U.S. comparable store sales over the last several years. That gap reflects not just marketing but the underlying operational advantages, supply chain infrastructure, franchisee quality, and delivery system efficiency, that Domino’s has built and Pizza Hut has not matched.

Papa John’s

Papa John’s operates approximately 6,000 stores globally, roughly a quarter of Domino’s footprint. The cost structure differential is telling: Papa John’s operating margin of approximately 5% compares to Domino’s 19.3%, and the gap is not primarily explained by scale. Papa John’s carries higher food and labour costs as a percentage of sales, operates with less supply chain leverage, and has a franchisee base that has been less profitable on average than Domino’s, which limits new unit investment and therefore limits the store count growth that drives the royalty income base. It is not a credible threat to Domino’s system economics.

Third-Party Delivery Platforms

DoorDash, Uber Eats, and Grubhub have permanently changed consumer behaviour; ordering delivery now means choosing from every available restaurant simultaneously. This is genuinely a structural change, not a cyclical one, and it reduces the advantage of delivery availability that was one of the original pillars of the Domino’s brand. The financial evidence that this has not yet materially damaged Domino’s is in the 2025 results, 3.0% U.S. same-store sales growth and 19.3% operating margins in a fully aggregator-competitive environment. But the risk is directional and worth monitoring; Domino’s selectively joined Uber Eats in the United States in 2023–2024, which captured incremental volume but introduced a strategic ambiguity about the long-term mix between direct and platform orders. The commercial rationale is sound. The strategic consequence is discussed in Risks.

6. Management

Russell J. Weiner - Chief Executive Officer

Russell Weiner joined Domino’s in 2008 as Chief Marketing Officer, following a decade at PepsiCo including a Vice President of Marketing role for Colas at Pepsi-Cola North America. His career at Domino’s progressed through President of Domino’s USA (2014–2018), Chief Operating Officer and President of the Americas (2018–2020), COO and President, Domino’s U.S. (2020–2022), and Chief Executive Officer from May 2022. His 14-year tenure before the top job spans almost every element of the brand’s transformation, the recipe overhaul, the technology investment, the shift to a digital-first ordering model, and the acceleration of international growth. The institutional knowledge embedded in that tenure is a genuine asset; Weiner does not need to learn the business or the brand. He built significant parts of it.

Weiner’s direct ownership stands at approximately 110,764 shares including exercisable options as of fiscal year-end 2025. At the current price, this represents a meaningful personal stake relative to his salary, though modest relative to the company’s market capitalisation. Total insider ownership across all directors and executive officers represents approximately 0.89% of shares outstanding. There is no founder stake and no controlling shareholder. Vanguard holds approximately 11.5% of shares, Berkshire Hathaway approximately 10.0%, BlackRock approximately 6.7%, and T. Rowe Price approximately 6.2%. Berkshire’s position is notable as a signal of quality recognition from a long-horizon institutional investor that is selective about franchise businesses.

Approximately 91% of Weiner’s target total direct compensation is variable: 18% annual cash incentive and 72% long-term equity. The equity mix is 55% performance-based restricted stock units, 25% stock options, and 20% time-vesting RSUs. PSU vesting is tied to three-year Consolidated Adjusted EBITDA growth and global retail sales growth, with a relative TSR modifier versus the S&P 1500 Restaurants Sub-Index. The heavy equity weighting creates genuine alignment, Weiner’s wealth is predominantly tied to the stock price over multi-year periods. The incentive metrics are EBITDA-based and do not penalise capital expenditure or stock-based compensation, which means management is not directly incentivised to minimise these costs. At current capex levels of approximately 2.4% of revenue, this is a modest structural concern rather than an immediate issue.

7. Growth Levers & Addressable Market

International Unit Expansion

International net store growth of 604 units in 2025, against a base of approximately 14,352 stores at year-end 2024, represents a growth rate of approximately 4.2%. This is the most direct and highest-conviction growth lever available because the economics are straightforward; each new franchised store generates an incremental royalty stream at negligible marginal cost to the company, and the store count grows on the franchisee’s capital, not Domino’s. The royalty income contribution from each new international store is small individually but compounds materially across hundreds of openings per year.

To quantify the contribution; if international same-store sales are flat and 600 new stores open annually, each averaging approximately $670,000 in annual retail sales at a 3% royalty rate, the incremental royalty income to Domino’s Inc. from new stores alone is approximately $12 million per year. That is a modest annual addition in isolation, but it compounds, each year’s cohort of new stores matures to higher sales volumes in subsequent years, and 600 openings annually over a decade builds a royalty base that is structurally larger than what exists today. The value of international unit growth is real but it is a long-duration compounder, not a near-term earnings driver

U.S. Same-Store Sales and Unit Expansion

The U.S. business delivered same-store sales growth of 3.0% in 2025 following a difficult 2022–2023 period. At a 5.5% royalty rate on approximately $9.9 billion in U.S. retail sales, a 1 percentage point increase in same-store sales generates approximately $100 million in incremental retail sales and approximately $5.5 million in incremental royalty income. The lever is real but not large on an absolute basis, its importance is as a compounding contributor to the royalty income base rather than a step-change generator. With approximately 7,186 domestic stores and management identifying potential for continued net unit growth in the low hundreds annually, each new domestic franchise store adds royalty income at no incremental capital cost to the company.

International Same-Store Sales Recovery

International same-store sales growth of 1.9% in 2025 was an improvement but remains below the historical average. The largest international master franchisee, Domino’s Pizza Enterprises (DMP: ASX), has been under pressure in certain markets including Japan and France, where competitive intensity and consumer affordability constraints have weighed on unit economics. A recovery in international same-store sales toward the historical 2–4% range would provide meaningful royalty income uplift across the 14,956-store international base. At a 3% royalty rate on approximately $10 billion in international retail sales, a 1 percentage point improvement in same-store sales generates approximately $100 million in incremental retail sales and approximately $3 million in incremental royalty income, again, a compounding contributor rather than a step-change.

8. Valuation

The future return on Domino's stock is a function of two engines; the future growth in free cash flow per share plus any valuation re-rating. Both are explained below:

Engine 1: Fundamentals

The first engine is the business itself. FCF per share grows over time through revenue expansion, operating leverage, share count reduction from buybacks, and the structural margin tailwind from refranchising. For Domino’s, I estimate FCF per share growth of approximately 8% annually over the next decade. That estimate is built from two components that have been quantified through the analysis in this report rather than assumed.

The operational component is approximately 5% annually. International unit growth of approximately 600 stores per year generates roughly $12 million in incremental annual royalty income at an average store retail sales of $670,000 and a 3% master franchisee royalty rate. U.S. same-store sales growth of approximately 3% on a $9.95 billion retail base at a 5.5% royalty rate adds approximately $16 million in incremental royalty income annually. The refranchising of remaining company-owned stores adds a modest margin improvement as lower-margin operational revenue converts to higher-margin royalty income. Combined, these levers produce approximately 5% organic FCF growth, a modest but honest rate that reflects the maturity of the U.S. market and the master franchisee layer that sits between Domino’s Inc. and individual store operators in most international markets.

The capital return component adds approximately 3 percentage points. Domino’s has retired shares continuously since 2005, twenty years of uninterrupted execution through multiple interest rate cycles, a pandemic, a commodity shock, and a labour crisis. The programme has not been interrupted once. The financial position today supports its continuation: the interest / OCF ratio has improved from 38% in 2016 to 25% in 2025, and the debt / OCF ratio has declined from its 2022 peak of 11.3x to 6.3x in 2025. Whether the outstanding share count is 55 million or 34 million is irrelevant to the sustainability of the programme, retiring 2–3% of whatever count is outstanding annually produces the same per-share amplification effect, and the cash generation to fund $300–400 million in annual buybacks is not in question at current OCF levels.

The combined 8% estimate is not conservative and it is not optimistic. It is the rate the business can sustain when the growth levers are quantified honestly and the buyback contribution is given its proper analytical weight alongside the operational growth rate.

Engine 2: Valuation Re-Rating

At today’s price of approximately $330, the investor is paying for everything this business will earn over roughly the next 19 years, in today’s money. Everything it earns beyond that point comes to you for free. The fewer the embedded years, the more of the future you receive without paying for it.

Domino’s sits in the Attractive zone. The expected return is the 8% fundamental growth rate plus a partial upward revaluation as the market prices in a longer earnings horizon over time. There is a decent margin of safety at this price for this type of business.

The Attractive zone does not mean the price cannot go lower in the near term, it means that at this price, the investor is not depending on a heroic growth assumption or a valuation re-rating to generate a reasonable return. The 8% fundamental growth delivers a reasonable return on its own. The partial re-rating is additional.

For a detailed explanation of how this valuation framework works and the thinking behind it, please check A Comprehensive Guide to Business Valuation

9. Risks

Commodity Costs, Particularly Cheese

The supply chain segment sells a food basket to franchisees at prices that move with commodity markets. Cheese is the single largest variable input, Domino’s explicitly identifies it as the primary commodity exposure in its market risk disclosures, and it carries the most direct and immediate impact on supply chain margins. A sustained increase in cheese prices creates pricing pressure that the company must either absorb or pass through to franchisees.

If the cost increase is passed to franchisees, unit economics weaken. Weaker unit economics reduce franchisee investment appetite, slow new store openings, and can accelerate closures, all of which directly reduce the royalty income base that drives the company’s value. If the cost increase is absorbed by the company, operating income declines directly. The 2022 experience, food basket costs up 13–15% driven by the Russia-Ukraine commodity shock, showed how quickly this mechanism works; operating margins fell from 17.9% to 16.5% in a single year, EPS declined, and FCF per share fell by 29%. That was a one-year commodity event. A multi-year structural increase in cheese or wheat prices, from climate disruption, supply concentration risk, or sustained feed cost inflation, would create a more persistent margin headwind than the 2022 episode and would be harder to recover from. The ABS covenant structure requires sustained OCF generation at levels sufficient to service the debt; a severe and prolonged commodity shock that compresses OCF meaningfully would narrow the financial flexibility available at the 2027 refinancing.

2027 Refinancing and Leverage

The 2017 Ten-Year Notes ($940 million) and 2018 9.25-Year Notes ($379 million) carry anticipated repayment dates in July 2027, creating a near-term refinancing event in a rate environment materially higher than when those notes were originally placed at rates of approximately 3.8–4.5%. The September 2025 refinancing, $1 billion in new notes at 4.93% and 5.22%, establishes the most current reference point for what the 2027 event will likely cost. Replacing $1.3 billion in notes at an average incremental rate of 50–100 basis points above their original coupons would increase annual interest expense by approximately $7–13 million. That is manageable at current OCF levels. The more significant risk is the combination; higher refinancing rates occurring simultaneously with a commodity-driven OCF compression, or a same-store sales deterioration. In isolation, the 2027 refinancing is a known and manageable event. In combination with a cyclical operating downturn, it would compress the debt / OCF ratio and potentially trigger closer scrutiny of the ABS covenants, which require a minimum coverage ratio of 1.75x total debt service to securitised net cash flow.

Aggregator Channel Erosion of the Direct Relationship

Domino’s selectively joined the Uber Eats platform in the United States in 2023–2024 to capture volume from consumers who order exclusively through aggregators. The commercial rationale is to grow total order volume by reaching a segment of consumers who would not otherwise order directly. But the strategic consequence is a structural shift in how consumers discover and order from the brand.

Domino’s built its competitive position around the direct ordering relationship, first-party customer data, commission-free unit economics, and the habit of going to Domino’s directly rather than browsing a platform. Each of these advantages erodes when a meaningful share of orders flows through an aggregator. First-party data advantages diminish as aggregators capture the ordering behaviour. Unit economics compress as commission fees of 15–30% apply to platform orders. And the habit of direct ordering weakens as consumers normalise the aggregator interface as their primary food discovery mechanism. The current financial evidence does not yet show these effects: 2025 operating margins are at a decade high. But the aggregator channel is growing, and the financial damage from habit erosion typically lags the strategic concession by several years. If aggregator-sourced orders grow beyond a threshold where they materially affect unit economics or same-store sales contribution, the margin trajectory would inflect downward in ways that would not be visible in the near-term data.

Shift in Consumer Taste

Domino’s is a single-category operator. The entire business is built around the consumer’s appetite for pizza, and specifically for delivered pizza. A sustained shift in dietary preferences, toward healthier options, different cuisines, or cooking at home, would reduce the frequency of the Domino’s order occasion regardless of how well the franchise executes. This risk is the longest-dated and hardest to quantify of the four, but it is structurally real and carries no operational hedge.

The QSR industry has watched several once-dominant categories lose relevance over decades as consumer preferences evolved, the decline of traditional fast food burgers in the early 2000s, the pressure on carbonated beverages from water and energy drinks, the gradual erosion of certain breakfast formats. Pizza has proven more durable than most QSR categories, partly because the format adapts well to both delivery and carryout, and partly because the price point remains competitive against alternatives. But Domino’s has no meaningful product diversification to offset a structural decline in pizza consumption frequency. Its brand, its supply chain, its franchisee network, and its entire operational infrastructure are built for one product category. If that category declines, there is no pivot available. The risk probability is low on any near-term horizon, but the consequence, a gradual and permanent reduction in global retail sales volumes, would directly reduce the royalty income base in a way that no management action could fully offset.

Master Franchisee Restructuring

Domino’s Pizza Enterprises (DMP: ASX) is the company’s largest master franchisee, operating approximately 16% of the global store count across 12 markets and contributing approximately 20% of Domino’s international franchise royalty income. The concentration in a single franchisee relationship of this scale creates a risk that is not visible in the headline disclosure, Domino’s Inc. reports DMP royalties as approximately 1.4% of consolidated revenues, which frames the relationship as immaterial when it is in fact the single most important bilateral relationship in the international business.

DMP is in active restructuring across two of its largest markets. The root cause in Japan was a capital allocation failure, not a rejection of the product. DMP opened a net of 403 stores in Japan between 2020 and 2023 during a period of pandemic-elevated delivery demand. When post-pandemic consumer behaviour normalised, a large portion of those stores could not generate sufficient sales to sustain the advertising investment required to make the Domino’s model work, lower sales reduced advertising funds, lower advertising reduced new customer acquisition, and declining customer counts further compressed store economics in a self-reinforcing cycle. DMP closed 233 stores in Japan in FY2025, following earlier rounds of closures in Japan, France, and Denmark. Total store closures across the group in FY2025 reached 312, incurring AUD $162.3 million in significant costs that drove the group to a statutory net loss of AUD $3.7 million despite an underlying EBIT of AUD $198.1 million. France closed 32 additional stores, is facing franchisee legal action, and appointed its third CEO in recent years. Japan is currently operating under an interim CEO while a permanent replacement with deep local expertise is recruited.

The financial risk to Domino’s Inc. operates through two channels. The first is direct and permanent: every store that closes eliminates a royalty stream that does not return. At average store retail sales of approximately $670,000 annually and a 3% royalty rate, the 312 stores closed in FY2025 reduce annual royalty income to Domino’s Inc. by approximately $6.3 million. That is not catastrophic in isolation, but the closures are permanent and the pace, 312 in a single year across a 3,500-store network, represents a 9% contraction of the network in twelve months. The second channel is indirect: DMP’s financial capacity to reinvest, fund marketing, support franchisees, and resume growth is constrained by the restructuring costs and by the earnings trajectory. Free cash flow fell to AUD $47.4 million in FY2025, down AUD $56.7 million year-on-year. A financially constrained DMP is a DMP that opens fewer new stores, which directly reduces the royalty income growth that underpins the international expansion thesis.

The distinction between a mismanagement failure and a demand failure matters for how permanent this risk is. Japan is a genuine pizza market with decades of Domino’s presence. Germany is achieving record weekly sales. Benelux recorded national sales records in FY2025. Australia delivered its highest franchisee profitability in three years. The evidence from DMP’s own portfolio shows that the Domino’s brand works when the store network is correctly sized and the unit economics are healthy. The failure in Japan and France was in the decision to expand aggressively into locations that could not support profitable operations at steady-state demand. That is correctable, but the correction takes years, reduces the royalty base in the interim, and creates leadership instability at the market level in both Japan and France simultaneously. For a franchisee that accounts for 20% of international royalty income, the timeline of that recovery is a material variable in the Domino’s Inc. investment thesis.

10. The Verdict

Domino’s earns Approved status on the strength of a franchise system that has demonstrated genuine competitive durability across a full decade and through a period of serious adversity. The case for the quality of this business rests on three things; the financial record, the recovery from 2022, and the structural economics of the royalty model.

The financial record is unambiguous. FCF per share compounded at 17.0% annually from 2015 to 2025. EPS grew at 17.6%. Global retail sales more than doubled. The blended operating margin held in a narrow 17–19% range through commodity shocks, a pandemic, a labour crisis, and the rise of aggregator platforms. A business that sustains those results across a decade of significant external disruption is not doing so by accident. It is doing so because the underlying competitive advantages, the value equation, the network density, the franchisee economics, are structural and self-reinforcing.

The 2022 recovery is the most analytically important single data point in this report. The year was genuinely bad; operating margins fell to 16.5%, EPS declined from $13.54 to $12.53, and FCF per share fell 29% from its 2021 peak. Three independent external shocks hit simultaneously, a commodity cost surge, a labour market dislocation that crippled delivery capacity, and an inflation-driven demand reduction among the price-sensitive consumer segment that Domino’s relies on most. Under that combination of pressures, a franchise with a structurally weakening competitive position would have struggled to recover. Domino’s recovered in a single year. By 2023, operating margins had already returned to 18.3%. By 2025, they had reached 19.3%, the highest of the decade. The speed and completeness of the recovery is the proof of structural quality, not just the 2025 results in isolation.

The royalty model’s economics deserve specific acknowledgment in the Verdict because they are what makes Approved the right designation despite the leverage and the competitive changes around aggregators. International franchise segment income of $288.5 million on $338.7 million in revenue, an 85.2% segment margin, is the financial expression of what it means to own a brand that the world pays royalties to use. That margin does not come from operational efficiency or cost management. It comes from the structural position of being the brand that 14,956 international stores pay to operate under. Adding 600 stores per year to that network, each paying a royalty on every dollar of sales, is a compounding mechanism that is independent of commodity prices, labour markets, or aggregator strategies.

The risks are real and have been stated plainly. Cheese prices can spike in ways that damage franchisee economics and compress the company’s margins. The 2027 refinancing will cost more than the notes it replaces. The aggregator partnership introduces a strategic ambiguity that did not exist five years ago, and its long-term consequence for the direct ordering relationship is genuinely uncertain. A structural decline in pizza consumption frequency would reduce the royalty base in ways no management team could offset. None of these risks individually, or even collectively in a realistic scenario, changes the Approved designation. The franchise quality is above the threshold, and the risks are risks to the return, not to the fundamental business model.

The business quality is not in question and the current price offers a decent margin of safety. At $330, this is a high-quality franchise available at a price that does not require a heroic growth assumption or a perfect execution outcome to generate a reasonable return. The 8% FCF per share growth estimate is built from quantified components: approximately 5% from the organic royalty income growth across U.S. and international markets, plus approximately 3 percentage points from a buyback programme that has run without interruption for twenty years. An investor who owns Domino’s at this price is buying the fundamental growth rate plus a partial re-rating, which is precisely what the Attractive zone is designed to capture.

This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. The author does not hold a position in DPZ. Read the full disclaimer here

Investors spend considerable time analysing businesses, studying competitive positions, reading annual reports, tracking management decisions, and then hand the most consequential part of the process to a set of tools that are, at best, incomplete and, at worst, quietly misleading. Ratios like Price-to-earnings, Price-to-sales, or Discounted cash flow models anchored to a terminal value. These are the instruments of professional finance, taught in every business school, used in every investment bank, and repeated in every equity research report published every day. Their ubiquity is mistaken for reliability. It is not the same thing.

This article is about why conventional valuation methods carry significant limitations that are rarely acknowledged, what those limitations mean for the investor trying to make honest decisions, and what a more rigorous approach looks like.

The Problem with Conventional Multiples

Price-to-Sales

The price-to-sales ratio divides market capitalisation by annual revenue. It became particularly fashionable during periods of high-growth technology investing, where many businesses had no earnings to speak of and analysts needed some anchor for valuation.

The fundamental problem with price-to-sales is that it ignores everything that happens between the top line and the bottom line. Revenue is what comes in the door. What matters to the investor is what remains after paying employees, suppliers, landlords, tax authorities, and the capital expenditure required to keep the business running. A business generating $10 billion in revenue and converting 2% of it into free cash flow is a fundamentally different investment from one converting 25% of the same revenue, but a price-to-sales ratio treats them identically. The metric is indifferent to cost structure, capital intensity, and the business’s actual ability to generate cash for its owners. Using it as a primary valuation tool is the equivalent of buying a restaurant based on how many tables it has without asking whether it makes any money.

Price-to-Earnings

The price-to-earnings ratio divides the current stock price by the earnings per share over the past twelve months. It is the most widely used valuation metric in investing. It is also one of the most easily misunderstood.

A P/E ratio tells you what the market is currently paying per dollar of historical earnings. What it does not tell you is whether that price is right. When analysts compare a stock’s current P/E to its historical average, they are implicitly assuming that the historical average was a reasonable price, which assumes the market was pricing it correctly in the past, which is circular reasoning. The market is not a reliable reference point for its own rationality.

The P/E ratio also uses accounting earnings, which are subject to non-cash adjustments, depreciation schedules, and one-time items that can make the same underlying business look cheap or expensive depending entirely on accounting choices. Two businesses with identical cash generation can carry very different P/E ratios based purely on how their accountants treat certain expenses. This is a structural flaw in the metric.

Price-to-Free-Cash-Flow

Price-to-free-cash-flow is a more meaningful metric than P/E or P/S because free cash flow, operating cash flow less capital expenditure, is closer to what the business actually generates for its owners. But it carries its own distortions.

Free cash flow fluctuates significantly with capital expenditure cycles. A business that is investing heavily in new capacity, building new stores, expanding manufacturing, upgrading infrastructure, will show depressed free cash flow during the investment period even if the underlying earnings power is growing strongly. Conversely, a business that has deferred necessary investment will show elevated free cash flow in the short term while quietly eroding its competitive position. Point-in-time price-to-FCF ratios capture neither dynamic accurately. When free cash flow is distorted by these cycles, earnings per share can serve as a more stable proxy, or the analyst must normalise free cash flow to reflect the mid-cycle level rather than the current year’s figure, adjusting for both capital expenditure timing and inventory movements that can temporarily inflate or depress the reported number.

Critically, free cash flow per share must always be adjusted for stock-based compensation. SBC is a real economic cost to shareholders, it either dilutes existing ownership or requires buyback activity to offset, but it does not appear as a cash outflow in the free cash flow statement. A business that reports strong free cash flow while issuing significant equity compensation to employees is overstating its true cash generation. The adjustment is not optional; it is the difference between what the business earns and what the owners actually receive.

Conventional multiples, taken together, are useful as a rough sanity check, a way of quickly orienting to whether a business is in the general vicinity of reasonable or clearly extreme. They should never be the decision anchor. They describe the present and the past. Investment returns are determined by the future.

Fair Value is a Fiction

Beyond the specific flaws of individual multiples lies a more fundamental problem: the concept of fair value itself.

When an analyst says a business has a fair value of $X per share, they are implicitly claiming to know the sum of all future cash flows the business will generate, discounted back to today. That is a claim about everything the business will earn for the rest of its existence, decades of future performance, compressed into a single number. The precision is false. No one knows what a business will earn in fifteen years accurately. No model, however sophisticated, can reliably project the competitive dynamics, technological changes, regulatory shifts, and management decisions that will determine cash flows decades from now.

The standard tool for producing this false precision is the discounted cash flow model. A DCF model constructs a series of projected cash flows over an explicit forecast period, typically five to ten years, and then adds a terminal value representing all cash flows beyond that period in perpetuity. The terminal value typically represents 60% to 80% of the total calculated value of the business. The number that drives most of the answer is the one with the least analytical foundation, a single assumption about a growth rate that will persist forever, applied to a business operating in a world that will look nothing like today’s.

Practitioners know this. The terminal value assumption is where the model’s conclusion is engineered. An analyst who wants to justify a higher price assumption raises the terminal growth rate by half a percentage point. The model produces a higher fair value. The analysis looks rigorous because it is expressed in a spreadsheet with many rows. The subjectivity is hidden inside a single cell.

The WACC, the weighted average cost of capital used as the discount rate, carries its own problems. It is derived partly from beta, a measure of how much a stock’s price moves relative to the market. Beta is a property of the stock price, not the business. Using price volatility as an input to value the business means the discount rate is partly determined by the market’s own mood swings. On a day when the market is fearful and the stock falls 20%, the beta rises, the WACC rises, and the model produces a lower fair value, not because anything changed in the business, but because the market was nervous. This is tautology expressed in the language of finance.

The honest position is this: the value of a business is the sum of all its future discounted cash flows. That number is unknowable with precision. Any model that claims to calculate it exactly is being misleading. What can be done honestly is to estimate a range, acknowledge the assumptions explicitly, require a meaningful margin of safety between the price paid and even the conservative end of that range, and focus analytical energy on businesses whose future is sufficiently clear to make the estimation meaningful at all.

Clarity is a Pre-requisite

This last point deserves emphasis, because it connects the valuation methodology directly to the quality of the business being analysed.

A valuation is a representation of what the investor believes the business will produce in the future. The reliability of that representation depends entirely on how predictable the business’s cash flows are. A business with volatile, cyclical, or structurally uncertain earnings produces projections with enormous error bars. Even the most sophisticated framework applied to an unpredictable business produces an unreliable output, not because the framework is flawed, but because the input is noise.

This is why selectivity in business quality and rigour in valuation are not separate disciplines. They are the same discipline. Focusing analytical energy on businesses with durable competitive advantages, stable gross margins, predictable revenue streams, and a long track record of generating consistent free cash flow is not conservatism, it is the precondition for valuation to be meaningful at all. A business whose earnings fluctuate by 40% from year to year cannot be projected with confidence, which means the estimated embedded years carry so much uncertainty that the margin of safety required to invest responsibly becomes impractically large.

The framework described in the next section is only reliable when applied to businesses with sufficient clarity about their future to make the projection credible. Applied to highly cyclical, leveraged, or structurally uncertain businesses, it produces numbers that feel precise but are not. The investor must know the difference.

A More Honest Framework

Rather than asking what a business is worth, a question that implies a precision no one possesses, a more useful question is: at today’s price, how many years of future cash flows am I paying for?

The framework constructs a year-by-year series of discounted free cash flow per share projections and asks precisely this. The output is not a fair value. It is a number of embedded years, the stretch of the future that today’s price has already purchased. Everything the business earns beyond that point comes to the investor for free. The fewer the embedded years, the more of the future the investor receives without paying for it. The more embedded years, the longer the investor waits before the pre-paid portion of the future is exhausted and genuine excess returns begin to accumulate.

To make this concrete: imagine analysing a business like McDonald’s. The investor projects the next 20 years of free cash flow per share, accounting for the company’s growth opportunities, addressable market, pricing power, and share buyback behaviour, and discounts that entire stream back to today. If the current stock price reflects only the present value of the first 8 of those 20 projected years, the investor is paying for 8 years of future earnings and receiving the remaining 12 years of the projection, plus everything beyond year 20, entirely for free.

The question then becomes one of conviction about the business. McDonald’s has operated for over 70 years, serves tens of millions of customers daily across more than 100 countries, and has demonstrated through multiple economic cycles that its cash generation is durable and growing. If an investor believes with reasonable confidence that McDonald’s will continue operating and generating cash for decades beyond year 8, which its track record strongly supports, then a price embedding only 8 years of future earnings is not merely cheap. It is a bargain that can absorb meaningful errors in the underlying projections and still produce an exceptional outcome. The investor does not need to be precisely right about the growth rate in year 14 or year 19. The margin between what they paid for and what the business will likely deliver is wide enough to accommodate imprecision.

This is precisely why the number of embedded years matters more than a calculated fair value. It does not tell the investor what the business is worth, no one knows that. It tells them how much of the future they are pre-paying for, and how much they are receiving for free. The wider that gap, the more room exists for the investor to be wrong and still win.

What matters is not whether the embedded years are 14 or 16, both are in the same vicinity and call for the same investor behaviour. What matters is the difference between 12 embedded years and 35.

The Importance of the Entry Price

The practical implication of all of this is that the price paid at entry is one of the most consequential investment decisions an investor makes, more consequential, in many cases, than which business they choose.

Consider two examples from recent market history.

Apple ($AAPL). At the end of 2016, Apple’s stock price embedded approximately 10 years of future cash flows, at a moment when the market was uncertain about iPhone saturation and the company’s ability to sustain its growth. Warren Buffett initiated Berkshire Hathaway’s first Apple position in the first quarter of 2016 and continued building it aggressively. Over the following nine years, Apple’s free cash flow per share grew at a compound annual rate of approximately 11.7%. The stock price grew at approximately 27.7% annually over the same period. The share count fell by around 32% over the period through consistent buybacks, which contributed to per-share growth, but the gap between the 11.7% fundamental growth and the 27.7% price growth cannot be explained by buybacks alone. The dominant force was valuation expansion: the market re-rated Apple from 10 embedded years to over 40 embedded years as confidence in the franchise grew, and that re-rating added approximately 16 percentage points of annual return on top of what the business itself delivered. An investor who owned Apple through this period did not merely capture the fundamental growth of the business. They captured the fundamental growth plus an enormous revaluation bonus that was only available because the entry price was so compelling. Buffett has since significantly reduced Berkshire’s Apple position as the valuation entered and remained in the most stretched territory.

Alphabet ($GOOG). In early 2022, Google’s stock traded at approximately $148, embedding around 22 years of future cash flows. An investor who bought at that price and holds today at approximately $384 has generated a compound annual return of 27%. An investor who waited, and bought instead in late 2023 at $87, when the embedded years had compressed to approximately 12 and the market was deeply pessimistic about digital advertising and the competitive threat from AI-powered search, and holds today has generated a compound annual return of approximately 64%. The business is identical. The competitive position did not change materially between those two entry points. The difference in return is almost entirely a function of valuation at entry.

These are not cherry-picked anomalies. They are illustrations of a principle that operates in every market, in every cycle, for every business: the price paid at entry determines a significant portion of the return received, independent of how the underlying business performs. A great business bought at an excessive valuation can produce mediocre returns. The same great business bought at a compelling valuation can produce exceptional ones.

What This Means in Practice

Valuation is an estimation exercise that produces a range of plausible outcomes, shaped by assumptions about the future that will inevitably be imperfect. The honest investor acknowledges this and builds their process around it, requiring a margin of safety that provides room to be wrong, focusing on businesses whose futures are sufficiently clear to make the estimation meaningful, and treating the entry price as one of the few genuinely controllable variables in an otherwise uncertain process.

Conventional multiples have their place as a quick orientation tool. They are not a substitute for thinking carefully about what the current price implies about the future, whether that implication is reasonable given the evidence, and how much of the future the investor is pre-paying for before the free portion begins.

The goal is not precision. The goal is honesty about uncertainty, discipline in requiring adequate compensation for the risks taken, and the patience to wait for prices that make the investment genuinely compelling rather than merely defensible.

This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

The Outlook

Beauty is one of the few retail categories where the physical experience has not merely survived digital disruption, it has remained the primary reason consumers shop at all. You cannot match a foundation shade on a screen with confidence. You cannot know whether a fragrance suits you until you smell it on your own skin. You cannot replicate the trust of a stylist’s recommendation through a product carousel. Discovery in beauty is tactile, social, and advisory, and for thirty five years Ulta Beauty has been constructing the infrastructure to own that moment, and then to extend it, through digital and loyalty channels, into everything that comes after.

The founding insight, when Richard George and Terry Hanson opened the first store in Bolingbrook, Illinois in 1990, was that the beauty retail market had fragmented itself by price tier in ways that served the trade rather than the consumer. Prestige products lived behind department store counters, mass products in drug store aisles, professional products in authorised salons. A consumer who wanted all three made three separate trips. Ulta collapsed those occasions into a single destination: a large format store in a suburban strip centre, carrying prestige, mass, and professional products side by side, with a full service salon at the back. That structure, breadth across price tiers, embedded services, and a loyalty programme that converts every purchase into a data point, is what has been scaling for three and a half decades.

The loyalty programme, Ultamate Rewards, is the operational heart of the model. With more than 46 million active members and approximately 95% of all net sales flowing through the programme, Ulta has built something rare: a consumer franchise where the relationship between brand and customer is mediated almost entirely through a proprietary data layer the company controls. A member who discovers a moisturiser at an in store consultation, confirms it works, and then reorders it through the Ulta app is not just a repeat customer, she is a data point that improves the next recommendation, the next promotion, and the next brand partner negotiation. The guest who shops both in store and digitally spends, historically, more than three times as much as the store only guest. That pattern, in store discovery leading to digital replenishment, is the highest value expression of the model, and Ulta has built its entire commercial infrastructure around deepening it.

The financial record produced by this model is, for most of the decade between fiscal 2015 and fiscal 2025, impressive. Revenue compounded from $3.9 billion to $12.4 billion. Return on invested capital (ROIC) averaged above 27% through much of the period. Free cash flow per share grew from approximately $1 in fiscal 2015 to approximately $22.90 in fiscal 2025, driven by both genuine earnings growth and a consistent programme of share repurchases that reduced the diluted share count from 64.3 million to 45.0 million over the same period. These are the numbers of a business that earned genuine returns on incremental capital and allocated that capital with discipline.

But a financial record is a description of where a business has been, not a guarantee of where it is going. And what the most recent three fiscal years describe, fiscal 2022 through fiscal 2025, is a business whose absolute earnings and cash flow have stopped growing. Net income in fiscal 2022 was $1,242 million; in fiscal 2025 it was $1,154 million. Operating cash flow in fiscal 2022 was $1,482 million; in fiscal 2025 it was $1,503 million, marginally higher over three years, before adjusting for the cost of the capital that generated it. Meanwhile, selling, general and administrative expenses as a percentage of revenue have risen from 23.5% in fiscal 2022 to 26.6% in fiscal 2025, a consistent and multi year trend that this report examines closely.

The question this report attempts to answer honestly is whether these developments represent a transitional period in a business that will resume compounding, or an inflection in the underlying economics of a model that is approaching the limits of its domestic growth runway.

At approximately $558 per share and a market capitalisation of roughly $24.3 billion, the current price embeds approximately 46 years of future cash flows, a level that demands a confident view of the growth trajectory that the current evidence does not fully support. The analysis that follows is an attempt to be precise about what the business has demonstrated, what it has not, and what would need to change to make this a compelling investment.

At a Glance

Company: Ulta Beauty, Inc.

Ticker: $ULTA · NASDAQ

Sector: Consumer Discretionary

Industry: Specialty Retail — Beauty

Market Cap: $24.3 billion (at $558)

First Coverage: April 2026

FY2025 Revenue: $12.4 billion

1. The Business

Ulta Beauty was founded in Bolingbrook, Illinois in 1990 on the premise that the fragmentation of beauty retail by price tier was a structural inefficiency serving the trade more than the consumer. The founding format, a large format freestanding store in suburban strip centres, carrying prestige, mass, and professional products side by side, with a full service salon at the back, was unconventional at the time and has proven durable over three and a half decades. The company went public on NASDAQ in October 2007 and used the capital to fund national expansion. By fiscal 2016 it operated 974 stores; by fiscal 2025, 1,505 stores across all 50 states, alongside 86 Space NK stores in the United Kingdom and Ireland acquired in July 2025.

Ulta is a specialty beauty retailer, not a brand owner. It acts as the discovery and distribution platform between beauty brands and consumers, carrying approximately 30,000 products from approximately 600 established and emerging brands across every major price tier and category. The typical US store is approximately 10,000 square feet, with roughly 950 square feet dedicated to a full service salon offering haircuts, colour, blowouts, brow services, and skincare treatments. A smaller store prototype of 5,000 to 7,500 square feet is used for secondary markets. E-commerce and the mobile app, where approximately 60% of online sales originate, serve as replenishment and loyalty engagement channels, with omnichannel members spending historically more than three times as much as store-only members.

Beyond its branded assortment, Ulta offers its own private label brand, Ulta Beauty Collection, as well as a portfolio of third party brands sold exclusively at Ulta, either on a limited time basis or as longer term exclusives. Examples of exclusive brand partnerships include Cécred and Peach & Lily. In fiscal 2025, Ulta Beauty Collection and long term exclusive products represented approximately 4% of net sales; including short term exclusive products, the combined figure was approximately 11% of net sales. These exclusive relationships serve a dual purpose, they differentiate the assortment from competitors and generate higher merchandise margins than branded product sales at standard terms.

In fiscal 2025, cosmetics accounted for 38% of net sales, skincare and wellness 24%, haircare 19%, fragrance 13%, services 4%, and other 2%. The cosmetics share has declined modestly as skincare and fragrance have grown, reflecting broader category trends. Services, at 4% of revenue, carry strategic weight disproportionate to their financial contribution: a guest who schedules colour appointments returns on a predictable cadence, and the stylist relationship is among the most durable loyalty anchors in the store.

Ulta centrally manages product replenishment through a merchandise planning group that operates an open to buy system updated weekly with point of sale data, receipts, and inventory levels. As of fiscal year end 2025, the company operates four regional distribution centres, two market fulfilment centres serving both stores and e-commerce, and one fast fulfilment centre dedicated to e-commerce orders. More than 1,000 US stores participate in a ship from store programme. The market fulfilment centres, smaller, focused on the most productive SKUs, are designed to improve responsiveness in high density markets. This distribution infrastructure is the operational backbone of the omnichannel model and a genuine barrier to replication for any new entrant seeking to compete at comparable scale.

The Ultamate Rewards loyalty programme is the commercial engine of the business. With more than 46 million active members as of fiscal year end 2025, and approximately 95% of net sales flowing through it, the programme has achieved a penetration rate that is exceptional in specialty retail. Annual member retention exceeds 70%. The $582.4 million deferred revenue balance represents unredeemed points and gift cards, a forward commitment to return that is growing faster than the membership base itself. In fiscal 2025, 73% of loyalty members transacted exclusively in stores, reflecting the enduring primacy of the physical shopping occasion for Ulta’s core guest.

In July 2025, Ulta acquired Space NK, a luxury beauty retailer with 86 stores in the UK and Ireland, for approximately $399 million, funded with cash and short term credit. Space NK carries a premium, niche forward assortment in a smaller store format than Ulta’s US stores and is well regarded within the UK prestige beauty market. Beyond Space NK, Ulta operates a joint venture in Mexico with Grupo Axo (9 stores at fiscal year end 2025) and a franchise arrangement in the Middle East with Alshaya Group (2 stores). The international platform is financially immaterial relative to the US business, Space NK was acquired only partway through fiscal 2025, and will require sustained execution to justify the capital deployed.

2. The Moat

Ulta’s competitive advantage is a self reinforcing commercial ecosystem built on loyalty data, multi tier product breadth, in store experience, and physical density. The mechanism has been operating for three and a half decades without being successfully replicated at scale.

The mechanism works as follows. More loyalty members generate more purchase data, which enables more precise personalisation, which increases visit frequency and spend per visit. Higher spend per member justifies investment in brand exclusives and deeper category assortment, which attracts more brands seeking access to the member base. More brands and a stronger assortment attracts new members. A larger member base gives Ulta stronger leverage in brand partner negotiations, on terms, on exclusives, and on being selected as the launch partner for new product introductions. Each element reinforces the others, and because 95% of transactions flow through the loyalty programme, the data layer captures nearly the entire economic output of the business and converts it into competitive intelligence.

Pillar One

With 46 million active members and 95% of sales processed through Ultamate Rewards, Ulta operates one of the most comprehensive first party consumer databases in US specialty retail. The practical value of this data is in personalisation that an anonymous transaction retailer cannot approach, targeted replenishment reminders, predictive discovery prompts, shade matching recommendations informed by purchase history, and in the leverage it provides in brand partner relationships. A brand partner placing a new product at Ulta is not just accessing shelf space; it is accessing a targeted, purchase verified audience of 46 million beauty consumers. The deferred revenue balance of $582.4 million at fiscal year end 2025, growing 16.3% year on year, is the most direct financial expression of the programme’s deepening engagement: members are earning points at a faster rate than they are spending them, indicating commitment rather than attrition.

Pillar Two

No competitor carries prestige, mass, and salon professional products at scale under one roof. Sephora is prestige focused and carries no mass products or in store salon services at comparable scale. Mass retailers carry mass products but no credible prestige assortment and no services. Department store beauty counters offer prestige but operate as brand specific concessions rather than a multi brand discovery environment. Closing this gap requires simultaneously maintaining trust with prestige brands, who are historically reluctant to be shelved alongside mass products, and building the operational infrastructure to deliver a genuine salon service. Both are multi year relationship and investment commitments. Ulta’s exclusive and private label products deepen this moat further: approximately 11% of net sales flowing through exclusive or proprietary brands creates assortment that simply cannot be found elsewhere.

Pillar Three

The salon services business is embedded in almost every one of the 1,505 US stores. Its strategic importance is precisely its non replicability: no e-commerce platform, social commerce channel, or shop in shop concept can offer a colour appointment, a skincare consultation, or the relationship between a guest and a stylist she has seen three times. A guest who books salon appointments is not weighing Ulta against Amazon or Sephora, she is returning to a person and an experience. Company research confirms what the transaction data suggests: its guests prefer to transact in physical stores, where they can discover and interact with products and other beauty enthusiasts. The 73% of loyalty members who transacted exclusively in stores in fiscal 2025 are, in meaningful part, the guests for whom the physical experience is itself the value.

Pillar Four

With 1,505 stores across all 50 states, predominantly in high traffic suburban strip centres, supported by four regional distribution centres, two market fulfilment centres, one fast fulfilment centre, and more than 1,000 ship from store locations, Ulta operates a physical and logistics network that functions as both a retail asset and a fulfilment infrastructure. Building this network from scratch would require not just capital but years of lease negotiation, supplier relationship development, and market by market customer acquisition. The combination of physical density and distribution capability is the operational foundation of same day delivery, in store pickup, and ship from store, services that require the network to already exist before they can be offered.

Assessment

The core moat is intact. The loyalty programme is deepening, the exclusive brand relationships are growing, the salon service infrastructure remains non replicable, and the data advantage compounds annually. The moat is not, however, without pressure. Social commerce is compressing Ulta’s role at the top of the discovery funnel for younger consumers. Sephora’s expansion at Kohl’s has improved prestige accessibility in a mass retail format at over 1100 locations. These are real competitive dynamics, though they are pressures on the perimeter of the model rather than challenges to its structural core. My assessment is that the moat is stable, and that the more pressing questions for this business are about the cost structure and the growth runway, not the durability of the competitive position itself.

3. Financial Performance

Revenue

Ulta’s revenue between fiscal 2015 and fiscal 2025 divides into three periods. From fiscal 2015 through fiscal 2019, the business grew from $3.9 billion to $7.4 billion, a compound annual growth rate of approximately 17%, driven by new store openings at pace and comparable sales growth consistently in the mid to high single digits. Fiscal 2020 was the COVID interruption: stores closed for approximately eight weeks, comparable sales fell 17.9%, and revenue declined 16.8% to $6.2 billion. From fiscal 2021 through fiscal 2023, revenue recovered sharply, growing 40.3%, then 18.3%, then 9.8%, as pent-up demand, stimulus spending, and the structural step change in gross margins combined to produce exceptional three year period in the company’s history. Fiscal 2024’s growth of 0.8% reflected a normalisation of that demand cycle, and fiscal 2025’s 9.7% growth, driven partly by the Space NK acquisition from July 2025 and a genuine 5.4% comparable sales recovery, represents the current run rate. What the revenue trajectory does not show clearly, but the earnings and cash flow lines do, is that the revenue growth of fiscal 2025 did not translate into earnings growth.

Gross Margin

Gross margins from fiscal 2015 through fiscal 2019 were stable in the 35% to 36% range. Fiscal 2020’s 31.7% reflects the deleverage of fixed store costs on dramatically lower revenue during the COVID closure period, the one clear anomaly in an otherwise consistent record. From fiscal 2021 onward, gross margins moved into a structurally higher band of 39% to 40%, reflecting a greater mix of prestige and skincare products carrying higher merchandise margins, reduced shrink, and supply chain efficiencies. This shift has been sustained for five consecutive years and represents a genuine structural improvement in the gross economics of the product mix. Gross margins have not been the source of the profitability pressure that has emerged since fiscal 2022; they have been a source of stability.

Operating Margin and SG&A

Operating margins tell the more complicated story. From fiscal 2015 through fiscal 2019, operating margins ran in the 12% to 14% range. During the post COVID demand surge of fiscal 2021 through fiscal 2023, operating margins expanded sharply, reaching 16.2% at peak in fiscal 2022, as revenue grew faster than the cost base could expand. Since fiscal 2022, operating margins have declined in each successive year: 15.1% in fiscal 2023, 14.0% in fiscal 2024, and 12.5% in fiscal 2025. The driver throughout has been SG&A.

SG&A as a percentage of revenue was 23.5% in fiscal 2022. It rose to 24.1% in fiscal 2023, to 24.9% in fiscal 2024, and to 26.6% in fiscal 2025, a consistent, multi year upward trend that predates fiscal 2025’s specific items and cannot be attributed to any single year’s activity. In absolute terms, SG&A grew $487.8 million, or 17.4%, in fiscal 2025, against revenue growth of 9.7%. The company attributed this increase to higher incentive compensation reflecting above plan performance, higher store payroll and benefits, higher corporate overhead from strategic investments, and higher store expenses.

Each of these components merits examination. Technology spending, amortisation of the Project SOAR enterprise resource planning implementation, cloud infrastructure costs, and AI personalisation systems, flows through SG&A over multiple years once the capital investment is made; it does not revert when the project is complete. Store payroll has repriced upward in a persistently tight labour market, and wage levels do not reverse when conditions ease. The Space NK acquisition, completed in July 2025, consolidated 86 stores’ worth of operating overhead into the SG&A line for the last two quarters of fiscal 2025, and that overhead is now a permanent part of the run rate. Marketing intensity has increased as the competitive environment requires greater promotional investment to maintain market share. Taken together, these are not temporary distortions around a stable underlying cost structure. They represent a cost base that has structurally repriced to a higher level, and the multi year trend in the SG&A-to-revenue ratio is the clearest evidence of that. Management has acknowledged the trajectory, CEO Kecia Steelman and the new CFO have introduced zero based budgeting and personal review of all new investment initiatives specifically to bring costs back into better alignment with revenue growth.

Net Income and Operating Cash Flow

The most important three numbers in this financial record are the ones that sit flat across the most recent three years. Net income was $1,242 million in fiscal 2022, $1,291 million in fiscal 2023, $1,201 million in fiscal 2024, and $1,154 million in fiscal 2025, lower at fiscal year end 2025 than it was three years earlier. Operating cash flow was $1,482 million in fiscal 2022, $1,476 million in fiscal 2023, $1,339 million in fiscal 2024, and $1,503 million in fiscal 2025, essentially flat over three years of revenue growth from $10.2 billion to $12.4 billion. The per share earnings growth that the EPS line shows over this period, from $24.01 to $25.64, is almost entirely the result of buybacks reducing the denominator rather than the numerator growing. The absolute earnings power of the business has not expanded since fiscal 2022.

Free Cash Flow

SBC adjusted free cash flow peaked at approximately $1.13 billion in fiscal 2022 and has since declined: $993 million in fiscal 2023, $921 million in fiscal 2024, and $1.03 billion in fiscal 2025. The fiscal 2025 figure recovered from fiscal 2024’s trough primarily through working capital timing rather than a structural improvement in earnings. FCF per share has grown modestly over this period, from approximately $22.61 in fiscal 2022 to approximately $23.74 in fiscal 2025, again driven almost entirely by the declining share count rather than FCF growth in absolute terms.

4. Capital Allocation

Ulta pays no dividend. Its capital return programme consists of share repurchases, supplemented in fiscal 2025 by the Space NK acquisition, the largest single inorganic capital commitment in the company’s recent history. This simplicity makes the allocation track record relatively easy to evaluate.

Over fiscal 2022 through fiscal 2025, Ulta repurchased approximately $3.8 billion of its own shares: $900 million in fiscal 2022, $1.01 billion in fiscal 2023, $1.02 billion in fiscal 2024, and $915 million in fiscal 2025. These repurchases reduced the diluted share count from approximately 51.7 million at the start of fiscal 2022 to approximately 45.0 million at fiscal year end 2025, a 13% reduction. As the absolute earnings base has been flat, buybacks have been the primary driver of per share metric growth over this period. Whether that represents value creation depends on whether the shares are being repurchased below their underlying worth. At 47 years of embedded cash flows, the current valuation does not make a compelling case that they are. As of fiscal year end 2025, approximately $1.8 billion remained available under the October 2024 $3.0 billion repurchase authorisation, and management has guided for approximately $1 billion in repurchases in fiscal 2026.

Capital expenditure has run at $150 million to $435 million annually across the decade, reflecting the varying intensity of store construction, remodelling, technology investment, and supply chain infrastructure. At approximately 3% to 4% of revenue, capex intensity is low relative to operating earnings, and the economics of new store construction, a net investment of approximately $2.4 million per location, with payback typically in under two years, make the expansion programme a high return use of capital. In fiscal 2025, Ulta opened 63 net new US stores and remodelled 42 existing locations.

The Space NK acquisition, at approximately $399 million net of acquired cash, placed $226 million of goodwill and $204 million of intangible assets on the balance sheet. These assets earn a return only if Space NK grows its contribution to Ulta’s brand partner relationships and, eventually, to revenue. The financial contribution from 86 stores in the UK and Ireland is currently immaterial, and the acquisition was completed partway through fiscal 2025, so its full year overhead impact will be visible for the first time in fiscal 2026. The capital was deployed at a moment when the domestic business was generating flat absolute earnings, which adds weight to the question of whether this was the highest return use of approximately $400 million.

Share

5. Competition

The US beauty retail market represented approximately $110 to $126 billion in annual sales in fiscal 2025. Ulta holds approximately 10% of that total, with no single competitor holding a comparably defined share of the multi format, multi tier beauty destination category.

Sephora (LVMH)

Sephora is Ulta’s most direct prestige competitor and has made the most strategically significant competitive move of the past five years in embedding shop in shops at Kohl’s, a programme that has grown to more than 1100 locations and brings prestige beauty into a mass retail format at scale. The Kohl’s partnership does not offer salon services, does not carry mass products, and does not operate a loyalty programme with Ultamate Rewards’ data depth, but it improves prestige beauty accessibility for a mainstream consumer who previously might have visited Ulta for the same occasion. The competitive overlap is direct and growing.

The Ulta Beauty at Target Partnership

From 2021 through its planned conclusion in August 2026, Ulta operated a shop in shop concept inside more than 600 Target locations. On August 14, 2025, both companies announced a mutual decision not to renew the agreement. The reasons that have been reported are instructive: analysts noted that Ulta Beauty at Target locations were frequently co-located in the same strip centres as standalone Ulta stores, cannibalising the company’s own traffic. Operational reports described understaffing and a lack of specialist beauty training at Target locations, producing a guest experience materially inferior to a standalone Ulta store. The exit also reflects the declining attractiveness of the Target retail environment itself, Target’s brand reputation and store traffic have weakened materially in recent years, and Ulta’s association with a deteriorating host retailer was an incremental liability rather than an asset. For Ulta, the decision to exit refocuses growth investment on the owned store fleet and international expansion, the businesses over which it has direct operational control and which benefit fully from the loyalty programme.

Social Commerce and the Discovery Shift

The most structurally significant long term competitive challenge to Ulta’s model is the migration of beauty discovery from physical retail toward social platforms. TikTok Shop, Instagram Checkout, and the influencer to cart ecosystem are compressing the role of the physical retailer at the top of the customer journey, particularly for younger consumers who build their beauty vocabulary through content rather than store browsing. Ulta has responded with its own TikTok Shop launch, the UB Collective influencer programme, and the UB Creates content platform. But the structural reality cuts in two directions simultaneously: if social commerce drives discovery, then Ulta’s in store discovery occasion, the foundation of its loyalty data engine, faces long term pressure. And if beauty consumers begin purchasing directly through social platforms rather than through Ulta’s own channels, the advantage of Ulta’s data and the threat from online only competitors both intensify. These two outcomes are not compatible with the thesis that physical experience is structurally non replicable, and that tension is worth holding honestly.

Amazon and Replenishment

Amazon’s competitive impact on Ulta is concentrated in replenishment, the reorder of a known product at a known price, and is limited in discovery, advisory, and service occasions. The loyalty programme is Ulta’s primary defence in the replenishment channel: a member who earns and redeems points on repeat purchases at Ulta has a financial incentive to return through Ulta’s channels rather than routing orders to Amazon. The data Ulta collects on replenishment purchases also feeds the personalisation that makes the discovery relationship stronger. The defence is real, but it is not absolute, and it depends on the loyalty programme maintaining its economic value to the consumer over time.

6. Management

Ulta has had three CEOs since June 2021. Mary Dillon, who oversaw the majority of the company’s growth from 2013 to 2021, stepped down in June 2021 and was replaced by then President Dave Kimbell. Kimbell unexpectedly retired in January 2025 and was replaced by Kecia Steelman, who had served as President and COO since September 2023 and as Chief Operating Officer since June 2021. In mid 2025, CFO Paula Oyibo resigned after just over one year in the role; her replacement, Christopher DelOrefice, joined from Becton Dickinson in December 2025. At the time of this report, the CEO has been in the role for approximately 15 months and the CFO for approximately five months. The frequency of leadership change at the top of the organisation, during a period when the competitive environment is intensifying and the cost structure is requiring active intervention, is a genuine risk factor, even if corporate strategy and capital allocation policies have not materially changed through the transitions.

Steelman’s background is operational: she joined Ulta in 2015 as Chief Store Operations Officer and has spent a decade inside the business building the store operations, supply chain, and guest experience systems that underlie the competitive position. That operational foundation is relevant for a business whose moat is delivered at store level, through the salon appointment, the specialist recommendation, the loyalty programme interaction. The Ulta Beauty Unleashed strategic plan, Drive Core Business Growth, Scale New Accretive Businesses, Align Foundation for Success, is the framework under which fiscal 2025’s 5.4% comparable sales recovery was delivered. Management has guided fiscal 2026 EPS at $28.05 to $28.55, implying growth of 9.4% to 11.4% from fiscal 2025’s $25.64, with operating income growing 6% to 9% on revenue growth of 6% to 7%.

Executive compensation is predominantly variable. Base salary represents a minority of total package; the balance is split between short term incentive awards tied to annual financial targets including revenue, operating income, and FCF, and long term equity awards split between time vesting restricted stock and performance based restricted stock tied to EPS and return metrics over a three year period. The performance equity pays on a 0% to 150% scale against targets. The above plan fiscal 2025 financial performance drove materially higher incentive compensation, a direct contributor to the SG&A increase, which is the design of the programme working as intended. Whether that design produces the right long term outcomes depends on whether the targets being set are genuinely stretching relative to the business’s underlying potential.

7. Growth Levers & Addressable Market

1. Domestic Store Expansion

Management’s stated view is that long term US freestanding store potential exceeds 1,800 locations, implying approximately 300 additional stores from the current 1,505. At fiscal 2025’s pace of 63 net new openings annually, that runway represents roughly five years of store driven revenue contribution. At an average unit volume of approximately $8 million per store, 300 additional stores represent roughly $2.4 billion of incremental revenue, meaningful over the period, but finite. Once the store count approaches the stated ceiling, the organic growth engine for the domestic business narrows to comparable sales growth alone. If comps stabilise in the 2% to 3% range, consistent with management’s fiscal 2026 guidance of 2.5% to 3.5%, the revenue growth algorithm becomes structurally more modest, and the ability to leverage a largely fixed cost base diminishes accordingly.

2. Comparable Sales and Operating Leverage

Fiscal 2025’s 5.4% comparable sales growth, driven by simultaneous improvement in both transaction count and average ticket, is the most encouraging near term signal in the business. Ulta’s store cost structure contains significant fixed and semi fixed elements, meaning that comparable sales growth above a threshold level translates into operating margin expansion. Management’s fiscal 2026 guidance of 2.5% to 3.5% comparable sales growth is below fiscal 2025’s actual result. Whether that reflects deliberate conservatism or genuine uncertainty about the durability of the recovery is unclear. What is clear is that the operating leverage available from comps is most powerful precisely at the point when structural cost pressures are also at their highest, and the net effect on operating margins will be the most important financial development to monitor in fiscal 2026.

3. International Expansion

The international platform, Space NK in the UK and Ireland, the Grupo Axo joint venture in Mexico, and the Alshaya Group franchise in the Middle East, is the strategic optionality that Ulta did not possess three years ago. Space NK provides an established brand, a curated prestige assortment, and a route to deepen brand partner relationships in European markets. The Mexico and Middle East operations are early stage and represent Ulta’s first testing of its format and brand in emerging international markets. The strategic rationale, that global brand partners increasingly value international distribution capability in their retail relationships, is coherent. The financial contribution is currently immaterial, and the execution risk of managing multiple international markets simultaneously, while the domestic business is under cost pressure, is real. International expansion is an option that requires several years of evidence before it can be underwritten as a meaningful earnings contributor.

4. Retail Media and Data Monetisation

UB Media, Ulta’s retail media network, earns advertising revenue from brand partners paying for targeted placement within the Ulta digital ecosystem. With 46 million loyalty members and purchase level data covering the vast majority of transactions, Ulta’s audience targeting precision in the beauty category is superior to what horizontal platforms can offer. The economics of retail media are attractive: revenue is earned on an audience the business already owns, with advertising inventory created by existing digital traffic rather than incremental capital. The model has been demonstrated at scale by Amazon, Walmart, and Target. For Ulta, UB Media remains early stage and is not currently a material revenue contributor, but it is a genuine candidate to generate high margin incremental revenue over a five year horizon without requiring significant capital investment.

5. Omnichannel Deepening

The omnichannel guest, shopping both in stores and digitally, represents the highest value member profile in the loyalty programme. In fiscal 2025, active app users grew 15% year on year, with approximately 60% of online sales originating through the app. Each enhancement to the digital platform, personalised recommendations, reorder shortcuts, shade matching capabilities, is an investment in converting store only members into omnichannel members and deepening the replenishment relationship. The data supports the investment: the spending differential between omnichannel and store only guests is the clearest financial proof that the digital channel is additive rather than substitutive.

8. Valuation

Every price paid for a business contains an implicit question: how many years of future cash flows are already baked into what you are paying today? Rather than assigning a terminal value, which requires many assumptions about growth in perpetuity that no analyst can honestly support, Bearhold’s framework constructs a year by year series of discounted free cash flows and asks: at today’s stock price, how many years of future earnings are embedded? Everything the business earns beyond that point comes to you for free. The fewer the embedded years, the more of the future you receive without paying for it.

At today’s price, you are paying for everything Ulta will earn over roughly the next 47 years, in today’s money. Everything it earns beyond that comes to you for free, but that free portion begins nearly half a century from now.

Growth Engine 1: Fundamentals

The first engine is the business itself. FCF per share grows over time through revenue expansion, operating leverage, and share count reduction from buybacks. That growth, compounded annually, is what the fundamental engine delivers regardless of any valuation re-rating. Based on the recent earnings trajectory, net income flat for three years, SG&A repricing structurally higher, the domestic expansion runway approaching its ceiling, I expect FCF per share growth at or below 6% annually.

Growth Engine 2: Valuation Re-Rating

The second engine is valuation. When the embedded years are low, the market is under pricing the business relative to what it will eventually pay as confidence grows, and that re-rating produces a return on top of the fundamental growth. At 47 embedded years, the opposite is true. The market is already pricing in a growth trajectory more optimistic than what the evidence supports. A negative re-rating is possible here, which could affect the future returns from engine 1 negatively.

9. Risks

1. Structural SG&A Repricing

This is the most important risk in the current period, and the one with the least favourable resolution path. SG&A as a percentage of revenue has risen from 23.5% in fiscal 2022 to 26.6% in fiscal 2025, a consistent, four year upward trend. The components driving it, technology amortisation from multi year ERP and cloud investments, store payroll repriced in a persistently tight labour market, consolidated overhead from the Space NK acquisition, do not revert automatically when conditions change. They represent a permanent repricing of the cost base. Management has introduced zero based budgeting and personal executive review of new investment initiatives as corrective measures, which signals that the trend has been recognised as a problem requiring active intervention rather than a cyclical effect that will self correct. Until the SG&A-to-revenue ratio stabilises and reverses across multiple consecutive years, the structural interpretation is the more honest one.

2. Flat Absolute Earnings

Net income has not grown in absolute terms since fiscal 2022. Operating cash flow is essentially flat over the same period. The per share earnings growth that the EPS line presents is a function of buybacks, not business growth. A business that is returning capital to shareholders faster than it is growing its earnings base may be creating per share value in the short run, but it is also reducing the asset base available to generate future earnings.

3. Management Instability

Three CEOs since 2021, a CFO who resigned after 14 months, and a replacement CFO five months into his tenure at the time of this report constitute a pattern of leadership instability that coincides with the period in which the cost structure has been most in need of discipline and the competitive environment has been most demanding. Corporate strategy and capital allocation have not materially changed through the transitions, but strategic continuity at the policy level is not the same as operational and cultural continuity at the execution level. The cost discipline initiatives, zero based budgeting, executive review of investments, will take time to demonstrate results, and the leadership team executing them is relatively new.

4. Social Commerce and Discovery Channel Erosion

The migration of beauty discovery toward social platforms is a slow but real structural pressure on Ulta’s model. A business whose fundamental advantage is in-store discovery is exposed to any sustained shift in where consumers form beauty preferences and initiate purchase journeys. Ulta’s response, TikTok Shop launch, influencer programmes, digital personalisation investment, is appropriate, but it is also a concession that the discovery channel is evolving. If a meaningful portion of the next generation of beauty consumers builds their product relationships through social channels and purchases through brand direct or social commerce channels, the loyalty programme’s acquisition funnel weakens at its source.

5. International Execution Risk

The Space NK acquisition, at approximately $399 million, and the early stage Mexico and Middle East operations represent Ulta’s first significant international capital commitments. International retail is operationally demanding, regulatory requirements, consumer preferences, supplier terms, real estate markets, and talent pools all differ materially from the US. Ulta has no track record of managing international retail operations at scale. The goodwill and intangible assets from Space NK ($430 million combined) earn a return only if the acquisition delivers its strategic rationale, and the execution risk during the first several years of managing a UK business while the domestic cost structure is under pressure is real.

The Verdict

Ulta Beauty built something real over three and a half decades. The loyalty programme with 46 million active members, 95% transaction penetration, and $582 million in deferred revenue growing at 16% annually. The multi tier store format, the in-store salon services, the exclusive brand relationships, and the physical distribution network are collectively a competitive position that has outlasted 35 years of disruption attempts and has not been successfully replicated at scale by any competitor. That track record earns genuine respect and earns the business a place on the Watchlist, a recognition that the quality is real, even if the current circumstances do not support a conviction investment.

The reasons it does not earn the Approved designation at this time are specific and data driven. Net income has not grown in absolute terms since fiscal 2022. Operating cash flow has been essentially flat over three years of revenue growth from $10.2 billion to $12.4 billion. SG&A as a percentage of revenue has risen in each of the past four years and is now structurally higher than the pre surge period, reflecting a cost base that has permanently repriced through technology investment cycles, labour market repricing, and the Space NK acquisition overhead. The domestic growth runway is finite, approximately 300 additional stores, and beyond it the business is dependent on comparable sales growth at a rate that management’s own guidance suggests will be modest. International expansion is early stage and unproven at scale. The leadership team has not been stable.

What Would Change My Mind

A significant improvement in the valuation, combined with demonstrated stability in the management team across at least two full annual reporting cycles, and evidence that international markets are becoming a meaningful and measurable earnings contributor, are the three conditions that would warrant upgrading Ulta from Watchlist to Approved and considering initiation. I would also want to see the SG&A-to-revenue ratio declining across at least two consecutive fiscal years before accepting that the structural repricing has been addressed. Until those conditions are met, the business sits on the Watchlist, acknowledged as a genuine franchise with a durable loyalty moat, but not one where the current evidence supports a conviction position.

This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

The Outlook

Approximately one in every five Americans will enter a hospital this year. When they do, there is roughly a one in six chance they will walk through the doors of an HCA Healthcare facility. HCA operates 189 hospitals across 19 US states and England, with 50,459 licensed beds and approximately 320,000 employees. It generated $75.6 billion in revenue in 2025 and a return on invested capital, the percentage return earned on every dollar deployed into the enterprise, of 18.9%. For a capital intensive, heavily regulated industry, those numbers are exceptional. No for profit hospital company in the United States comes close.

The business was founded in Nashville in 1968 by Dr. Thomas Frist Jr. and entrepreneur Jack Massey on the conviction that professional management and shared infrastructure could transform a fragmented, inefficient hospital industry. That conviction has been validated by five decades of compounding. The Frist family, now in its third generation, with Thomas Frist III serving as Chairman of the Board, still owns approximately 32% of the company, a continuity of ownership and institutional purpose that has shaped the long term orientation of management throughout.

HCA’s competitive position is built on scale, market density, and institutional depth that no competitor has replicated. Its return on invested capital has averaged 16.7% over the past decade, a 7 to 9 percentage point premium over its nearest publicly traded for profit peers. Gross margins have expanded from 37.6% in 2015 to 41.5% in 2025. The cash generation of the business has grown consistently enough that, despite a decade of aggressive share repurchases funded partly through debt, the leverage ratio has improved from 6.4 times debt to operating cash flow in 2015 to 3.85 times in 2025.

REFERENCE

Key Terms

Several terms in this report are specific to the healthcare industry. The following definitions are intended to make the analysis accessible without interrupting it each time a term appears.

Admission

An admission is when a patient is formally checked into a hospital for at least one overnight stay. It is the primary unit of volume measurement in the hospital business, the equivalent of passengers for an airline. A related metric, equivalent admissions, adjusts this figure to also capture outpatient procedures, giving a more complete picture of total patient volume across both inpatient and outpatient settings.

Reimbursement

Hospitals do not set their prices freely. Most revenue is collected through reimbursement, the amount that insurers and government programmes agree to pay for a given service. Reimbursement rates vary widely by payer: government programmes typically pay at rates set below the cost of care, while private managed care plans negotiate higher rates. The mix of who is paying is one of the most important determinants of hospital profitability.

Medicare

Medicare is the US federal government’s health insurance programme for Americans aged 65 and over, and for certain disabled individuals. It is administered directly by the federal government and sets its own reimbursement rates by regulation.

Managed Medicare

Managed Medicare, also known as Medicare Advantage, refers to private health insurance plans that receive a fixed payment from the federal government to provide Medicare benefits to enrolled patients. Rather than the government paying hospitals directly, a private insurer manages the coverage and negotiates rates with hospitals on the government’s behalf. Managed Medicare typically pays hospitals somewhat better than traditional Medicare, which is why its growing share of the Medicare population is generally viewed as a modest positive for hospital operators. HCA derived approximately 18% of its 2025 revenues from Managed Medicare.

Medicaid

Medicaid is a joint federal state programme covering lower income individuals. Reimbursement rates are set by each state within federal guidelines and are typically the lowest of any payer category, often below the cost of providing care. Together, Medicare and Medicaid account for approximately 45% of HCA’s revenues.

Managed Care

Managed care refers to private health insurance companies, such as UnitedHealth, Cigna, and Aetna, that negotiate directly with hospitals on the rates they pay for procedures. These negotiated rates are typically the highest of any payer category, making managed care patients the most commercially valuable to hospital operators. HCA derives approximately 49% of its revenues from managed care and private insurers.

Supplemental Payments

Many states make additional payments to hospitals above their base Medicaid rates, to partially bridge the gap between what Medicaid pays and what care actually costs. These are called state directed payments or supplemental payments. For HCA, these represented approximately $6.2 billion of 2025 revenues. They are now under active pressure from federal legislation, and their expected gradual decline is the most important near term financial risk in this report.

At a Glance

Company: HCA Healthcare, Inc.

Ticker: $HCA · NYSE

Sector: Health Care

Industry: Hospital Operations & Health Services

Market Cap: $98.4 billion (at $438)

First Coverage: April 2026

FY2025 Revenue: $75.6 billion

This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

1. The Business

Hospital Corporation of America was founded in Nashville in 1968 by Dr. Thomas Frist Jr., a physician and former US Air Force flight surgeon, alongside entrepreneur Jack Massey. The founding premise was that the US hospital industry was unnecessarily fragmented, hundreds of independently managed facilities each reinventing the wheel on purchasing, staffing, and administration. Professional management and shared resources, applied at scale, could lower costs and improve outcomes. That premise has been validated across five decades of operation.

The company has passed through multiple ownership structures, a leveraged buyout (an acquisition financed primarily with debt rather than equity) in 1989, a return to public markets in 1992, a second and larger leveraged buyout in 2006 at $33 billion, and a re listing in 2011. Through each transition, the operating business was uninterrupted. HCA Healthcare, Inc. as it exists today was incorporated in Delaware in 2010 and listed on the New York Stock Exchange in 2011. The Frist family’s continued 32% ownership stake is a thread of institutional continuity running through every structure the business has had.

What HCA Does

HCA operates hospitals and related health care facilities. Patients arrive through emergency rooms, physician referrals, or scheduled procedures, receive care, and are discharged. HCA bills the relevant payer, Medicare, Medicaid, a private insurer, or the patient directly, for the services rendered. The margin between the cost of delivering care and the reimbursement received is the economic engine of the business.

As of March 31, 2026, HCA operated 189 hospitals: general acute care facilities, behavioural health hospitals treating mental health and substance use conditions, and rehabilitation hospitals. It also operated approximately 2,600 ambulatory sites of care, including freestanding ambulatory surgery centres, freestanding emergency rooms, urgent care centres, and physician clinics. These outpatient facilities are an increasingly important part of the network as medicine shifts toward procedures that do not require overnight hospital stays.

Geographic Structure

HCA organises its US operations into three geographic groups. The National Group covers hospitals across states including California, Tennessee, Virginia, and Nevada. The Atlantic Group covers hospitals concentrated in Florida, Georgia, and South Carolina. The American Group covers hospitals primarily in Texas, Colorado, and Louisiana. Eight hospitals in England are managed within the Corporate segment.

Florida and Texas together generated 51% of HCA’s total revenues in 2025. They are also the two fastest growing major US states by net domestic migration, Florida gained approximately 370,000 net new residents in 2024 and Texas approximately 230,000. Each new resident is a potential future patient. Florida’s above average share of residents over 65, the heaviest users of hospital services, creates structural demand that compounds quietly year after year regardless of the economic cycle.

Revenue Mix

Managed care and private insurers represent approximately 49% of HCA’s revenues, the commercially negotiated, higher paying category that drives most of the profitability. Medicare accounts for approximately 15% of revenues, with Managed Medicare adding a further 18%. Medicaid contributes approximately 8%, with Managed Medicaid adding 5%. Uninsured and other sources account for the remainder.

Embedded within the Medicaid figure is approximately $6.2 billion in supplemental payments from state governments, additional reimbursement above base Medicaid rates intended to bridge the gap between what Medicaid pays and what care actually costs. New federal legislation enacted in 2025 restricts these payments going forward. Their expected gradual decline is the most important near term financial risk in this analysis, and it is addressed in the Capital Allocation and Risks sections.

2. The Moat

HCA’s competitive advantage is scale driven operational superiority, the ability to deploy shared infrastructure, purchasing power, clinical data, and capital access across a hospital network that no competitor has matched in size or geographic density. This advantage was built over five decades, facility by facility, and it compounds with each passing year.

Consider what it means to be a private health insurer trying to offer a competitive plan for employers and families in metropolitan Houston. To offer meaningful network coverage across cardiology, oncology, emergency care, and surgical services, you need access to HCA’s Texas hospitals. Excluding them is not commercially viable, your members would be directed away from facilities they already rely on. So you negotiate. And in those negotiations, HCA’s network density is leverage. This dynamic repeats in every major market where HCA has built density. More density means stronger insurer relationships. Stronger relationships generate better reimbursement rates. Better rates fund further investment in facilities and physician recruitment. Better facilities attract more physicians, which drives more patient referrals. The cycle reinforces itself continuously.

1. Purchasing Scale

At $75.6 billion in annual revenue across 189 hospitals, HCA is the largest buyer of medical supplies, equipment, and pharmaceuticals in the for profit hospital sector. This purchasing scale translates into supplier terms that smaller operators cannot access at equivalent pricing. The gross margin expansion from 37.6% in 2015 to 41.5% in 2025, a 390 basis point improvement over a decade, reflects this purchasing leverage compounding over time.

2. Clinical Data Infrastructure

HCA has accumulated clinical outcome data from tens of millions of patient encounters across its entire network over decades. This allows the company to benchmark performance across all facilities, identify operational inefficiencies, and standardise best practices system wide, a capability that no regional competitor can replicate without comparable scale. The ongoing investment in a new enterprise wide electronic health record platform and an AI assisted nursing platform will materially strengthen this analytical foundation over the next several years.

3. Capital Access and Infrastructure Compounding

HCA’s scale gives it access to debt and equity capital markets on terms that smaller hospital operators cannot match. This access funds a continuous programme of facility construction, bed additions, physician practice acquisitions, and technology upgrades. For 2026, HCA has guided capital expenditure of approximately $5.1 to $5.4 billion, a figure that reflects not just maintenance of the existing network but deliberate expansion into high growth markets. Every dollar spent on this programme compounds the competitive advantage that took five decades to build.

Financial Evidence

The most compelling financial evidence of the moat is the sustained ROIC gap relative to peers. HCA’s return on invested capital averaged approximately 16.7% over the decade from 2015 to 2025. Tenet Healthcare averaged approximately 7% ROIC over the same period. Universal Health Services averaged approximately 9%. A 7 to 9 percentage point ROIC premium, sustained for ten consecutive years in a capital intensive regulated industry, is the financial expression of a structural competitive advantage. The moat is stable to strengthening.

3. Financial Performance

The ten year financial record of HCA Healthcare reflects consistent operational excellence alongside a financial structure that demands careful reading. The table below presents key metrics across all available years from 2015 through 2025.

Revenue grew from $39.7 billion in 2015 to $75.6 billion in 2025, a compound annual growth rate of approximately 6.6%. The growth was driven by volume increases in admissions and equivalent admissions, price improvement from commercial contract renewals, geographic expansion, and the supplemental Medicaid payment programmes. In 2025, same facility revenues grew 6.6%, driven by 2.4% equivalent admissions growth and 4.1% revenue per equivalent admission growth.

The $6.2 billion in Medicaid supplemental payments embedded in 2025 revenues requires specific attention. New federal legislation enacted in 2025, referred to throughout this report as the FBA, or Federal Budget Act, restricts these mechanisms going forward. The Q1 2026 results, discussed in the update subsection below, indicate the near term impact is tracking materially better than initially feared.

Gross margin expanded from 37.6% in 2015 to 41.5% in 2025, a 390 basis point improvement over ten years. The direction of travel has been consistent throughout and reflects the compounding effect of better commercial contract pricing relative to the cost of delivering care. A business losing competitive ground does not expand gross margins at this pace.

Operating margin was 15.8% in 2025, above the decade average of approximately 14.8%. The peak in the available record was 16.5% in 2021, reflecting the combination of pandemic era volume and government support before the full labour cost inflation materialised. By 2022, the nursing shortage crisis had hit at full force, hospitals across the industry were forced to rely heavily on temporary travelling nurses hired on short term contracts at exceptional premium rates, inflating the industry wide labour cost ratio by an estimated 200 to 250 basis points and compressing operating margin to 15.0%. As that crisis resolved through 2023 and 2024, costs receded and margins recovered toward the current 15.8%. The current level is structurally sound, though it is worth noting that the labour cost ratio has not returned to the pre pandemic baseline of approximately 38% of revenues, the current level of approximately 43 to 44% represents a structural upward shift of several percentage points from the pre 2020 norm, which is relevant context for modelling the margin ceiling.

Diluted earnings per share grew from $4.99 in 2015 to $28.33 in 2025, a compound annual growth rate of approximately 19%. HCA’s revenues grew at 6.6% annually over the same period. The gap between 6.6% revenue growth and 19% EPS growth is almost entirely explained by the share buyback programme. HCA reduced its diluted share count from approximately 427 million in 2015 to approximately 240 million in 2025, a 44% reduction over the decade. The mechanics of how this reduction was funded are addressed in the Capital Allocation section.

Free cash flow, operating cash flow less capital expenditure, grew from approximately $2.4 billion in 2015 to $7.7 billion in 2025, a compound annual growth rate of approximately 12.4%. The trajectory has been consistently upward with one interruption in 2022 when elevated capital investment temporarily reduced FCF. The recovery was sharp: $4.7 billion in 2023, $5.6 billion in 2024, and $7.7 billion in 2025. I deduct stock based compensation of $401 million in 2025 as a real economic cost to shareholders. After this adjustment, normalised FCF is approximately $7.3 billion, or approximately $30.50 per share at the average 2025 diluted share count of 239.5 million.

ROIC of 18.9% in 2025 is the highest reading in the decade long record and comfortably above any reasonable estimate of the cost of capital. Averaged across the full decade, ROIC was approximately 16.7%. This consistency, through a global pandemic, an industry labour crisis, and sustained regulatory uncertainty, is the most reliable indicator that HCA’s competitive advantages are structural rather than circumstantial.

Q1 2026 Update

HCA reported its first quarter 2026 results on April 24, 2026. The full year financial analysis above is anchored to FY2025 annual figures, quarterly results are too noisy to anchor financial ratios on and are included here solely to confirm or challenge the annual thesis.

Volume was softer than the 2025 trend, with same facility admissions up 0.9% and equivalent admissions up 1.3%. Management attributed this directly to two temporary factors: respiratory related admissions declined 42% year over year following an unusually strong respiratory season in Q1 2025, and a winter storm in January disrupted operations in certain markets. Volumes improved progressively through the quarter. Full year 2026 guidance was reaffirmed without revision, projecting revenues of $76.5 to $80.0 billion and diluted EPS of $29.10 to $31.50.

The most important update concerns the supplemental payment headwind. The Q1 2026 results revealed that certain state supplemental programmes, Georgia’s grandfathering approval, the reinstatement of the ATLAS programme in Texas, and the ongoing benefit from the Tennessee programme, generated approximately $200 million more in adjusted EBITDA benefit than management had initially guided. Management revised their full year SDP net benefit decline to a range of $50 to $250 million versus prior year. The near term SDP risk is proving less severe than the cautious tone of initial management guidance suggested.

4. Capital Allocation

Capital allocation is the section that most clearly illustrates both the strength and the structural complexity of HCA’s financial model.

Between 2015 and 2025, HCA deployed capital in three primary ways. Capital expenditure accounted for approximately $41.2 billion, spent on new facilities, additional licensed beds, technology upgrades, and physician practice acquisitions. Share repurchases accounted for approximately $45.3 billion. Dividends accounted for approximately $4.5 billion. Together, these three uses of capital over the decade exceeded the cumulative operating cash flow the business generated during the same period. HCA was a net borrower to fund its capital return programme. Total financial debt, including all short term and long term debt and lease obligations, which represent fixed future cash commitments that behave economically like debt, grew from approximately $30.5 billion in 2015 to approximately $48.7 billion in 2025.

In 2025 alone, HCA repurchased approximately $10.1 billion of its own shares, the single largest annual buyback in the company’s history, while issuing approximately $3.3 billion in net new debt to help fund it. The diluted share count fell from approximately 262 million at the start of 2025 to approximately 240 million by year end, a reduction of approximately 9% in a single year.

The 19% annual EPS compound annual growth rate is real in the sense that shareholders who held HCA shares did see per share earnings compound at that rate. But the source of that growth deserves precise disaggregation. The underlying business, growing revenues at approximately 6.6% annually with operating leverage, generates perhaps 9 to 11% annual growth in total net income. The remaining 8 percentage points of EPS growth came from the mechanical effect of a shrinking share count. That share count reduction has been funded substantially through continuous new debt issuance.

The leverage picture at any single point in time is less informative than the trajectory over the full decade. The debt to OCF ratio started at 6.4 times in 2015 and ended at 3.85 times in 2025. That improvement happened despite the buyback programme running aggressively throughout the full period. OCF grew faster than debt in the majority of years. The interest to OCF ratio declined from 35.2% in 2015 to 17.8% in 2025. The business is carrying more absolute debt than a decade ago, but carrying it significantly more comfortably relative to what it generates. However, the structural dependency on government reimbursement, approximately 45% of revenues, means the OCF that underpins this improving ratio is itself subject to political and legislative risk. That dependency, not the leverage ratio in isolation, is the primary basis for the rejection.

The growth capex programme is the most strategically important use of capital in the HCA story. The $5.1 to $5.4 billion planned for 2026 represents the continued construction of the physical infrastructure moat, new facilities, additional licensed beds in high growth markets, expanded freestanding emergency rooms, and the enterprise wide technology overhaul. This is genuine competitive investment, not maintenance spending.

Share

5. Competition

The for profit hospital industry in the United States has a clear competitive structure: one dominant national platform, two significantly smaller publicly traded operators, and a large network of not for profit and government owned systems operating under different financial constraints. HCA is the dominant platform by every relevant financial metric.

Universal Health Services

Universal Health Services (UHS) operates approximately 400 acute care and behavioural health facilities across the United States, the United Kingdom, and Puerto Rico, generating $17.4 billion in revenue in 2025. UHS maintains a conservative balance sheet relative to the sector and has delivered consistent EPS growth through operational improvement and a disciplined buyback programme. ROIC of approximately 11.5% in 2025 reflects a legitimate, well run operator that has nonetheless consistently trailed HCA by 7 to 9 percentage points over the decade. The gap is structural: UHS does not have HCA’s market density in high growth markets or HCA’s system wide purchasing and data advantages.

Tenet Healthcare

Tenet Healthcare operates approximately 60 hospitals alongside a large ambulatory care business, generating $21.3 billion in revenue in 2025. Tenet has spent the better part of a decade restructuring its balance sheet and divesting underperforming hospital assets. ROIC improved to 11.7% in 2025 following a decade average of approximately 7%, the weakest sustained performance among the major for profit operators. The 2024 results were significantly distorted by approximately $5 billion in gains from facility sales. Stripping those out, Tenet remains a business in operational recovery mode rather than a genuine competitive threat to HCA’s market position.

Not for Profit Systems

The most substantive competitive pressure HCA faces does not come from its for profit peers. Large not for profit integrated health systems, organisations like Ascension, CommonSpirit Health, and Advocate Health, operate in many of the same markets under materially different financial conditions. Not for profit hospital systems do not pay federal or state income taxes, can issue tax exempt bonds at lower rates, and receive philanthropic donations and government grants. These advantages are particularly significant in physician recruitment, the leading competitive indicator I monitor most closely.

6. Management

Samuel N. Hazen - CEO

Samuel Hazen has served as Chief Executive Officer since January 2019. He joined HCA in 1984 and spent his entire 41 year career within the organisation, progressing from hospital level financial roles through regional and group leadership before becoming President and Chief Operating Officer in 2016. His predecessor was also an internal promotion. HCA has never appointed an external CEO in its modern operating history, a reflection of both the institutional depth of the management bench and the genuine complexity of the role. Managing 189 hospitals, 320,000 employees, and hundreds of reimbursement negotiations across 19 states requires operational and regulatory knowledge that cannot be acquired quickly from outside the institution.

Hazen’s tenure since 2019 covers an unusually difficult operating period: COVID 19, the labour crisis of 2021 and 2022, the post pandemic normalisation, and the current regulatory headwinds around supplemental payments. The financial record through those years, ROIC consistently above 15%, gross margins expanding, no meaningful market share loss, reflects operational execution that is difficult to dismiss.

Ownership and Alignment

Samuel Hazen beneficially owned 2,164,071 shares of HCA common stock as of February 23, 2026. At approximately $438 per share, this represents approximately $948 million in personal wealth tied directly to the company’s long term performance. That alignment is genuine and material.

The broader ownership picture is shaped by the Frist family. Their holding vehicles, Frisco Holding II and Hercules Holding II, collectively represent the Frist Group, which owned approximately 32% of shares outstanding as of February 23, 2026, per the 2026 proxy statement. Thomas F. Frist III, grandson of co founder Dr. Thomas Frist Jr., serves as Chairman of the Board. The family retains the contractual right to nominate two directors for as long as they hold at least 3% of outstanding shares. All directors and executive officers as a group, 16 persons, beneficially own approximately 3,354,148 shares, or approximately 1.5% of outstanding shares. Including the Frist Group, total affiliated ownership is approximately 33 to 34% of the company.

Compensation

Hazen’s total direct compensation for 2025 was approximately $26.5 million. Base salary was $1.58 million, approximately 6% of total. Stock appreciation rights and restricted stock awards comprised approximately 64% of total compensation, creating multi year alignment with the share price. Annual performance cash through HCA’s Performance Excellence Programme comprised the remaining 30% and paid out at approximately 196% of target for 2025. For 2026, Hazen’s base salary was increased by 2.5% to $1,620,555. The compensation structure is appropriate: a CEO whose pay is predominantly variable and linked to long term share price performance has incentives pointing in the right direction.

7. Growth Levers & Addressable Market

• Organic Volume in Sunbelt Markets

HCA’s geographic concentration in Florida and Texas is its most durable growth engine. These states are experiencing structural net population inflows that have persisted through multiple economic cycles. Each new resident is a potential future patient. Each ageing resident, Florida’s above average proportion of over 65s is a sustained structural tailwind, creates more intensive recurring demand for hospital services. The 2025 same facility admissions growth of 2.3% is consistent with this demographic compounding.

• Revenue Per Admission Through Commercial Pricing

HCA’s most controllable near term growth lever is the rate at which it grows revenue per equivalent admission through managed care contract renewals. In markets where HCA holds network density, private insurers cannot construct a competitive health plan without including HCA facilities. This gives HCA structural pricing power at contract renewal that has consistently translated into revenue per admission growth of 3 to 4% annually. Even with the FBA reducing government reimbursement, the commercial pricing lever remains intact and partially offsets.

• Outpatient and Ambulatory Expansion

The long term structural shift in healthcare from inpatient to outpatient settings is both a challenge and an opportunity for HCA. It is a challenge because outpatient procedures generate lower revenue per case than inpatient equivalents. It is an opportunity because HCA is investing aggressively in ambulatory surgery centres, freestanding emergency rooms, and urgent care facilities that capture patient volume at lower cost while maintaining the physician and patient relationships that drive future inpatient referrals.

• Technology and Data Investment

HCA is deploying a new enterprise wide electronic health record platform across all hospitals and implementing an AI assisted nursing platform. The financial returns from this investment cycle will become visible in the 2027 to 2030 period. The competitive advantage it creates begins to compound from the moment of deployment: no regional operator can justify investment at this scale, widening the analytical and operational gap between HCA and its peers.

8. Risks

1. Political and Legislative Dependency

Approximately 45% of HCA’s revenues flow from government programmes, Medicare, Medicaid, and their managed equivalents, whose reimbursement rates are set by political and regulatory decisions rather than market negotiation. This is the central risk and the one that no management team, regardless of capability, can fully control or predict.

The concern is not only the current FBA supplemental payment restriction, which is quantifiable and tracking better than feared. The deeper concern is the structural nature of the dependency itself. A future administration pursuing aggressive Medicaid base rate cuts, reducing per admission payments rather than supplemental payments, would create a sustained, multi year margin compression with limited commercial offset. Unlike the supplemental payment mechanism, which affects a discrete and identifiable revenue layer, base rate cuts affect every government payer admission. The historical record shows that Washington has periodically used Medicare and Medicaid reimbursement as a lever for fiscal adjustment, the sequestration cuts of 2013, the managed Medicaid rate pressures of 2016 to 2019, and the FBA provisions of 2025 are all examples of this pattern. The frequency and unpredictability of these interventions, rather than any single event, is what makes the dependency uncomfortable as a long term holding.

The scenario I monitor most closely is a slow, multi year compression, where base reimbursement rates are held flat or increased below the rate of cost inflation for an extended period. This does not produce a visible crisis but gradually erodes margins in a way that is difficult to offset commercially and hard to identify clearly until the trend is well established. HCA’s commercial pricing leverage is real, but it has limits: managed care plans cannot pass unlimited cost increases to employers and individuals, and the ceiling on commercial rate extraction is lower than it might appear.

2. Exchange to Uninsured Payer Mix Shift

The expiration of enhanced premium tax credits at year end 2025, federal subsidies that had made exchange based private health insurance affordable for lower income Americans, has caused a portion of that population to lose coverage and become uninsured. HCA estimates that same facility exchange equivalent admissions declined approximately 15% in Q1 2026 versus the prior year, while uninsured equivalent admissions increased approximately 16%. An uninsured patient generates significantly less reliable revenue than a commercially insured patient, and may generate no revenue at all. This shift will persist through 2026 and beyond depending on federal policy, another dimension of the same structural dependency on government programme design that drives Risk 1.

3. FBA Supplemental Payment Restrictions

HCA received approximately $6.2 billion in Medicaid supplemental payments in 2025, representing approximately 8% of total revenues. The FBA restricts these mechanisms going forward: arrangements not grandfathered before July 4, 2025 face immediate limitations, and grandfathered arrangements will be reduced by 10 percentage points annually from January 1, 2028 until they reach legislatively defined caps. Management guided for a full year 2026 net benefit decline of $50 to $250 million, materially better than the cautious tone of initial guidance suggested, driven by Georgia’s grandfathering approval, the reinstatement of the ATLAS programme in Texas, and the ongoing Tennessee programme benefit.

The risk is real but the near term trajectory is better than feared. The longer term 2028 phase down remains intact and will create a more sustained headwind from that point. The scale of that headwind will depend on how many additional state programmes receive grandfathering approvals between now and January 2028, a variable that is genuinely uncertain and worth monitoring closely as the schedule approaches. What is clear is that the partial commercial pricing offset available to HCA, through its network density leverage with private insurers, means the net OCF impact will be smaller than the gross revenue decline in any scenario.

4. Leverage Interacting With Regulatory Risk

HCA carries approximately $48.7 billion in total financial debt against $12.6 billion in annual operating cash flow. The leverage is improving, the debt to OCF ratio declined from 6.4 times in 2015 to 3.85 times in 2025, and the interest burden relative to OCF has fallen from 35.2% to 17.8% over the same period. But the combination of this debt level with the structural government reimbursement dependency creates an interaction risk that neither element would produce independently. If OCF comes under sustained pressure from legislative action while the debt balance remains elevated, the financial margin for error narrows in a way that a business without this regulatory dependency would not face. A sustained reversal of the debt to OCF improvement trend, or a meaningful rise in the interest burden relative to operating cash flow, would intensify this concern materially.

5. Labour Market

The United States faces a projected shortage of 100,000 to 200,000 nurses by 2030, driven by an ageing nursing workforce and insufficient training pipeline capacity. The 2021 to 2022 period demonstrated how quickly the cost structure can deteriorate under supply constraints, HCA’s labour cost ratio rose by an estimated 200 to 250 basis points above pre-pandemic levels at the peak. The subsequent normalisation has been genuine, but the labour cost ratio has not returned to the pre pandemic baseline and likely will not. Any future supply disruption would compound upward from the current elevated starting point.

6. Legal and Compliance Exposure

HCA operates in a heavily regulated environment and faces several active legal matters. The most significant ongoing investigation relates to the Anti Kickback Statute and the False Claims Act, federal laws governing physician referral arrangements and billing accuracy. The Department of Justice is investigating whether HCA provided illegal incentives to physicians in exchange for patient referrals, and whether the company engaged in upcoding, meaning billing for more expensive services than were actually provided. HCA is cooperating with the investigation. The potential financial consequences are unknown. Additionally, in late 2025, a federal court granted final approval for HCA to settle a class action lawsuit arising from a 2023 data breach that affected approximately 11 million patients. The Mission Health litigation, the North Carolina Attorney General’s lawsuit against HCA over emergency and cancer care services at Mission Hospital, remains a significant ongoing legal risk. HCA also faces continuing scrutiny over billing practices related to trauma centre fees.

9. The Verdict

Exceptional Business. Structural Dependency We Cannot Ignore.

HCA Healthcare is Rejected in the Bearhold Universe. The designation has nothing to do with the quality of the competitive position, which is genuine and documented throughout this report. ROIC averaging 16.7% over a decade. Gross margins expanding from 37.6% to 41.5% over ten years. A leverage trend improving from 6.4 times debt to OCF to 3.85 times despite running one of the most aggressive capital return programmes of any major US company. A management team that has navigated a global pandemic, an industry wide labour crisis, and sustained regulatory headwinds without losing meaningful market share. The business earns every bit of the admiration directed at it.

The rejection is driven by the structural dependency on government reimbursement decisions that approximately 45% of HCA’s revenues are subject to. This is not a temporary risk that resolves with a single legislative outcome. It is a permanent feature of the hospital business model that creates a category of uncertainty, the decisions of politicians and regulators in Washington, that no management team can fully anticipate, control, or offset. The FBA supplemental payment restriction is one concrete manifestation of this dependency. The exchange to uninsured payer mix shift, driven by the expiration of federal premium tax credits, is another. The history of Medicare and Medicaid reimbursement is a series of periodic legislative adjustments, sequestration cuts, rate freezes, managed care expansion, supplemental payment restrictions, that have recurred across administrations of both parties for four decades.

The scenario I am most cautious about is a slow, grinding multi year compression where base reimbursement rates are held flat or increased below the rate of cost inflation. This is the version of the political risk that is hardest to identify in real time, hardest to offset commercially, and most damaging to a business carrying $48.7 billion in financial debt. HCA’s commercial pricing leverage is real, but it has limits, managed care plans cannot indefinitely absorb cost increases that government programmes push toward the commercial sector.

The leverage position, while improving, interacts with the regulatory dependency in a way that neither element would produce independently. A business with minimal debt can absorb a sustained government reimbursement headwind. A business with $48.7 billion in debt and $2.2 billion in annual interest costs has less room to manoeuvre when OCF comes under pressure from sources outside management’s control.

There is genuine respect in this analysis for what HCA has built. The competitive infrastructure, the management track record, and the demographic tailwinds in Florida and Texas make this a business worth monitoring. The Bearhold framework requires that the investment can be held with conviction through periods of regulatory turbulence. HCA cannot be held with that conviction given the structural nature and historical frequency of government reimbursement interventions. The designation stands until the dependency is structurally reduced or the regulatory environment becomes demonstrably more stable and predictable.

This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

THE OUTLOOK

There are approximately 6.1 million in-ground swimming pools in the United States. Each one needs chemicals, replacement parts, and regular maintenance throughout its lifetime, regardless of what interest rates are doing, regardless of whether anyone is building new pools, regardless of the broader economy. The market for maintaining these pools does not disappear in a downturn. It grows, steadily, as the installed base expands year after year.

Pool Corporation (POOL) sits at the wholesale distribution layer between the manufacturers who make pool products and the 125,000 contractors, service companies, and retailers who sell those products to end consumers. It is the largest business of its kind in the world, with 456 sales centres, approximately 40% of the US wholesale distribution market, and a flywheel of scale that has been compounding for over four decades.

The business is currently earning below its normalised level. New pool construction fell to just below 60,000 units in 2025, roughly half of pandemic-era peak volumes. Elevated financing costs have suppressed homeowner discretionary spending on pools, renovations, and upgrades for three consecutive years. The result is a peak-to-trough earnings-per-share (EPS) compression from $18.70 in 2022 to $10.85 in 2025.

The maintenance revenue base, which represents approximately 64% of Pool’s sales and comes from the inelastic, recurring demand of existing pool owners, held steady throughout this period and grew modestly as the installed base expanded. The competitive position did not weaken. Gross margins held within a few basis points of their historical range. Return on invested capital (ROIC) declined from its peak but remained above 16%, above the cost of capital, in a trough year for the industry. No meaningful market share was lost to competitors.

Pool Corporation is Approved in the Bearhold Universe. The business has demonstrated over four decades that its scale advantages compound, its competitive position strengthens through cycles, and its maintenance revenue base is structurally permanent.

My valuation puts Pool at approximately 15 years of embedded discounted cash flows at current prices. I hold a position initiated before publication of this report. This report explains the business, the thesis, and where the risks sit.

Disclosure: The author holds a position in POOL. This report reflects the author’s personal views and is not investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

At a Glance

Company: Pool Corporation

Ticker: $POOL · NASDAQ

Sector: Industrials

Industry: Wholesale Distribution

Market Cap: $8.3 billion (at $225)

Status: Approved

First Coverage: April 2026

Valuation Zone: Attractive (last updated in April 2026)

1. The Business

The Origin

Pool Corporation traces its roots to 1980, when Frank St. Romain, a former warehouse manager, and his partner Richard Smith founded South Central Pool Supply in New Orleans. The founding insight was simple and durable: insurance companies and pool professionals needed a professional, geographically distributed source for pool supplies and equipment. The fragmented local dealers serving that need were doing it poorly.

For its first decade, South Central Pool Supply grew modestly, building a reputation for service and expanding steadily across the Southeast and into Oklahoma, Texas, and Tennessee. Growth was constrained by access to capital, as then-president Manuel Perez de la Mesa later described it, the company funded expansion almost entirely from retained earnings. By 1993, annual revenues had reached approximately $67 million.

The inflection came in 1993, when private equity firm Code Hennessey & Simmons acquired the company in a leveraged buyout (LBO), incorporated it in Delaware as SCP Holding Corp, and set out to use South Central Pool Supply as a platform for aggressive national consolidation. The strategy was straightforward: the US pool distribution market was deeply fragmented, and a well-capitalised consolidator with the right model could roll it up. Wilson B. ‘Rusty’ Sexton became Chairman and Chief Executive Officer (CEO).

In 1995, the company renamed itself SCP Pool Corporation and went public on the NASDAQ stock exchange under the ticker POOL, raising capital that retired its debt and funded further expansion. The initial public offering (IPO) proceeds unleashed the acquisition campaign: within five years, SCP had acquired dozens of regional distributors and opened scores of new sales centres. Annual revenues grew from $102 million in 1994 to $670 million by 2000.

A pivotal expansion came in August 2000, when SCP acquired Superior Pool Products from Arch Chemicals, at the time a 19-location distributor operating primarily in California, Arizona, and Nevada with revenues exceeding $80 million. Rather than absorbing Superior into the SCP network, management made the strategic decision to operate two distinct domestic distribution networks side by side, each with its own product selection, sales personnel, and supplier relationships. The logic was deliberate competition between internal networks to drive service quality, an unusual approach that has proven effective.

Manuel Perez de la Mesa, who joined as Chief Operating Officer (COO), became President and CEO in 2001 and led the company for nearly two decades. Under his leadership, Pool expanded internationally, launched the Horizon Distributors irrigation business, and broadened the product offering far beyond pool chemicals into building materials, outdoor living, and commercial pool products. At the end of 2018, Peter D. Arvan succeeded him as CEO, bringing over 20 years of distribution industry experience. On May 16, 2006, SCP Pool Corporation became Pool Corporation, a single name for what had become the world’s dominant force in pool wholesale distribution.

What Pool Corporation Does

Pool Corporation does not build pools. It does not install them, service them, or repair them. It is the wholesale distribution layer, the intermediary that sits between manufacturers and the fragmented network of pool professionals who serve end consumers.

When a pool builder needs concrete, pumps, filters, tiles, and chemicals for a new installation, they order from Pool. When a service technician needs a replacement part for a malfunctioning heater, they call Pool. When a specialty retailer needs to restock their shelves with chemicals and accessories, they order from Pool. Pool takes possession of product from over 2,200 manufacturers, holds inventory across 456 geographically distributed sales centres, and delivers to contractors and retailers, often the same day. It earns a margin on every product it passes through the supply chain.

This hub-and-spoke model is the foundation of the business. Pool does not compete nationally in any meaningful sense, it competes market by market. Each sales centre is positioned within a population centre, close to contractor customers, with well-stocked inventory and local delivery capability. A pool professional in suburban Houston does not care about national market share; they care whether their local Pool centre can get them what they need, today, at a competitive price. Pool’s network is built to answer yes to that question in virtually every significant pool market in North America.

The Five Networks

Pool Corporation operates through five wholly-owned subsidiary distribution networks, each serving a distinct segment of the market. Understanding these networks matters because they are not divisions of the same business in a superficial sense, they have different brand identities, different product selections, and in some cases, different types of customers. Pool maintains them separately by design.

SCP Distributors (SCP) is the original network, descended from South Central Pool Supply. It is the largest of the five, operating 224 sales centres domestically and 48 internationally as of year end 2025. SCP handles the full range of swimming pool supplies, equipment, and related leisure products for the domestic market and serves as Pool’s primary international distribution platform.

Superior Pool Products (Superior) is the second domestic swimming pool network, acquired in 2000 and deliberately maintained as a separate operation. Superior operates 75 centres, primarily serving pool builders, service companies, and retailers with a different product mix and distinct supplier relationships from SCP. The rationale for two separate domestic pool networks is intentional competitive tension: SCP and Superior compete in many markets, which management believes drives better service quality than a single monopoly distributor would provide. This may seem counterintuitive, why compete with yourself? but the track record suggests it works.

Horizon Distributors (Horizon) is Pool’s irrigation and landscape maintenance subsidiary, operating 88 sales centres focused on irrigation system components, professional turf care equipment, hardscapes, and landscape maintenance supplies. Horizon serves landscape contractors and commercial operators rather than pool professionals. The business shares many characteristics with the pool distribution model, fragmented customers, recurring demand, local delivery, and benefits from Pool’s purchasing scale and supplier relationships.

National Pool Trends (NPT), formerly known as National Pool Tile until a rebrand in November 2025, is a specialised network focused on swimming pool tile, composite pool finishes, decking materials, and interior pool surfacing products. NPT operates 19 standalone sales centres, but its reach is substantially broader: 124 SCP and Superior locations also feature NPT consumer showrooms where contractors and homeowners can view and select tile, decking, and surfacing options. NPT’s products are more discretionary in nature than chemicals or replacement parts, making this segment more sensitive to the construction and renovation cycle.

Sun Wholesale Supply is the most recently added network, acquired as part of Pool’s December 2021 purchase of Porpoise Pool & Patio. Sun Wholesale’s primary role is servicing the Pinch A Penny franchise network, a chain of independently owned specialty retail pool stores, the largest pool franchise system in the United States. Sun Wholesale supplies these franchisees with pool chemicals, equipment, and accessories, and owns a chemical re-packaging plant in Florida that produces proprietary branded products sold through the Pinch A Penny system. The Pinch A Penny network grew to over 300 franchise locations by year-end 2025, adding 10 new stores during the year and expanding into two new states.

The Revenue Mix

In 2025, approximately 64% of Pool’s sales came from recurring maintenance and minor repair of existing pool installations. These are the chemicals, replacement parts, and minor consumables that pool owners must purchase to keep their pools functional and safe, the non-discretionary foundation of the business. Approximately 22% came from remodeling, renovation, and upgrades, and the remaining 14% from new pool construction. This structure matters because the 64% non-discretionary base does not compress in downturns. It grows every year with the installed base, providing the revenue floor that sustains the business through every economic cycle.

Scale and Geography

Pool’s 456 sales centres at year-end 2025 are disproportionately concentrated in the markets with the greatest pool density. California, Florida, Texas, and Arizona together account for approximately 53% of annual net sales. Pool operates 77 locations in California, 67 in Florida, 55 in Texas. These are also the states receiving the largest net domestic migration inflows. The demographic tailwind of population movement toward warmer climates creates pool installation demand and maintenance volume growth that flows directly to Pool’s most dense network regions.

Internationally, Pool operates in Europe, primarily through the UK, France, Spain, Germany, Belgium, Croatia, Italy, and Portugal, and in Australia. International operations represented approximately 5% of net sales in 2025, growing 5% in local currency terms. Europe is structurally earlier in its pool distribution evolution than the US, representing a long-runway optionality rather than a near-term growth driver.

2. The Moat

Pool’s competitive advantage is scale economies shared, one of the most durable forms of moat in distribution because it is self-reinforcing and strengthens with each passing year.

How the Flywheel Works

Pool’s scale allows it to purchase from 2,200 suppliers at better prices than any regional distributor can negotiate. It passes a portion of those better economics to contractor customers as better pricing, better product availability, and faster delivery. Contractors consolidate purchasing with Pool. Pool’s volumes grow. Purchasing leverage increases. Smaller competitors are squeezed on margins and cannot match Pool’s service levels. They lose customers or exit. Pool absorbs their volume. Repeat.

This flywheel has been running for over 40 years. Revenue per sales centre has grown at nearly 6% per year since 2014, outpacing the approximately 3% annual growth in centre count over the same period. Each location is becoming more productive, not just the network expanding. That is the flywheel operating.

Four Pillars

The first pillar is purchasing leverage from scale. Pool’s volumes across 2,200 suppliers give it negotiating power that no regional competitor can match. Its preferred vendor programme concentrates purchasing to extract better terms, rebates, early-buy discounts, priority allocation, which flow into gross margin stability even as the revenue mix shifts through cycles.

The second pillar is product breadth. Pool offers over 200,000 products across more than 700 product lines and 40 product categories. A contractor purchasing from a smaller regional distributor faces a fundamentally inferior selection. In a service business where time is money, the convenience of a single trusted source with comprehensive inventory is worth more than marginal savings on individual items. No competitor can replicate this breadth without decades of supplier relationship building and the capital to finance the inventory position.

The third pillar is local delivery infrastructure. Pool’s sales centres sit within population centres near customer concentrations. The ability to deliver same-day or next-day to contractors in their local market is operationally critical. A pool professional who needs a pump motor today cannot wait for an online order. This geographic density is a physical infrastructure moat, expensive to build, slow to replicate, and self-reinforcing as Pool adds 8 to 12 new centres per year.

The fourth pillar is POOL360 digital integration. POOL360 is Pool’s proprietary business-to-business (B2B) digital platform, which includes e-commerce ordering, water testing software (POOL360 WaterTest), and a field service management application (POOL360 PoolService) that allows pool professionals to manage their scheduling, routing, billing, and customer relationships from a single mobile application. A contractor who has embedded POOL360 into their daily workflow is not switching distributors to save 2% on one product category. POOL360 reached an all-time high of 15% of total sales in FY2025, up from 10% in 2023. The trend has been consistently upward for four consecutive years, which is the most important forward-looking signal in the moat analysis.

Financial Evidence

Gross margins averaged approximately 29% to 30% across every year of the past decade, including the trough years of 2023 through 2025. A business losing its competitive position would see gross margins compress as it discounts to retain volume. Pool’s gross margins have not compressed.

ROIC averaged above 20% over the decade, and in 2025, with earnings per share (EPS) having fallen from a peak of $18.70 in 2022 to $10.85, ROIC still sits at approximately 16%. For a wholesale distribution business with no proprietary physical products, sustaining returns above the cost of capital through a decline of that magnitude is a meaningful signal that the structural economics of the business are intact. The capital invested in the network is generating returns. No meaningful market share has been lost to competitors in this period.

The supplier concentration itself confirms market power. Pool’s top three suppliers, Pentair, Zodiac, and Hayward, collectively account for approximately 43% of Pool’s cost of goods sold (COGS). These are large, sophisticated manufacturers who sell through Pool because Pool is the most efficient route to the fragmented contractor market. They depend on Pool. That dependency is evidence of distribution leverage, not exposure.

3. Financial Performance

The financial record of Pool Corporation over the past ten years tells two stories simultaneously. The first is structural: a business with genuine competitive advantages compounding revenue, earnings, and free cash flow at exceptional rates over the long arc. The second is cyclical: a business whose earnings expanded dramatically during an extraordinary pandemic-era demand surge and have since normalised back toward their historical range. Reading the numbers correctly requires keeping both stories in view.

Revenue

Revenue grew from $2.36 billion in 2015 to a peak of $6.18 billion in 2022, a compound annual growth rate (CAGR) of approximately 15% over seven years. Since 2022, revenue has declined to $5.29 billion in 2025, entirely reflecting the reduction in new pool construction and renovation activity. The maintenance revenue base did not contract. The compression is entirely in the discretionary segment.

The Pandemic Surge and the Normalisation

Understanding the operating margin trajectory requires understanding what happened during 2020 through 2022. For the decade prior to the pandemic, Pool’s operating margin averaged approximately 10%, a stable, predictable range that reflected the economics of a distribution business with consistent gross margins and a fixed cost structure.

The COVID-19 pandemic created an extraordinary and temporary departure from that baseline. As families spent more time at home and sought to create or expand outdoor living spaces, demand for new pool construction surged dramatically. Combined with homeowners who were already invested in their properties, supported by rising home values, low mortgage rates, and a perception that their homes had become their primary entertainment and recreation venues, Pool’s revenue grew from $3.9 billion in 2020 to $6.2 billion in 2022. Operating leverage on a fixed cost base that could not scale as fast as revenue drove operating margins to 15.7% in 2021 and 16.6% in 2022, levels that had never been seen in the company’s history.

Since the second half of 2022, this surge has reversed. Elevated interest rates have suppressed new pool construction. Consumer discretionary spending has moderated from pandemic highs. Revenue has declined from its peak, and operating margins have returned to approximately 11% in 2025, essentially the pre-pandemic normal. This is not deterioration. The operating margin has returned to its historical range, not fallen below it. The 2021 and 2022 margins were the anomaly.

Earnings Per Share

Diluted EPS grew from $2.90 in 2015 to $18.70 at the 2022 peak, a 7-year CAGR of approximately 30%. From the peak, EPS has declined to $10.85 in 2025, reflecting the revenue normalisation described above. Neither number represents the mid-cycle earning power of the business. The $18.70 incorporated extraordinary pandemic demand; the $10.85 reflects a construction market at approximately half of normalised levels. The normalised earning power sits somewhere in between, and the Valuation section addresses this directly.

The share count has declined from approximately 44.3 million diluted shares in 2015 to 37.3 million in 2025, a reduction of approximately 16% through consistent buyback programmes. In 2025 alone, Pool repurchased $341 million of its own shares. That discipline compounds EPS growth on top of the underlying business performance.

Gross Margin

Gross margin has held in a narrow band of 28.6% to 31.3% across the full decade. The 2025 gross margin of 29.7% is essentially identical to 2024. Adjusting for the one-off $12.6 million import tax reversal that benefited 2024’s gross margin, the underlying 2025 gross margin actually improved 20 basis points year over year, reflecting Pool’s pricing discipline and supply chain management even in a softer demand environment.

Free Cash Flow and the OCF Story

Operating cash flow (OCF) was $888 million in 2023, $659 million in 2024, and $366 million in 2025. The decline from 2024 to 2025 appears dramatic but is substantially explained by working capital timing rather than a deterioration in the underlying business.

Three components of working capital combined to suppress OCF in 2025. First, inventory increased by $165 million during the year. Management explicitly attributed this to strategic purchasing ahead of anticipated vendor price increases, a deliberate decision to build stock before tariff-related and inflation-driven cost increases took effect. Second, accounts receivable increased by approximately $33 million, primarily driven by higher sales in December 2025, which fell outside the collection window for year-end cash. Third, accounts payable declined by approximately $44 million as Pool paid down supplier balances at a faster rate relative to the elevated payable levels of 2024, when the company had benefited from extended seasonal payment terms. These three working capital movements together subtracted approximately $150 million from operating cash flow. The fourth and largest factor was a $68.5 million federal income tax payment in 2025 that had been deferred from 2024, a one-time cash outflow with no impact on the underlying profitability of the business.

Adjusting for the deferred tax payment alone, 2025 OCF would have been approximately $434 million, or 107% of net income, consistent with Pool’s historical cash conversion rate. Free cash flow of $310 million therefore understates run-rate cash generation. The 2024 OCF of $659 million, with normal working capital dynamics, is the more reliable anchor for what the business can produce at stable conditions.

Inventory Days: A Decade-High That Deserves Scrutiny

Days inventory outstanding (DIO), the number of days Pool holds inventory before it is sold, has climbed steadily from approximately 96 days in 2020 to 135 days in 2025, the highest level in a decade. This is worth examining carefully because elevated inventory days affect multiple financial metrics simultaneously: they tie up working capital, reduce free cash flow, and, if the inventory cannot be sold at full margin, compress profitability.

The 2025 inventory build reflects a deliberate strategic decision by management. Pool purchased ahead of anticipated price increases, both from inflation running at approximately 2% to 3% in 2025 and from tariff impacts that management expected to flow through the supply chain. Pool explicitly disclosed this in the Q4 2025 earnings presentation, noting that inventory growth reflected inflation, strategic pre-buy purchasing, acquisitions, and new sales centre additions.

The bull case for this strategy is straightforward: if vendor prices rise as expected, Pool’s early-bought inventory sits on the balance sheet at below-market cost, and when sold, generates better margins than inventory purchased at higher post-increase prices. Pool has a long history of making similar strategic inventory decisions during inflationary periods, the company’s preferred vendor programme and early-buy arrangements with manufacturers are specifically designed for this kind of counter-cyclical purchasing.

The risk case is equally clear. If the price increases management anticipated do not materialise, if tariff impacts are reversed, if inflation moderates, or if demand remains soft and inventory sits longer than planned, then Pool is holding a larger stock of product than it needs, at cost prices that may be above what it can charge in a deflationary environment. The company acknowledges this explicitly in its risk factors: overestimating demand and purchasing too much of a particular product creates the risk that prices fall, leaving inventory that cannot be sold at optimal margins or, in a worst case, requires a write-down.

The chemical and maintenance portion of Pool’s inventory, approximately 14% of net sales comes from pool and hot tub chemicals, adds a specific wrinkle. Pool chemicals such as chlorine products, algaecides, and pH adjusters have finite shelf lives. While Pool manages this risk through its reserve for inventory obsolescence (currently $23.9 million), elevated holding periods increase exposure to degradation, regulatory change, and shifts in consumer preferences for specific chemical formulations. Equipment and building materials carry lower obsolescence risk but are more sensitive to technology cycles and construction activity levels.

To contextualise the scale: the 2023 DIO of approximately 139 days was the decade peak, coinciding with the period when Pool was drawing down the inventory it had aggressively built during the pandemic surge. The 2025 level of 135 days is approaching that level again from a different direction, a deliberate build rather than a demand-driven drawdown. The distinction matters, but the risk of being wrong is real and I carry it explicitly.

Balance Sheet and Equity Trajectory

Pool’s balance sheet has undergone a meaningful structural shift over the past several years that is worth examining carefully.

Total equity grew consistently from $256 million in 2015 through $1.31 billion in 2023, an expansion driven by profitable growth, modest leverage, and retained earnings accumulating on the balance sheet. From 2023 onward, equity has declined, from $1.31 billion to $1.27 billion in 2024 and $1.19 billion in 2025. This reversal is not a sign of financial distress, but it does reflect a clear and deliberate capital allocation choice.

The primary driver is the share buyback programme. Pool repurchased $306 million of shares in both 2023 and 2024, and $341 million in 2025, the largest annual repurchase in company history. These buybacks are funded partly from operating cash flow and partly from incremental borrowing, which is why total debt increased by $249 million in 2025. When a company borrows to buy back its own shares, equity shrinks, buyback proceeds reduce equity directly, while the debt that funded them sits on the liability side of the balance sheet.

Retained earnings tell the same story. Retained earnings peaked at approximately $700 million in 2023 and declined to $521 million in 2025, as the combination of buybacks and dividends paid out more than the net income being retained. Pool paid $185 million in dividends in 2025, marking the 21st consecutive annual dividend increase.

The debt-to-equity (D/E) ratio has risen from 1.00x at year-end 2024 to 1.30x at year-end 2025. This remains within management’s stated target leverage range of 1.5x to 2.0x on a debt/EBITDA basis (Pool’s preferred internal leverage metric). For context, the D/E ratio reached 2.98x in 2018 at a prior leverage peak, and the business remained healthy throughout. The current level is moderate and well within the boundaries of Pool’s financing capacity.

The question this raises for a long-term investor is whether aggressive buybacks at current prices represent good capital allocation. At $225 and approximately 15 years of embedded cash flows, buying back shares at attractive prices is a reasonable use of capital. Management has consistently demonstrated that they would rather deploy capital to buybacks than hold excess cash, and the per-share compounding effect of a declining share count is real regardless of entry price.

4. Competition

A Fragmented Market with One Dominant Player

The competitive structure of US pool wholesale distribution is unlike most industries. At national scale, Pool Corporation is effectively the only fully-formed competitor. The remaining approximately 60% of the US market is distributed among regional and local distributors who lack Pool’s purchasing leverage, product breadth, and logistics infrastructure. This is not a duopoly or a tight oligopoly, it is one dominant national platform and several hundred smaller regional players.

Pool holds approximately 40% of the US wholesale pool distribution market. Management’s 2025 annual report notes that the company believes its selection of pool products is the most comprehensive in the industry, with more than 700 product lines across approximately 40 product categories. That breadth, combined with geographic density that allows same-day delivery in virtually every major pool market, is a service proposition that smaller distributors simply cannot replicate at comparable cost.

The competitive gap has widened over time. While specific current data on competitor facility counts versus Pool’s is not available from the 2025 annual report, the long-term trajectory is clear from the financial record: Pool has been consistently gaining share through network expansion at a pace that smaller competitors cannot match, and the structural advantages of scale, purchasing leverage, product breadth, POOL360 digital integration, compound each year.

The Amazon Question

The e-commerce and direct distribution question is the one I hold with genuine uncertainty over a long horizon. Amazon already sells pool chemicals and basic equipment directly to consumers and some contractors. The question is whether direct-from-manufacturer or Amazon purchasing becomes cost-effective enough for contractor workflows to displace Pool as the primary source.

Pool’s defence has three components, and the evidence on each is currently favourable. Same-day local delivery is an advantage that Amazon cannot replicate without the same physical infrastructure investment Pool has made over four decades. Product breadth of 200,000 SKUs means a contractor relationship involves hundreds of different items across dozens of categories, the convenience premium of a single trusted source is real. And POOL360 integration at 15% of total sales and rising means Pool is building its own digital capability before the competitive challenge fully develops.

None of this permanently closes the question. It means the defence is well-constructed, the early evidence is encouraging, and the competitive outcome over the next decade looks meaningfully better than the disruption narrative implies. I monitor it rather than dismiss it.

The Leslie’s Contrast

Leslie’s (LESL), the publicly traded specialty pool supply retailer, is sometimes cited as a peer. It is not a direct competitor. Leslie’s is a consumer-facing retail operation, not a wholesale distributor, and its financial trajectory has been one of significant distress in recent years, with deep losses and balance sheet stress. The contrast with Pool’s wholesale distribution model is instructive: serving professional contractors with a more defensible service proposition, at higher volumes, with better economics, is structurally superior to consumer retail in this industry.

5. Management

Peter Arvan became President and CEO of Pool Corporation at the end of 2018, succeeding Manuel Perez de la Mesa, who had led the company for nearly two decades. Arvan brought over 20 years of distribution industry experience to the role, which matters more here than it would in most industries. Pool’s business model is operationally intensive, managing 456 sales centres, 2,200 supplier relationships, a 200,000-SKU inventory position, and a contractor customer base that values service consistency above all else. A CEO who understands distribution economics at the operational level is better equipped to manage this complexity than a generalist executive would be.

The tenure since 2019 coincides with a period of significant operational challenge: the pandemic demand surge, the subsequent normalisation, three years of construction suppression, and a deliberate technology platform build-out in POOL360. Through this cycle, the structural economics of the business have remained intact, gross margins held, ROIC stayed above the cost of capital at the trough, and market share was not lost. That is not a given outcome; it reflects operational execution.

Arvan holds approximately 86,400 shares, worth roughly $19 million at current prices. That represents approximately 0.23% of shares outstanding, a meaningful personal position for an individual, though not large enough to constitute a controlling interest or to align management and shareholder incentives in the way founder ownership does. It is the kind of holding that keeps a CEO focused on share price over a five-year horizon; it is not the kind that makes him a co-owner in spirit.

In December 2025, Arvan sold a portion of his holdings (approximately 11,000 shares) in a single transaction. I note this honestly rather than dismissing it. A single sale during a period when the stock was trading below its 52-week high, by a CEO who still holds $19 million in company shares, does not strike me as a meaningful negative signal. But it is a data point worth tracking. A pattern of consistent net selling would change my view; one transaction does not.

On the board, Manuel Perez de la Mesa, Arvan’s predecessor as CEO and the architect of Pool’s modern business model, remains a director and holds approximately 97,500 shares. His continued involvement at board level and his personal economic stake in the business is a meaningful signal: the person who built the flywheel believes in its continued value. Total insider ownership across all directors and officers stands at approximately 388,000 shares, or 1.04% of shares outstanding. This is not a founder-led business in terms of insider concentration, but neither is it a company where management has no economic skin in the outcome.

Compensation Structure

Arvan’s total compensation for FY2025 was approximately $5.3 million, below the median of the peer group Pool uses for benchmarking. Base salary is $900,000, roughly 17% of total compensation, meaning 83% of pay is variable and tied to performance outcomes. I consider this an appropriate structure. A CEO whose pay is predominantly fixed has limited downside exposure to poor decisions; a CEO whose pay is predominantly variable is aligned with shareholders in a meaningful way.

The long-term equity component, the largest slice of total pay, is split equally between time-based restricted stock (three-year cliff vesting) and performance-based restricted stock tied to diluted EPS targets. The performance awards pay out on a 0% to 150% scale depending on whether EPS targets are met, providing upside for outperformance and meaningful forfeiture risk if results disappoint. EPS as the performance metric is well-chosen for Pool: it captures the combined effect of earnings growth and the share buyback programme, both of which are within management’s control and directly relevant to shareholder value creation. The overall compensation structure is judged appropriate.

6. Growth Levers & Addressable Market

Four Structural Drivers

1. Construction Recovery

New pool installations fell from pandemic peaks of over 100,000 units annually to just below 60,000 units in 2025. The suppression is entirely financial: pools are primarily financed through home equity borrowing, and when mortgage rates rose sharply from 2022 onwards, homeowners deferred the decision. This is not a permanent structural decline in demand for pools, it is a rate-driven deferral.

The important nuance is that management’s 2026 guidance explicitly assumes new construction units consistent with 2025. Pool is not projecting a recovery; they are projecting another trough year. That conservatism is appropriate given current rate levels, but it also means the construction recovery is not priced into the business at current earnings levels. When rates normalise and construction recovers toward the historical average of 80,000 to 85,000 units annually, Pool captures that revenue incrementally, on top of a maintenance base that is growing regardless.

Each new pool is also not a one-time event for Pool. It joins the installed base permanently and begins generating recurring annual maintenance demand for 20 to 30 years. A recovery in construction from 60,000 to 80,000 units adds not just current-year construction revenue but a compounding permanent addition to the non-discretionary revenue base.

2. The Technology Upgrade Cycle

The installed base of US pools is ageing. Pools installed in the 1990s and early 2000s are now 25 to 35 years old and require equipment replacement. The technology gap between old and new equipment is substantial. Variable speed pumps use 75% to 80% less electricity than single-speed equivalents. LED pool lighting uses 70% less energy than incandescent. Automated pool controls, allowing smartphone management of pump schedules, heating, lighting, and chemical dosing, are now standard on new installations and desired retrofits on older ones.

California mandated variable speed pumps statewide from 2025. Pool operates 77 locations in California, making it the single largest state in Pool’s network. Other states historically follow California’s energy efficiency leadership with a multi-year lag. This mandate creates a legally-enforced replacement cycle across Pool’s largest market, with similar mandates likely spreading. The upgrade cycle is broad-based, multi-year, and structural, it does not depend on consumer confidence, interest rates, or new construction activity.

3. Sunbelt Demographics

Florida, Texas, California, and Arizona account for approximately 53% of Pool’s net sales. These are also the states receiving the largest net domestic migration inflows. Pool’s network concentration in these markets is not accidental, it is the result of decades of market-by-market expansion following population density. The ongoing migration toward warmer climates creates pool installation demand and maintenance volume growth that accrues directly to Pool’s most concentrated network regions without requiring any strategic repositioning.

4. Fragmented Market Consolidation

Pool adds 8 to 12 new sales centres annually. Each new centre is positioned to serve a local market more effectively than smaller competitors, absorbing volume through better service and pricing. In 2025, Pool added 8 new greenfield centres and acquired 3, for a net addition of 8 after 3 closures. At this pace, Pool’s structural lead over regional competitors widens year after year, and the flywheel described in the Moat section turns one more cycle.

Adjacent Opportunity

Pool’s expansion into irrigation, landscape maintenance, hardscapes, and outdoor living products through Horizon and NPT is early-stage. I treat it as optionality rather than a core driver. The Horizon 24/7 B2B platform and the NPT consumer showroom network are genuine value additions, but they do not yet move the needle on overall earnings in a material way. The potential is there; the execution record in these adjacencies is still developing.

7. valuation

What Today’s Price Assumes

My valuation framework expresses intrinsic value as years of embedded discounted cash flows. Rather than using a terminal value, which requires assumptions about perpetuity growth rates I find too speculative to be reliable. I model an explicit series of annual free cash flows per share, discount each one back to the present at an appropriate rate, and ask: how many years of future cash flows does today’s price already contain?

The framework has five zones. Exceptionally Attractive sits below 15 years. Attractive runs from 15 to 20 years. Hold covers 20 to 30 years. Expensive runs from 30 to 35 years. Exceptionally Expensive is anything above 35 years. I initiate new positions only in the Attractive or Exceptionally Attractive zones

The single most important decision in valuing Pool is choosing the right starting point for free cash flow (FCF) per share. Current FCF of approximately $8 to $9 per share is not the right number, it reflects a construction environment at roughly half of normalised levels, working capital timing distortions from the 2025 inventory build, and the deferred tax payment described in the financial section. Using current FCF as the base would be like pricing a hotel chain on occupancy rates during a recession.

The framework I apply here is the same used in prior Bearhold reports where current FCF understates normalised earning power: I use a normalised FCF per share estimate with an explicit explanation of why current figures are distorted. My base case is $15 per share, representing mid-cycle conditions, construction volumes recovering to approximately 80,000 to 85,000 units annually, normal renovation activity, maintenance base growth continuing at approximately 1% to 2% per year, and stock-based compensation (SBC) deducted from operating cash flow as a real economic cost to shareholders. The upper end of my range is approximately $17 per share, anchoring to 2024 OCF of $659 million as a more representative year for underlying cash generation capability.

I present the range rather than a single number because the honest answer is that normalised FCF has genuine uncertainty. If mid-cycle earning power settles at $13 rather than $15, because cost inflation proves stickier, or because the construction recovery is shallower than expected, the valuation picture is less attractive. I carry that uncertainty explicitly.

The Result

At approximately $225, my model puts Pool at around 15 years of embedded discounted cash flows, the lower boundary of the Attractive zone, approaching Exceptionally Attractive territory. I hold a position initiated before this report’s publication.

The 2026 guidance from Pool’s management, projecting EPS of $10.85 to $11.15 with no construction recovery assumed, confirms that the market is pricing the business at close to trough earnings. That is a different and more interesting situation than being priced at trough earnings with a trough valuation multiple. At 15 years in the Attractive zone, Pool’s current valuation is attractive, especially considering we are at a cyclical low point for earnings in such a high-quality business

Growth Engines

I evaluate the return potential of any business through two engines running simultaneously.

The first engine is FCF per share growth, the fundamental driver of intrinsic value over time. For Pool, this engine has multiple components: the construction recovery adds to the revenue base as rates normalise; operating leverage on a cost structure maintained through the downturn amplifies earnings as revenue recovers; and a consistent share buyback programme reduces the denominator. Pool repurchased $341 million of its own shares in 2025 at prices well below any reasonable mid-cycle intrinsic value estimate. That per-share compounding is real and operates independently of the business cycle.

The second engine is valuation re-rating. At 15 years at the lower boundary of Attractive, this engine is beginning to work in the investor’s favour. An investor adding at current prices captures the construction recovery through fundamental earnings growth and the subsequent re-rating from attractive territory simultaneously. That combination, fundamental compounding plus valuation correction, is what the framework is designed to identify.

8. Risks

Where the Thesis Can Be Wrong

1. Cyclical Earnings Compression

This is the most important risk, and the one most often understated. EPS declined from a peak of $18.70 in 2022 to $10.85 in 2025, a 42% compression over three years, driven by the normalisation of pandemic-era construction demand and elevated financing costs. This will happen again. In the next significant economic downturn, Pool’s discretionary revenue segment will compress. Construction will slow. Renovations will be deferred.

A long-term investor can look through cycles if the business is structurally intact, and the evidence strongly suggests it is. But the volatility is real and must be understood before entering a position. Pool is more cyclical than a pure-maintenance business would be, precisely because 36% of revenues are discretionary. The cyclicality is a feature, not a bug, of a business that participates fully in the upside of construction booms. But it means the entry price matters considerably, and owning Pool at the wrong price through a downturn is a genuinely uncomfortable experience.

2. Inventory Pile-Up

Inventory days of 135 in 2025 are approaching decade-high levels. Management’s rationale, purchasing ahead of anticipated price increases, is a standard and historically successful practice for Pool. But the downside scenario is real: if anticipated price increases do not materialise, or if demand remains soft, Pool is carrying more inventory than it needs at cost prices that may be above what the market will bear. This could result in either margin compression on the sale of elevated-cost inventory, or in a worst case, write-downs. Pool’s reserve for inventory obsolescence was $23.9 million at year-end 2025, not alarming in absolute terms, but worth monitoring against actual write-off trends in coming quarters.

3. E-Commerce Structural Challenge

Amazon and direct-from-manufacturer purchasing represent a long-term structural question for wholesale distribution economics. Pool’s defence, same-day local delivery, 200,000 SKU breadth, POOL360 digital integration, is well-constructed and already working. But the question is not closed over a 20-year horizon. I monitor POOL360 adoption rates, gross margin trends, and any signals of customer defection as the most important leading indicators of this risk.

4. Tariff Exposure

Pool sources products from manufacturers globally, including Chinese-manufactured pool equipment. The current tariff environment introduces cost uncertainty that Pool largely passes through to contractors, but the timing mismatch between cost increases and price realisation creates quarterly earnings volatility. Inflationary product cost increases included a 1% tariff impact in 2025. The tariff environment remains dynamic and will continue to create noise in quarterly results.

5. Housing Market Dependency

New pool construction correlates strongly with housing market activity, home equity availability, and consumer willingness to take on debt for home improvement. In a scenario where housing prices decline significantly, from a broader recession or from housing-specific stress, the construction recovery thesis is delayed or reversed. Consumers who have seen home equity erode are unlikely to finance pool installations. This is the scenario where my normalised FCF estimate of $15 proves too optimistic in the medium term.

6. Normalised Earnings Uncertainty

The honest acknowledgment is that $15 per share as normalised FCF is an estimate, not a number readable from the financial statements. If structural operating cost inflation proves stickier than expected, or if the construction recovery is shallower or slower than my model assumes, the normalised earning power may settle lower. That is a risk I hold explicitly rather than papering over with a point estimate.

What Would Change My Mind

Persistent gross margin compression below 28% for two or more consecutive years, not explained by a temporary mix shift, would signal something more structural than a cyclical trough. A sustained reversal in POOL360 adoption rates. A major supplier announcing direct distribution capability at scale. EPS on a normalised basis, after rates decline meaningfully, failing to recover toward $14 to $15. Any of these would warrant a fundamental reassessment of the thesis.

9. The Verdict

Pool Corporation is Approved in the Bearhold Universe. The business has demonstrated over four decades that its scale advantages compound, its competitive position strengthens through economic cycles, and its maintenance revenue base is structurally permanent. The financial track record, ROIC consistently above 16% through a 42% EPS compression from peak to trough, gross margins stable at 29% to 30% throughout, is empirical evidence of a genuine and durable moat. The cyclicality of the business does not disqualify it from the Approved designation; what matters is that the moat itself has not weakened during the downturn.

At approximately $225 and 15 years of embedded cash flows, Pool sits at the lower boundary of the Attractive zone. I hold a position initiated prior to this publication.

What makes the current moment analytically interesting is this: Pool’s management is guiding for 2026 EPS in line with 2025 and explicitly assumes no recovery in new pool construction. The market is therefore pricing the business at trough earnings, with no meaningful premium for a recovery that, at some point, is structurally inevitable. The construction suppression is rate-driven and financial in nature, not a permanent structural loss of demand for pools. When rates normalise and construction recovers, the earnings recovery is expected to be significant, and investors who entered in the Attractive zone will capture both the fundamental compounding and the re-rating from trough levels.

The risks are real, cyclical earnings volatility, the inventory build, the long-term e-commerce question. None of them, assessed honestly against the quality of what has been built over 40 years and the price at which it is currently available, changes my view that Pool Corporation belongs in the Bearhold Universe.

Quarterly Update Log

This section is updated with each subsequent quarterly result and is kept separate from the annual analysis above, which reflects the fiscal 2025 full year record.

Disclosure: The author holds a position in POOL. This report reflects the author’s personal views and is not investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

Sources

Pool Corporation FY2025 Annual Report on Form 10-K (filed February 2026).

Pool Corporation Q4 2025 Earnings Presentation (February 19, 2026).

Pool Corporation company history at poolcorp.com.

P.K. Data, Inc., US in-ground pool installation data.

The Outlook

There is a hormone produced in the human gut after you eat. It signals to your brain that you have had enough. It slows the stomach from emptying. It tells the pancreas to release insulin. For most of medical history, this hormone, glucagon-like peptide-1, or GLP-1, was just a footnote in endocrinology textbooks. Then a Danish pharmaceutical company spent thirty years studying it, synthesising molecules that mimic it, extending their half-life in the bloodstream from a few minutes to a full week, and iterating on the formulation until they could put it in a once-weekly injection. And then, remarkably, into a pill.

What Novo Nordisk has built is not just a drug franchise. It is a century-old institution that made the right scientific bet at the right moment in history, and found itself at the centre of what may be the most commercially significant pharmacological development of our generation. GLP-1 drugs are not a weight loss trend. They are a reclassification of obesity from a lifestyle problem to a treatable chronic disease, and Novo Nordisk is the company that did the reclassifying. My valuation framework puts the stock at 17 years of embedded discounted cash flows, firmly in the Attractive zone.

The business is on the Bearhold Watchlist, not yet Approved, and this report explains the distinction.

At a Glance

Company: Novo Nordisk A/S

Ticker: NVO · NYSE / NOVO B · Nasdaq Copenhagen

Sector: Healthcare

Industry: Pharmaceuticals

Market Cap: ~$168 billion

Dividend Yield: ~4.8% (price $37.5)

Current Stock Price: $37.50

First Coverage: April 2026

Bearhold Universe Status: Watchlist

Valuation Zone: Attractive (last updated April 2026)

This report reflects the author's personal views and does not constitute investment advice. Investing carries the risk of permanent capital loss. The author held a position in NVO during the research process and exited prior to publication. No position is held at the time of publishing. Read the full disclaimer here

1. The Business

From Insulin to the Drug That Changed Everything

The story of Novo Nordisk starts in 1923, the same year insulin was first commercially produced, just two years after its discovery in Canada. A group of Danish scientists recognised that this life-saving hormone would need to be manufactured reliably, at scale, for the millions of people with type 1 diabetes who would otherwise die without it. They built a small laboratory in Copenhagen and began producing insulin from pig and cow pancreas. That business became Novo Nordisk.

For most of the 20th century, the company’s identity was simple: it made insulin. Its early products were animal-derived insulins, extracted directly from livestock pancreas. These worked, but they were not identical to human insulin, which meant the body sometimes rejected them. In the 1980s, Novo Nordisk was among the first companies to produce human insulin through recombinant DNA technology, meaning scientists could engineer bacteria to produce an exact replica of the human molecule. This was a step-change in treatment quality and marked the company’s transition from a manufacturer to an innovator.

Through the 1990s and 2000s, the company developed long-acting insulins, versions that are released slowly into the bloodstream over 24 hours, eliminating the need for multiple daily injections. Tresiba (insulin degludec), one of Novo Nordisk’s flagship insulins, is a once-daily injection that lasts over 40 hours, offering far more flexibility than older formulations. These innovations matter because the management of type 2 diabetes, which affects roughly 500 million people globally, traditionally relied entirely on insulin injections. The more convenient and precise those injections became, the more patients could comply with treatment, and the better their outcomes.

The GLP-1 Discovery

In the 1980s, researchers discovered that the intestinal hormone GLP-1 had remarkable properties: it stimulated insulin release only when blood sugar was elevated, suppressed glucagon (the hormone that raises blood sugar), and slowed digestion. Unlike insulin, which works regardless of blood sugar levels and can cause dangerous hypoglycaemia (dangerously low blood sugar) if dosed incorrectly, GLP-1 had a built-in safety mechanism. It only worked when it was needed.

The problem was that natural GLP-1 is destroyed in the bloodstream within a few minutes. To be useful as a drug, scientists needed to create a version that lasted long enough to have a therapeutic effect. This is where Novo Nordisk’s decades of molecular engineering experience paid off. Their scientists modified the GLP-1 molecule to make it resistant to the enzyme that breaks it down, and bound it to a carrier protein to extend its life in the body. The result was semaglutide, a once-weekly injectable that mimics GLP-1 with dramatically extended duration.

The Same Drug, Different Names

This is one of the most frequently misunderstood aspects of Novo Nordisk’s business, so I want to explain it clearly.

Ozempic and Wegovy contain the exact same active ingredient: semaglutide. The difference is the dose. Ozempic, approved for type 2 diabetes, is available at doses of 0.5mg and 1mg per week. Wegovy, approved for obesity, is dosed at 2.4mg per week. Rybelsus is the oral version of semaglutide, available in daily pill form at doses of 7mg and 14mg, approved for diabetes. The Wegovy pill, approved by the FDA (US Food and Drug Administration) in January 2026, is an oral version for obesity at 25mg per day.

The reason these identical molecules have different names is both regulatory and commercial. Regulatory agencies approve drugs for specific indications at specific doses, a company cannot simply sell its diabetes drug off-label for obesity without a separate approval process. More importantly, it is commercial. Insurance companies in the US have historically refused to cover obesity as a disease, meaning they will reimburse Ozempic for a diabetic patient but not Wegovy for an obese patient who does not have diabetes, even though the molecule is the same. By separating the brands, Novo Nordisk can price and position each product for its specific reimbursement channel. Ozempic’s lower dose and diabetes indication gives it a clearer path to insurance coverage. Wegovy’s obesity approval opens a different, harder, but rapidly expanding reimbursement channel.

Why GLP-1 Is Replacing Traditional Insulin Therapy

The conventional treatment pathway for type 2 diabetes used to look like this: start with oral medication (metformin), add more oral medications as the disease progresses, and eventually transition to daily insulin injections as the pancreas loses its ability to produce enough insulin on its own. Patients often spent years on multiple medications and ended up injecting insulin multiple times daily, managing complex carbohydrate intake, and still experiencing high rates of cardiovascular disease, kidney disease, and nerve damage.

GLP-1 drugs changed this trajectory. Clinical trial after clinical trial showed that semaglutide not only controlled blood sugar as effectively as insulin but also reduced body weight, lowered blood pressure, reduced inflammation, and, critically, reduced cardiovascular mortality. The SELECT trial, completed in 2023, showed that Wegovy reduced major adverse cardiac events such as heart attack and stroke by 20% in people with obesity and established cardiovascular disease. The FLOW trial showed Ozempic reduced the progression of chronic kidney disease by 24%. These are outcomes that insulin, despite decades of use, has never convincingly demonstrated.

The result is that GLP-1 drugs are no longer just an add-on to diabetes therapy. They are increasingly the first-line treatment, with insulin reserved for patients who cannot tolerate GLP-1 drugs or whose disease has progressed beyond what GLP-1 can manage. This is why Novo Nordisk’s older insulin products, Victoza, Levemir, are declining. Victoza sales fell 43% in constant currency terms in FY2025. These are not accidents. They are the natural consequence of a superior drug replacing its predecessor.

How a Diabetes Drug Became the Defining Weight Loss Treatment

The weight loss effect of GLP-1 drugs was noticed early in clinical trials but treated initially as a side effect. Patients taking these drugs for diabetes were losing significant body weight, not through stimulant effects, but because the brain was receiving genuine satiety signals, reducing appetite naturally. Novo Nordisk’s scientists understood what this meant: there was a separate, enormous market here.

The STEP trials, completed in 2021, tested semaglutide 2.4mg specifically for obesity in people who did not have diabetes. Participants lost an average of 14.9% of their body weight. That may sound modest, but in the context of obesity pharmacology, where most approved drugs had achieved 3–5% weight loss at best, it was extraordinary. The FDA approved Wegovy in June 2021, and the obesity treatment market was never the same.

Today the business operates across three segments. Obesity care generated DKK 82.3 billion in FY2025, up from essentially zero in 2019, when it barely existed as a category, growing 31% at CER (constant exchange rates). Diabetes care generated DKK 207.1 billion, growing 4% at CER. Rare disease, treatments for growth hormone disorders and haemophilia, generated DKK 19.6 billion, growing 9% at CER. Total revenue reached DKK 309 billion in FY2025, up from DKK 157.5 billion five years earlier.

2. The Moat

What Makes This Business Hard to Compete with

Novo Nordisk’s competitive position rests on four reinforcing pillars, and understanding each one is important before looking at the financial results.

The first is molecular depth. Semaglutide has been in development since the early 2000s and has accumulated a clinical evidence base that no competitor can replicate quickly. Cardiovascular outcomes trials take five to seven years to complete and cost hundreds of millions of dollars. Novo Nordisk has completed the SELECT trial for obesity, the SUSTAIN-6 trial for diabetes, and the FLOW trial for kidney disease. These are not marketing claims, they are data sets generated from tens of thousands of patients over years. A new entrant today, even with a technically equivalent molecule, would need to spend a decade and billions of dollars to generate comparable evidence. That is structural protection.

The second is manufacturing expertise. GLP-1 drugs are biologics, they are not simple chemical compounds. They are produced through complex biological processes that require precision at every step, from fermentation to purification to formulation for injection or oral delivery. The development of a stable oral semaglutide formulation, which required solving the problem of getting a large peptide molecule through the stomach without being destroyed, is a technical achievement that took years of R&D investment. The current DKK 60 billion annual capital expenditure is explicitly aimed at expanding this infrastructure. It takes time and expertise that cannot be purchased overnight.

The third is commercial infrastructure. Novo Nordisk has one of the deepest specialist sales forces in pharmaceutical history, built over a century of selling to endocrinologists and diabetologists. These relationships are not purely transactional, prescribers who have spent fifteen years trusting Novo Nordisk’s insulin products were natural early adopters of Ozempic. That trust transfers, and it creates a distribution advantage that is invisible in the financial statements but profoundly real.

The fourth is patient stickiness. GLP-1 drugs require continued use to maintain their effect, body weight returns on discontinuation, and blood sugar control deteriorates. This means a patient who starts on Ozempic or Wegovy is, in practice, a recurring revenue stream. It is not a perfect annuity, discontinuation rates are real and I will discuss them in the Risks section, but the baseline adherence creates a revenue durability that few pharmaceutical franchises can match.

The empirical evidence of the moat is in the margins. The operating margin has ranged from 41.3% to 45.8% across every year from 2015 to 2025, averaging 43.1% over the decade. A business that is losing its competitive position does not sustain margins at that level across ten years of significant disruption, including pricing pressure from biosimilars on older products, a global pandemic, supply constraints, and a complete transformation of the revenue mix.

3. The Paradox at the Heart of the Business

One Company Treating the Same Disease it is Helping Prevent

I want to pause on something that I have not seen discussed clearly enough in most analyses of Novo Nordisk. It is a genuine strategic tension at the heart of the business model, and it deserves honest examination.

Novo Nordisk sells two categories of products. In the diabetes segment, it sells drugs that treat and manage diabetes, products that patients typically use for life, generating stable, recurring revenue. In the obesity segment, it sells drugs that cause significant weight loss, and we now have substantial evidence that sustained weight loss reverses or prevents type 2 diabetes in a meaningful share of patients.

I do not think this resolves neatly. Here is how I think about it.

In the near term, the two businesses are growing simultaneously and serve largely different patient populations. Most Ozempic patients are type 2 diabetics with established disease. Most Wegovy patients are obese without a diabetes diagnosis. The overlap exists but it is not yet the dominant dynamic.

In the medium term, say five to ten years, if GLP-1 drug adoption reaches a meaningful share of the obese population, and if adherence rates are sustained, we should expect a measurable reduction in the incidence of new type 2 diabetes cases. This is good for society and genuinely good for patients. For Novo Nordisk’s diabetes franchise, it means the pool of newly diagnosed type 2 diabetics will eventually shrink. At the same time, the surviving diabetes franchise will treat a patient population with more advanced and complex disease, the patients for whom lifestyle intervention and GLP-1 therapy alone were not enough.

In the long term, the company’s own strategic positioning tells you what management believes: obesity care is the growth engine of the next decade, and diabetes care is the stable cash-generating foundation. The restructuring announced in FY2025, redirecting DKK 8 billion in annualised savings toward obesity and diabetes innovation, confirms this. They are not treating this as a zero-sum game within the portfolio. They are betting that the obesity market is large enough to more than offset any erosion in the diabetes base.

I think this is probably correct, but I hold it with appropriate uncertainty. The honest risk is that if obesity drugs penetrate much faster and at much higher adherence rates than current models project, the diabetes franchise could decline faster than the obesity franchise grows. I do not think this is the base case, the sheer scale of the undiagnosed and untreated obesity population is simply enormous, but it is the kind of second-order risk that deserves a place in any serious analysis of this business.

This unresolved dynamic is one of the reasons the obesity franchise has not yet earned the Approved designation, the long-term interaction between these two segments is genuinely uncertain in ways that a decade of insulin history was not.

4. Financial Performance

A Decade in Numbers

The ten-year financial record of Novo Nordisk is, on almost every metric except one, exceptional.

Revenue grew from $15.7 billion in FY2015 to $48.5 billion in FY2025, a compound annual growth rate of approximately 11.9% over ten years. The growth was not linear. Through 2021, the diabetes franchise expanded steadily. Then the GLP-1 obesity inflection arrived: from 2022 onwards, the company added roughly seven to nine billion dollars of revenue per year. The 2025 figure is more than three times the 2015 base.

Diluted EPS grew from $0.99 in FY2015 to $3.61 in FY2025, a compound annual growth rate of 13.8%. This is the number I trust most as a proxy for earnings power, because it is clean, consistent, and not distorted by the current capex cycle. The share count declined from 5,155 million to 4,448 million over the decade, a consistent buyback programme that reduces the per-share denominator. Dividends per share grew from $0.37 in 2015 to $1.82 in 2025.

The gross margin averaged approximately 83.9% from 2015 through 2025, near the pharmaceutical ceiling, reflecting proprietary manufacturing and durable pricing power. In FY2025, gross margin fell to 81.0%. This is a real and material decline, driven primarily by the enormous surge in cost of goods sold as the company scaled manufacturing rapidly and absorbed restructuring costs related to facility consolidation.

The operating margin has ranged from 41.3% to 45.8% across every year of the decade, averaging 43.1%. FY2025 came in at 41.3%, adjusted for the DKK 8 billion restructuring charge (In September 2025, Novo Nordisk announced a “company-wide transformation” involving approximately 9,000 job cuts, this resulted in a one-off DKK 8.0 billion restructuring cost), underlying operating profit grew 13% at constant exchange rates, and the reported operating margin would have been meaningfully higher. The consistency of margins at this level across ten years of significant business model change is one of the most powerful signals of competitive quality I have seen in this type of analysis.

ROIC (return on invested capital) was 73.4% in FY2015 and declined to 26.8% in FY2025 as the capital base expanded with the manufacturing buildout. The directional decline is expected, the denominator grew faster than the numerator as capital was deployed into assets not yet generating returns. The absolute level of 26.8% is still exceptional for a business of this scale. Eli Lilly’s ROIC reached 33% in FY2025 after a decade of expansion from 10.9% in 2015. The two companies are converging at the high end of the global pharmaceutical industry.

The FCF Story, Why the Headline Number is Not the Full Story

Free cash flow (FCF: cash left after all operating expenses and capital investment) was remarkably stable from 2015 through 2023, growing from $4.7 billion to $10.2 billion. OCF (operating cash flow: cash generated from the business before investment) margins throughout this period ranged from 35% to 47%, and FCF margins ranged from 24% to 36%.

In FY2025, FCF collapsed to $4.5 billion, a margin of 9.4%, compared to a ten-year average of approximately 28%.

The cause is entirely capital expenditure. Capex (spending on factories and equipment) was $935 million in FY2015, representing 17% of OCF. By FY2025, it had reached $14.1 billion, 76% of OCF. The company spent DKK 60 billion on property, plant, and equipment in FY2025, principally to build manufacturing capacity for GLP-1 drugs.

The important distinction is that OCF margins remained within historical norms: 38.5% in FY2025. The business is not generating less cash from its operations, it is reinvesting aggressively in infrastructure. Because FCF per share is temporarily distorted, I use EPS as my primary earnings proxy throughout this report. The operating health of the business is intact.

The Balance Sheet Has Changed

Debt-to-equity was 0.02x in FY2015, essentially no debt. By FY2025, it had risen to 0.68x. The company now carries meaningful net debt, having taken on borrowings to fund both the manufacturing buildout and several acquisitions, including the Catalent manufacturing sites that Novo Holdings purchased in 2024 for $11.7 billion and subsequently deployed to Novo Nordisk’s production. This is manageable at current earnings levels, but it represents a structural shift from the near-pristine balance sheet that characterised this company through most of the last decade.

5. Regional Breakdown

The Numbers by Region (FY2025)

The detailed revenue data from the FY2025 annual report tells a story that the headline figures do not.

US Operations generated DKK 173.2 billion in total sales in FY2025, growing 3.4% as reported (8% at CER). Within that, Wegovy in the US generated DKK 51 billion, up from DKK 45.8 billion in 2024. Ozempic US sales were DKK 88.5 billion. These are extraordinary numbers for two products that barely existed five years ago.

International Operations generated DKK 135.9 billion, growing 10.5% as reported (14% at CER). The breakdown within International Operations reveals where the real opportunity sits:

EUCAN (Europe and Canada) generated DKK 66.1 billion, growing 14.9% as reported (16% at CER). Wegovy in EUCAN generated DKK 15.4 billion, up from DKK 7.7 billion in 2024, a doubling in a single year. This is what the early phase of a proper launch looks like. Europe is roughly two years behind the US in GLP-1 obesity adoption, constrained by more conservative payer systems and slower reimbursement approvals. The trajectory is clear.

Emerging Markets (mainly Latin America, Middle East, and Africa) generated DKK 30.4 billion, growing 3.1% as reported (8% at CER). Wegovy in Emerging Markets generated DKK 6.1 billion in FY2025, up from DKK 2.7 billion in 2024. This is one of the most interesting long-term opportunities and one of the most underdiscussed. Obesity prevalence in Latin America and the Middle East is extremely high, Brazil, Mexico, and Saudi Arabia are among the most obese nations on earth. The barrier is affordability and reimbursement coverage. As Novo Nordisk develops lower-cost formulations and access programmes, this market has a long runway.

APAC (Japan, Korea, Oceania, and Southeast Asia) generated DKK 20.7 billion, growing 18.8% as reported (25% at CER). Wegovy in APAC generated DKK 5.8 billion, up from DKK 1.9 billion in 2024, a tripling in a single year. Japan and South Korea have both launched Wegovy relatively recently, and the cultural and clinical context is different from the West. Japanese patients tend to be obese at lower BMI (body mass index) thresholds than Western patients, and the regulatory framework for obesity treatment has historically been restrictive. As awareness grows and reimbursement expands, APAC represents a meaningful expansion opportunity.

Region China generated DKK 18.7 billion, growing 0.8% as reported (5% at CER). This is the most complicated region, and I will address it directly in the Risks section. Wegovy in China generated DKK 796 million, still a very small number relative to the scale of the opportunity. China has a massive obesity and diabetes burden, but the semaglutide active ingredient patent expires there in 2026, which means low-cost domestic biosimilar competition is coming. The next two to three years in China will be a test of brand loyalty versus price.

The Global Penetration Opportunity

Here is the number I keep coming back to: the World Health Organization estimates approximately 890 million adults globally have obesity. Current GLP-1 treatment penetration is in the low single digits. The United States has an obesity prevalence of roughly 42% in adults, and fewer than 6% of eligible patients are currently on a branded GLP-1 drug. Even after the explosive growth of the last three years, the penetration story is genuinely in its early chapters.

6. Competition: Novo Nordisk vs. Eli Lilly

The Duopoly That Defines the GLP-1 Market

Novo Nordisk and Eli Lilly together represent the vast majority of commercial GLP-1 (glucagon-like peptide-1) prescriptions globally. No other company is remotely close to their combined scale in either diabetes or obesity. Understanding how these two businesses compare is essential.

Novo Nordisk pioneered this market. It was the first to achieve large-scale commercial success with semaglutide, the first to build a manufacturing infrastructure capable of supplying tens of millions of patients globally, and the first to bring an oral GLP-1 pill for obesity to market. That first-mover advantage is real and it matters, both commercially and in terms of the clinical evidence base accumulated across cardiovascular disease, kidney disease, and liver disease.

But Eli Lilly has overtaken Novo Nordisk in prescription market share, and that shift deserves honest acknowledgment. By the third quarter of 2025, Lilly held more than 57% of US monthly GLP-1 prescriptions across diabetes and obesity, with Novo Nordisk at approximately 43%, down from a position of clear leadership just two years earlier. The primary driver is tirzepatide, which activates two hormone receptors simultaneously, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), compared to semaglutide’s one. In Lilly’s SURMOUNT-1 trial, tirzepatide produced average weight loss of approximately 21–22% at the highest dose, compared to semaglutide’s 15% in the STEP trials. When a drug delivers meaningfully better efficacy and is available in adequate supply, prescribers and patients notice. Lilly’s 2026 revenue guidance projects approximately 27% growth. Novo Nordisk’s 2026 guidance is for negative adjusted sales growth at constant exchange rates. The divergence in near-term momentum is real and not easily dismissed.

Where It Gets More Complicated — The Pill Battle

The injectable competition is clear: Lilly leads on efficacy. But the oral market, which is where the next major wave of GLP-1 adoption is likely to come from, driven by patients who have consistently refused injections, is a more nuanced picture, and one that has shifted meaningfully in Novo Nordisk’s favour in just the past two weeks.

Novo Nordisk’s Wegovy pill was approved by the FDA in December 2025 and reached over 600,000 US prescriptions in its first few weeks. On April 1, 2026, 12 days before this report, the FDA approved Eli Lilly’s oral GLP-1, orforglipron, now branded as Foundayo. The pill competition is now live and direct.

The initial market framing was that Novo had first-mover advantage but Lilly had a convenience edge: Foundayo is a small-molecule drug that can be taken at any time with or without food, while the Wegovy pill is a peptide that requires a 30-minute fast each morning. For patients who already struggle with daily medication adherence, that restriction was seen as a meaningful disadvantage for Novo.

Then, on April 2, 2026, one day after Foundayo’s approval, Novo Nordisk presented the ORION study at the Obesity Medicine Association’s annual conference in San Diego. The study used a population-adjusted indirect comparison of data from the OASIS 4 trial (Wegovy pill) and the ATTAIN-1 trial (Foundayo), and the results were notable. Oral semaglutide showed 3.2 percentage points greater weight loss than orforglipron on a real-world adherence basis. On tolerability, patients on orforglipron had approximately four times higher odds of discontinuing due to any adverse event, and nearly 14 times higher odds of discontinuing specifically due to gastrointestinal side effects. A separate patient preference survey of 800 adults found that 84% favoured the oral semaglutide profile over orforglipron, and 65% of those respondents said the morning fasting requirement would not significantly disrupt their daily routine.

I want to be clear about what this data is and what it is not. The ORION study is an indirect comparison across two separate trials, not a head-to-head study with identical protocols. The researchers themselves flagged substantial uncertainty in the tolerability findings, the confidence interval on the gastrointestinal discontinuation figure runs from 2.0 to 96.0, which is wide enough to counsel humility. The study was also funded and presented by Novo Nordisk, which means it should be read with appropriate critical distance even if the methodology is standard. No direct head-to-head trial between these two pills exists, and neither company is likely to fund one voluntarily.

With those caveats stated, the direction of the finding is meaningful. In a chronic disease drug that patients take daily for the rest of their lives, tolerability and real-world adherence matter more than any single efficacy number. A drug that patients stay on compounds its benefit over years and generates recurring revenue. A drug that patients are significantly more likely to discontinue due to side effects loses both the clinical benefit and the commercial durability. The convenience narrative that Lilly was relying on to offset Novo’s first-mover advantage in the oral market has been meaningfully complicated by this data.

The Margin and Balance Sheet Picture

On financial quality, Novo Nordisk maintains the structural advantage. Its gross margin averaged approximately 83.9% from 2015 through 2024, falling to 81.0% in FY2025, compared to Eli Lilly’s expansion from 74.8% in 2015 to 83.0% in FY2025. Lilly has only just reached the margin level that Novo Nordisk has sustained for a decade. Operating margins tell the same story: Novo Nordisk’s range of 41.3% to 45.8% throughout the decade versus Lilly’s expansion from 18% in 2015 to 45.6% in FY2025. Both companies are now experiencing the same capex-driven FCF (free cash flow) compression, Lilly’s FCF margin was 9.2% in FY2025 versus Novo Nordisk’s 9.4%, as both build manufacturing infrastructure for the same market opportunity. On leverage, Novo Nordisk is more conservatively capitalised at 0.68x debt-to-equity versus Lilly’s 1.60x.

One metric I flag for both companies is inventory. Eli Lilly’s Days Inventory Outstanding, a measure of how long products sit in inventory before being sold, increased from 196 days in FY2021 to 352 days in FY2025, nearly a doubling in four years. This could reflect pre-launch positioning or manufacturing buffer-building, but it is a number worth watching in future quarterly reports for signs of demand forecasting error.

The Summary

The injectable market: Lilly leads on efficacy with tirzepatide and has taken prescription share from Novo Nordisk. That is a fact.

The oral market: Novo Nordisk leads on efficacy and, based on the most current available data, leads on tolerability as well, though the evidence is indirect and requires a head-to-head trial to confirm definitively.

The financial quality: Novo Nordisk has the stronger historical margin profile and more conservative balance sheet.

The pipeline: Novo Nordisk’s CagriSema, filed for FDA approval in December 2025 with a decision expected around October 2026, produced 22.7% weight loss in the REDEFINE 1 trial, essentially matching tirzepatide’s injectable efficacy. If approved, it closes the injectable efficacy gap before Lilly’s next-generation retatrutide (a triple receptor agonist) reaches market.

I would describe the current state as a genuine competition between two exceptional businesses, with Lilly holding the commercial momentum in injectables and Novo Nordisk mounting a more credible defence in the oral market than the market appears to currently price in. The coming 18 months, CagriSema approval, head-to-head oral data if it emerges, and the real-world prescription trends between Wegovy pill and Foundayo, will determine whether Novo Nordisk’s defensive position stabilises or continues to erode. At $37.50, I believe the current price more than compensates for that uncertainty.

7. Growth Levers & Addressable Market

The Pipeline: Novo Nordisk’s Response to the Lilly Challenge

CagriSema is the most important near-term pipeline catalyst. It is a fixed-dose combination of cagrilintide (a long-acting amylin analogue, amylin is another satiety hormone produced by the pancreas) and semaglutide 2.4mg. In the REDEFINE 1 Phase 3 trial, participants lost an average of 22.7% of body weight assuming full adherence to treatment, and 20.4% on a real-world basis regardless of adherence. Both figures substantially exceed Wegovy’s current results. Novo Nordisk filed the NDA (new drug application) with the FDA in December 2025, and a decision is expected approximately October 2026.

Zenagamtide (amycretin), a single molecule that activates both GLP-1 and amylin receptors, is entering Phase 3 trials in 2026 in both injectable and oral forms, with early-phase data showing weight loss in the 20% range. The semaglutide 7.2mg dose achieved 20.7% weight loss and has received a positive opinion from the EMA (European Medicines Agency), with an FDA submission also filed. Wegovy was approved for MASH in the US in FY2025, MASH affects approximately 6% of the global population and has very limited approved treatment options, making this a meaningful new revenue channel.

The oral Wegovy pill, approved by the FDA in December 2025, is worth emphasising specifically. Injection hesitancy is a real and documented barrier to GLP-1 adoption. A meaningful share of patients who would benefit from these drugs decline or discontinue them because of the injection requirement. An oral formulation that achieved 16.6% average weight loss in trials, better than any previously approved oral obesity drug, removes that barrier entirely. This is a market expansion story, not just a market share story.

8. Management

Lars Fruergaard Jørgensen, Mike Doustdar, and a CEO Transition at a Critical Moment

Lars Fruergaard Jørgensen served as CEO from 2017 through August 2025. His tenure included the most transformative period in Novo Nordisk’s modern history, the pivot to obesity care, the launch of Wegovy, the extraordinary growth from 2021 to 2023, and the beginning of the current manufacturing buildout. On May 16, 2025, the company announced he would be stepping down following a period of market challenges and declining share price. On July 29, 2025, Mike Doustdar, then head of International Operations, was named as successor, with the formal handover taking place on August 7, 2025.

I read the transition thoughtfully. Jørgensen built the strategic architecture of the current business. Doustdar is, in many ways, the commercial architect of its execution: as head of International Operations, he oversaw the global Wegovy launch and was responsible for the market access strategy that determined how quickly the drug reached patients outside the US. His appointment is not a reversal of strategy. It is a shift in emphasis, from the scientific and strategic decisions of the build-out phase to the commercial and operational execution required to turn that investment into revenue.

The capital allocation record under the previous leadership is solid. Share count declined by approximately 14% over the decade through consistent buybacks. R&D (research and development) spending reached DKK 52 billion in FY2025, 16.8% of revenue, reflecting a genuine commitment to the pipeline rather than cost-cutting to protect near-term margins. The DKK 8 billion restructuring announced in FY2025, reducing the global workforce by approximately 9,000 positions, signals that management is willing to make uncomfortable structural decisions. I read that positively.

The governance structure deserves a note. Novo Holdings, controlled by the Novo Nordisk Foundation, holds approximately 77% of the voting rights through a dual-class share structure. This insulates management from short-term market pressure. It is a structural positive for a business with a multi-decade strategic horizon, though minority shareholders have limited influence over capital allocation decisions.

9. The Compounding Pharmacy Story

The GLP-1 compounding story is important context for understanding the FY2025 performance, and its resolution is one of the reasons I believe the near-term earnings trajectory is better than the FY2026 guidance implies.

When demand for Wegovy and Ozempic surged in 2022 and Novo Nordisk’s manufacturing could not keep pace, the FDA placed semaglutide on its official drug shortage list. Under US law, compounding pharmacies can produce copies of drugs on the shortage list. What followed was a large parallel market: an estimated 3.7 million Americans accessing compounded semaglutide through telehealth platforms at $150–$400 per month versus the $1,349 list price of Wegovy.

The FDA declared the shortage resolved on February 21, 2025. The legal basis for most large-scale compounding of semaglutide no longer exists. Courts sided with Novo Nordisk and the FDA in the key preliminary injunction hearings. As of September 2025, Novo Nordisk had filed 140 lawsuits and issued over 1,000 cease-and-desist letters against compounders. The management team acknowledged that the persistence of compounded semaglutide was a meaningful drag on branded volumes in 2025. As compounding recedes, that volume either transitions to branded Wegovy or is lost, but the channel overhang is clearing.

The TrumpRx Pricing Deal, Volume for Price

In November 2025, Novo Nordisk reached an agreement with the Trump administration under which Wegovy and Ozempic prices will be reduced to $350 per month through the TrumpRx government portal, down from the $1,349 Wegovy list price. The deal also extends Medicare coverage of Wegovy for obesity for the first time. In exchange, Novo Nordisk received a three-year exemption from the pharmaceutical tariffs the administration announced, tariffs that would otherwise apply at 100% to patented drugs imported without a Most Favored Nation (MFN) pricing agreement. Given that Novo Nordisk manufactures substantially in Denmark and Europe, the tariff exemption through approximately 2028 is valuable insurance during the period when its US manufacturing buildout is still coming online.

Management expects a negative low-single-digit impact on global sales growth in 2026 from the pricing agreement. That is a real near-term headwind. The medium-term logic is that lower prices plus expanded Medicare access could ultimately drive higher volumes that more than offset the per-unit reduction. I believe that logic is sound, but it will take time to play out.

10. Valuation

What the Market is Pricing in, and What I Think it is Missing

My valuation framework for Bearhold Research expresses intrinsic value as a number of years of embedded discounted cash flows. Rather than using a terminal value, which requires assumptions about perpetuity growth rates that I find too speculative to be reliable, I model an explicit series of annual free cash flows, discount each one back to the present, and ask a simple question: how many years of future cash flows does today’s price already contain? The answer tells me whether I am paying a fair price, a cheap price, or an expensive one.

The framework has five zones. Exceptionally Attractive sits below 15 years. Attractive runs from 16 to 20 years. Hold covers 21 to 30 years. Expensive runs from 31 to 35 years. Exceptionally Expensive is anything above 36 years. I initiate new positions only in the Attractive or Exceptionally Attractive zones and add most aggressively when a business I understand well enters Exceptionally Attractive territory. I sell when a position reaches Expensive or Exceptionally Expensive and reallocate to Attractive names in the Bearhold Universe.

17 Years — Attractive Zone

At $37.50 per share, Novo Nordisk sits at around 17 years of embedded cash flows, firmly in the Attractive zone of the Bearhold framework.

The most important thing to understand about this number is what it does and does not assume. It does not assume a flawless recovery. It explicitly accounts for the near-term FCF (free cash flow) compression driven by the capex cycle, modelling the gradual normalisation as the manufacturing buildout matures rather than assuming an immediate return to historical cash generation levels. It applies a growth rate that is a meaningful haircut to the company’s historical FCF per share CAGR, acknowledging competitive pressure from Lilly in the injectable market, gross margin headwinds from the TrumpRx pricing deal, and patent expiries in China. And it uses a discount rate at the conservative end of the reasonable range for a business of this quality, reflecting the genuine operational uncertainty of this particular moment.

In other words, 17 years is not an optimistic number dressed up as a conservative one. It is what the arithmetic produces when you take the near-term headwinds seriously.

At 17 years, the thesis requires the capex cycle to normalise broadly on schedule, revenue to recover from the 2026 transition year, and FCF per share to compound at a rate that reflects the underlying quality of the franchise rather than the distortions of the current investment cycle. If those things happen, and I believe they will, for reasons I have set out throughout this report, then 17 years represents a genuine margin of safety in a business whose quality justifies a much higher price.

Growth Engines

I evaluate the return potential of any business through two engines running simultaneously.

The first engine is FCF per share growth, the fundamental driver of intrinsic value over time. For Novo Nordisk, the near-term FCF figure is distorted by the capex cycle, and as that distortion clears over the next two to three years, FCF per share growth should re-converge with the underlying earnings power of the franchise. The combination of revenue growth, operating leverage, and a consistent share buyback programme, which has reduced the diluted share count from 5,155 million in FY2015 to 4,448 million in FY2025, provides a quiet compounding mechanism that operates in the background of every other assumption in the model. Even modest share count reduction adds to per share growth without requiring any improvement in the absolute cash generation of the business.

The second engine is valuation re-rating. At 17 years in the Attractive zone, this engine is working in the investor’s favour. The real optionality lies in the scenario where execution delivers, CagriSema approved, capex cycle matures, gross margins recover, oral market share consolidates in Novo Nordisk’s favour, and the market re-rates the stock from Attractive back toward the upper end of Hold or beyond. In that scenario, the investor earns the fundamental compounding of FCF per share growth and a valuation multiple expansion simultaneously. That combination is what makes the Attractive zone entry compelling for a long-term investor

11. Risks

Every investment thesis has a version of events where it is wrong. I want to walk through the scenarios that would genuinely change my view on Novo Nordisk, not the boilerplate risks that appear in every pharmaceutical analysis, but the specific dynamics that keep me thinking carefully about this position.

The Gross Margin is the Number I Watch Most Closely

This is not the risk that gets the most attention, but it is the one I consider most important to the long-term thesis. Novo Nordisk’s gross margin fell from a decade average of approximately 83.9% to 81.0% in FY2025. The official explanation is a combination of rapid manufacturing scale-up costs, one-off restructuring charges, and the initial inefficiency of newly commissioned facilities. If that explanation is correct, gross margins normalise as the new capacity reaches full utilisation over the next two to three years, and the underlying earnings power of the business is largely intact.

But there is an alternative explanation that I cannot dismiss. The TrumpRx pricing deal reduced Wegovy and Ozempic prices to $350 per month on government channels. Competitive pressure in the oral market is pushing both Novo Nordisk and Lilly toward $149 starting prices for their pills. Biosimilar competition is coming in China and eventually in Western markets as patents expire. If these pricing pressures are structural rather than temporary, the long-term gross margin of this business may settle permanently lower than its historical range. A business that earns 79% gross margins rather than 84% is still exceptional, but the difference compounds significantly over a decade of growth at this scale. I do not think this is the most likely outcome, but it is a risk I watch carefully.

The Capex Cycle

Novo Nordisk is spending DKK 60 billion per year, approximately $9 billion, on capital expenditure, and has committed approximately USD 5.6 billion in additional US manufacturing investment through 2028. The total committed capital across the current buildout cycle runs into the tens of billions of dollars. This infrastructure is being built on the assumption that GLP-1 demand will continue to grow rapidly for years and that Novo Nordisk will capture a meaningful share of that growth.

The risk is not that demand for GLP-1 drugs disappoints in aggregate. I believe the structural demand case is overwhelming, as I discussed in the market view section. The risk is more specific: that Novo Nordisk’s share of that demand disappoints relative to the assumptions embedded in the capex decisions. If Lilly continues to gain injectable market share at Novo Nordisk’s expense, and if the oral market develops more slowly than projected, then the company will have built manufacturing capacity for volumes it cannot fill. Capital expenditure is largely irreversible. Factories cannot be unbuilt. The financial consequence would be years of elevated depreciation charges on underutilised assets, compressing returns on invested capital precisely when the business needs to demonstrate that the investment cycle is paying off.

I think this risk is manageable but it is not theoretical. Management made their capacity decisions when Novo Nordisk’s growth trajectory looked dramatically more positive than it does today. The FY2025 full-year sales growth of 10.3% at constant exchange rates versus the FY2026 guidance of negative adjusted sales growth represents a sharp deceleration. How much of that deceleration is transitional, compounding headwinds, pricing adjustments, China patent expiry, and how much of it represents a more durable slowdown in the underlying franchise, will determine whether the capex cycle was visionary or premature.

China Patent Expiry

All of Novo Nordisk’s core semaglutide products have their active ingredient patents expiring in China in 2026. Ozempic, Wegovy, Rybelsus, the entire franchise. China generated DKK 18.7 billion in FY2025 sales and was growing at 5% at constant exchange rates. Novo Nordisk’s Wegovy launch in China has barely begun, with only DKK 796 million in FY2025 revenue, meaning the obesity opportunity there is largely untapped at the moment the moat is about to be breached.

The practical impact will not be immediate. Biosimilar manufacturers need time to build commercial scale, achieve regulatory approvals, and establish distribution networks. Novo Nordisk’s brand recognition, safety data, and clinical relationships provide a buffer. But Chinese pharmaceutical companies are sophisticated, well-capitalised, and experienced in bringing biosimilars to market quickly. Several domestic companies were already preparing semaglutide biosimilars well before the patent expiry. The pricing pressure in China over the next two to three years will be significant, and the obesity market, which was supposed to be a major long-term growth driver in the world’s most populous country, will develop in a far more competitive and lower-margin environment than the one that drove the Western growth story.

The Injectable Efficacy Gap

Tirzepatide’s approximately 21% average weight loss versus semaglutide’s 15% is a real clinical difference that is influencing prescribing behaviour. Novo Nordisk held approximately 59.6% of global branded GLP-1 volume market share in FY2025, but the US prescription trend, Lilly at 57% of monthly prescriptions and rising versus Novo at 43% and falling, is the more relevant near-term signal. The direction matters as much as the level.

The honest risk here is timing. CagriSema, which matches tirzepatide’s efficacy at 22.7% weight loss, is filed for FDA approval with a decision expected around October 2026. If the approval is delayed, through an unexpected complete response letter, additional data requests, or manufacturing inspection issues, Novo Nordisk remains in the gap year for longer than projected. Every additional month without CagriSema is another month of injectable market share drifting toward Lilly, another month of compounders and prescribers defaulting to tirzepatide for new obesity patients, and another month of the narrative calcifying around Lilly as the dominant player. The business does not collapse in this scenario, but the re-rating catalyst is deferred and the share count of prescribers who have built tirzepatide habits grows.

Real-world GLP-1 Adherence, The Recurring Revenue Moat May be More Fragile Than it Appears

I described the recurring revenue nature of GLP-1 drugs as a feature of the moat, patients who stay on therapy for life generate predictable, growing cash flows. The critical assumption is that patients actually stay on therapy. The real-world data on this is sobering. First-year discontinuation rates for injectable GLP-1 drugs in real-world settings have been estimated at 40 to 50% in multiple analyses, significantly higher than the dropout rates observed in tightly controlled clinical trials.

The reasons are well-documented: gastrointestinal side effects concentrated in the dose-escalation phase, cost and coverage barriers, weight loss plateaus that disappoint patients expecting linear progress, and the practical difficulty of managing a weekly injection in daily life over years. If a meaningful share of the patients who started on Wegovy or Ozempic in the 2022 to 2024 wave have already discontinued, the installed base of recurring prescriptions is smaller than the volume data implies, and the forward revenue from that cohort is lower than a pure adherence model would project.

This dynamic also has a second-order implication for the capex cycle. If real-world adherence is significantly worse than clinical trial data suggests, the demand projections management used when authorising DKK 60 billion annual capital expenditure may have been built on an assumption that the treated population compounds reliably over time. If the population turns over faster, patients starting, stopping, and restarting, the demand profile becomes more volatile and harder to forecast accurately.

The Diabetes-obesity Paradox, long-term Structural Uncertainty

I discussed this in section 3 as a paradox rather than a risk, but at a multi-decade horizon it becomes one. If GLP-1 obesity drugs achieve the penetration rates the most optimistic projections envision, treating hundreds of millions of people globally over the next twenty years, the downstream effect on type 2 diabetes incidence will be measurable. The patients who avoid diabetes because of sustained GLP-1 treatment are patients who do not eventually need insulin, metformin, and diabetes-specific medications. Novo Nordisk’s diabetes franchise, still generating DKK 207 billion in FY2025, by far the larger segment, will face a structurally shrinking addressable market over a long enough time horizon.

I do not think this plays out as a crisis. The transition will be gradual, the diabetes franchise will continue generating strong cash flows for many years, and the obesity revenue replacing it operates at similarly high margins. But any honest long-range model for this business needs to account for the possibility that the company’s most important product is, over a long enough horizon, cannibalising the market for its second most important product line. The net effect is probably positive, obesity revenue grows faster than diabetes revenue declines, but the uncertainty is real and deserves acknowledgment.

The Verdict

Bearhold Universe Status: Watchlist

The Approved designation in the Bearhold Universe is purely qualitative. It has nothing to do with valuation, price, or near-term earnings visibility. It asks one question: has this business demonstrated, through a sufficient track record, that it can sustain excellence in its competitive arena the way the best businesses in history have? The answer determines the designation. The price determines when I act.

Novo Nordisk’s insulin franchise answers that question without hesitation, and I want to be clear about why. This is not a business that stumbled into a good decade. It is a business that built a durable competitive position over a century, through two world wars, through the transition from animal insulin to recombinant DNA technology, through the commoditisation of older molecules, through the arrival of new drug classes that threatened its core. In every one of those transitions, Novo Nordisk did not just survive. It adapted, invested, and emerged with a stronger position than it entered with. The operating margin holding between 41% and 46% across every single year from 2015 to 2025, through a global pandemic, a complete revenue mix transformation, and a manufacturing buildout of historic proportions, is the financial expression of a century of that institutional resilience. The insulin franchise is Approved, unambiguously and permanently.

The obesity franchise is where I have to be honest about what I know and what I do not yet know. And the distinction matters enormously to me, because the Approved designation is a statement about demonstrated quality, not about the quality I believe is coming.

What I know is this. Semaglutide’s clinical evidence base is exceptional. The SELECT trial reducing major adverse cardiac events by 20% in people with established cardiovascular disease. The FLOW trial reducing chronic kidney disease progression by 24%. The STEP trials producing average weight loss of 14.9%, extraordinary by any historical standard in obesity pharmacology. These are not marginal results. They are practice-changing outcomes that have permanently altered clinical guidelines across cardiology, nephrology, and obesity medicine simultaneously. The commercial execution behind these results has been equally impressive. DKK 82 billion in obesity care revenue in FY2025 from essentially nothing six years ago, with a global manufacturing buildout that represents the largest capital commitment in the company’s history. Management made the right strategic bet, made it early, and executed it at scale.

What I do not yet know is whether Novo Nordisk will dominate the obesity market the way it dominated the insulin market. And that distinction is exactly where the Watchlist designation lives.

Eli Lilly’s tirzepatide currently demonstrates superior injectable efficacy, approximately 21% average weight loss versus semaglutide’s 15% in their respective pivotal trials. That gap is real and it is influencing prescribing behaviour in measurable ways. By the third quarter of 2025, Lilly held more than 57% of US monthly GLP-1 prescriptions, having overtaken Novo Nordisk from a position of no market presence just three years earlier. That is a competitive trajectory that deserves honest acknowledgment. Novo Nordisk pioneered this market and is currently being challenged within it by a competitor with a better efficacy number in the most commercially important indication.

CagriSema is Novo Nordisk’s answer. Filed with the FDA in December 2025 with a decision expected around October 2026, it produced 22.7% weight loss in the REDEFINE 1 trial, essentially matching tirzepatide’s headline figure and doing so with a novel dual-mechanism approach combining semaglutide with a long-acting amylin analogue. If CagriSema is approved and demonstrates competitive real-world efficacy, it closes the injectable gap before Lilly’s next-generation retatrutide reaches market. The pipeline response is credible. But it is a promise, not yet a result. And the Approved designation requires results.

The oral market is equally unresolved. On April 1, 2026, twelve days before this report was published, the FDA approved Eli Lilly’s orforglipron, now branded Foundayo, as the second oral GLP-1 pill for obesity. The ORION indirect comparison data, presented the following day, suggests the Wegovy pill has meaningful advantages in both efficacy and tolerability. Patients on orforglipron showed approximately four times higher odds of discontinuing due to adverse events and nearly fourteen times higher odds of discontinuing specifically due to gastrointestinal side effects. These are striking numbers and they support a compelling narrative for the Wegovy pill’s commercial position. But this is an indirect comparison across separate trials, funded and presented by Novo Nordisk, with wide confidence intervals and no head-to-head trial to settle the question definitively. The oral market battle between these two drugs will play out in real prescriptions over the next twelve to eighteen months, and those real-world results are what the quality assessment requires, not an indirect comparison published the day after a competitor’s approval.

This is what the Watchlist is designed to capture. The insulin franchise is proven. The obesity franchise is promising, credibly positioned, and backed by a pipeline that could decisively establish Novo Nordisk’s leadership in the new competitive arena. But the competitive outcome has not yet been determined. The prescription share trajectory, the CagriSema approval and launch, and the oral market real-world data will together tell the story that the insulin franchise told over decades, except compressed into the next two to three years because the competitive intensity demands it.

The specific triggers that would move Novo Nordisk from Watchlist to Approved are these. CagriSema receiving FDA approval and demonstrating competitive or superior real-world efficacy versus tirzepatide in its first year of commercial prescription data. And the oral market prescription trends confirming over at least two to three quarters that the Wegovy pill’s tolerability advantage holds in actual patient behaviour, that patients are staying on it longer and discontinuing less than Foundayo in the real world, not just in an indirect trial comparison. When those two conditions are met, the obesity franchise will have earned the track record the designation requires. It will have demonstrated that Novo Nordisk can do in obesity what it did in insulin, build a leadership position and defend it against serious competition through product quality, not just first-mover advantage.

At $37.50 and 17 years of embedded cash flows, the price sits in the Attractive zone of the Bearhold valuation framework. The business I have described in this report is exceptional. The near-term headwinds, negative 2026 guidance, China patent expiry, the capex cycle compressing free cash flow, the CEO transition, are all real and all visible in the numbers. None of them concern me as a long-term investor. What keeps Novo Nordisk on the Watchlist rather than in the Approved column is not weakness. It is the honest acknowledgment that the most important competitive chapter of this company’s modern history is being written right now, in real time, with the outcome still genuinely uncertain. I will be watching that chapter closely. And when the evidence confirms what the insulin franchise already demonstrated about this company’s ability to build and defend category leadership, the designation will change.

This report reflects the author’s personal views and does not constitute investment advice. Investing carries the risk of permanent capital loss. The author held a position in NVO during the research process and exited prior to publication. No position is held at the time of publishing. Read the full disclaimer here

Sources:

Novo Nordisk Annual Report FY2025 (DKK)

Novo Nordisk Annual Report FY2024;

FDA Declaratory Order on semaglutide shortage, February 21, 2025;

Novo Nordisk NDA filing for CagriSema, December 18, 2025; REDEFINE 1 and REDEFINE 2 Phase 3 trial data;

SELECT cardiovascular outcomes trial;

FLOW kidney disease trial;

ORION indirect treatment comparison, Obesity Medicine Association 2026, April 10–12, San Diego;

OPTIC patient preference study, Novo Nordisk, October–November 2025;

FDA approval of Foundayo (orforglipron), April 1, 2026;

White House TrumpRx / MFN pricing announcement, November 2025;

Trump Administration pharmaceutical tariff Executive Order, April 2026;

Morningstar GLP-1 market analysis, December 2025;

J.P. Morgan GLP-1 market projections, 2026.

There is a line in Accenture’s FY2025 annual report that I keep returning to. It appears in the section about AI adoption among enterprise clients, and it reads with the kind of candour that large companies rarely commit to print. The gap between AI mindshare and actual adoption, the company writes, exists because “the enterprise reinvention required to truly unlock the value of advanced AI is hard and has significant costs.” They go on to note that data preparedness is nascent, organisations are siloed, cloud and ERP modernisation is still incomplete, and workforces lack the skills to operate in an AI-enabled environment.

This is Accenture explaining, in its own annual report, exactly why its clients need Accenture.

And here is the paradox at the centre of the most important question in enterprise technology right now: is AI the thing that makes Accenture indispensable, or is it the thing that eventually makes Accenture unnecessary? I do not think the answer is simple. I think it is one of the most genuinely complex questions in business strategy today, and I want to work through it honestly rather than offer the comfortable narrative that Accenture’s investor relations team would prefer.

What Accenture Actually is?

Before discussing AI’s impact, it is worth being precise about what Accenture actually sells. It is not a technology company. It is not a software company. It is the world’s largest professional services firm, a business that sells human expertise, at scale, to the world’s largest organisations. Its 779,000 employees generated $69.7 billion in revenue in FY2025. That revenue splits almost exactly in half between consulting, project-based work advising clients on strategy, technology implementation, and transformation, and managed services, longer-term contracts where Accenture runs operations, maintains systems, and manages processes on behalf of clients.

The consulting half is what most people think of when they think of Accenture: teams of analysts and consultants deployed to client sites to deliver projects. The managed services half is less visible but more financially durable, multi-year contracts with meaningful termination costs that convert to revenue slowly and predictably. The consulting business grew 5% in local currency in FY2025. The managed services business grew 9%. That divergence is not an accident, and it is central to understanding how AI will affect this company.

The Surface Narrative, and Why it is Wrong in Both Directions

There are two simple narratives about AI and Accenture, and I think both are wrong.

The first is the bull narrative: AI creates enormous demand for implementation, change management, and enterprise transformation work. Clients need help deploying AI safely and at scale. Accenture is the partner they turn to. GenAI (generative AI) bookings reached $5.9 billion in FY2025, nearly doubled from the prior year. Revenue from generative AI and agentic AI reached $2.7 billion, tripling year-over-year. The company has 77,000 AI and data professionals, up from 40,000 in FY2023. It has trained over 550,000 of its employees in generative AI fundamentals. This is a company that positioned itself early, invested $3 billion in AI capability beginning in FY2023, and is now capturing the implementation wave. The AI opportunity is additive, not destructive.

The second is the bear narrative: AI automates exactly what junior consultants do. Writing code, analysing data, producing presentations, drafting documents, summarising research, building financial models, all of these tasks are being compressed by AI tools that any client can buy for $20 per user per month. The pyramid model that underlies Accenture’s economics, many juniors supporting fewer seniors, with juniors doing the volume work and seniors doing the judgment work, collapses when AI does the junior work. Revenue per engagement compresses. Headcount requirements fall. The business model is structurally impaired.

Both narratives capture something real. Neither captures the full picture.

The Pyramid Problem, This is the Real Risk

Let me start with the bear case because I think it is more structurally important than the bull case, even though the bull case is more visible in the near-term numbers.

Accenture’s operating model is built on a leverage pyramid. A small number of senior partners and managing directors sell and oversee client relationships. A larger number of managers and senior analysts do the intellectual work, designing solutions, leading workstreams, managing client relationships day-to-day. And a very large base of junior analysts and associates does the volume work, building models, writing code, conducting research, producing deliverables. This pyramid works economically because the juniors are relatively cheap, they generate billable hours that the senior layer monetises at a premium, and the pyramid widens at the base as the firm grows.

AI directly compresses the base of this pyramid. A junior analyst who previously spent three days building a financial model can now produce the same output in three hours with AI assistance. A developer who previously wrote 200 lines of code per day can write 800 lines with an AI coding assistant. A research team that previously spent two weeks analysing industry data can complete the same analysis in two days with AI-powered synthesis tools. These are not hypothetical capabilities — they are tools that Accenture’s own clients are deploying right now, and that Accenture’s own employees are using internally.

The implications for the business model are significant. If junior labour is three to four times more productive with AI, you need three to four times fewer juniors to deliver the same volume of work. That is not a problem if revenue grows proportionally, if the addressable market expands fast enough to absorb the productivity gain. But it is a fundamental structural problem if clients start asking why they should pay for 20 junior consultants when 5 can now deliver the same output. The answer, “because we have 779,000 people and can deploy them globally”, becomes less compelling when the leverage comes from AI rather than headcount.

The financial evidence of this tension is already visible, though subtle. Accenture’s gross margin fell to 31.9% in FY2025 from 32.6% in FY2024. The company attributed this to higher payroll costs. But the more revealing data point is the headcount reduction the company initiated in FY2025, $344 million in severance charges for “headcount reductions we are making in a compressed timeline.” A company that is simultaneously tripling its AI revenue and cutting headcount in a compressed timeline is not just managing capacity. It is restructuring its delivery pyramid in real time.

The Managed Services Moat

Here is where I think the bear narrative goes too far. It focuses almost entirely on the consulting business and largely ignores the managed services business, which is both larger and structurally different in ways that make it far more resistant to AI disruption.

Managed services, the $34.6 billion half of Accenture’s business, are long-term contracts where Accenture runs operations on behalf of clients. Application maintenance, infrastructure management, business process outsourcing, security operations. These contracts typically run three to five years with significant termination costs. They are based on outcome commitments, Accenture guarantees certain service levels, response times, and cost savings, rather than on the hourly billing of consultant time.

This is critically important. A client who has outsourced their SAP environment, their finance operations, or their cybersecurity monitoring to Accenture on a five-year contract does not reduce their payments because AI makes Accenture’s delivery team more efficient. Accenture captures the productivity gain from AI as margin expansion rather than passing it through as price reductions. The economics of managed services actually improve with AI, the same service level can be delivered with fewer people at lower internal cost, while the contractual revenue remains fixed.

This is the opposite dynamic from the consulting business, where clients can and will renegotiate based on observed productivity improvements. In managed services, the productivity gain is Accenture’s to keep. And the managed services business grew 9% in FY2025, faster than consulting at 5%, suggesting that clients are moving more work into this format precisely because they want to lock in AI-enabled efficiency gains without managing the complexity themselves.

The Agentic AI Moment

There is a dimension of the AI story that I think deserves specific attention because it is moving faster than most investors appreciate. Agentic AI, AI systems that can take autonomous actions, chain multiple tasks together, and operate continuously without human intervention, is beginning to change what enterprise AI deployment looks like.

Accenture describes deploying agentic AI systems that can “reinvent core business operations, streamline workflows and boost agility.” A client referenced in the annual report is deploying a system with 90 agents and 3,000-plus employees working alongside them. This is not a productivity tool layered on top of an existing workflow. It is a fundamental redesign of how work gets done, with AI agents operating in parallel with humans rather than simply assisting them.

For Accenture, agentic AI is both an opportunity and an existential question. The opportunity is that designing, deploying, and managing multi-agent systems at enterprise scale is genuinely complex work that requires deep expertise in AI architecture, change management, and process redesign, exactly the kind of work Accenture sells. The existential question is whether the agents themselves eventually replace the consultants who deployed them. An agentic system that automates a business process does not need to be maintained by a team of consultants indefinitely, it runs. The deployment engagement generates one-time revenue. The ongoing advisory relationship it displaces was recurring revenue.

This is the deepest tension in Accenture’s AI story. It is selling the tools that, if fully successful, reduce the long-term demand for its core product. Every enterprise AI transformation it helps a client achieve makes that client slightly less dependent on Accenture. The most successful consulting relationship is one that eventually makes itself unnecessary, and AI is accelerating that timeline.

The $5.9 Billion Number

Accenture reported $5.9 billion in generative AI bookings in FY2025 and $2.7 billion in generative AI revenue. These numbers are cited prominently in the annual report and in every investor communication. They are real, they are growing fast, and they tell you something important: clients are paying Accenture to help them deploy AI.

But the annual report contains a parenthetical that most analysts gloss over. These numbers, Accenture notes, “reflect only revenue and bookings specifically related to advanced AI and do not include data, classical AI or AI used in delivery of our services.” In other words, the $2.7 billion is a narrow slice of AI-related activity, specifically defined to exclude AI that Accenture uses internally to deliver its services more efficiently.

This matters because the most transformative AI happening inside Accenture right now is not the $2.7 billion, it is the AI that its own consultants and engineers are using daily to do their jobs faster. That AI does not show up in the headline AI revenue figure. It shows up in the gross margin compression, the headcount restructuring, and the quiet redesign of delivery pyramids that is happening across every large professional services firm simultaneously.

The $5.9 billion in generative AI bookings is the revenue opportunity. The pyramid restructuring is the cost reality. The net effect of both determines whether AI is a net positive or net negative for Accenture’s long-term economics.

My Honest Assessment

I think Accenture navigates the near-term AI transition better than most investors expect and worse than the company’s own narrative implies.

Better than expected because the managed services business, which now represents 50% of revenue and is growing faster than consulting, is structurally insulated from AI-driven price compression in ways that the consulting business is not. The long-term contractual nature of managed services means Accenture captures AI productivity gains as margin rather than passing them through as price cuts. This is a meaningful and durable economic advantage that the bear case on Accenture’s business model largely ignores.

Worse than the company’s narrative implies because the consulting business is facing a genuine structural challenge that cannot be resolved by rebranding it as AI-enabled transformation work. Clients who are becoming more sophisticated about AI, who are building internal capabilities, hiring their own AI teams, and deploying their own tools, will increasingly ask whether they need a 20-person Accenture consulting team or whether three of their own people with AI tools can deliver comparable output. That question gets harder to answer in Accenture’s favour with each passing year as AI tools improve.

The most honest summary is this: Accenture is one of the most capable organisations on earth at helping large companies navigate technology transitions. It has done this successfully through the internet era, the cloud era, and the mobile era. Each transition generated significant consulting revenue as clients needed help adapting. Each transition also eventually reduced the long-term demand for certain types of advisory work as the new technology became standard.

AI is the same pattern, but faster and more fundamental. Will the business emerge from the AI transition as large, as profitable, and as structurally advantaged as the one that entered it. On that question, I am genuinely uncertain. The managed services business argues yes. The consulting pyramid economics argue no. And the agentic AI dynamic, where Accenture’s most successful work makes its clients less dependent on it, introduces a long-term structural headwind that has no easy resolution.

For investors, the honest framing is not whether Accenture is a good business, it clearly is. It is whether the current price adequately reflects the structural uncertainty of a 779,000-person consulting firm navigating a technology transition that is, by its own admission, compressing the economics of the very work that built it.

That question deserves its own valuation analysis. But the starting point for that analysis has to be honest about what AI does to the consulting pyramid, not just what it does for the AI bookings number.

This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

There is a number that appears in almost every corporate earnings release, every leveraged buyout pitch, every bank credit memo, and almost every discussion of whether a company is financially healthy.

That number is EBITDA, Earnings Before Interest, Taxes, Depreciation, and Amortisation.

And in my view, it is one of the most overused and most misleading metrics in corporate finance.

This is not a fringe opinion. Charlie Munger once called EBITDA “Bullsh*t earnings.” Warren Buffett has spent decades explaining why depreciation is a very real cost that management teams conveniently prefer to ignore. But despite those warnings, EBITDA remains the dominant lens through which banks assess a company’s ability to repay debt, and the dominant shorthand through which analysts compare businesses.

The better alternative, Operating Cash Flow, sits right there in every set of financial statements, far more revealing, far harder to manipulate, and almost universally ignored in favour of the number that makes everything look bigger.

Here is why that matters, and why as a long-term investor, you should train yourself to reach past EBITDA every time.

What EBITDA Actually Is

EBITDA starts with net income and adds back four things: interest expense, tax expense, depreciation, and amortisation. The resulting number is supposed to represent a company’s core operating earnings, what the business generates before the effects of how it is financed, how it is taxed, and how its assets wear out over time.

The logic behind the addbacks seems reasonable on the surface. Interest expense varies depending on how much debt a company carries, strip it out so you can compare businesses with different capital structures. Tax rates vary by jurisdiction, strip those out too. Depreciation and amortisation are non-cash charges, add them back because no cash actually left the building when the accountant recorded them.

The problem is that the moment you reconstruct EBITDA in your mind, you realise it lives entirely in the income statement. It is built from revenue and expenses as recognised by the company’s accountants, not from cash that actually moved. And that distinction, which seems technical, turns out to be enormous in practice.

What Operating Cash Flow Actually Is

Operating Cash Flow (OCF) starts in a completely different place. It begins with net income and then adjusts for everything that happened between the income statement and the company’s actual bank account.

The most important adjustments are the working capital movements: things like changes in accounts receivable (money owed to the company by customers), inventory (goods sitting in a warehouse waiting to be sold), and accounts payable (money the company owes to its suppliers).

These three items represent the business cycle in brief, the lag between when revenue is recognised on the income statement and when cash actually arrives, and the lag between when expenses are recognised and when they are actually paid.

A company that books $100M in revenue but has not yet collected any of it has a wonderful income statement and an empty bank account. OCF captures that reality. EBITDA does not.

Why EBITDA Is Almost Always Higher

Here is a mechanical truth that most financial commentary glosses over: in most businesses, in most years, EBITDA will be higher than Operating Cash Flow. Sometimes significantly higher.

The reasons are structural. Working capital typically consumes cash as a business grows, receivables and inventory expand as sales increase, and this cash outflow never touches the income statement. Meanwhile, depreciation and amortisation, which were added back to create EBITDA, represent real economic consumption of the asset base that will eventually require real cash to replace. A piece of machinery that depreciates over ten years does not magically regenerate itself at the end of year ten. The cash to replace it has to come from somewhere.

When you add back depreciation to create EBITDA and then use that number to assess a company’s financial health, you are implicitly claiming that the machinery doesn’t need replacing. Every manufacturing company knows that is not true.

The Manipulation Problem

EBITDA is not just theoretically imprecise. It is also practically easy to inflate.

The most straightforward manipulation is recognising revenue aggressively. A company can book a sale the moment goods leave the warehouse, even if the customer hasn’t paid or won’t pay for six months. That revenue flows directly into EBITDA. It does not flow into Operating Cash Flow, where the receivables balance would swell visibly and alert any attentive analyst that something is off.

This is not a hypothetical risk. It is one of the most common patterns in corporate fraud.

Sunbeam, the American appliance manufacturer, provides a textbook case. In the late 1990s, CEO Al Dunlap, known as “Chainsaw Al”, drove reported earnings higher by selling products to retailers at heavily discounted prices with generous return rights, recognising the revenue immediately. EBITDA looked healthy. Operating Cash Flow told a very different story, the company was consuming cash at an alarming rate as receivables ballooned. Sunbeam filed for bankruptcy in 2001.

Closer to the present, many highly leveraged companies that appeared financially manageable through the EBITDA lens, revealed their true fragility when interest rates rose and their working capital cycles deteriorated. The income statement said they were profitable. The cash flow statement said they were running dry.

Why Banks Use EBITDA Anyway

If EBITDA is so flawed, why does almost every bank in the world use it as the primary measure of debt capacity?

The answer is partly historical, partly structural, and partly, I will be direct, because it serves the bank’s commercial interests.

Historically, EBITDA became the standard in leveraged finance during the 1980s leveraged buyout boom. Dealmakers needed a metric that could justify higher debt levels on acquisitions, and EBITDA, which ignores working capital movements, strips out the cost of replacing assets, and excludes the interest expense on the very debt being assessed, produced the highest possible number. It became institutionalised.

Structurally, the banking system adopted it so broadly that any single bank switching to OCF-based underwriting would be at a competitive disadvantage, they would approve smaller loans than their peers, lose deals, and see revenue decline. The incentive to use the more conservative metric is weak when competitors are not.

And then there is the commercial reality: a higher EBITDA justifies a larger loan. A larger loan generates more fee income, more interest income, and a bigger balance sheet. There is a direct financial incentive for the banking system to use the metric that produces the highest debt capacity, and EBITDA is that metric.

I spent fifteen years in institutional finance. I have sat in credit committees where the EBITDA multiple was the headline figure and the cash flow statement was barely discussed. This is not a theoretical observation, it is a standard practice.

What to Use Instead

Operating Cash Flow is not perfect either. It can be managed through timing of receivables collections, stretching of payables, and opportunistic working capital draws before year-end. A skilled CFO can compress the working capital cycle in the fourth quarter to produce a better-looking OCF number than the underlying trend warrants.

But the manipulation is harder, the signals are clearer, and the number is fundamentally more honest because it reflects cash that actually moved.

For assessing a company’s debt capacity, OCF minus maintenance capex, what some call Owner Earnings or Free Cash Flow, is the most relevant figure. It represents what the business actually generated after keeping the existing asset base functional. That is what is available to service debt, pay dividends, fund growth, or return to shareholders. EBITDA does not answer that question cleanly. FCF does.

For comparing profitability across businesses, operating margin, operating income as a percentage of revenue, is a more reliable starting point than EBITDA margin, because operating income includes depreciation and therefore acknowledges the cost of the assets generating the revenue.

The Investor’s Takeaway

When I look at a business, I use EBITDA as a starting point at most, a rough orientation before I do the real work. The questions that matter to me are:

How does Operating Cash Flow compare to EBITDA? If the gap is consistently large, I want to understand why. A large and growing gap is often the first sign that something is wrong in the working capital cycle.

Is FCF growing alongside revenue, or is the business consuming more cash as it scales? A business that grows revenue but consistently burns cash is not compounding, it is borrowing against the future.

What is the capex-to-OCF ratio, and how much of capex is maintenance versus growth? Maintenance capex is not optional. It should never be ignored when assessing a business’s true earning power.

EBITDA will tell you what a company wants you to think about its earnings. Operating Cash Flow will tell you what is actually happening.

The Outlook

There is a condition that affects nearly one billion people on earth. Most of them don’t know they have it. Their doctors haven’t diagnosed it. Their partners have complained about the snoring, the gasping, the restless sleep, but the link to a treatable medical condition has never been made. Obstructive sleep apnea, or OSA, is one of the most prevalent and undertreated chronic conditions in modern medicine, and ResMed has spent thirty years quietly building the most comprehensive platform for diagnosing, treating, and managing it.

This is not a story about a niche medical device company. It is a story about a platform business with thirty million cloud-connected patients, a proprietary data advantage that compounds with every device sold, and a software layer that makes it operationally difficult for the healthcare providers who use it to switch to anyone else. The hardware is just the door into the ecosystem.

Revenue has grown at 11.9% annually for a decade. Operating margins have expanded from 24% to 33%. Free cash flow has increased more than fivefold. And yet fewer than 20% of the people who need this product have ever received it.

The stock is not cheap. At 23 years of embedded cash flows, ResMed sits in the Hold zone of the Bearhold valuation framework, a fair price for a business of exceptional quality. I am not buying here. But I am watching, and this report explains exactly what I am waiting for.

At a Glance

Company: ResMed Inc.

Ticker: $RMD · NYSE

Sector: Healthcare

Industry: Medical Devices & Instruments

Market Cap: $32.65 billion (at $224)

Dividend Yield: ~0.95% ($2.12 per share, FY2025)

Status: Approved, Bearhold Universe

First Coverage: April 2026

Valuation Zone: Hold (last updated April 2026)

Disclaimer: This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

The author does not currently hold a position in $RMD at the time of publication.

1. The Business

What the Company Does

ResMed makes the devices and software that treat sleep-disordered breathing. The flagship products are CPAP (Continuous Positive Airway Pressure) and APAP (Automatic Positive Airway Pressure) machines, compact bedside devices that deliver pressurised air through a mask while the patient sleeps, keeping the airway open and eliminating the breathing disruptions that cause OSA. The condition, if left untreated, is associated with hypertension, stroke, type 2 diabetes, and coronary artery disease, which is why the clinical community increasingly treats it as a cardiovascular risk factor, not just a sleep nuisance.

Revenue breaks down into three streams: devices at approximately 52% of the total, masks and accessories at 36%, and Residential Care Software at 12%. The structure matters. Devices are event-driven, a patient buys one at diagnosis and replaces it every few years. Masks are recurring, replaced every three to six months for as long as the patient stays on therapy. Software is subscription-based. The combination produces a revenue profile far more stable than a pure device company, with the recurring mask and software streams anchoring the base even in softer device years.

How the Business Was Built

ResMed traces its origins to June 1989, when Dr. Peter Farrell founded the company, originally called ResCare, in Sydney, Australia, to commercialise nasal CPAP technology invented by Professor Colin Sullivan at the University of Sydney in 1981. Baxter Healthcare had licensed the technology and then decided not to pursue it. Farrell recognised what Baxter had missed.

ResMed Inc. was incorporated in Delaware in March 1994 and went public on June 1, 1995, trading on NASDAQ. The company moved its primary listing to the New York Stock Exchange in September 1999.

For its first two decades, ResMed was a device company that grew by making better CPAP machines and expanding geographically. The inflection came around 2014, when the company began embedding cellular connectivity into devices as standard, a decision that looks obvious in hindsight but required genuine conviction at the time. Connected devices enabled remote monitoring at scale. Clinicians could adjust therapy settings without requiring patients to return to a clinic. And every connected patient became a source of real-world clinical data. That data now feeds the machine learning algorithms that make each new device generation smarter than the last. Today, ResMed manages over 30 million cloud-connected patients through its AirView platform, with more than 10 million active on myAir, the patient-facing therapy management app.

The flywheel is real: more patients generate more data, which improves therapy outcomes, which attracts more patients and more providers into the ecosystem.

The Philips Recall, and What Actually Happened

In June 2021, Philips issued a recall of millions of CPAP, bilevel, and ventilator devices after discovering that the polyester-based sound abatement foam inside the machines was degrading and potentially releasing particles and gases into the patient’s airway. It was a significant product safety failure that triggered multi-billion euro legal settlements and years of operational disruption for Philips.

ResMed was the only large-scale alternative with the manufacturing capacity to absorb displaced patients quickly. The impact on ResMed’s numbers was real but more targeted than widely reported. Overall revenue growth remained broadly consistent with historical trends. The visible surge was concentrated in the US, Canada, and Latin America device segment specifically, where device revenue grew approximately 24% in FY2022 and approximately 35% in FY2023, compared with around 9% in the year before the recall. By FY2024, device growth in that segment had normalised to approximately 11%, and FY2025 came in at 9.8% for total revenue, a return to the underlying demand trajectory. The recall pulled forward some volume and concentrated it geographically, but the business was not propped up by it.

Scale

ResMed employs more than 10,600 people across more than 140 countries. The US, Canada, and Latin America generate approximately 58% of Sleep and Breathing Health revenue. Combined Europe, Asia, and other markets contribute approximately 29%. Residential Care Software, sold only in the US and Germany, rounds out the remaining 12%. Manufacturing is split across Australia, Singapore, and the US, with the company running an active foreign currency hedging programme to manage the exposure this creates.

2. The Moat

Four Walls, One Ecosystem

ResMed’s competitive position is not a single advantage, it is four advantages that reinforce each other.

The first is clinical data. ResMed has more real-world sleep therapy data than any organisation on earth. Thirty million cloud-connected patients generate continuous information, therapy compliance, apnea-hypopnea index, mask leak, breathing patterns. This data feeds the algorithms that make the AirSense 11, and whatever comes after it, progressively more effective. A competitor launching a CPAP device today faces not just a product quality gap but a data gap that will take years to close.

The second is the installed base and the recurring revenue attached to it. Thirty million active patients buying masks every three to six months is a durable annuity that does not depend on the next product launch. Patients who have established a functioning therapy routine are unlikely to switch ecosystems.

The third is the software layer. Brightree, the leading home medical equipment (HME) software platform in the US, and MEDIFOX DAN in Germany are deeply integrated into the administrative and clinical workflows of thousands of care providers. These platforms are not standalone software businesses, they are the connective tissue between device sales and the care delivery system. When a provider uses Brightree to manage billing, patient records, and inventory, switching to a competitor means disrupting those workflows entirely. That is a meaningful switching cost that goes well beyond product preference.

The fourth is regulatory and clinical credibility. ResMed’s devices are approved across virtually every major regulatory jurisdiction globally, supported by decades of peer-reviewed clinical evidence. New entrants face not just a commercial challenge but a multi-year regulatory validation process. That is a barrier that does not exist in consumer device categories.

The Wearables Tailwind

An often overlooked accelerant is the integration of OSA detection into consumer wearables. Apple Watch and Samsung Galaxy Watch now feature FDA (US Food and Drug Administration)-cleared breathing disturbance detection. These devices are identifying undiagnosed OSA patients at population scale and nudging them toward clinical care. ResMed has positioned itself as the natural destination for that flow, its myAir app integrates directly with Apple Health and Samsung Health, and CEO Mick Farrell has explicitly described the consumer wearables ecosystem as building the company’s “data lake.” The most powerful referral engine ResMed could imagine is a device worn by hundreds of millions of people, many of whom don’t yet know they need a CPAP machine.

The Numbers Don’t Lie

The financial record is the most reliable evidence of a moat. ResMed’s operating margin expanded from 24.4% in FY2015 to 32.8% in FY2025. ROIC (Return on Invested Capital) averaged 18.9% over the decade, well above the estimated cost of capital throughout. A business losing competitive position does not do that while tripling its revenue.

The comparison with Philips makes the point most cleanly. Before the recall, Philips operated at approximately 8% operating margin in its health technology division, a level ResMed was already far above and moving away from. After the recall, Philips fell into losses in 2022 and 2023. By 2025, it had only recovered back to that same 8% baseline. Over the same period, ResMed’s operating margin continued to expand. Two companies nominally competing in the same market, on very different structural trajectories.

3. Financial Performance

A Decade in Numbers

Revenue grew from $1.68 billion in FY2015 to $5.15 billion in FY2025, an 11.9% compound annual growth rate (CAGR) over ten years. That growth was primarily organic. Two meaningful acquisitions, the Brightree HME software business in FY2016 and MEDIFOX DAN in FY2023, added inorganic revenue, but the underlying Sleep and Breathing Health segment has compounded consistently without acquisition support.

Operating margin expanded from 24.4% to 32.8%, with a ten-year average of 26.5%. Gross margin averaged 57.6% across the decade, reflecting the premium positioning of ResMed’s clinical products relative to commodity device alternatives. Net margin in FY2025 reached 27.2%, up from 21.0% in FY2015, aided in part by a below-trend effective tax rate of 16.5% due to one-time items, a level that should not be assumed to repeat.

Diluted EPS (Earnings Per Share) grew from $2.47 in FY2015 to $9.51 in FY2025, a 14.4% CAGR. The share count has been essentially stable over this period, rising only 3.2% from 142.7 million to 147.3 million diluted shares. EPS growth here reflects genuine business improvement rather than financial engineering.

ROIC averaged 18.9% over the decade and reached 23.3% in FY2025. In every year of the available record, ResMed earned returns materially above its estimated cost of capital, a consistency that is more impressive than any single-year figure.

Free Cash Flow, the Real Story

Free cash flow (FCF) grew from $311M in FY2015 to $1,651M in FY2025, a 5.3x increase at an 18.2% CAGR. There was one significant dip: FY2022, when FCF collapsed to $195M despite strong revenue. The cause was working capital. The Philips recall demand surge required ResMed to draw down inventories and then rapidly rebuild them, creating a large transient cash outflow. Simultaneously, an elevated FY2021 effective tax rate of 46.3%, driven by a one-time $200M charge related to pre-acquisition earnings, further compressed cash in that period. Both were temporary. FCF recovered to $559M in FY2023, $1,286M in FY2024, and $1,651M in FY2025.

The FCF margin of 32.1% in FY2025 is the highest in the company’s history. Capex (capital expenditure) as a percentage of operating cash flow has fallen from 19% in FY2015 to just 6% in FY2025, reflecting the asset-light nature of a platform built primarily on software, data, and intellectual property rather than physical infrastructure.

Balance Sheet

Cash and equivalents stood at $1.21 billion at June 30, 2025, against total debt of approximately $670M, producing a net cash position of roughly $540M. Debt-to-equity has improved dramatically from the 0.38 reading in FY2023 (following the MEDIFOX DAN acquisition) to 0.14 at year-end FY2025. The revolving credit facility of $1.5 billion remains fully undrawn, maturing in 2027.

One genuine weakness worth naming: goodwill of $3.05 billion represents approximately 37% of total assets. This reflects the accumulated premium paid for acquisitions, primarily Brightree, Propeller Health, and MEDIFOX DAN. Tangible book value per share is substantially lower than reported book value. The intrinsic value of this business rests almost entirely on intangible assets, data, software, clinical relationships, regulatory approvals. That is a strength when the business performs and an accounting vulnerability if any major acquisition disappoints.

ResMed also pays a dividend of $2.12 per share in FY2025, representing a yield of approximately 0.95% at the current price, a signal of financial maturity that has grown steadily from $1.12 per share a decade ago.

4. Growth Levers

The Diagnosis Gap, the Single Biggest Lever

Here is the most important number in this entire report: fewer than 20% of OSA sufferers in the United States have been diagnosed and treated. In most international markets, the figure is closer to 10%.

ResMed does not need to take market share from anyone. It just needs the healthcare system to get better at finding the patients who already exist. Every percentage point improvement in diagnosis rates represents millions of people entering a care pathway that runs directly through ResMed’s ecosystem. This is the kind of structural growth driver that does not require macroeconomic tailwinds, product cycles, or competitive displacements. It just requires time.

ResMed is actively investing to accelerate this. NightOwl, a portable, cloud-connected, fully disposable diagnostic device that measures OSA severity overnight without requiring a clinic visit, launched across the US in April 2025. The acquisition of VirtuOx, an independent diagnostic testing facility, in May 2025 further expands the company’s ability to bring diagnosis into the home. The goal is to compress the traditional pathway, specialist referral, sleep lab, equipment pickup, device initiation, into something much closer to a single session at home.

International Penetration, COPD, and Software

The international opportunity mirrors the domestic one, large, underpenetrated, and growing as clinical awareness spreads and reimbursement coverage expands. International Sleep and Breathing Health revenue grew 9% in FY2025, and this segment operates at a fraction of US penetration levels across most geographies.

COPD (Chronic Obstructive Pulmonary Disease) affects approximately 480 million people globally and is the world’s third leading cause of death. ResMed’s non-invasive ventilation (NIV) and high-flow therapy (HFT) products for COPD patients represent a growing segment that the revenue breakdown does not currently call out separately, but it is a meaningful adjacency that deepens the platform’s clinical reach beyond sleep.

Residential Care Software, currently sold only in the US and Germany, grew 10% in FY2025 to $641M. Geographic expansion of this segment is a medium-term option that has not yet been exercised.

5. Management

The Farrell Family and Long-Term Alignment

ResMed is, at its core, a founder-influenced business. Dr. Peter Farrell built ResCare from a single licensed technology in Sydney in 1989 and steered it to become the global leader in sleep therapy. His son Mick Farrell has served as CEO since 2013, presiding over the company’s transformation from a device manufacturer into a connected care platform.

The family maintains meaningful skin in the game. Mick Farrell holds approximately 0.32% of outstanding shares, valued at roughly $105M at current prices. Dr. Peter Farrell, as founder and board director, directly owns a further 60,773 shares. While institutional investors including Vanguard and BlackRock collectively own the majority of the company, the Farrell family’s retained ownership signals genuine long-term conviction rather than founders who cashed out at the earliest opportunity.

Mick Farrell’s compensation structure reinforces that alignment. Approximately 91-92% of his total pay is performance-based, stock awards and options tied to specific financial metrics including revenue growth and EPS. Base salary accounts for only about 8% of total compensation. This is the kind of structure I look for in management: the CEO is economically motivated by the same outcomes that matter to long-term shareholders.

His communication style has been consistently direct on difficult topics. When the GLP-1 (glucagon-like peptide-1) panic hit in mid-2023 and ResMed’s stock fell more than 30%, Farrell engaged with the clinical evidence head-on rather than deflecting. He presented ResMed’s own patient data on GLP-1 users, made the probability-weighted case for ongoing demand, and continued investing in the business rather than cutting costs to manage short-term numbers. That is the kind of management behaviour that matters over a full market cycle.

Capital Allocation

R&D (Research and Development) spending of $331M in FY2025, representing 6.4% of revenue, has been sustained consistently across the decade. This is the right posture for a business whose competitive position depends on staying ahead clinically and technically.

On acquisitions, the track record is mixed but acceptable. Brightree has been clearly value-creating, it transformed ResMed from a device company into a platform company with deep provider relationships. The MEDIFOX DAN acquisition at approximately EUR 975M in FY2023 is too early to assess definitively, though integration appears to be progressing. The Propeller Health acquisition in FY2019 at $225M has been harder to evaluate but is smaller in scale.

Shareholder returns have grown steadily: dividends increased from $1.12 to $2.12 per share over the decade, and buybacks of $300M were executed in FY2025. Together with dividends, that represents approximately 37% of FCF returned to shareholders, the remainder retained for investment. I find that balance reasonable given the available organic growth runway.

6. Valuation

What the Market Is Pricing In

At $224 per share, I estimate the market is pricing ResMed at approximately 23 years of discounted future cash flows. My valuation framework expresses price as the number of years of a company’s future cash flows, discounted at an appropriate rate, that are already embedded in today’s price. The assumptions I use are consistent with the company’s current and historical operating performance. Nothing heroic, nothing pessimistic.

23 years puts ResMed in the Hold zone.

To be direct about what that means for me: I don’t initiate new positions in the Hold zone. The Bearhold framework is built around the idea that when you are buying a stake in a business, you want the price working in your favour, not just the fundamentals. The Attractive zone (16–20 years) and the Exceptionally Attractive zone (below 15 years) are where I look to deploy capital. At those levels, the price embeds significantly less of the company’s future than the business’s quality justifies, and an investor captures both the fundamental compounding and the valuation correction as it plays out.

At 23 years, I am essentially paying a fair price for quality I can see clearly. The fundamentals of this business are genuinely exceptional, but there is limited margin of safety in the entry price. Every dollar of return has to be earned through the business’s ongoing performance, there is no valuation tailwind to help.

What I Am Waiting For

ResMed becomes interesting to me as a new position somewhere in the Attractive and the Exceptionally Attractive zones. That does not happen often for businesses of this quality. It tends to happen when the market becomes temporarily preoccupied with a specific risk, a GLP-1 study result, a reimbursement cut, an earnings miss driven by inventory timing, and the stock reprices faster than the underlying business warrants.

7. Risks

The GLP-1 Question

Since mid-2023, the dominant narrative around ResMed has been the GLP-1 risk. Glucagon-like peptide-1 agonist drugs, Ozempic, Wegovy, Zepbound and others, cause significant weight loss in a meaningful proportion of users, and obesity is a primary driver of OSA in a large patient population. If these drugs reduce OSA prevalence materially, the argument goes, ResMed’s addressable market shrinks.

The clinical evidence is real. The FDA approved tirzepatide (Zepbound) in December 2024 specifically for the treatment of moderate-to-severe OSA in adults with obesity, after clinical trials demonstrated meaningful reductions in apnea-hypopnea index among treated patients.

I take this risk seriously. But I believe it is more limited than the 2023 market reaction implied, for three reasons.

First, OSA is not purely mechanical. The condition has neurological and anatomical components, airway geometry, muscle tone, neural respiratory drive, that weight loss does not fully resolve. ResMed’s own connected patient data shows that a meaningful proportion of GLP-1 users who achieve significant weight reduction continue to require CPAP therapy.

Second, the undiagnosed population dwarfs the treated population. The 80% of OSA sufferers who have never received a diagnosis are entering the care pathway as awareness grows. This demand source is entirely independent of GLP-1 penetration.

Third, real-world GLP-1 adherence is substantially lower than clinical trial completion rates. Weight regain is common on discontinuation. Access constraints, particularly outside developed markets, further limit penetration.

This is a risk that deserves ongoing monitoring, particularly as longer-duration GLP-1 data accumulates. It is not a reason to avoid the business; it is a reason to track it carefully and incorporate it into the price I am willing to pay.

Reimbursement and Policy Risk

A meaningful portion of ResMed’s revenue flows through Medicare, Medicaid, and private insurers. The US DMEPOS (Durable Medical Equipment, Prosthetics, Orthotics and Supplies) Competitive Bidding Program has historically placed downward pressure on Medicare reimbursement rates. CMS (Centers for Medicare & Medicaid Services) rate changes and ACA (Affordable Care Act) enrollment policy are ongoing headwinds. The recently enacted One Big Beautiful Bill Act makes changes to Medicaid funding and ACA enrollment that could reduce the insured patient population over time, though the specific effect on sleep therapy demand remains uncertain.

This is a persistent risk that ResMed has navigated through multiple policy cycles. It acts as a headwind to pricing power but has not historically disrupted the underlying demand trajectory.

Goodwill and Acquisition Risk

Goodwill of $3.05 billion, 37% of total assets, reflects the cumulative premium paid for acquisitions. The MEDIFOX DAN acquisition at approximately EUR 975M is the largest and most recent at scale. If integration underdelivers, or if the German software market dynamics shift unfavourably, a material impairment charge would hit reported equity significantly. This is the honest weakness in an otherwise strong balance sheet.

Tariffs and Supply Chain

ResMed manufactures primarily in Australia and Singapore. The tariff environment as of early 2025 has created some input cost uncertainty, though medical device tariff relief has been confirmed through US Customs as of the FY2025 filing date. The situation remains dynamic and worth monitoring.

What Would Change My Mind?

If GLP-1 clinical data continues to accumulate showing high real-world adherence and sustained OSA resolution, not just single-study results, that would require a fundamental reassessment of the long-term volume outlook. If operating margins begin contracting despite revenue growth, that signals competitive pricing pressure and potential moat erosion. If a major acquisition integrates poorly or requires a goodwill writedown, that is a capital allocation warning I would take seriously.

8. The Verdict

ResMed is one of the clearest examples of a business with genuine, compounding structural advantages. The data platform took thirty years to build. The installed base generates recurring revenue that grows with each diagnosis. The software layer makes providers sticky. The clinical evidence is deep and growing. And the addressable market, driven by the vast undiagnosed population, has decades of runway left.

The financial record across ten years confirms the quality: revenue tripled, operating margins expanded by 8.4 percentage points, ROIC averaged 18.9%, and free cash flow grew fivefold. This is what a durable competitive advantage looks like in the numbers.

The GLP-1 risk is real. The goodwill load deserves monitoring. Reimbursement policy is a persistent headwind. These are honest weaknesses and they belong in any fair assessment of the business.

ResMed is Approved in the Bearhold Universe. It sits in the Hold zone at the time of this publication. I am not buying today. But if the price moves into the Attractive zones, whether through a market correction, a temporary earnings disruption, or another episode of fear about a risk the market overstates, I will be ready to act.

Disclaimer: This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

The author does not currently hold a position in $RMD at the time of publication.

Sources

• ResMed Inc. Form 10-K, Fiscal Year Ended June 30, 2025 (filed August 8, 2025)

• ResMed Inc. Form 10-K, Fiscal Year Ended June 30, 2024 (filed August 9, 2024)

• GuruFocus Financial Database — ResMed (NYSE: RMD), extracted April 4, 2026

• GuruFocus Financial Database — Philips (NYSE: PHG), extracted April 5, 2026

• Philips Annual Reports 2020–2025

• Lancet Respiratory Medicine (2019): “Estimation of the global prevalence and burden of obstructive sleep apnoea”

• FDA Drug Approval: Tirzepatide (Zepbound) for OSA, December 2024

• ResMed Press Releases: NightOwl US launch (April 2025); VirtuOx acquisition (May 2025)

• CMS DMEPOS Competitive Bidding Program documentation

• ResMed Proxy Statement (DEF 14A), filed October 2025 — executive compensation and insider ownership

There is a question I ask about every business before anything else: can I tell, with reasonable confidence, how this company will look in five years?

Not the exact numbers. Not the precise revenue figure or the margin to the decimal. Just the shape of it, the competitive position, the pricing power, the reason customers keep coming back regardless of what is happening in the world around them.

For most businesses I cover, the answer is grounded in something structural. An automotive parts distributor benefits from an ageing vehicle fleet that gets more complex and more expensive to repair every year. A salvage auction operator sits at the intersection of rising total loss frequency and a global buyer network that took decades to build. A payment network processes more volume every time a cash transaction moves to digital. These businesses have tailwinds I can reason about independently of consumer sentiment, cultural trends, or what happens to be fashionable this season.

Nike does not have that. And that is the reason it is not included in the Bearhold Universe.

What Nike Actually Sells

Nike is one of the most recognised brands on earth. The marketing is exceptional. The athlete relationships are unmatched. The distribution is global. None of that is in question.

But when you strip it back to what the customer is actually paying for, the answer is identity. The person buying a pair of Air Maxes or a Nike training kit is not primarily paying for a functional outcome. They are paying to be associated with something they find culturally relevant, a feeling, an image, an aspiration. That relationship is real. It is also fragile in a way that other business models simply are not.

Identity is subject to taste. And taste shifts without warning, without logic, and without giving management teams much time to respond.

The Problem with Taste as a Business Driver

The history of consumer brands is full of businesses that looked like compounders until the moment they didn’t. Brands that commanded premium pricing, built loyal followings, and generated strong returns for years, right up until something shifted in the culture and the loyal customer turned out to be loyal to the aesthetic, not the company.

This is not a management failure. It is a category characteristic. When your competitive advantage rests on cultural relevance, you are permanently exposed to a risk that no amount of operational excellence can fully insulate you from. Competitors do not need to engineer a superior product. They just need to feel fresher at the right moment.

Nike is experiencing exactly this right now. Revenue declined roughly ten percent in its most recent fiscal year. Operating margins have compressed significantly from historical levels. Competitors have established meaningful positions in running, a category that historically reinforced Nike’s performance credibility and pricing power.

The company is rebuilding its wholesale relationships after a strategic overcommitment to direct-to-consumer that did not deliver on its promise. China, which represents a meaningful share of the business, has been declining for several consecutive quarters.

Some of this is execution. But not all of it. Some of it is simply what happens when taste moves on and the brand has to work harder to stay relevant than it used to.

Subscribe now

What I Need to See Instead

When I build a position in a business, I want to be able to answer one question clearly: why will this company’s customers still be here in five years?

For the businesses that pass the quality filter, the answer is almost always structural. The switching costs are high, the network effects are real, or the service is so deeply embedded in the customer’s operations that replacing it is more painful than paying for it. These businesses do not need to be culturally relevant. They need to be necessary.

Nike is not necessary. It is desired. And desire, unlike necessity, is something that has to be earned back every season.

The status

Nike is Rejected in the Bearhold Universe. Not because it is a bad company, it is not. Not because the brand is broken, it is not. But because the uncertainty embedded in its revenue model is not the kind of uncertainty I am willing to hold through cycles.

The quality filter exists precisely for moments like this. A well-known name, a strong brand, a long operating history, none of that is sufficient if the fundamental question cannot be answered with confidence.

I want to own businesses where the answer to “why will customers still be here in five years” is obvious. For Nike, it is not.

Subscribe now

This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

The Outlook

Copart is one of the most quietly exceptional businesses in the United States. It operates in a market that many investors have never thought about, the online auctioning of salvage vehicles, and it has built a position in that market that is almost impossible to challenge. The business requires more land than almost any competitor can afford to acquire, it improves as it gets bigger, and its primary customers have no viable alternative. The stock price at the time of writing reflects a business priced for moderate expectations, which is unusual for a business of this quality.

The two risks that matter, concentration among insurance sellers, and the long-term question of autonomous vehicles, are real and deserve honest treatment. Neither, in my view, overrides the fundamental quality of what has been built here. This report addresses both directly.

At a Glance

Company: Copart, Inc

Ticker: $CPRT · NASDAQ

Sector: Industrials

Industry: Online Vehicle Auctions & Remarketing

Market Cap: $31.9 billion (at $33.06)

Status: Approved

First Coverage: April 2026

Valuation Zone: Attractive (last updated in April 2026)

Disclosure update: The author now holds a position in CPRT. The position was initiated after the original publication date of this report. All analysis and conclusions remain unchanged. This report reflects the author’s personal views and is not investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

1. The Business

What it Does

Copart operates online auctions for salvage and total-loss vehicles. When a car is involved in an accident and the insurance company determines that the cost of repair exceeds the vehicle’s value, the car is declared a total loss. The insurance company pays the policyholder the car’s pre-accident value, takes title to the vehicle, and then needs to dispose of it. That is where Copart comes in.

Copart takes possession of the vehicle, transports it to one of its storage facilities, photographs and documents it thoroughly through its proprietary technology, and lists it for sale on its VB3 online auction platform. Buyers from around the world, vehicle dismantlers, rebuilders, used car dealers, exporters, bid against each other in real time. Copart collects fees from both the seller and the buyer. The vehicle sells. The process repeats.

This description makes the business sound simple. It is operationally complex at scale, and that complexity is the foundation of the moat.

How the Company Makes Money

Copart earns fees at multiple points in the process. Sellers, primarily insurance companies, pay processing fees, listing fees, transportation fees, and storage fees. Buyers pay transaction fees, title fees, and loading fees. Because a significant portion of fees are tied to the final auction selling price under Copart’s Percentage Incentive Program, the company has a direct financial incentive to maximise the value each vehicle achieves. This alignment between Copart’s revenue and its sellers’ outcomes is a structural differentiator.

In fiscal year 2025 (ended July 31, 2025), Copart generated total revenues of $4.65 billion, of which $3.97 billion was service revenue and $678 million was vehicle sales revenue, the latter from markets like the UK, where Copart purchases and resells vehicles on a principal basis.

History and Origin

Copart was founded in 1982 by Willis Johnson in Vallejo, California with a single salvage yard. The founding insight was straightforward but consequential: insurance companies needed a professional, efficient, and geographically distributed way to dispose of total-loss vehicles. The fragmented industry of local salvage dealers was not meeting that need well.

The business grew through acquisitions of regional salvage yards over the following decade and went public in 1994. For most of its early history Copart held physical auctions, buyers would travel to its yards to bid on vehicles in person. The transformative moment came when the company began migrating its auction process online in the early 2000s, completing the transition across its US operations by the mid-2000s. This was not an incremental improvement. It was a fundamental reshaping of who could participate in each auction.

By opening every sale to buyers anywhere in the world with internet access, Copart dramatically expanded the pool of bidders competing for each vehicle. More bidders means more competition. More competition means higher prices. Higher prices means insurance companies get better returns on their salvage. Better returns means insurance companies want to work with Copart. The flywheel that would define the business for the next twenty years was set in motion.

Willis Johnson stepped back from day-to-day operations and the company is now led by Jeffrey Liaw, who joined Copart in 2016 as CFO. He was promoted to President in 2019 and became Co-CEO in 2022 before taking over the sole CEO position.

Scale and Footprint

Copart operates in the United States, Canada, the United Kingdom, Germany, Brazil, Spain, Ireland, Finland, the UAE, Oman, and Bahrain. The US business generates approximately 83% of total revenues and is the operational core of the company.

Copart operates over 21,000 acres of land globally, they own more than 90% of their operational land outright, a key differentiator from competitors who typically lease their facilities. In the US alone, Copart owns or leases facilities in every state. The company owns approximately $2.39 billion worth of land on its balance sheet, a figure that significantly understates fair value given how long much of this land has been held and how dramatically land prices around major population centres have appreciated.

The international business is less mature and operates differently in some markets, particularly the UK, where Copart buys vehicles outright. But the global buyer base is central to the model: Copart now maintains a database of approximately 1 million registered members across every continent. The scale of that global buyer pool, and the competitive pressure it places on every auction, remains central to the financial returns Copart delivers to its insurance sellers.

2. The Moat

Source of Competitive Advantage

Copart’s competitive position rests on three interlocking advantages that have strengthened over time. Understanding each one individually understates how they reinforce each other.

The first is physical infrastructure. Copart requires large parcels of land near major population centres to store the high volume of vehicles it processes before they sell. This land is expensive, increasingly scarce, and subject to complex local zoning restrictions that make new entrants face a fundamentally different cost environment than the one Copart faced when it was building its network. The company has spent decades and billions of dollars assembling a footprint that a competitor would need to replicate entirely, at today's land prices, with today's zoning restrictions, competing for the same properties in the same markets. No rational capital allocator would attempt it. This is not a moat that can be disrupted by software or a new technology. It is a physical asset base that took forty years to build.

The second is the global buyer network. Copart has accumulated hundreds of thousands of registered buyers across every continent. The value of this network is directly proportional to its size: more buyers means more competition for each vehicle, which means higher selling prices for insurance companies, which means insurance companies prefer Copart. A new entrant cannot simply build a marketplace without supply. It cannot build supply without having already demonstrated it can achieve competitive selling prices. The chicken-and-egg nature of this problem is the classic marketplace moat, and Copart has been building its side of it for four decades.

The third is the contractual relationships with insurance companies. While no single insurance company accounts for more than 10% of Copart's revenues, an important point to which we will return, the company has established long-term supply agreements with the major carriers. These agreements are built on trust, track record, and the demonstrable financial returns Copart generates for its sellers. Switching costs are not contractual so much as they are practical: an insurance company that moves its business to a smaller competitor will likely see lower auction returns, a worse buyer experience, and disruption to its operations. The cost of switching exceeds the benefit in almost every realistic scenario.

Evidence of the Moat

The financial record is unusually clean on this point. Copart has maintained ROIC consistently above 20% in every year of the past decade, averaging approximately 28% over the last ten years. Operating margins have ranged between 32% and 42% throughout this period. Gross margins have held in a narrow band around 45% for a decade. These are not the numbers of a business that competes on price. They are the numbers of a business that sets the standard.

The most revealing evidence of moat is what has happened to the competition. Insurance Auto Auctions (IAA), Copart's primary US competitor, was acquired by Ritchie Bros. Auctioneers in 2023 after years of underperformance relative to Copart. The combined entity has not threatened Copart's position in any meaningful way.

Moat Trajectory

The moat is strengthening, not weakening. Each additional facility Copart opens makes the network more valuable to insurance sellers because of improved geographic coverage. Each additional buyer who registers on the platform increases the competitive pressure on every auction. Each year of accumulated auction data improves the company’s IntelliSeller tool, which uses machine learning to help sellers optimise their pricing decisions. These are all self-reinforcing dynamics that become harder to replicate as they compound.

Competitive landscape

Copart’s meaningful competition is effectively limited to IAA (now part of Ritchie Bros.) in the US. This is a two-player market for insurance-company salvage vehicles at national scale. Local and regional operators exist but cannot replicate the global buyer network or the geographic coverage that national carriers require. The fact that this market has not attracted more serious competition in four decades is itself informative. The capital requirements are enormous, the zoning challenges are real, and the buyer network takes decades to build.

3. Financial Performance

Revenue Growth

Copart has grown revenue from $1.15 billion in fiscal 2015 to $4.65 billion in fiscal 2025, a compound annual growth rate of 15% over a decade. For a business operating in physical infrastructure with significant real-world constraints, sustaining that rate over ten years is exceptional.

The growth has been driven by four forces operating simultaneously: an increase in total loss frequency rates as vehicles have become more technologically complex and therefore more expensive to repair; market share gains at the expense of smaller regional competitors; geographic expansion both within the US and internationally; and an increase in revenue per transaction driven by higher average vehicle values and an expanded global buyer network.

In fiscal 2025, total revenues grew 9.7% year over year to $4.65 billion. Service revenues, the higher-quality, fee-based component, grew 11.4% to $3.97 billion. The recent moderation from earlier rates reflects the natural effect of a larger base and some normalisation following the elevated total-loss activity of the pandemic years.

Profitability

Copart’s profitability record is one of the clearest expressions of the structural strength of its competitive position. Operating margin in fiscal 2025 was 36.5%, above the ten-year average of 36.3% and meaningfully higher than the 30.1% the business generated a decade ago in fiscal 2015. The direction of travel matters as much as the level: a business that has expanded operating margins by 6.4 percentage points over ten years while growing revenue at 15% annually is not merely maintaining its competitive position, it is strengthening it. Operating income compounded at 17.3% annually from fiscal 2015 to fiscal 2025, growing from $344 million to around $1.70 billion. This outpaced revenue growth, which is precisely what margin expansion looks like in the financials.

Net income in fiscal 2025 was $1.55 billion, up 13.9% from $1.36 billion in fiscal 2024. The net margin of 33.4% is above the ten-year average of 29.6% and almost double the 19.2% the business earned in fiscal 2015. The steady expansion in net margin reflects operating leverage, the benefit of a larger and more efficient network, and the growing contribution of interest income, the company earned $178.9 million in net interest income in fiscal 2025 on its $4.79 billion net cash position, a meaningful source of earnings that did not exist a decade ago.

On earnings per share: diluted EPS grew from $0.21 in fiscal 2015 to $1.59 in fiscal 2025, a compound annual growth rate of 22.4%, ahead of both revenue and net income growth. This performance was bolstered by an overall reduction in diluted share count, which fell from approximately 1.05 billion in fiscal 2015 to 978 million in fiscal 2025. While the share count has drifted slightly higher since 2021 due to stock-based compensation, the long-term decline reflects the cumulative impact of Copart’s historical share buybacks (especially the aggressive buybacks between 2015-2017) and disciplined capital allocation.

Free Cash Flow

Free cash flow grew from $186 million in fiscal 2015 to $1.23 billion in fiscal 2025, a compound annual growth rate of 20.8% over a decade. That represents a 6.6-fold increase in the business’s capacity to generate cash, which is a meaningful claim about the quality of the underlying economics.

The capex-to-operating-cash-flow ratio tells a particularly revealing story about where the business stands today. Over the past decade, this ratio averaged approximately 44%, meaning Copart reinvested roughly 44 cents of every operating dollar back into the physical infrastructure that generates its competitive moat. In fiscal 2025, that ratio fell to 31.6%, its second lowest level in ten years. The business is indeed entering a higher-harvest phase in the US, but it remains an investment-heavy business globally.

Return on Invested Capital

Over the past decade, ROIC has averaged 28.4% and reached as high as 32% in fiscal 2022. In fiscal 2025, ROIC was 29%, essentially in line with the long-run average. This consistency is more impressive than a single peak figure. A business that has compounded at 15% annually in revenue while sustaining high returns on incremental capital is, by the standard definitions, a genuine compounder. Every dollar reinvested in the business has generated returns well above any reasonable estimate of the cost of capital in every year of the available record.

Balance Sheet

Copart’s balance sheet at July 31, 2025 was exceptional. The company held $2.78 billion in cash and restricted cash plus $2.01 billion in held-to-maturity securities, a combined liquid position of $4.79 billion against total financial debt of effectively zero. Total liabilities of $883 million were overwhelmingly operational in nature. This is a fortress balance sheet. It provides management with complete flexibility to act, whether to acquire land, weather a severe recession, respond to catastrophic weather events, or return capital to shareholders. The net cash position also generates meaningful interest income that did not exist in prior cycles, adding a new dimension to earnings quality.

Capital Expenditure

Copart spent $569 million on capex in fiscal 2025, the majority directed toward land acquisition and facility development. Importantly, the majority of Copart’s capex is growth-oriented, acquiring land and building new facilities that generate long-term structural barriers, rather than maintenance capex spent on preserving the existing asset base. This distinction matters when evaluating the quality of the free cash flow figure.

4. Growth Levers & Addressable Market

Copart is not a business that has exhausted its runway. The US network is maturing, but that maturation is precisely what frees capital and management attention for the next phase of growth. There are four distinct levers that can drive the business forward from here, and they are not speculative: each has evidence of traction today.

A) The structural Tailwind in Total Loss Frequency

The single most important driver of Copart’s domestic volume is total loss frequency, the percentage of accident-involved vehicles that insurers choose to declare a total loss rather than repair. In fiscal 2025, CEO Jeff Liaw described the full-year total loss frequency rate of 22.2% as an all-time annual high. This is not an anomaly. It is the result of forces that have been building for decades and show no sign of reversing.

Modern vehicles are fundamentally more expensive to repair than their predecessors. Advanced driver assistance systems, cameras, sensors, integrated infotainment, and complex structural materials mean that even moderate collision damage frequently triggers repair estimates that exceed the vehicle's value. Electric vehicles add a further dimension: EVs require approximately four additional labour hours per repair compared to internal combustion vehicles and carry roughly 30% higher repair costs. As EV penetration grows and as ADAS technology becomes standard across more model lines and price points, the economics of repair versus total loss continue to shift in Copart's favour. The average age of vehicles on US roads has also reached 12.8 years, meaning a large portion of the fleet consists of older vehicles where even modest damage tips the repair-versus-salvage calculation toward salvage. Each of these trends compounds the other, and none of them is cyclical.

B) International Expansion, the Majority of the Opportunity

The US salvage auction market (calculated based on the Auction Fees paid to the auction house) is estimated at $3.8 billion in 2025 and is projected to reach $7.2 billion by 2030, growing at around 13.6% CAGR. Copart’s domestic service revenue in fiscal 2025 was approximately $3.4 billion (including buyer fees, seller fees, transportation fees, and title processing) meaning the company is already capturing the largest share of a market that is still growing. The domestic runway is real but finite.

The international opportunity is a different order of magnitude. The global online salvage auction market was estimated at $12.4 billion in 2025 and is projected to reach $27.2 billion by 2030 at a 17% CAGR, a faster growth rate than the US market and from a base where Copart's penetration is a fraction of what it has achieved domestically. In fiscal 2025, international service revenue growth reached 18.9% for the full year, significantly outpacing the 10.4% growth in U.S. service revenue. The direction of travel is clear.

The specific international market opportunities are substantial. Germany's online salvage market was worth approximately $1.1 billion in 2025 and is projected to grow at a 21% CAGR through 2030, a market where Copart has been building infrastructure since 2017 and where the transition from a principal-based model to a consignment model is already delivering margin improvement. Brazil sits at approximately $480 million with mid-teens growth. India, which Copart briefly entered and then paused to wait for the market to develop further, is estimated at $230 million and growing at approximately 23% annually, a market that Copart is well-positioned to re-enter as formal insurance penetration and salvage regulation matures. In the UK, Copart already holds approximately 60–70% of the insurance-customer market, making it the dominant operator in Europe's most developed salvage market. Asia-Pacific is the fastest-growing region globally, expanding at a 16–24% CAGR depending on the source.

Copart's international buyer pool is a direct competitive advantage in these markets. The most recent available data indicates that international buyers purchasing US vehicles were acquiring vehicles significantly higher in value than comparable vehicles purchased by domestic US buyers, a reflection of the quality and purchasing power of the global member base Copart has assembled over four decades. That same buyer network can be directed toward inventory in Germany, Brazil, or any market Copart enters, providing an immediate advantage that a local competitor could not replicate. This is network effects working across geographies, not just within them.

C) Expanding Beyond Insurance, Blue Car and Adjacent Categories

Approximately 81% of Copart’s vehicle volume originates from insurance company sellers. That concentration is a risk, but it also reveals the size of the untapped opportunity in non-insurance channels.

Blue Car, Copart’s service offering aimed at banks, rental car companies, and fleet operators, delivered strong double-digit growth in fiscal 2025, as reported in the annual report. This is not a minor product line. Banks and financial institutions need to liquidate repossessed vehicles and lease maturities efficiently; fleet operators and rental companies cycle through vehicles on a regular cadence and need the same combination of geographic reach, global buyer access, and transparent pricing that insurance companies value. As Copart's platform becomes better known outside the insurance vertical, the addressable supply base expands materially without requiring any new infrastructure investment.

Purple Wave, Copart's heavy equipment and agricultural machinery auction platform, delivered continued growth in fiscal 2025. Heavy equipment and farm machinery represent a large and fragmented global market that benefits from exactly the same dynamics that made Copart successful in salvage vehicles: a global buyer pool competing for local inventory, transparent price discovery, and specialist services for sellers who lack efficient alternatives. This is early innings, but the model is proven.

D) The EV Transition as a Structural Accelerator

Electric vehicles are widely discussed as a long-term threat to Copart through the autonomous vehicle channel. The near-term reality is almost exactly the opposite. EVs are more expensive to repair than internal combustion vehicles by a meaningful margin. Battery damage, which occurs in a significant proportion of EV collisions, is frequently uneconomical to repair at all, either because the battery module is deeply integrated into the vehicle’s structure or because replacement costs are prohibitive. This drives EV total loss rates materially above ICE vehicle rates at comparable damage severity levels. As EV penetration of the vehicle fleet grows, still in its early stages globally, it adds a structural tailwind to Copart’s volume that did not exist a decade ago and that will intensify over the coming years before autonomous vehicle adoption becomes a countervailing force.

What the TAM Picture Tells us

A business that controls roughly half of the US domestic market, that is in the early stages of penetrating a $10.6 billion global market growing at 15% annually, and that is actively expanding into adjacent vehicle categories through Blue Car and heavy equipment, is not running out of room. The presence of a massive growth runway is undeniable; the real variable is Copart’s ability to scale operations and deploy capital with its trademark efficiency. Given its historical financial performance, the company has already proven it possesses the discipline to execute.

5. Management

Leadership and Tenure

Copart is effectively a founder-influenced business. Willis Johnson, who founded the company in 1982, remains Chairman of the Board. His operating philosophy, own the land, build the infrastructure, focus on seller returns, expand the buyer network, is deeply embedded in how the company operates.

Liaw joined in 2016 as CFO. He brought a sophisticated private equity background (formerly at TPG Capital) that sharpened the company's approach to capital allocation, ROIC, and international M&A. He served as Co-CEO with Jay Adair before becoming the sole CEO on April 1, 2024.

The transition from founder Willis Johnson to his son-in-law Jay Adair (now Executive Chairman), and then to Jeff Liaw, represents one of the most successful leadership successions in the industrial sector. The team's ownership mindset is reflected in their lack of a dividend; they prefer to reinvest every dollar into land or opportunistic buybacks.

Skin in the Game

Insiders, including Willis Johnson and his affiliates, collectively own a significant portion of Copart’s outstanding shares, exceeding 11% of shares outstanding as of the most recent proxy. Executive compensation is weighted heavily toward equity, tying financial outcomes directly to long-term share price performance. Options issued to senior executives include market conditions requiring the stock to trade above a specified price threshold before exercise, a feature that further aligns incentives with shareholder value creation.

Capital Allocation Track Record

Copart’s capital allocation record reflects a management team that has consistently prioritised long-term value over short-term return metrics. The primary deployment of free cash flow has been into land acquisition and facility development, investments that have generated ROIC averaging 28% over the past decade and that have deepened the structural barriers protecting the business.

Copart has historically been a reluctant repurchaser, preferring to build a massive cash pile for internal reinvestment. Aside from a defining $739 million buyback in 2017, the company remained largely dormant on this front until early 2026, when it deployed $500 million to take advantage of recent share price volatility. Combined with a total absence of dividends since its 1994 IPO, this reflects a management team strictly focused on long-term compounding over immediate distributions.

The primary reservation is the accumulation of $4.79 billion in liquid assets earning treasury rates when the business historically generates returns above 20% on invested capital. This is capital that could be working harder.

Communication and Transparency

Copart’s management communicates with shareholders in a manner that reflects genuine confidence in the business and a willingness to engage with difficult questions. Earnings calls are substantive. The risk factor disclosures in annual filings acknowledge real challenges rather than papering over them. The 10-K filings are unusually detailed about the operational mechanics of the business.

6. Valuation

Current valuation

Our valuation framework measures how much of the sum of a company’s future cash flows, discounted back to today at an appropriate rate, is already embedded in the current stock price. Rather than expressing this as a precise figure, we express it as an approximation in years.

At the time of this report, with the stock trading at $33.06, the market is pricing Copart at approximately 16 years of discounted future cash flows. This is an approximation, not an exact calculation. The assumptions embedded in our model are consistent with the company’s current and historical operating performance, they are not heroic, and they are not pessimistic. This figure is monitored and updated on a monthly basis as the stock price and business performance evolve. This places the business in the Attractive zone of the valuation gauge.

What 16 years means

What 16 years means in practical terms is this: the current price assumes that Copart will stop generating meaningful cash flows after year 16. Every year of cash generation beyond that point comes to you as an investor for free.

For a business with the structural characteristics described in this report, physical infrastructure that compounds in value, a buyer network that deepens with each passing year, contractual relationships with insurance companies that have persisted for decades, and a non-discretionary market that has existed since automobiles did, the question of whether Copart will still be generating substantial cash flows in year 17 and beyond seems like a reasonable bet.

Hold, Add, and Exit Logic

The valuation framework is not a buy-and-sell signal generator. It is a tool for thinking about price relative to value, and for making disciplined capital allocation decisions across the Bearhold Universe.

The current Attractive zone suggests the price does not demand excessive optimism about the future. For a business of this quality, that is a reasonable entry point.

The general logic across all five zones is as follows. In the Exceptionally Attractive and Attractive zones, the price is working in your favour, you are receiving more embedded future cash flows per dollar deployed than the market typically offers for a business of this quality. In the Hold zone, the business is fairly recognised, neither compelling to initiate a new position nor a reason to exit one already held. In the Expensive and Exceptionally Expensive zones, the price is embedding a level of optimism that the historical record does not automatically support.

My approach is straightforward: when a position moves into the Expensive zone, I sell and reallocate the capital to other quality businesses in the Bearhold Universe where the price sits in the Attractive and Exceptionally Attractive zones. The logic is simple, if you own a collection of exceptional businesses, your capital should always be working in the most attractively priced names available to you. Holding an Expensive position when an Attractive alternative exists is an opportunity cost that compounds against you over time. Discipline on the exit is as important as discipline on the entry.

Growth Engines

Every stock price is driven by one of two engines, or both simultaneously. Understanding which is working in your favour, and which might work against you, is as important as understanding the business itself.

The first engine is fundamental growth. Over time, a stock price tracks the growth of free cash flow per share. If a business compounds its FCF per share at 15% annually, that is roughly what the fundamental engine contributes to investor returns over a full holding period. It is steady, it is predictable, and it is the engine that quality businesses run on indefinitely.

The second engine is valuation re-rating. When a stock is mispriced, when the market is embedding fewer years of future cash flows than the business's quality and durability justify, the price tends to correct upward simply to reach fair value. This engine can produce returns that dwarf what fundamentals alone would deliver. It can also run in reverse: when a stock sits in the Expensive zone, the market is embedding too many years, and any mean reversion subtracts from returns even as the business continues to perform. A good business at the wrong price is still a poor investment.

For Copart at the time of writing, both engines appear to be working in the investor's favour. Over the past decade, Copart has compounded FCF per share at approximately 21% annually, one of the strongest rates among large businesses in any sector. That is the fundamental engine, running in full. The valuation engine has room to contribute as well: at 16 years of embedded cash flows in the Attractive zone, the market is not fully pricing the duration and quality of what Copart has built. An investor entering at this price is not relying on optimism, they are being paid by both the business performing and the price catching up.

The risk scenario is equally clear. If the stock moves into the Expensive zone, driven by price appreciation that outpaces fundamental growth, the valuation engine begins working against the position. In that scenario, the approach is to sell and reallocate capital to a quality business in the Bearhold Universe.

7. Risks

Risk 1 - Insurance Company Concentration

Copart obtains approximately 81% of its vehicle volume from insurance company sellers. While no single insurer accounts for more than 10% of consolidated revenues, the collective dependence on a relatively small number of large carriers is a genuine structural risk. If the major US insurers were to consolidate their salvage operations, pursue vertical integration, or develop a credible alternative platform, Copart’s supply would be at risk.

The probability of this materialising is low. Insurance companies are not in the business of operating salvage yards. The operational complexity, the land requirements, and the need to build a global buyer network from scratch are formidable disincentives. Moreover, the financial returns Copart delivers to its insurance partners, through higher auction prices enabled by its global buyer network, are difficult to replicate. An insurer attempting to internalise this function would almost certainly achieve worse financial outcomes than it does today working with Copart.

The risk is real but its probability of materialising is low, and the mechanism by which it would occur requires insurance companies to act against their own financial interests.

Risk 2 - Autonomous Vehicles and Declining Accident Rates

This is the risk that deserves the most honest treatment in any Copart analysis, and the one with the longest time horizon.

The thesis is straightforward: if autonomous vehicles eventually reduce accident rates materially, or eliminate them entirely, the supply of total-loss vehicles that feeds Copart’s business would decline in parallel. A 50% reduction in accident rates would, all else being equal, reduce Copart’s volume significantly.

There are several important qualifications a serious investor must hold simultaneously.

First, the timeline for meaningful autonomous vehicle adoption is deeply uncertain. The promises of full self-driving technology have been pushed out repeatedly over the past decade. Even optimistic estimates place widespread adoption of truly autonomous vehicles well into the 2030s or beyond in the United States.

Second, vehicle complexity has historically been a tailwind for total loss frequency, not a headwind. Modern vehicles, with advanced driver assistance systems, cameras, sensors, and complex structural materials, are more expensive to repair than older vehicles. This has driven total loss frequency higher over the past thirty years even as vehicle safety technology has improved. The transition period from human-driven to autonomous vehicles is likely to involve even more complex and expensive-to-repair vehicles, maintaining or increasing total loss frequency in the near and medium term.

Third, even in a world where US domestic accident rates eventually decline, Copart’s international business and its global buyer network provide a degree of diversification that pure domestic exposure would not.

The autonomous vehicle risk is real, horizon-dependent, and does not present itself as an imminent threat to the business. An investor with a ten-year horizon should have it on the watch list. An investor with a twenty-year horizon needs to weigh it more carefully as part of any thesis.

What Would Change my Mind?

Meaningful and sustained market share losses to IAA or a new entrant, over two or more consecutive years, would be an early warning signal that the moat is weakening. If total loss frequency begins a sustained multi-year decline attributable to measurable reductions in accident rates from driver assistance technology, not just a single year of mild weather, that would require a fundamental reassessment of the long-term volume outlook. If a major insurance carrier publicly announces plans to internalise salvage operations, that would warrant immediate re-evaluation.

8. The Verdict

Copart is the kind of business that takes decades to build and is almost impossible to replicate once built. It occupies a structural position in a non-discretionary market, behind barriers that compound in strength each year, run by a management team whose interests are aligned with long-term shareholders and whose operational record demonstrates consistent execution across three decades.

The two risks discussed, insurance concentration and autonomous vehicles, are not trivial. They are real, they deserve ongoing monitoring, and they prevent this from being a thesis where no adverse scenario is imaginable. But neither risk, assessed honestly against the current time horizon, overrides the fundamental quality of what has been built.

At a valuation of 16 years of embedded cash flows, the market is asking for reasonable performance from a business with an exceptional track record. That is a combination worth owning.

Copart is the kind of business that quietly makes you wealthy if you give it time and leave it alone.

Disclosure update: The author now holds a position in CPRT. The position was initiated after the original publication date of this report. All analysis and conclusions remain unchanged. This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here